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Although chemically-mediated neuronal signaling was discovered nearly a century ago, it was only 
relatively recently, in the 1980s, that the study of neurotransmitter receptor pharmacology 
markedly accelerated, with the widespread use of specific radiotracers capable of labelling receptors 
in tissue preparations. This led to the discovery of an amazing (at the time) diversity of receptor 
subtypes with distinct physiological properties and pharmacological profiles. Among the principal 
neurotransmitter receptors to be investigated were those of the monoamines: serotonin 
(5-hydroxytryptamine, 5-HT), dopamine and noradrenaline, which act at a combined total of at least 
27 receptors. The focus of the present D.Sc. thesis is to review the contribution of my own research 
to the understanding of the molecular signalling, neurochemistry and behavioural pharmacology of 
central nervous system monoamine receptors. A somewhat unusual feature of this work is that it 
was mostly carried out in pharmaceutical industry laboratories. These had the enlightened view that 
creative (and marketable) applied science requires a commitment to innovative basic science. My 
work therefore combined exploration of previously-unsuspected mechanisms of receptor function 
with the identification and characterisation of new drugs for use as exploratory tools and/or as 
therapeutic candidates. The principal advances made in the course of my work were as follows.  
 Serotonin 5-HT1A receptor signalling: the in vitro studies I conducted revealed the presence of 
constitutive activity in both recombinant cell lines and native rat brain tissue. The level of 
G-protein activation by 5-HT1A receptors varies with receptor expression, receptor:G-protein 
stoichiometry and interactions at specific G-protein subtypes. 
 5-HT1A receptor subpopulations: I demonstrated the presence of “biased agonism” at 5-HT1A 
receptors in specific brain regions. This translated to distinct neurochemical, behavioural and 
therapeutic-like responses. My work led to the identification of a new selective agonist, F15599, 
which exhibits reinforced anti-depressant-like activity and was taken to early clinical trials. 
 5-HT1A receptor activation in psychotic disorders: the pharmacological studies that I directed 
showed that compounds possessing 5-HT1A agonist properties exhibit a superior profile of action 
in models of negative symptoms and cognitive deficits compared with conventional 
antipsychotics. My work led to the identification of novel drugs, notably F15063.  
 5-HT1B, 5-HT1D, 5-HT2A, 5-HT2B and 5-HT2C receptors: my research showed that these receptors 
exhibit diverse profiles of G-protein coupling, biased agonism and constitutive activity. Notably, 
5-HT1B receptors exhibited “protean” agonism for the endogenous neurotransmitter, 5-HT. 
 Dopamine D2, D3 and D4 receptors: these displayed specific molecular signalling mechanisms. 
D4 receptors showed complex signalling and “promiscuous” activation by noradrenaline, in 
addition to dopamine. My studies contributed to the identification of novel ligands at D3 and D4 
receptors. Of these, S33138, a D3 receptor antagonist, was later tested in schizophrenia patients. 
 Noradrenergic α2 receptors: I conducted the first multiparametric study of anti-Parkinson’s 
disease agents with differing profiles of action at α2 and other monoamine receptors. The clinical 
drug, piribedil, was shown to possess α2 receptor antagonism.  
D.Sc. Thesis  Candidate Declaration 
 
Part A: Page 6 of 206 
Candidate Declaration 
 
 From reference 1 up to reference 54: when named as first author (28 references), I wrote the 
manuscript and either carried out the experimental work or supervised its execution. When 
named as second author (16 references) or last author (3 references), I made a major 
contribution to conceiving and supervising the project and to writing the manuscript. When 
named as a minor author (7 references), I performed or supervised some of the experimental 
work necessary to the completion of the paper.  
 From reference 55 to reference 103: when named as first author (8 references), I conceived and 
supervised the project and wrote the manuscript. When named as last author (23 references), 
I conceived and supervised the project and made a major contribution to writing the manuscript. 
When named as second author or minor author (18 references), then I had a substantial 
intellectual input to conceiving the project and writing the manuscript. 
 Publications 1 and 2 were based on results included as part of a submission for a Ph.D. thesis to 
the University of Kent at Canterbury in 1992. 
I confirm that this is a true statement and that, subject to any comments above, the submission is 
my own original work. 
 
25 June 2012 
 
Applicant’s Qualifications 
Doctor of Philosophy, Neuropharmacology, University of Kent (1992) 
Bachelor of Science (with honours), Biochemistry, University ofKent (1988) 
D.Sc. Thesis  Publications 
 
Part A: Page 7 of 206 
Publications included in this Thesis 
 
(Abstracts listed in Part B) 
1992 - 1996 
1. Newman-Tancredi A, Wootton R, Strange PG (1992). High level stable expression of 
recombinant 5-HT1A 5-hydroxytryptamine receptors in Chinese Hamster Ovary cells. Biochem J 
285:933-938. 
2. Sundaram H, Newman-Tancredi A, Strange PG (1993). Characterisation of recombinant human 
serotonin 5-HT1A receptors expressed in Chinese Hamster Ovary cells: [
3
H]spiperone 
discriminates between the G-protein-coupled and uncoupled forms. Biochem Pharmacol 
45:1003-1009. 
3. Newman-Tancredi A, Audinot V, Jacques V, Peglion J-L, Millan MJ (1995). [
3
H](+)S14297: a 
novel, selective radioligand at cloned human dopamine D3 receptors. Neuropharmacology 34: 
1693-1696. 
4. Newman-Tancredi A, Chaput C, Verrièle L, Millan MJ (1996). Clozapine is a partial agonist at 
cloned, human serotonin 5-HT1A receptors. Neuropharmacology 35:119-121. 
5. Newman-Tancredi A, Chaput C, Verrièle L, Millan MJ (1996). S15535 and WAY100635 
antagonise 5-HT-stimulated [
35
S]GTPγS binding at cloned human 5-HT1A receptors. Eur J 
Pharmacol 307:107-111. 
1997 
6. Lejeune F, Newman-Tancredi A, Audinot V, Millan MJ (1997). Interactions of (+) and (-)-8- and 
7-OH-DPAT at human (h)D3, hD2 and h5-HT1A receptors and their modulation of the activity of 
serotoninergic and dopaminergic neurones in rats. J Pharmacol Exp Ther 280:1241-1249. 
7. Newman-Tancredi A, Audinot V, Gobert A, Millan MJ (1997). Noradrenaline and adrenaline are 
high affinity agonists at dopamine D4 receptors. Eur J Pharmacol 319:379-383. 
8. Newman-Tancredi A, Conte C, Chaput C, Spedding M, Millan MJ (1997). Inhibition of the 
constitutive activity of human 5-HT1A receptors by the inverse agonist, spiperone but not the 
neutral antagonist, WAY100635. Br J Pharmacol 120:737-740. 
9. Millan MJ, Newman-Tancredi A, Rivet J-M, Brocco M, Audinot, V, Cistarelli L, Gobert A (1997). 
S15535, a novel benzodioxopiperazine ligand of serotonin 5-HT1A receptors: interaction with 
cloned human (h)5-HT1A, dopamine hD2/hD3 and hα2A-adrenergic receptors in relation to 
modulation of cortical monoamine release and potential antidepressant properties. J Pharmacol 
Exp Ther 282:132-147. 
10. Newman-Tancredi A, Conte C, Chaput C, Verrièle L, Millan MJ (1997). Agonist and inverse 
agonist efficacy at human recombinant serotonin 5-HT1A receptors as a function of 
receptor:G-protein stoichiometry. Neuropharmacology 36:451-459. 
11. Audinot-Bouchez V, Lochon S, Newman-Tancredi A, Lavielle G, Millan MJ (1997). Binding profile 
of the novel 5-HT1B/1D receptor antagonist, [
3
H]GR125,743, in guinea pig brain: a comparison 
with [3H]5-carboxamidotryptamine. Eur J Pharmacol 327:247-256. 
D.Sc. Thesis  Publications 
  
Part A: Page 8 of 206  
12. Newman-Tancredi A, Audinot V, Chaput C, Verrièle L, Millan MJ (1997). [
35
S]GTPγS binding as a 
measure of efficacy at human recombinant dopamine D4.4 receptors: actions of antiparkinsonian 
and antipsychotic agents. J Pharmacol Exp Ther 282:181-191. 
13. Newman-Tancredi A, Conte C, Chaput C, Verrièle L, Audinot-Bouchez V, Lochon S, Lavielle G, 
Millan MJ (1997). Agonist activity of antimigraine drugs at recombinant human 5-HT1A 
receptors: potential implications for prophylactic and acute therapy. Naunyn-Schmiedeberg's 
Arch Pharmacol 355:682-688. 
1998 
14. Millan MJ, Gobert A, Newman-Tancredi A, Audinot V, Lejeune F, Rivet J-M, Cussac D, Nicolas J-
P, Muller O, Lavielle G (1998). S16924 ((+)-2-{1-[2-(2,3-Dihydro-benzo[1,4]dioxin-5yloxy)-ethyl]-
pyrrolidin-3yl}-1-(4-fluoro-phenyl)-ethanone), a novel potential antipsychotic with marked 
serotonin 5-HT1A agonist properties I: Receptorial and neurochemical profile in comparison with 
clozapine and haloperidol. J Pharmacol Exp Ther 286:1341-1355. 
15. Newman-Tancredi A, Chaput C, Gavaudan S, Verrièle L, Millan MJ (1998). Agonist and 
antagonist actions of (-)pindolol at recombinant human 5-HT1A receptors. 
Neuropsychopharmacology 18:395-397. 
16. Newman-Tancredi A, Verrièle L, Chaput C, Millan MJ (1998). Labelling of recombinant human 
and native rat 5-HT1A receptors by a novel, selective radioligand, [
3H]S15535: definition of its 
binding profile using agonists, antagonists and inverse agonists. Naunyn-Schmiedeberg's Arch 
Pharmacol 357:205-217. 
17. Newman-Tancredi A, Gavaudan S, Chaput C, Touzard T, Verrièle L, Millan MJ (1998). Actions of 
α2 adrenoceptor ligands at α2A and 5-HT1A receptors: the antagonist, atipamezole, and the 
agonist, dexmedetomidine, are highly selective for α2 sites. Naunyn-Schmiedeberg's Arch 
Pharmacol 358:197-206. 
18. Millan MJ, Newman-Tancredi A, Brocco M, Gobert A, Lejeune F, Audinot V, Rivet J-M, Schreiber 
R, Dekeyne A, Spedding M, Nicolas J-P, Peglion J-L (1998). S18126 ([2-[4-(2,3-
dihydrobenzo[1,4]dioxin-6-yl)piperazin-1-yl methyl]indan-2-yl]), a potent, selective and 
competitive antagonist at dopamine D4 receptors: an in vitro and in vivo comparison with 
L745,870 (3-(4-[4-chlorophenyl]piperazin-1-yl)methyl-1H-pyrrolo[2,3b]pyridine) and raclopride. 
J Pharmacol Exp Ther 287: 167-186. 
19. Newman-Tancredi A, Gavaudan S, Conte C Chaput C, Touzard M, Verrièle L, Audinot V, Pasteau 
V, Millan MJ (1998). Agonist and antagonist actions of antipsychotic agents at serotonin 5-HT1A 
receptors: a [35S]GTPγS binding study. Eur J Pharmacol 355: 245-256. 
1999 
20. Newman-Tancredi A, Cussac D, Audinot V, Pasteau V, Gavaudan S, Millan MJ (1999). G-Protein 
activation by human dopamine D3 receptors in high-expressing chinese hamster ovary cells: a 
[35S]GTPγS binding and antibody study. Mol Pharmacol 55: 564-574. 
21. Millan MJ, Brocco M, Gobert A, Joly F, Bervoets K, Rivet J-M, Newman-Tancredi A, Audinot V, 
Maurel S (1999). Contrasting mechanisms of action and sensitivity to antipsychotics of 
phencyclidine versus amphetamine: importance of nucleus accumbens 5-HT2A sites for PCP 
induced locomotion in the rat. Eur J Neuroscience 11: 4419-4432 
22. Newman-Tancredi A, Cussac D, Audinot V, Millan MJ (1999). Actions of roxindole at dopamine 
hD2 hD3 hD4 and serotonin h5-HT1A, h5-HT1B and h5-HT1D receptor subtypes: preferential 
D.Sc. Thesis  Publications 
  
Part A: Page 9 of 206  
activation of hD3 and h5-HT1A receptors revealed by [
35
S]GTPγS binding. Naunyn-Schmiedeberg's 
Arch Pharmacol 359: 447-453. 
23. Cussac D, Newman-Tancredi A, Pasteau V, Millan MJ (1999). Dopamine hD3 receptors mediate 
MAPK activation via a PI3-kinase and an atypical PKC-dependent mechanism. Mol Pharmacol 
56: 1025-1030. 
24. Newman-Tancredi A, Chaput C, Touzard T, Verrièle L, Millan MJ (1999). The 5-HT1A receptor 
ligand, S15535, antagonises G-protein activation: a [
35
S]GTPγS and [
3
H]S15535 autoradiography 
study. Eur J Pharmacol 384: 111-121. 
25. Millan MJ, Gobert A, Audinot V, Dekeyne A, Newman-Tancredi A (1999). Inverse agonists and 
serotonergic transmission: from recombinant human 5-HT1A and 5-HT1B receptors and 
quantification of G-protein coupling to function in corticolimbic structures. 
Neuropsychopharmacology  21: 61S-67S 
2000 
26. Cussac D, Newman-Tancredi A, Quentric Y, Millan MJ (2000). An innovative method for rapid 
characterisation of phospholipase C activity: SB242084 competitively antagonises 5-HT2C 
receptor-mediated [
3
H] phosphatidylinositol depletion. Naunyn-Schmiedeberg's Arch Pharmacol 
361: 221-223. 
27. Millan MJ, Gobert A, Newman-Tancredi A, Cussac D, Lejeune F, Rivet J-M, Boutin JA, Depoux N, 
Peglion J-L (2000). S18327 (1-[2-[4-(6-fluoro-1, 2-benzisoxazol-3-yl)piperid-1-yl]ethyl]3-phenyl 
imidazolin-2-one), a novel, potential antipsychotic displaying marked antagonist properties at 
α1- and α2-adrenergic receptors: I. Receptorial, neurochemical and electrophysiological profile. J 
Pharmacol Exp Ther 292:38-53. 
28. Newman-Tancredi A, Chaput C, Touzard M, Millan MJ (2000). [35S]GTPγS autoradiography 
reveals α2 adrenoceptor-mediated G-protein activation in amygdala lateral septum. 
Neuropharmacology 39: 1111-1113. 
29. Cussac D, Newman-Tancredi A, Sezgin L, Millan MJ (2000). The novel antagonist, S33084, and 
GR218,231 interact selectively with cloned and native rat dopamine D3 receptors as compared 
with native, rat dopamine D2 receptors. Eur J Pharmacol 394: 47-50. 
30. Cussac D, Newman-Tancredi A, Sezgin L, Millan MJ (2000). [3H]S33084: a novel, selective and 
potent radioligand at cloned, human dopamine D3 receptors. Naunyn-Schmiedeberg’s Arch 
Pharmacol 361: 569-572.  
31. Newman-Tancredi A, Audinot V, Moreira C, Verrièle L, Millan MJ (2000). Inverse agonism and 
constitutive activity as functional correlates of serotonin h5-HT1B receptor / G-protein 
stoichiometry. Mol Pharmacol 58: 1042-1049. 
32. Cussac D, Newman-Tancredi A, Nicolas JP, Boutin JA, Millan MJ (2000). Antagonist properties of 
the novel antipsychotic, S16924, at cloned, human serotonin 5-HT2C receptors: a parallel 
phosphatidylinositol and calcium accumulation comparison with clozapine and haloperidol. 
Naunyn-Schmiedeberg’s Arch Pharmacol 361: 549-554. 
33. Millan MJ, Gobert A, Newman-Tancredi A, Lejeune F, Cussac D, Rivet J-M, Audinot A, Dubuffet 
T, Lavielle G (2000). S33084, a novel, potent, selective and competitive antagonist at dopamine 
D3-receptors: 1. Receptorial, electrophysiological and neurochemical profile compared with 
GR218,231 and L741,626. J Pharmacol Exp Ther 293: 1048-1062.  
D.Sc. Thesis  Publications 
  
Part A: Page 10 of 206  
2001 
34. Audinot V, Newman-Tancredi A, Millan MJ (2001). Constitutive activity at serotonin 5-HT1D 
receptors: detection by homologous [
35
S]-GTPγS versus GTPγS binding isotherms. 
Neuropharmacology 40: 57-64. 
35. Newman-Tancredi A, Verrièle L, Millan MJ (2001). Differential modulation by GTPγS of agonist 
and inverse agonist binding to h5-HT1A receptors revealed by [
3
H]WAY100635. Br J Pharmacol 
132: 518-524. 
36. Newman-Tancredi A, Chaput C, Touzard M, Millan MJ (2001). Pindolol antagonises G-protein 
activation at both pre- and post-synaptic serotonin 5-HT1A receptors: a [
35S]GTPγS 
autoradiography study. Naunyn-Schmiedeberg’s Arch Pharmacol 363: 391-398.  
37. Audinot V, Newman-Tancredi A, Cussac D, Millan MJ (2001). Inverse agonist properties of 
antipsychotic agents at cloned, human (h) serotonin 5-HT1B and h5-HT1D receptors. 
Neuropsychopharmacology 25: 410-422.  
38. Millan MJ, Cussac D, Milligan G, Carr C, Audinot V, Gobert A, Lejeune F, Rivet J-M, Brocco M, 
Duqueyroix D, Nicolas JP, Boutin JA, Newman-Tancredi A (2001). The antiparkinsonian agent, 
piribedil, displays antagonist properties at native rat and cloned human α2-adrenoceptors: a 
cellular and functional characterization. J Pharmacol Exp Ther 297: 1-12.  
39. Newman-Tancredi A, Verrièle L, Touzard M, Millan MJ (2001). Efficacy of antipsychotic agents 
at human 5-HT1A receptors determined by [
3
H]WAY100635 binding affinity ratios: relationship 
to efficacy for G-protein activation. Eur J Pharmacol 428: 177-184. 
40. Millan MJ, Newman-Tancredi A, Quentric Y, Cussac D (2001). The 'selective' dopamine D1 
receptor antagonist, SCH23390, is a potent agonist at cloned, human serotonin2C receptors. 
Psychopharmacology 156: 58-62. 
41. Millan MJ, Newman-Tancredi A, Duqueyroix D, Cussac D (2001). Agonist properties of pindolol 
at h5-HT1A receptors coupled to mitogen-activated protein kinase. Eur J Pharmacol 424: 13-17. 
42. Newman-Tancredi A, Cussac D, Brocco M,  Rivet J-M, Chaput C,  Touzard M,  Pasteau V,  Millan 
MJ (2001). Dopamine D2 receptor-mediated G-protein activation in rat striatum: functional 
autoradiography and influence of unilateral 6-hydroxydopamine lesions of the substantia nigra. 
Brain Research 920: 41-54.  
2002 
43. Millan MJ, Newman-Tancredi A, Lochon A, Touzard M, Audinot V (2002). Specific labelling of 
serotonin 5-HT1B receptors in frontal cortex with the novel phenylpiperazine derivative 
[3H]GR125743: a pharmacological characterisation. Pharmacol Biochem Behaviour 71: 589-298.  
44. Cussac D, Duqueyroix D, Newman-Tancredi A, Millan MJ (2002). Stimulation by antipsychotic 
agents of mitogen-activated-protein kinase (MAPK) coupled to cloned, human (h) serotonin 
5-HT1A receptors. Psychopharmacology 162: 168-177.  
45. Cussac D, Newman-Tancredi A, Duqueyroix D, Pasteau V, Millan MJ (2002). Differential 
activation of Gq/11 and Gi3 proteins at 5-hydroxytryptamine2C receptors revealed by antibody 
capture assays: Influence of receptor reserve and relationship to agonist-directed trafficking. 
Mol Pharmacol 62: 578-589. 
46. Newman-Tancredi A, Cussac D, Marini L, Millan MJ (2002). Antibody capture assay reveals bell-
shaped concentration-response isotherms for h5-HT1A receptor-mediated Gαi3 activation: 
D.Sc. Thesis  Publications 
  
Part A: Page 11 of 206  
conformational selection by high-efficacy agonists and relationship to trafficking of receptor 
signalling. Mol Pharmacol 62: 590-601.  
47. Cussac D, Newman-Tancredi A, Quentric Y, Carpentier N, Poissonnet G, Parmentier JG, 
Goldstein S, Millan MJ (2002). Characterization of phospholipase C activity at h5-HT2C compared 
with h5-HT2B receptors: Influence of novel ligands upon membrane-bound levels of 
[
3
H]phosphatidylinositols. Naunyn-Schmiedeberg’s Arch Pharmacol 365: 242-252.  
48. Millan MJ, Maiofiss L, Cussac D, Audinot V, Boutin J, Newman-Tancredi A (2002). Differential 
actions of antiparkinsonian agents at multiple monoamine receptors. I. A multivariate analysis 
of the binding profiles of 14 drugs at 20 recombinant human monoamine receptor subtypes. J 
Pharmacol Expt Ther 303: 791-804. 
49. Newman-Tancredi A, Cussac
 
D, Audinot A, Nicolas J-P, De Ceuninck F, Boutin J, Millan MJ 
(2002).
 
Differential actions of antiparkinson agents at multiple classes of Monoamine 
Receptors. II. Agonist and antagonist profiles at dopaminergic and adrenergic receptors. J 
Pharmacol Expt Ther 303: 805-814. 
50. Newman-Tancredi A, Cussac D, Quentric Y, Touzard M, Verrièle L, Carpentier N, Millan MJ 
(2002). Differential actions of antiparkinsonian agents at multiple classes of monoamine  
receptor. III. Agonist and antagonist profiles at serotonin 5-HT1 and 5-HT2 receptors. 
J Pharmacol Expt Ther 303: 815-822. 
2003 
51. Millan MJ, Gobert A, Lejeune F, Dekeyne A, Newman-Tancredi A, Pasteau V, Rivet J-M, Cussac 
D (2003). The novel melatonin agonist, Agomelatine (S20098), is an antagonist at 
5-Hydroxytryptamine2C receptors, blockade of which enhances the activity of frontocortical 
dopaminergic and adrenergic pathways. J Pharmacol Expt Ther 306: 954-964. 
52. Newman-Tancredi A, Rivet J-M, Cussac D, Touzard M, Chaput  C, Marini L, Millan MJ  (2003). 
Comparison of hippocampal G-protein activation by 5-HT1A receptor agonists and the atypical 
antipsychotics clozapine and S16924. Naunyn-Schmiedeberg’s Arch Pharmacol 368: 188-199.  
53. Newman-Tancredi A, Cussac D, Marini L, Touzard M, Millan MJ (2003). h5-HT1B receptor-
mediated constitutive G-protein activation: antibody capture assay reveals protean efficacy of 
5-HT. Br J Pharmacol 138: 1077-1084. 
54. Newman-Tancredi A (2003). Differential ligand efficacy at h5-HT1A receptor-coupled G-protein 
subtypes: a commentary. Esteve Foundation Symposia vol. 10. Excerpta Medica International 
Congress Series 1249: 101-117. 
2005 
55. Kleven MS, Assié M-B, Cosi C, Barret-Grévoz C, Newman-Tancredi A (2005). Anticataleptic 
properties of α2 adrenergic antagonists in the crossed leg position and bar tests: differential 
mediation by 5-HT1A receptor activation. Psychopharmacology 177: 373-380. 
56. Newman-Tancredi A, Assié M-B, Leduc N, Ormière A-M, Danty N, Cosi C (2005). Novel 
antipsychotics activate recombinant human and native rat serotonin 5-HT1A receptors: affinity, 
efficacy and potential implications for treatment of schizophrenia. Int J Neuropsychopharmacol  
8: 341-356 
57. Bardin L, Assié M-B, Pelissous M, Royer-Urios I, Newman-Tancredi A, Ribet J-P, Sautel F, Koek W, 
Colpaert FC (2005). Dual, hyperalgesic and analgesic effects of the high-efficacy 5-HT1A agonist, 
D.Sc. Thesis  Publications 
  
Part A: Page 12 of 206  
F13640: relationship with 5-HT1A receptor occupancy and kinetic parameters. J Pharmacol Expt 
Ther 312: 1034-1042. 
58. Cosi C, Rollet K, Tesori V, Waget A, Newman-Tancredi A (2005). Clozapine, ziprasidone and 
aripiprazole but not haloperidol protect against kainic acid-induced lesion of the striatum in 
mice, in vivo: role of 5-HT1A receptor activation. Brain Research 1043: 32-41 
59. Kleven MS, Barret-Grévoz C, Bruins Slot L, Newman-Tancredi A (2005). Novel antipsychotic 
agents with 5-HT1A agonist properties: role of 5-HT1A receptor activation in attenuation of 
catalepsy induction in rats. Neuropharmacology 49: 135-143. 
60. Assié M-B, Ravailhe V, Faucillon V, Newman-Tancredi A (2005). Contrasting contribution of 
5-HT1A receptor activation to neurochemical profile of novel antipsychotics: frontocortical 
dopamine and hippocampal serotonin release in rat brain. J Pharmacol Expt Ther 315: 265-272. 
61. Heusler P, Pauwels PJ, Wurch T, Newman-Tancredi A, Tytgat J, Colpaert FC, Cussac FC (2005). 
Differential ion current activation by human 5-HT1A receptors in Xenopus oocytes: evidence for 
agonist-directed trafficking of receptor signalling.  Neuropharmacology 49: 963-976 
62. Bruins Slot LA, Kleven MS, Newman-Tancredi A (2005). Effects of novel antipsychotics with 
mixed D2 antagonist / 5-HT1A agonist properties on PCP-induced social interaction deficits in the 
rat. Neuropharmacology 49: 996-1006 
2006 
63. Bruins Slot L, De Vries L, Newman-Tancredi A, Cussac D (2006). Differential profile of 
antipsychotics at serotonin 5-HT1A and dopamine D2S receptors coupled to extracellular signal-
regulated kinase. Eur J Pharmacol  535: 63-70 
64. Cosi C, Carilla-Durand E, Assié M-B, Ormière AM, Maraval M, Leduc N, Newman-Tancredi A 
(2006). Partial agonism of the antipsychotics SSR181507, aripiprazole and bifeprunox at 
dopamine D2 receptors: G-protein activation and prolactin release. Eur J Pharmacol 535: 135-
144. 
65. Bardin L, Kleven MS, Barret-Grévoz C, Depoortere R, Newman-Tancredi A (2006). Antipsychotic-
like vs cataleptogenic actions in mice of novel antipsychotics having D2 antagonist and 5-HT1A 
agonist properties. Neuropsychopharmacology  31: 1869-1879 
66. Auclair AL, Kleven MS, Besnard J, Depoortere R, Newman-Tancredi A (2006). Actions of novel 
antipsychotic agents on apomorphine-induced PPI disruption: influence of combined serotonin 
5-HT1A receptor activation and dopamine D2 receptor blockade. Neuropsychopharmacology  31: 
1900-1909 
67. Assié M-B, Ravailhe V, Faucillon V, Newman-Tancredi A (2006). Rapid desensitization of 
somatodendritic 5-HT1A receptors by chronic administration of the high efficacy 5-HT1A agonist, 
F13714: a microdialysis study in the rat. Br J Pharmacol  149: 170-178 
68. Assié M-B, Ravailhe V, Faucillon V, Newman-Tancredi A (2006). In vivo occupancy of dopamine 
D2 receptors by novel antipsychotic drugs in the mouse striatum and olfactory tubercles 
Naunyn-Schmiedeberg’s Arch Pharmacol  373: 441-450 
2007 
69. Martel J-C, Ormière AM, Cussac D, Newman-Tancredi A (2007). Native rat hippocampal 5-HT1A 
receptors show constitutive activity. Mol Pharmacol  71: 638-643 
D.Sc. Thesis  Publications 
  
Part A: Page 13 of 206  
70. Heusler P, Newman-Tancredi A, Castro-Fernandez A, Cussac D (2007). Differential agonist and 
inverse agonist profile of antipsychotics at D2L receptors coupled to GIRK potassium channels. 
Neuropharmacology  52: 1106-1113 
71. Newman-Tancredi A, Assié M-B, Martel J-C, Cosi C, Bruins Slot L, Palmier C, Rauly-Lestienne I, 
Colpaert F, Vacher B, Cussac D (2007). F15063, a potential antipsychotic with D2/D3 antagonist, 
5-HT1A agonist and D4 partial agonist properties: (I) in vitro receptor affinity and efficacy profile. 
Br J Pharmacol  151: 237-252    
72. Depoortère R, Bardin L, Auclair AL, Kleven MS, Prinssen E, Colpaert F, Vacher B, Newman-
Tancredi A (2007). F15063, a potential antipsychotic with D2/D3 antagonist, 5-HT1A agonist and 
D4 partial agonist: (II) Profile in tests predictive of activity against positive symptoms of 
schizophrenia. Br J Pharmacol  151: 253-265    
73. Depoortère R, Auclair AL, Bardin L, Bruins Slot L, Kleven MS, Colpaert F, Vacher B, Newman-
Tancredi A (2007). F15063, a compound with D2/D3 antagonist, 5-HT1A agonist and D4 partial 
agonist properties: (III) Activity in models of cognition and negative symptoms. Br J Pharmacol  
151: 266-277    
74. Assié M-B, Bardin L, Auclair A, Consul-Denjean N, Sautel F, Depoortère R, Newman-Tancredi A 
(2007). F15063, a potential antipsychotic with D2/D3 antagonist, 5-HT1A agonist and D4 partial 
agonist: (IV) duration of brain D2-like receptor occupancy and antipsychotic-like activity versus 
plasma concentration in mice. Naunyn-Schmiedeberg’s Arch Pharmacol 375: 241-250    
75. Newman-Tancredi A, Cussac D, Depoortère R (2007). Neuropharmacological profile of 
bifeprunox: merits and limitations in comparison with other “third generation” antipsychotics. 
Current Opinion in Investigational Drugs 8:539-554.   
76. Bardin L, Auclair A, Kleven MS, Prinssen EPM, Koek W, Newman-Tancredi A, Depoortère R 
(2007). Pharmacological profiles in rats of novel antipsychotics with combined dopamine D2 / 
serotonin 5-HT1A activity: comparison with typical and atypical antipsychotics. Behavioural 
Pharmacol  18: 103-118   
77. Auclair AL, Galinier A, Besnard J, Newman-Tancredi A, Depoortère R (2007). Putative 
antipsychotics with pronounced agonism at 5-HT1A receptors and partial agonist activity at 
dopamine D2 receptors disrupt basal PPI of the startle reflex in rats. Psychopharmacology  193: 
45-54   
78. Martel J-C, Ormiere A-M, Leduc N, Faucillon V, Danty N, Culie C, Cussac D, Newman-Tancredi A 
(2007). WAY100635 has high selectivity for serotonin 5-HT1A versus dopamine D4 receptors. Eur 
J Pharmacol  574: 15-19 
2008 
79. Millan MJ, Mannoury la Cour C, Novi F, Maggio R, Audinot V, Newman-Tancredi A, Cussac D, 
Pasteau V, Boutin JA,  Dubuffet T, Lavielle G (2008). S33138 [N-[4-[2-[(3aS,9bR)-8-cyano-
1,3a,4,9b-tetrahydro[1]-benzopyrano[3,4-c]pyrrol-2(3H)-yl)-ethyl]phenylacetamide], a 
preferential dopamine D3 versus D2 receptor antagonist and potential antipsychotic agent: I. 
Receptor-binding profile and functional actions at G-protein-coupled receptors. J Pharmacol 
Expt Ther  324: 587-599 
80. Heusler P, Newman-Tancredi A, Loock T, Cussac D (2008). Antipsychotics differ in their ability to 
internalise human dopamine D2S and human serotonin 5-HT1A receptors in HEK293 cells.. Eur J 
Pharmacol  581: 37-46 
D.Sc. Thesis  Publications 
  
Part A: Page 14 of 206  
81. Bruins Slot AL, Bardin L, Auclair A, Depoortere R, Newman-Tancredi A (2008). Effects of 
antipsychotics and reference monoaminergic ligands on marble burying behavior in mice. 
Behav Pharmacol  19: 145-152 
82. Newman-Tancredi A, Heusler P, Martel J-C, Ormière A-M, Leduc N, Cussac D (2008). Agonist and 
antagonist properties of antipsychotics at human Dopamine D4.4 receptors : G-protein 
activation and K+ Channel modulation in transfected cells. Int J Neuropsychopharmacol  11: 
293-307  
83. Assié M-B, Carilla-Durand E, Bardin L, Maraval M, Aliaga M, Malfètes N, Barbara M, Newman-
Tancredi A (2008). The antipsychotics clozapine and olanzapine increase plasma glucose and 
corticosterone levels in rats: comparison with aripiprazole, ziprasidone, bifeprunox and F15063. 
Eur J Pharmacol  592:160-166  
84. Cussac D, Boutet-Robinet E, Ailhaud M-C, Newman-Tancredi A, Martel J-C, Danty N, Rauly-
Lestienne I (2008). Agonist-directed trafficking of signalling at serotonin 5-HT2A, 5-HT2B and 
5-HT2C-VSV receptors mediated Gq/11 activation and calcium mobilisation in CHO cells. Eur J 
Pharmacol  594: 32-38 
85. Depoortère R, Barret-Grévoz C, Bardin L, Newman-Tancredi A (2008). Apomorphine-induced 
emesis in dogs: differential sensitivity to established and novel DA D2 / 5-HT1A antipsychotic 
compounds. Eur J Pharmacol 597:34-38 
2009 
86. Assié M-B, Mnie-Filali O, Ravailhe V, Benas C, Marien M, Bréty C, Zimmer L, Haddjeri N, 
Newman-Tancredi A (2009). F15063, a potential antipsychotic with dopamine D2/D3 receptor 
antagonist, 5-HT1A receptor agonist and dopamine D4 receptor partial agonist properties: V) 
Influence on neuronal firing and neurotransmitter release. Eur J Pharmacol 607: 74-83 
87. Depoortère R, Bardin L, Rodrigues M, Abrial E, Aliaga M, Newman-Tancredi A (2009). Penile 
erection and yawning induced by DA D2-like receptor agonists in rats: influence of the strain, 
and contribution of dopamine D2, but not D3 and D4 receptors. Behav Pharmacol 20:303-11 
88. Newman-Tancredi A, Martel J-C, Assié M-B, Buritova J, Lauressergues E, Cosi C, Heusler P, Bruins 
Slot L, Colpaert FC, Vacher B, Cussac D (2009). Signal transduction and functional selectivity of 
F15599, a preferential post-synaptic 5-HT1A receptor agonist. Br J Pharmacol 156: 338-353  
89. Auclair A, Besnard J, Newman-Tancredi A, Depoortère R (2009). The five choice serial reaction 
time task: comparison between Sprague-Dawley and Long Evans rats on acquisition of task, and 
sensitivity to phencyclidine. Pharmacol Biochem Behav  92: 363-9 
90. Auclair AL, Kleven MS, Barret-Grévoz C, Barreto M, Newman-Tancredi A, Depoortère R (2009). 
Differences among conventional, atypical and novel putative DA D2/5-HT1A antipsychotics on 
catalepsy-associated behaviour in Cynomolgus monkeys. Behav Brain Res 203:288-95 
91. Martel J-C, Assié M-B, Bardin L, Depoortere R, Cussac D, Newman-Tancredi A (2009). Implication 
of 5-HT1A receptors in the influence of xaliproden on G-protein activation, neurotransmitter 
release and nociception. Br J Pharmacol 158:232-242 
92. Bruins Slot L, Lestienne F, Grevoz-Barret C, Newman-Tancredi A, Cussac D (2009). F15063, a 
potential antipsychotic with dopamine D2/D3 receptor antagonist and 5-HT1A receptor agonist 
properties: influence on immediate-early gene expression in rat prefrontal cortex and striatum. 
Eur J Pharmacol 620:27-35.  
D.Sc. Thesis  Publications 
  
Part A: Page 15 of 206  
2010 
93. Lemoine L, Verdurand M, Vacher B, Blanc E, Le Bars D, Newman-Tancredi A, Zimmer L (2010). 
[
18
F]F15599, an atypical 5-HT1A receptor agonist, as a radioligand for PET neuroimaging. Eur J 
Nucl Med Mol Imaging 37:594-605 
94. Lladó-Pelfort L, Assié M-B, Newman-Tancredi A, Artigas F, Celada P (2010). Preferential in vivo 
action of F15599, a novel 5-HT1A receptor agonist, at postsynaptic 5-HT1A receptors. Br J 
Pharmacol 160(8):1929-40 
95. Depoortère R, Auclair AL, Bardin L, Colpaert FC, Vacher B, Newman- Tancredi A (2010). F15599, 
a preferential post-synaptic 5-HT1A receptor agonist: activity in models of cognition in 
comparison with reference 5-HT1A receptor agonists. Eur Neuropsychopharmacol 20(9):641-654 
96. Newman-Tancredi A (2010). The importance of 5-HT1A receptor agonism in antipsychotic drug 
action: rationale and perspectives. Current Opinion in Investigational Drugs 11: 802-12. 
97. Assié M-B, Bardin L, Auclair AL, Carilla-Durand E, Depoortère R, Koek W, Kleven MS, Colpaert F, 
Vacher B, Newman-Tancredi A (2010). F15599, a highly selective postsynaptic 5-HT1A receptor 
agonist: in vivo profile in behavioural models of antidepressant and serotonergic activity. Int J 
Neuropsychopharmacol 13(10):1285-98  
98. Auclair AL, Cathala A, Depoortère R, Piazza PV, Newman-Tancredi A, Spampinato U (2010). The 
central serotonin2B receptor: a new pharmacological target to modulate the mesoaccumbens 
dopaminergic pathway activity. J Neurochemistry 114(5):1323-32.  
2011 - 2012 
99. Newman-Tancredi A (2011). Biased agonism at serotonin 5-HT1A receptors: preferential post-
synaptic activity for improved therapy of CNS disorders. Neuropsychiatry 1(2): 149-164. 
100. Rauly-Lestienne I, Lestienne F, Ailhaud MC, Binesse J, Newman-Tancredi A, Cussac D. (2011) 
Competitive interaction of 5-HT1A receptors with G-protein subtypes in CHO cells demonstrated 
by RNA interference. Cellular Signalling 23: 58–64  
101. Newman-Tancredi A, Kleven MS (2011). Comparative pharmacology of antipsychotics 
possessing combined dopamine D2 and serotonin 5-HT1A receptor properties. 
Psychopharmacology 216(4):451-73 
102. Lladó-Pelfort L., Assié M-B, Newman-Tancredi A, Artigas F, Celada P (2012). In vivo 
electrophysiological and neurochemical effects of the selective 5-HT1A receptor agonist, F13640, 
at pre- and postsynaptic 5-HT1A receptors in the rat. Psychopharmacology 221(2):261-72. 
103. Lemoine L, Becker G, Vacher B, Billard T, Lancelot S, Newman-Tancredi A, Zimmer L. (2012) 
Radiosynthesis and preclinical evaluation of [18F]F13714 as a fluorinated 5-HT1A receptor agonist 
radioligand for PET neuroimaging. J Nuclear Medicine 53:969–976 
  
D.Sc. Thesis  Metrics 
 
Part A: Page 16 of 206 
Publication metrics 
The Table shows citation and Impact Factor (IF) information concerning the author’s publications. 
These are identified in accordance with the numbering shown in the publications list. Citation 
information was obtained from Google Scholar (www.scholar.google.com) on 21 May 2012.  
The 36 publications that have 40 or more citations are shown in bold font. IFs are from 2012 listings 
and the “Average IF” refers to the mean score of the 103 publications included in this Thesis. 
Overall, the author’s entire work (including over 130 peer-reviewed publications plus patents and 
conference proceedings) has been cited 5238 times with an h-index of 41 and an i10-index of 104. 
JOURNAL 
No. of 
ref.s 
Publication number and citations IF 
Behavioral Brain Research 1 902 3.393 
Behavioural Pharmacology 3 7632, 8115, 878 2.530 
Biochemical J 1 143 5.016 
Biochemical Pharmacology 1 244 4.889 
Brain Research 2 4222, 5836 2.623 
British J Pharmacology 10 
876, 3522, 5311, 6720, 7131, 7225, 7341,  
8819, 913, 947 
4.925 
Cellular Signalling 1 100 4.243 
Current Opinion Invest Drugs 2 7546, 9621 3.395 
European J Neuroscience 1 2197 3.658 
Eur J Nuclear Med Mol Imaging 1 938 5.036 
European J Pharmacology 17 
550, 744, 1120, 19175, 2415, 2916, 3927, 4111, 
6348, 6455, 7818, 8010, 839, 8421, 855, 865, 923 
2.737 
Eur Neuropsychopharmacology 1 95
6
 4.201 
Excerpta Medica Int Congress 1 54
4
 N/A 
Int J Neuropsychopharmacology 3 56
88
, 82
12
, 97
6
 4.699 
J Neurochemistry 1 983 4.337 
J Nuclear Medicine 1 103 7.022 
J Pharmacology Exp Therapeutics 15 
657, 931, 1248, 14119, 1851, 2761, 3393, 3828, 
48199, 4989, 50124, 51239, 5713, 6073, 799 
4.017 
Molecular Pharmacology 6 2073, 2384, 3130, 4587, 4634, 6925 4.725 
Naunyn-Schmiedeberg's  
Archives Pharmacology 
12 
1333, 1618, 1783, 2213, 2610, 3015, 3210, 364, 
4755, 5220, 6823, 747 
2.500 
Neuropharmacology 9 311, 490, 1078, 288, 3423, 5956, 6113, 6257, 7020 4.677 
Neuropsychiatry 1 993 N/A 
Neuropsychopharmacology 5 1552, 2529, 3727, 6567, 6640 6.685 
Pharmacol Biochem Behaviour 2 4315, 895 2.624 
Psychopharmacology 6 4060, 4429, 5513, 7716, 1019, 102 3.817 
Total: 24 journals 
Tot.: 
103 
Total: 3859 citations 
Average 
IF: 3.821 
D.Sc. Thesis  Abbreviations 
 
Part A: Page 17 of 206 
Abbreviations 
 
AR Adrenergic receptor 
cAMP Cyclic Adenosine monophospate 
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CNS Central Nervous System 
5CSRTT 5-choice serial reaction time test 
5-CT 5-carboxyamidotryptamine  
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MAPK Mitogen-activated-protein kinase 
MDD Major Depressive Disorder 
MDMA 3,4-methylene-
dioxymethamphetamine 
MPTP 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine  
NAc Nucleus Accumbens 
NAD Noradrenaline 
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Part A: Overview of the publications  
included in this Thesis 
 
Part A is sub-divided into 8 chapters describing the significance of the author’s publications on 
monoamine receptor signaling and function. The work is presented in the context of the knowledge 
available at the time of publication and in relation to its contribution to studies by other researchers. 
The thesis covers 103 peer-reviewed publications and the discussion sections concentrate on those 
publications that made the most notable conceptual advances. A “Key points” section summarises 
the main messages of each chapter. 
Throughout the text, the author’s publications are referenced numerically ([1], [2], [3] …etc.) in 
accordace with the numbering shown in the list of publications.  
Abstracts from the author’s publications included in this Thesis are shown in Part B. 
Publications by other authors and the author’s publications that were not peer-reviewed (such as 
conference proceeedings) are referenced in the text by numbers in superscript 
(1, 2, 3, …etc.)
 and listed in 
the Bibliography at the end of the thesis. 
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1. Introduction 
 
1.1 Key points 
 CNS disorders constitute a major medical need and result in large social burden and financial 
liability. Each year, an estimated 38% of the European population suffers from a mental disorder. 
 Schizophrenia, depression and Parkinson’s disease are three of the major CNS disorders and their 
treatment often relies on medications that are only partially effective or poorly tolerated. 
 Many psychotropic agents target the activity of monoamine neurotransmitter systems: 
dopamine, serotonin and noradrenaline. These neurotransmitters act at several dozen subtypes 
of receptors, most of which belong to the family of G-protein-coupled receptors (GPCRs). 
 The study of the signalling and therapeutic applications of monoamine GPCRs constitutes the 
main focus of the author’s work described in this thesis. 
1.2 Social burden of psychiatric and neurological disorders 
Whereas physical injury or disorders such as cancer or HIV often attract considerable sympathy and 
arouse public consciousness, such responses are noticeably less present for central nervous system 
(CNS) disorders 
(3,4)
. No doubt part of the reason for this is that psychiatric and neurological disorders 
may be associated with unflattering notions of being “mad” or “senile” and often occur in patient 
populations, such as the elderly, that have less socioeconomic influence. In addition, the complexity 
of the CNS and the substantial financial investments necessary to develop novel therapeutics for CNS 
disorders have recently resulted in an exodus of pharmaceutical research from this field. Over recent 
years, several large pharmaceutical companies, including AstraZeneca, Pfizer, Novartis, Sanofi and 
GlaxoSmithKline have ceaased CNS drug discovery operations and/or have de-emphasized CNS 
research, causing concern that advances in this field will be compromised (5). 
However, great medical needs exist in the area of CNS disorders.  A recent report published by the 
European College of Neuropsychopharmacology (ECNP) highlighted the burden of neuropsychiatric 
and neurological disorders in Europe (6). The report surveyed the situation in 30 countries covering a 
population of 514 million people and concluded that, each year, 38.2% of the European population 
(164.8 million people) suffers from a mental disorder, the most common being anxiety disorders 
(14%), insomnia (7%), major depression (6.9%), somatoform disorders (6.3%), alcohol and drug 
dependence (>4%), attention-deficit and hyperactivity disorders (ADHD, 5% in the young), and 
dementia (1% among those aged 60-65, 30% among those aged 85 and above). In addition, the study 
reported that only one third of cases receive adequate treatment, and this often occurs with delays 
of up to several years. The financial costs of mental disorders in Europe are estimated at a colossal 
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€ 798 billion per year, of which € 296 billion are needed to cover direct medical costs. Only about € 
30 billion is spent on medications, the remainder being spent on non-medical and indirect costs, 
such as lost working time and community care(6). It is therefore reasonable to surmize that even 
modest advances in the understanding of mental disorders could bring substantial advances in the 
care of millions of patients, diminish their suffering and lighten the burden on society. This mission, 
notably as regards the discovery of improved medications, has been the focus of my research for the 
past two decades, particularly as regards three of the major mental disorders: schizophrenia, 
depression and Parkinson’s disease. 
 
Schizophrenia 
Schizophrenia was identified as a serious thought disorder in antiquity (7,8) and has a major socio-
economic impact not only because of its debilitating influence on social activity (9), but also because 
of the high costs of treatment associated with  chronic pathology. So-called ‘positive’ symptoms of 
schizophrenia include hallucinations and delusions. In contrast, ‘negative’ symptoms consist of 
behavioral impairments, including social interaction deficits, disorganized speech and blunted affect. 
In addition, a variety of cognitive disturbances are observed, including working and reference 
memory deficits, executive function impairments and decreased vigilance. Cognitive impairment has 
been proposed to constitute a core symptom of schizophrenia in its own right (10,11). The etiology of 
schizophrenia is likely to include numerous elements, such as genetic vulnerability, environmental 
and developmental insults (12,13).  
Depression 
Major depressive disorder (MDD; commonly called major depression or clinical depression) is a 
clinical syndrome with a multitude of symptoms, including lowered mood, fatigue and disturbed 
sleep, inability to experience pleasure from activities usually found enjoyable (anhedonia), low self-
Figure 1.1 The way things were before the advent of psychopharmacology. 
Methods of “treating” patients with psychiatric disorders used in the early and mid-1900s. Left: 
electroconvulsive shock; Centre: intranasal glucose administration following insulin-induced coma;  
Right: chains, straight-jacket, covered bath-tub. 
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esteem and self-confidence, loss of appetite, and low libido. Depression runs a chronic or recurrent 
course and suicidal ideation/behavior is a particularly troubling component. According to the World 
Health Organization (14), depressive disorders (major depression, dysthymia, and other depressive 
disorders) are one of the leading causes of disability and will affect approximately 17% of the 
population in their lifetime. Although use of antidepressants has tripled over the past decade and a 
half, drug discovery efforts have fallen short: less than one-third of major depressive disorder 
patients administered adequate doses of current antidepressants show significant improvement 
after months of treatment. At least a third of patients can be described as suffering from treatment-
resistant depression, and, as a group, the latter are more likely to suffer a higher symptom burden 
and a more chronic illness course compared to their non-treatment-resistant counterparts(15,16). 
Parkinson’s disease 
Parkinson’s disease is characterized by massive degeneration of dopaminergic cell bodies in the 
substantia nigra pars compacta (SNPC) and a profound depletion of dopamine (DA) in the striatum 
(17,18)
. This loss of nigrostriatal dopaminergic innervation elicits a spectrum of motor symptoms, 
including bradykinesia, rigidity, tremor, impaired gait, and postural instability. Parkinsonian patients 
also display depressed mood and cognitive deficits (19). Symptomatic treatment with 
L-dihydroxyphenylalanine (L-DOPA), which is metabolized into DA, still provides the mainstay of 
symptom management (20,21). Unfortunately, L-DOPA is poorly effective against symptoms such as 
cognitive dysfunction and, upon prolonged exposure, its efficacy fluctuates. Moreover, L-DOPA may 
be neurotoxic through transformation to 6-hydroxydopamine and elicits both autonomic side effects 
and dyskinesia (22). Direct dopaminergic agonists provide advantages in terms of potential 
neuroprotective properties and a lesser propensity to elicit dyskinesia(23). However, they can elicit 
psychiatric side effects and their efficacy in long-term monotherapy remains limited. 
In summary, effective treatment of major neuropsychiatric and neurological disorders represent a 
large significant unmet medical need: new therapeutic agents are needed that are more effective, 
have a faster onset of action, and a reduced side-effect profile.  
1.3 Rise of psychopharmacology 
It is remarkable that the rise of psychopharmacology can be traced to specific events that took place 
in the early 1950s, with the discovery of psychoactive molecules which led to the identification of 
underlying mechanisms of neurotransmission, notably of monoamine neurotransmitters. The 
prototypical drug that led to these advances was the phenothiazine antipsychotic, chlorpromazine. 
Although originally synthesised as an antihistaminergic sedative, it was tested in schizophrenia 
patients in 1952 and found to elicit “spectacular results in the most violent states of agitation” (24). 
The observation that psychoses could be pharmacotherapeutically-controlled represented a 
revolutionary advance over practices that (nowadays) appear primitive, such as insulin-induced 
coma, electroshock therapy or surgical lobotomy (Fig. 1.1) but that were current only a few decades 
ago (25). Not surprisingly, the discovery of pharmacological means of controlling psychotic symptoms 
triggered intense interest in synthesising new drugs and investigating their mechanism of action. 
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It became apparent that chlorpromazine and other antipsychotics interacted with cell-surface 
neuronal receptors of monoamine neurotransmitters (Fig. 1.2), notably dopamine, serotonin 
(5-hydroxytryptamine, 5-HT) and noradrenaline. Other advances from the middle of last century 
provided further impetus to research on neurotransmitters, including the discovery of monoamine 
oxidase inhibitors (MAOI) which increased CNS levels of 
monoamine neurotransmitters by inhibition of the 
enzymes responsible for their metabolism (26,27), and the 
synthesis of the tricyclic antidepressants, such as 
imipramine or amitriptyline, which were among the first 
molecules to be identified that exert antidepressant 
activity by inhibiting the reuptake of monoamine 
neurotransmitters from extracellular compartments (28). 
These findings attracted additional attention to the 
mechanism of action of monoamine neurotransmitters. 
The identification and characterization of the receptors 
that mediate the effects of these neurotransmitters has 
been a focus of major research efforts over recent 
decades and constitutes the basis for the work presented 
in this thesis. 
Multiple monoamine receptor subtypes  
Despite the discovery of the drugs mentioned above, it was only relatively recently, in the 1970s, 
that the molecular study of neurotransmitter receptor pharmacology markedly accelerated, with the 
widespread use of radiotracers capable of specifically labelling receptors in tissue preparations. This 
led to the discovery of an amazing (at the time) diversity of receptor subtypes with distinct 
anatomical distributions, pharmacological profiles and physiological properties (see Fig. 1.3). Among 
the first receptors to be identified were those of serotonin, dopamine and noradrenaline, which act 
at a combined total of at least 27 receptors, not counting splice variants and receptor isoforms (29). 
Almost all of these monoamine neurotransmitter receptors belong to the super-family of G-protein-
coupled receptors (GPCRs; the exception is the 5-HT3 receptor, which is an ion channel) and are 
differentiated by their coupling to distinct G-protein subtypes, second messenger systems and 
effector responses, as well as their diverse physiological distributions and behavioural responses. 
The elucidation of this immense diversity has been the objective of many researchers for several 
decades.  
1.4 Contribution of author’s work 
Two major areas of interest underlie my contribution to the field of monoamine receptor function: 
(i) the investigation of in vitro responses of monoamine receptors to their endogenous 
neurotransmitters and to synthetic ligands (described in Chapters 2, 5, 6, 7 and 8); and (ii) the 
Figure 1.2:  Structures of monoamine 
neurotransmitters. 
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translation of in vitro responses to in vivo physiological effects using neurochemical substrates 
and/or behavioural read-outs (described principally in Chapters 3 and 4). 
A substantial proportion of my work (over half the publications in this thesis) has focused on 
serotonin 5-HT1A receptors. This receptor subtype was identified by pharmacological means 
(30,31)
 and 
attracted much attention as a target for novel anxiolytic drugs, offering an alternative treatment to 
benzodiazepine anxiolytics that suffer from a range of short-comings, including sedation and 
dependence liability (32). Researching the function of 5-HT1A receptors has been a “leitmotif” of my 
work since my doctoral research at the University of Kent, which was focused on the cloning and 
characterisation of a Chinese Hamster Ovary (CHO) cell line stably expressing high levels of 
recombinant human 5-HT1A receptors [1]. This cell line was subsequently extensively charachterized 
in pharmacological assays, notably focusing on the capacity of 5-HT1A receptors to constitutively 
activate different subtypes of coupled G-proteins (see Chapter 2).  In addition, my studies 
contributed to a growing consensus that distinct sub-populations of 5-HT1A receptors expressed in 
different brain regions exhibit markedly separate (or even opposing) functions. These sub-
populations may be pharmacologically targeted by novel pharmacological tools commonly referred 
Figure 1.3:  Monoamine neuronal circuitry. 
Circles represent dopaminergic, noradrenergic, serotonergic and GABAergic  cell bodies. The lines  and 
triangles represent neuronal projections to different brain regions, notably the frontal cortex. A feed-back 
glutamatergic loop from the frontal cortex to GABA neurons controlling serotonergic transmission is also 
shown. Diagram adapted from 
(1)
. 
 
Note: for copyright reasons, this Figure is omitted from the public access version of the thesis. 
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to as “biased” or “functionally-selective” agonists. 
The discovery of a prototypical 5-HT1A receptor 
biased agonist (F15599) in the course of my 
research is described in Chapter 3. Although the 
number of publications on 5-HT1A receptors 
diminished in the late 1990s, it rebounded between 
2000 and 2005 (Fig. 1.4). Part of the reason for this 
resurgence of interest was the realization that 5-
HT1A receptors are implicated in a variety of clinical 
disorders in addition to anxious states. Thus, my 
work contributed to the recognition that activation 
of 5-HT1A receptors is important for the improved 
treatment of some aspects of psychotic disorders, 
notably negative symptoms and cognitive deficits. 
This work is described in Chapter 4. 
As concerns other serotonin receptors, the present 
thesis describes work that I carried out on 5-HT1B, 5-HT1D, 5-HT2A, 5-HT2B and 5-HT2C receptors. Their 
diverse intracellular signalling mechanisms were investigated using novel methodologies that were 
developed and characterised under my supervision. In the case of 5-HT1B and 5-HT1D receptors, this 
involved developing a method to measure their constitutive activation of coupled G-proteins (see 
Chapter 5). At 5-HT2 receptor subtypes, exploratory studies showed the presence of functional 
selectivity (5-HT2A), regulation of dopamine release (5-HT2B) and “promiscuous” coupling to multiple 
G-proteins (5-HT2C). This work is described in Chapter 6.  
Although dopamine D2 receptors are the primary target for antipsychotic activity (discussed 
principally in Chapter 4), other dopamine receptor subtypes, such as D3 and D4, contribute to the 
activity of antipsychotic drugs. Chapter 7 describes the work I carried out to characterize D2, D3 and 
D4 receptor pharmacology. Finally, I investigated the mechanism of action of antiparkinsonian drugs 
that I had been using as reference dopaminergic agonists. I realized that some of these drugs 
possessed multireceptor profiles that had only been superficially characterized in a few scattered 
studies, despite the drugs’ extensive clinical usage. I therefore carried out an extensive in vitro 
caracterization of anti-Parkinson’s disease drugs, showing that their receptor profiles vary widely. In 
particular, antagonism of noradrenergic α2 receptors constitutes a distinguishing feature of some 
antiparkinsonian drugs, such as piribedil. This work is described in Chapter 8. 
Overall, my research has demonstrated that the diverse agonist / antagonist actions of drugs at 
monoamine receptors profoundly influences their physiological effects and therapeutic potential. 
Figure 1.4:  5-HT1A publications by year 
Searches carried out on 25 May 2012 in the 
National Institutes of Health repository for 
peer-reviewed research reports in the life 
sciences (PubMed). 
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2. Serotonin 5-HT1A receptor signalling:  
G-protein activation 
 
2.1 Key points 
 Using agonist ([
3
H]8-OH-DPAT), partial agonist ([
3
H]S15535) and antagonist ([
3
H]WAY100635) 
radioligands to label human recombinant 5-HT1A receptors, compounds were shown to exhibit 
differences in binding affinity and binding density depending on receptor / G-protein coupling 
status [2,16,35,39] 
 The author developed and optimised novel methods to determine agonist action at 5-HT1A 
receptors by G-protein activation using [
35
S]GTPγS binding. These measures were demonstrated 
to provide useful measures of efficacy at 5-HT1A receptors [5,13,15] 
 Cloned human and native rat hippocampal 5-HT1A receptors were shown to constitutively activate 
G-proteins in vitro [8,69]. The capacity of agonists and inverse agonists to elicit G-protein 
activation was found to depend on receptor-G-protein stoichiometry [10]. 
 Regional variations exist in native brain activation of G-proteins by 5-HT1A receptors, as 
demonstrated by [35S]GTPγS autoradiography [24,36,52] 
 A methodology was developed to determine 5-HT1A receptor-mediated activation of G-protein 
subtypes using antibody capture and scintillation proximity assay.  5-HT1A receptors were shown 
to modulate different G-protein subtypes with differing levels of constitutive activity [46]. 
2.2 Background to author’s work 
5-HT1A receptors as targets for CNS disorders 
Since the identification of serotonin as a central nervous system neurotransmitter in 1954 
(33), extensive investigation has been devoted to its complex functions. Indeed, 5-HT interacts with 13 
receptor subtypes, divided into 7 families (5-HT1 to 5-HT7) based on amino acid sequence and 
functional homologies (29). 5-HT1A receptors have attracted particular interest because they exert 
inhibitory influence on serotonergic tone and are widely distributed in post-synaptic brain regions 
such as cortex, septum and hippocampus, implicated in the control of mood, cognition and pain (32,34-
36). Accordingly, 5-HT1A receptors are targets for pharmacotherapy of a variety of CNS disorders. The 
partial agonists, buspirone and tandospirone, are clinically-available anxiolytics (32,37). The 
antidepressant effects of 5-HT1A receptor agonists 
(38-40) have been explored with flesinoxan (41,42), and 
with flibanserin (43,44). 5-HT1A receptor activation is also a prominent feature of several anti-
Parkinson’s disease (PD) drugs, including bromocriptine, lisuride and pardoprunox (SLV308) [48,50] 
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(45,46)
 and plays an important role in the action of atypical antipsychotics [75,96,101] 
(47)
. Indeed, 
clozapine, ziprasidone, aripiprazole and lurasidone act as 5-HT1A receptor partial agonists (as well as 
possessing other pharmacological properties) [4,56,101] (48,49) (see Chapter 4). 5-HT1A receptor 
agonists such as xaliproden and repinotan have been tested for potential neuro-protective activity 
[91] 
(50-52)
 and the potent and high-efficacy agonist, befiradol, is active in chronic pain models [57] 
(35,53)
.  
The 5-HT1A receptor was the first human serotonergic receptor to be cloned 
(54)
 and was 
heterologously expressed in various different cellular environments (including COS7, HeLa, CHO, 
NIH3T3, Sf9 and E. Coli cells) enabling the study of its coupling to G-proteins and second messenger 
systems [1] (55). Although 5-HT1A receptors interact with potassium channels and calcium channels, 
inositol phosphate metabolism and arachidonic acid production
(55)
, their best-characterised 
intracellular functional response was, for many years, the inhibition of adenylyl cyclase activity. This 
had been the principal read-out used to differentiate the agonist/antagonist activity of serotonergic 
ligands at this receptor 
(56,57)
.  
However, it is known that apparent agonist efficacy at central nervous system 5-HT1A 
Figure 2.1: complexity of serotonergic function 
Note: for copyright reasons, this Figure is omitted from the public access version of the thesis. 
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receptors can differ depending on the brain region studied. In cortical neurons in primary culture, for 
example, ipsapirone and buspirone act as antagonists whereas in hippocampal neurons they acted 
as partial agonists (57). Further, ipsapirone acts as a full agonist at presynaptic 5-HT1A autoreceptors 
(58)
. These differences in efficacy have been attributed to the presence of significant receptor reserve 
at presynaptic but not at postsynaptic 5-HT1A receptors 
(59-61)
 and highlight the fact that 5-HT1A 
receptors in different brain regions can have markedly different properties.  One cause for such 
differences is likely to be that 5-HT1A receptors can adopt different G-protein coupling conformations 
in different brain regions and/or couple to different G-protein subtypes. My initial research in the 
early 1990s was therefore aimed at elucidating the coupling of 5-HT1A receptors to G-proteins using 
agonist / antagonist and inverse agonist radiotracers that bind differentially to 5-HT1A receptors.  
Subsequently, my interest focussed on measuring the first step in the intracellular activation 
cascade by measuring the activation of the G-protein itself. Indeed, like other members of the 
superfamily of heptahelical cell surface receptors, 5-HT1A receptors couple to heterotrimeric 
intracellular guanine nucleotide binding proteins (G-proteins). Under the influence of agonists, 
G-protein coupled receptors (GPCRs) promote nucleotide exchange by G-protein α subunits, which 
release GDP and bind GTP. This exchange triggers subunit dissociation and transmission of signalling 
to a variety of intracellular second messenger systems. Hydrolysis of GTP by the Gα subunit and re-
association with Gβγ subunits re-establishes the initial basal state (62). The GDP/GTP exchange step is 
therefore of considerable interest in the investigation of ligand efficacy. Some authors had 
investigated G-protein activation by measuring GTPase activity in hippocampal tissue 
(63)
 but it can 
also be investigated by use of the hydrolysis-resistant GTP analogue, [35S]GTPγS (Fig. 2.2). This was a 
key tool in my research and marked an effort to investigate receptor activation at a level that was 
close to the receptor, rather than using more distal read-outs such as adenylyl cyclase inhibition.  
2.3 Contribution of author’s work  
Investigating agonist and inverse agonist influence on ligand binding. 
My interest in the effects of agonists and inverse agonists on serotonin 5-HT1A receptor/G-protein 
coupling began in studies conducted during my Ph.D. studentship at the University of Kent, under 
Prof. Philip Strange’s supervision. This early work consisted of transfecting Chinese hamster ovary 
(CHO) cells with a plasmid vector containing the coding sequence (G21) of the human 5-HT1A 
receptor [1] and characterizing the highly-expressed recombinant receptor. The latter showed high 
affinity for the prototypical 5-HT1A receptor selective agonist radiotracer, [
3H]8-OH-DPAT, and 
exhibited the expected capacity to inhibit forskolin-stimulated adenylyl cyclase activity. At that time, 
no selective antagonist was available, so the question of distinguishing between G-protein-coupled 
and –uncoupled receptors was problematic. In an attempt to address this issue, I decided to use 
[3H]spiperone as an antagonist radiotracer. Spiperone is a potent dopamine D2 receptor antagonist 
which has only modest 5-HT1A affinity but I surmised that it might be a useful tool when tested on a 
cell line which expressed a “pure” population of 5-HT1A receptors. I anticipated that it would label 
only a small (but measurable) number of 5-HT1A receptors but, surprisingly, [
3H]spiperone showed a 
high level of labelling, its Bmax value in saturation binding experiments being similar to that of 
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[
3
H]8-OH-DPAT [2]. In addition, [
3
H]spiperone’s Bmax value was almost doubled when incubations 
were carried out in the presence of GTP, which uncouples GPCRs from coupled G-proteins [2] (Fig. 
2.2). Conversely, the binding of [3H]8-OH-DPAT was almost eliminated in the presence of GTP [1]. 
These data provided some of the first evidence that reciprocal agonist and inverse agonists “states” 
of 5-HT1A receptors can be identified and paved the way for a series of more detailed studies that I 
carried out in my later research. In particular, I investigated the coupling of 5-HT1A receptors to 
G-proteins by testing the effects 
of GTP on the affinity of a variety 
of serotonergic ligands, notably 
inverse agonists such as 
spiperone, in competition with 
selective radiolabels of different 
efficacies: the agonist [
3
H]8-OH-
DPAT 
(64)
, the partial agonist 
[
3
H]S15535, which was 
synthesized and characterised in 
my laboratory [5,9,16,24], and the 
novel (at the time) antagonist 
[
3
H]WAY100635 
(65,66)
. This 
compound was the first selective 
“neutral” antagonist that became 
available for characterizing 5-HT1A 
receptors and was therefore an 
important tool throughout my 
work in this field. Notably, its 
“neutral” antagonism was initially confirmed in sensitive in vitro assays [8,41,78] although it later 
became apparent that weak agonist or inverse agonist activity may be detected depending on the 
specific G-protein subtypes present in the assays [46] (67,68). 
In a study of the same CHO-h5-HT1A cell line cloned during my Ph.D. studentship, [
3H]WAY100635 
labelled about twice as many sites as the agonist, [3H]8-OH-DPAT [35]. These data are consistent 
with the hypothesis that it labels both G protein-coupled and uncoupled rat 5-HT1A receptors 
(69) and 
that the total number of h5 HT1A receptor sites is equivalent to the sum of sites previously detected 
with [3H]8-OH-DPAT and the inverse agonist, [3H]spiperone [2] (70). [3H]S15535 labelled more sites 
than [3H]8-OH-DPAT but fewer than [3H]WAY100635, reflecting its partial agonist activity at 5-HT1A 
receptors [5,16]. In competition binding experiments with [3H]WAY100635, a series of ligands 
showed binding affinity changes induced by GTP-elicited G-protein coupling. The magnitude of the 
affinity changes at 5-HT1A receptors correlated with agonist or inverse agonist efficacy determined in 
[35S]GTPγS binding experiments [35,39]. Agonist affinities were considerably decreased whereas 
those of partial agonists were only modestly reduced. WAY100635 was the only ligand which 
exhibited no sensitivity to GTP-induced receptor uncoupling, consistent with “neutral” antagonist 
Figure 2.2:  Simplified model of receptor/G-protein coupling 
The Figure shows an early understanding of the interaction 
between receptors (R) and G-proteins (G). Agonists preferentially 
label receptors that are coupled to G-proteins (RG), whereas 
inverse agonists preferentially label uncoupled receptors. “Neutral” 
antagonists do not differentiate between G-protein coupling states. 
GTP elicits RG uncoupling and [
35
S]GTPγS labels activated G-
proteins, providing a measure of agonist efficacy. Later studies led 
to a more sophisticated model (see Fig. 5.1). 
[3H]-Antagonist
R RG G+
[3H]-GTPgS
[3H]-Agonist [3H]-Inverse
AgonistGTP
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properties in this system. In comparison, the competition isotherms of methiothepin, (+)butaclamol 
and spiperone, were modestly, but significantly displaced to the left (higher affinity) consistent with 
their inverse agonist properties in [35S]GTPγS binding studies (see next section) [8,10,19] (71-73). 
 Two intriguing observations from these studies attracted my attention. Firstly, the correlation 
between affinity changes and agonist efficacy did not apply to all the ligands tested: two chemically 
related compounds, S14506 and S14761, exhibited only modest affinity shifts [35], despite acting as 
efficacious agonists in in vitro and in vivo functional models [19] (74). [3H]S14506 also exhibits 
'atypical' binding properties at rat 5-HT1A receptors, being insensitive to G protein uncoupling 
induced by guanine nucleotides and the alkylating agent, N-ethyl-maleimide (NEM) 
(75)
, properties 
usually associated with antagonists. Further, another study found that S14506 displayed little 
difference in its affinity for rat 5-HT1A receptors labelled by [
3
H]8-OH-DPAT or by the antagonist 
[3H]p-MPPF (76). Secondly, the atypical antipsychotic, clozapine, also showed little sensitivity to G-
protein uncoupling at 5-HT1A receptors [39], despite showing clear partial agonism [4,19]. These data 
indicating unusual agonist interactions with 5-HT1A receptors led me to investigate two issues: (i) the 
influence of different G-protein subtypes on 5-HT1A receptor signalling (see below and Chapter 3); 
and (ii) the effects of different atypical antipsychotics on 5-HT1A receptor activation (described in 
Chapter 4).  
Investigating agonist and inverse agonist influence on G-protein activation. 
Although the majority of in vitro studies on 5-HT1A receptors up to the 1990s had used adenylyl 
cyclase as a measure of receptor activation, I was interested to use another measure which reflected 
molecular events which lie closer to the receptor itself and, specifically, its G-protein coupling status. 
The use of [
35
S]GTPγS binding , a non-hydrolysable analogue of GTP that binds to agonist-activated 
G-proteins, had been described at other receptor subtypes, notably muscarinic m1 to m4 and 
serotonin 5-HT1D 
(77,78). I therefore adapted the methodology to 5-HT1A receptors and rapidly found 
that it constitutes a powerful tool to investigate receptor/G-protein coupling and the actions of 
serotonergic drugs [5,13,15]. In addition, it provided the means to elucidate the surprising behaviour 
of spiperone that I had observed during my Ph.D. studentship [2] (see above). In fact, spiperone 
markedly inhibited the basal binding of [35S]GTPγS to membranes prepared from CHO-5-HT1A cells, 
confirming its inverse agonist propertites and the capacity of 5-HT1A receptors to elicit constitutively 
activation of G-proteins in vitro [8]. This was later extended to native rat hippocampal 5-HT1A 
receptors, which were shown to constitutively activate a specific G-protein subtype (Gαo) using a 
G-protein targeting procedure (see next section) [69]. In contrast to spiperone, WAY1000635 did not 
exhibit any positive or negative efficacy but blocked the actions of both agonists and inverse 
agonists, consistent with “neutral antagonist” antagonist properties [8]. This was an important 
finding because other compounds which were claimed as antagonists at 5-HT1A receptors, such as 
NAN190, BMY7378, SDZ216,525 and WAY100135, had subsequently been found to display partial 
agonist properties when tested in systems which exhibit high degrees of receptor reserve (79,80). 
These studies therefore established that stimulation of [35S]GTPγS binding could usefully 
differentiate between agonists, antagonists and inverse agonists [4,5,8]. Nevertheless, many 
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questions remained, notably concerning the effect of changes in receptor expression level on 
functional responses. This is important in view of the fact that different brain regions can exhibit 
different levels of 5-HT1A receptors with distinct physiological influence. Thus, while some 
laboratories had studied cell lines with different receptor expression levels 
(81)
, the relationship of 
receptor to G-protein expression levels had not been quantitatively evaluated. I therefore 
investigated this issue by determining in CHO-5-HT1A cell membranes the expression level of 
recombinant 5-HT1A receptors and also of their coupled G-protein(s) by [
35S]GTPγS saturation 
binding, providing measures of R:G ratios [10]. I found that cells grown in adherent culture in the 
presence of cationic liposomes displayed much greater receptor expression levels than cells grown in 
suspension culture conditions. However, no significant difference in G-protein expression was 
observed, resulting in a three-fold increase in receptor:G-protein ratio. Under these conditions, I 
observed almost a doubling of the relative efficacy of a partial agonist, eltoprazine (from 53% to 
93%), without a change in its potency. In contrast, the full agonist, 5-HT, exhibited a two-fold 
decrease in its EC50 value. Notably, in addition to these changes, the increase in 5-HT1A 
receptor:G-protein ratio roughly doubled the negative efficacy of spiperone. Two conclusions may 
be drawn from these observations. First, it might be expected that a higher receptor expression level 
might increase basal G-protein activation. However, in this study, the three-fold increase in receptor 
number did not affect basal [35S]-GTPγS binding. This suggested that basal G-protein activation was 
already at its maximum (i.e. the number of G-proteins was limiting). Second, it appeared that 
spiperone stabilised G-protein-coupled receptors in a conformation which is not capable of 
G-protein activation. Thus a higher density of spiperone-occupied receptors, which 'traps' G-proteins 
in an inactive state, reduces the pool of G-proteins available for activation by non-spiperone-
occupied receptors. This hypothesis is consistent with the 'cubic' or 'general' ternary complex model 
(2,82)
, in which inactive receptors can exist not only in an uncoupled state but also in a state which is 
coupled to G-protein (see Fig. 5.1).  
Determination of activation at G-protein Gα subunits by antibody capture 
Almost all the studies described above employed membrane preparations expressing mixed 
populations of G-proteins, and the resultant measures of [35S]GTPγS binding were therefore 
composed of the cumulated responses of all the G-protein subtypes activated or inhibited by the 
receptor (83). Total [35S]GTPγS binding measures, which lack resolution at the level of specific 
G-protein subtypes, may, therefore, conceal complex interactions which may arise from differential 
coupling of receptors to specific G-protein subtypes as well as ligand-dependent activation of 
specific transduction pathways (biased agonism, see Chapter 3) [54]. 
Efforts had been made to characterise the pharmacological profiles of ligands at 5-HT1A receptors by 
examining coupling to specific G-protein subtypes. Thus, specific G-proteins had been co-expressed 
or reconstituted with 5-HT1A receptors in bacterial, insect and mammalian cells 
(84-87). In addition, 
5-HT1A receptor-G-protein fusion constructs had been designed to constrain the coupling of the 
receptor to specific G-protein subtypes in HEK293 cells (68,88,89). While these strategies yielded useful 
information, they were not adapted to detect regulatory mechanisms that depend on availability of 
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multiple G-proteins. In addition, such techniques require the use of recombinant systems expressing 
mutant receptor constructs and are unsuitable for investigation of receptor coupling in native 
tissues. 
At the end of the 1990s, a novel approach for determining G-protein subtype activation was 
reported at muscarinic receptors (90), using a rapid methodology which lends itself to the 
investigation of numerous ligands and experimental conditions. The experimental principle is based 
on rapid immunoprecipitation and [
35
S]GTPγS binding, whereby activated G-proteins (ie. [
35
S]GTPγS-
bound) are captured by specific antibodies (91). These are detected using scintillant-impregnated 
polymer beads coated with a secondary antibody. While no data were reported concerning the 
action of inverse agonists, it was demonstrated that this technique allows targeting of differing 
G-protein families (Gαq/11 and Gαi1,2,3) in membranes prepared from both recombinant CHO cells and 
native rat striatum 
(90)
.  
Gαi3 activation at 5-HT1A receptors: protean agonism and inverse agonism.  
In my laboratory, we used the novel antibody-capture / SPA procedure to investigate the activation 
of G-proteins by 5-HT1A receptors [46]. This study, revealed complex interactions in receptor-
G-protein coupling, which were later confirmed in another study using siRNA knock-down technique 
[100]. Thus, 5-HT and other high-efficacy agonists, such as 5-CT, S14506 and (+)8-OH-DPAT, yielded 
bell-shaped [
35
S]GTPgS binding isotherms at Gαi3 subunits, with peaks at nanomolar concentrations 
(Fig. 2.3). Hence the direction of the response to agonists (stimulation or inhibition) was dependent 
on the ligand concentration range examined and suggested that a conformational change occurs by 
which 5-HT1A receptors ‘switched’ signalling to other G-protein subtypes. This hypothesis was 
supported by the fact that, in classical [35S]GTPγS binding assays which do not distinguish G-protein 
subtypes, 5-HT-induced stimulation was found to be biphasic [46], consistent with sequential 
activation of at least two G-protein subtypes. The identity of the second G-protein was probably 
Gαi2, in view of its known high level of expression in CHO cells, and its known interaction with 5-HT1A 
receptors [54] (92,93).  
These unexpected data differed markedly 
from those obtained in previous studies. 
Indeed, observations of bell-shaped drug 
concentration-response isotherms in in 
vitro models had classically been 
attributed to the presence of cross-
reacting receptors (94) or promiscuous 
coupling to two or more signal 
transduction systems (for example to both 
stimulation and inhibition of adenylyl 
cyclase activity (95,96). In contrast, in the 
case of Gαi3 activation by 5-HT1A receptors, 
Figure 2.3: [35S]GTPγS binding at G-protein subtypes. 
Simulated G-protein activation curves are shown for total 
G-proteins in CHO cells and for Gαi3 and Gαi2. 
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no interfering receptors were present in the recombinant system, as demonstrated by the absence 
of response in membranes from non-transfected cells. Secondly, unlike 5-HT, the partial agonist, 
(-)pindolol, displayed sigmoidal stimulation isotherms for Gαi3 activation, suggesting that it is not 
capable of inducing the conformational switch observed with higher efficacy agonists. Thus, when 
acting at 5-HT1A receptors, (-)pindolol maintains 5-HT1A receptor signalling to Gαi3 over a wide 
concentration range. We had previously reported that pindolol behaves as a partial agonist in 
classical [35S]GTPγS binding assays [15], but, for  Gαi3 activation, its maximal stimulation was 
comparable to that of 5-HT. (-)Pindolol may therefore display higher efficacy at Gαi3 compared with 
other G-protein subtypes. Thirdly, ligand actions on Gαi3 activation were highly susceptible to 
modulation by sodium ions. Indeed, when the sodium concentration was lowered (increasing basal 
Gαi3 activation), the actions of (-)pindolol were reversed from activation of Gαi3 to inhibition, 
Conversely, WAY100635, which exhibits sodium-dependent inverse agonist properties in HeLa cells 
(67)
, stimulated Gαi3 activation in CHO cell membranes (in the presence of sodium), indicating that it 
possesses mild agonist properties under these conditions. Sodium ions also profoundly influenced 
Gαi3 activation by 5-HT: only stimulatory actions were observed at high sodium concentration, 
whereas only inhibitory ‘pseudo-inverse agonist’ actions were seen at low sodium concentration. 
Thus, for this G-protein subtype, the actions of the endogenous agonist, 5-HT, can be altered, not 
just in magnitude, but also in direction. More generally, ligands which display variable direction of 
response, depending on the level of constitutive activity (or ‘tone’), are known as ‘protean agonists’ 
(97) and the results discussed above for 5-HT1A receptors suggests that Gαi3 subunit activation may be 
particularly sensitive to such ligands (a later study identified similar responses for Gαi3 coupling to 
5-HT1B receptors; Chapter 5 [53]). Fourthly, the inverse agonists, spiperone and methiothepin, 
sigmoidally inhibited [
35
S]GTPgS binding. Their isotherms were not mirror images of those of 5-HT: 
no stimulatory phase was observed, producing U-shaped curves. Further, spiperone and 
methiothepin did not exhibit protean behaviour, that is, even when sodium concentration was 
modified, they invariably exhibited inhibition of basal activity. These data suggest that spiperone and 
methiothepin selectively stabilise/induce receptor conformation(s) which are distinct from those 
recognised by agonists or partial agonists. Further, these observations indicate that, to distinguish 
true inverse agonism from protean agonism, assays must be carried out under a variety of conditions 
(e.g. different sodium ion concentrations) favouring or suppressing constitutive activity. It is 
interesting that spiperone exhibited greater negative efficacy than methiothepin in CHO cell 
membranes [9,10,19] but opposite effects were observed in HeLa cells (67). Further, in HeLa cells, the 
negative efficacy of spiperone, but not methiothepin, was significantly increased by removal of 
sodium from the incubation buffer (67,98), providing additional support for differential influence of 
these ligands on receptor-G-protein coupling. 
2.4 Conclusions and perspectives. 
Taken together, the experiments that I conducted demonstrated extensive complexity on the 
interaction of 5-HT1A receptors with coupled G-protein(s). In particular, the bell-shaped 
concentration-repsonse curves observed for Gαi3 activation were unprecedented and surprising [46]. 
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Those data led me to speculate that the differences in magnitude and direction of G-protein 
activation may have been due to coupling of 5-HT1A receptors to distinct G-protein populations, 
raising the prospect of identifying ligands which selectively signal via specific G-proteins subtypes 
(see discussion of “biased agonism”, Chapter 3). It is worth noting that the complex actions of 
ligands on 5-HT1A receptor-mediated Gαi3 activation may be paralleled by similar effects at other 
GPCRs. In a preliminary study, Browning et al. 
(99)
 reported bell-shaped [
35
S]GTPγS binding isotherms 
at adenosine A1 receptors expressed in CHO cells. The precise G-protein subtypes activated were not 
identified, but the presence of bell-shaped isotherms was dependent on high receptor expression 
levels and, as in the case of 5-HT1A receptors, the use of high efficacy agonists, whereas an inverse 
agonist exhibited sigmoidal inhibition isotherms (100). These data suggest that changes in receptor 
conformation producing sequential activation of different G-protein populations may occur for a 
variety of GPCRs.  
More broadly, my work contributed to the discovery of promiscuous coupling of receptors to 
multiple G-protein subtypes and “ligand-directed trafficking of receptor signalling”, which later 
became known as “functional selectivity” or “biased agonism” (see next chapter). These advances 
highlighted the need to refine descriptions of drug efficacy for G-protein activation. In this context, 
antibody-capture / SPA methodology provides a useful means of elucidating diverse receptor 
interactions with specific G-protein subtypes. Nevertheless, it should be noted that a limitation of 
the antibody capture / SPA methodology is its financial cost: the antibodies and the SPA beads don’t 
come cheap! To date, most of the published studies using this technique come from industrial 
laboratories (91) for which, presumably, the cost of consumables is less limiting than for many 
academic research labs. Thus, in the case of these scientifically innovative but financially onerous 
experiments, I was privileged to be able to make the most of opportunities offered by a 
pharmaceutical industry research environment. 
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3. Serotonin 5-HT1A receptor subpopulations 
and biased agonism 
 
3.1 Key points  
 The author demonstrated that the in vitro signaling profile of the endogenous agonist, 5-HT, 
differs from that of selective 5-HT1A receptor agonists (8-OH-DPAT, F13714 and F15599). 
Comparison of several intracellular responses indicated that each agonist exhibited its own 
distinctive “signalling fingerprint” [61,88]. 
 F15599 was found to preferentially activate post-synaptic 5-HT1A receptors at low doses that do 
not activate pre-synaptic 5-HT1A receptors in raphe nuclei [88,94]. This preferential post-synaptic 
activity is not observed with other 5-HT1A agonists [102]. Preferential cortical labelling by F15599 
was also shown in micro-PET experiments in rat using [
18
F]F15599 [93] but not the pre-synaptic 
agonist, [18F]F13714 [103]. However, micro-PET experiments in cat generate discrepant data 
[93,103] 
 In rat, F15599 exhibited potent anti-depressant-like activity in the forced swim test, inhibited 
stress-induced ultrasonic vocalization, and attenuateed phencyclidine-induced cognitive 
impairments in reversal learning and in a hole-board test [95,97]. 
 Preferential activation of post-synaptic 5-HT1A receptor by F15599 was found to elicit less 
serotonin syndrome and less disruption of attentional performance or impairment of working 
memory than elicited by activation of pre-synaptic receptors with F13714.  F15599 was shown to 
be free of dirsuption of pre-pulse inhibition of startle response [95,97]. 
 The 5-HT1A receptor ligand (and beta-blocker), pindolol, was shown to exhibit partial agonist 
activity in vitro. This activity likely underlies its capacity to accelerate onset of therapeutic efficacy 
of antidepressants by interaction with pre-synaptic 5-HT1A receptors [15,36,41,46]. 
3.2 Background to the author’s work 
Differential functions of pre- and post-synaptic 5-HT1A receptors 
Aboundant electrophysiological, pharmacological and neurochemical data provide 
compelling evidence that 5-HT1A receptors expressed in different brain regions possess distinct 
signalling and physiological properties and those region-specific effects are therapeutically-relevant. 
For example, at a neurochemical level, activation of pre-synaptic 5-HT1A receptors expressed on 
serotonergic neurons elicits inhibition of serotonin release in terminal regions such as hippocampus 
and cortex. In contrast, activation of post-synaptic cortical 5-HT1A hetero-receptors expressed on 
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glutamatergic pyramidal cells and/or GABAergic (Gamma-aminobutyric acid) interneurons, elicits 
increased dopamine release in cortex [60] 
(101,102)
.  
In rodent behavioral tests, anxiolytic activity is mediated by activation of pre-synaptic 5-HT1A 
receptors 
(32,38)
, whereas anti-depressant-like activity is mediated by activation of post-synaptic 
receptors 
(38)
. Accordingly, mice that were genetically manipulated to increase raphe 5-HT1A 
autoreceptor expression exhibited depressive-like behavior and were resistant to antidepressant 
treatment (103). These observations are consistent with clinical observations in depressed patients 
treated with serotonin reuptake inhibitors: desensitization of pre-synaptic 5-HT1A receptors is 
necessary before antidepressant efficacy is achieved 
(1,104)
. 
In cognition tests, 8-OH-DPAT facilitated rat passive avoidance at low doses, whereas higher 
doses impaired performance 
(105,106)
. This is likely due to differential effects at pre- and post-synaptic 
5-HT1A receptors, respectively 
(36). Indeed, micro-injection of the 5-HT1A receptor weak partial agonist, 
S15535, into the hippocampus, reversed the memory deficit elicited by systemic injection of 
8-OH-DPAT in a spatial discrimination task 
(107)
, indicating that activation of post-synaptic receptors 
in this brain region was detrimental to mnesic performance. Finally, activation of pre-synaptic 5-HT1A 
receptors may facilitate addiction-related behaviors, whereas activation of post-synaptic 5-HT1A 
receptors inhibits them 
(108). 
The diverse effects of pre- and post-synaptic 5-HT1A receptor activation are not due to the 
presence of receptor subtypes. Indeed, only a single 5-HT1A receptor gene has been identified in 
human and rat: it is intron-less and without splice variants (54,109) so the variety of responses 
described above are attributable to regional differences in other factors, such as G-protein subtypes 
(110)
, Regulators of G-protein Signaling (RGS) 
(111)
 or transcriptional regulation. Indeed, the expression 
of 5-HT1A receptors is differentially regulated by a single nucleotide polymorphism (SNP) in the 
promoter region of the 5-HT1A receptor gene (C-1019G substitution) 
(112,113)
. This SNP impairs 
repression of the 5-HT1A promoter by the NUDR/DEAF-1 transcription factors in raphe cells, 
consistent with over-expression of pre-synaptic 5-HT1A receptors 
(43,114)
. Thus, C-1019G polymorphism 
is associated with higher levels of remission failure and suicidal behavior in depressed patients, 
consistent with impaired antidepressant efficacy due to excessive feed-back inhibition by pre-
synaptic 5-HT1A receptors. Further, schizophrenia patients expressing the C-1019G polymorphism 
exhibit impaired negative symptoms and cognitive deficit response to antipsychotics (115-118). This 
observation is likely related to the fact that the C-1019G polymorphism also causes hypofunction of 
5-HT1A receptors in cortex 
(112,119,120) thus resulting in an overall imbalance of pre- versus post-synaptic 
receptor function.  
The above considerations indicate that 5-HT1A receptors elicit differential, and sometimes 
opposing, responses in different brain regions. At a molecular level, receptor inactivation studies 
using N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline (EEDQ) demonstrated the existence of 5-HT1A 
receptor reserve in the raphe for inhibition of serotonin synthesis (59). In contrast, receptor reserve 
was not observed in hippocampus for inhibition of adenylyl cyclase or for control of hypothermia 
(61,121).  
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The agonist radiotracer, [
3
H]8-OH-DPAT showed five-fold higher affinity in hippocampus than 
in raphe membranes 
(122)
, suggesting that the receptor-G-protein coupling state of the receptor 
differs between the two brain regions. Further, whereas 5-HT1A receptors are coupled to inhibition of 
adenylyl cyclase in hippocampus, they are not coupled to this response in raphe homogenates 
(123)
. In 
contrast, 5-HT1A receptor-mediated inhibition of inositol phosphate synthesis by 8-OH-DPAT and 
flesinoxan was observed in Raphe but not in hippocampus 
(122)
.  
An immuno-precipitation study found that, in raphe, 5-HT1A receptors preferentially couple 
to Gαi3 subtypes whereas they couple preferentially to Gαo in hippocampus and to a combination of 
G-proteins in cortex and hypothalamus 
(110)
. 5-HT1A receptor agonists also increased Extracellular 
Signal-regulated Kinase (ERK1/2) phosphorylation in the cortex, presumably by direct activation of 
post-synaptic 5-HT1A receptors. In contrast, 5-HT1A receptor agonists inhibited ERK1/2 
phosphorylation in hippocampus, likely via an inhibition of serotonin release due to activation of 
pre-synaptic 5-HT1A receptors 
(124-126)
.  
In my laboratory, we used functional ([
35
S]GTPγS) autoradiography experiments to show that 
regional variations exist in native brain activation of G-proteins by 5-HT1A receptors [24,36,52]. Thus, 
in a comparison of the stimulatory influence of 5-HT in four different brain regions (dentate gyrus, 
septum, substantia nigra and cingulate cortex), 5-HT-dependent [35S]GTPγS binding was greatest in 
the dentate gyrus, with maximal stimulation of 2.25-fold above basal values, whereas in the other 
brain regions stimulation was lower (1.39- to 1.56-fold) [52]. However, marked differences were also 
observed in the potency of 5-HT: low in the dentate gyrus and substantia nigra (pEC50 values ~5) but 
higher in the septum and cingulate cortex (pEC50~6.5). Some of these differences may be 
attributable to the presence of other receptor subtypes (e.g. 5-HT1B) but it is likely that 5-HT1A 
receptors provide the predominant response in structures such as dentate gyrus and lateral septum. 
These observations are therefore consistent with brain region-dependent differences in receptor-
G-protein coupling. 
Biased agonism: differential activation of 5-HT1A receptor signaling  
Increasing attention has recently been given to the idea of “biased agonism” (also known as 
“functional selectivity” or “agonist-directed signaling”) (127-130). According to this concept, agonists 
may preferentially direct receptor signaling to one response whilst not affecting, or even blocking, 
another response (Fig. 3.1). If the different signaling responses mediate distinct functional effects 
(e.g. therapeutic versus side-effects), then biased agonism offers a strategy to identify more 
effective and better-tolerated drugs. Examples of “biased agonism” have been reported at 5-HT2 
receptors in vitro and in vivo and may underlie pro-psychotic effects of some CNS agents [84] (131,132).  
At 5-HT1A receptors, a study examining G-protein subtype activation in a cloned CHO cell line 
(92), found that different agonists displayed a varying balance of activation of Gαi2 and Gαi3, 
determined using a photoreactive GTP analogue (4-azidoanilido-[α-32P]GTP). Thus, whereas 
rauwolscine displayed similar EC50 values for activation of the two G-protein subtypes, ipsapirone 
showed a nearly four-fold lower EC50 for Gαi3 activation. 5-HT and 8-OH-DPAT had intermediate EC50 
ratios (92). These data indicated that 5-HT1A receptor agonists can be distinguished by their relative 
capacity to activate different G-protein subtypes. 
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A study carried out under my direction found that G-protein activation elicited by 5-HT via 
5-HT1A receptors in a CHO cell line was partly blocked by pre-incubation with anti-Gαi3 antibodies, 
indicating that other G-protein subtypes also couple to 5-HT1A receptors in this cell line [46], as 
discussed in Chapter 2. However, in the case of the partial agonist, pindolol, pre-incubation with 
anti-Gαi3 antibodies almost completely suppressed G-protein activation [46]. This suggested that 
pindolol preferentially elicits 5-HT1A receptor coupling to Gαi3 and not to other G-protein subtypes, a 
mechanism that may underlie some of pindolol’s signalling properties [14,36,41] and its preferential 
interaction with 5-HT1A receptors in the raphe, as observed in positron-emission tomography (PET) 
studies 
(133,134)
. Drug differences were also seen in rat raphe transduction: buspirone elicited 5-HT1A 
receptor coupling to Gαi2, Gαi3 and Gαo and inhibition of adenylyl cyclase (135). In contrast, 
(+)8-OH-DPAT only elicited coupling to Gαi3 and did not elicit the other responses.  
Similar considerations apply to physiological tissues. Indeed, in a coimmunoprecipitation 
study, rat brain 5-HT1A 
receptors in raphe nuclei 
coupled preferentially to 
Gαi3 subunits, whereas 
5-HT1A receptors in 
hippocampus coupled 
preferentially to Gαo 
(110)
. 
In addition, although the 
density of 5-HT1A receptors 
in these brain regions is 
similar, agonist-induced 
[35S]GTPγS labelling was 
markedly lower in pre-
synaptic than in post-
synaptic regions in some 
studies (136). It may be speculated that differential coupling to intracellular G-proteins may explain 
some of these contrasting responses of pre- and post-synaptic 5-HT1A receptors.  
Whilst the observations described above are somewhat disparate, they provided a strong 
rationale for supposing that some 5-HT1A receptor ligands may act as “biased agonists” with distinct 
influence on receptor signaling in different brain regions. Hence, the identification of novel ligands 
that preferentially target brain regions of interest appeared pharmacologically feasible and led me to 
carry out detailed studies of this issue using novel, selective and efficacious 5-HT1A agonists. 
3.3 Contribution of author’s work  
The concept of biased agonism progressively attracted my interest over the course of the 
studies described in Chapter 2. For example, in ligand binding experiments the napthylpiperazine 
derivative, S14506, and the antipsychotic, clozapine, contrasted with other agonists by exhibiting 
Figure 3.1: Intrinsic activity vs Biased Agonism 
The classical agonist (Ago) elicits activation of all signalling responses that 
are available to the receptor (R). In contrast, the biased agonists (Ago1 
and Ago2) preferentially activate one response or another.  
G1 & G2 = G-protein subtypes; E1 & E2 = Effectors. 
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much smaller decreases in binding affinity when receptor-G-protein dissociation was induced by GTP 
[19,35,39]. These data suggested that S14506 and clozapine preferentially bind to receptors which 
are coupled to a tightly-associated G-protein subtype whereas other agonists preferentially bind to 
receptors coupled to other G-protein subtypes. Further, whereas ERK phosphorylation elicited by 
most agonists correlated with their efficacy in G-protein activation experiments, clozapine only 
modestly stimulated ERK phosphorylation [35], suggesting that it does not principally signal via this 
intracellular mechanism.  
In later electrophysiological experiments on Xenopus oocytes transiently expressing 5-HT1A 
receptors, the agonists, 5-HT, L694247 and F13714, stimulated G-protein-activated Inwardly-
Rectifying K+ (GIRK) currents with similar efficacy [61]. In contrast, L694247 was more efficacious 
than 5-HT for stimulation of a G-protein-independent smooth inward current (Ismooth) whereas 
F13714 acted as an antagonist for this response, as did the selective 5-HT1A receptor antagonist, 
WAY100635 [61]. These results further supported the concept that different signalling responses 
could be individually targeted with appropriate pharmacological tools and encouraged me to search 
for such tools in the course of my work. When I arrived at the Pierre Fabre research centre, I found 
that an ongoing serotonin drug discovery program had built a chemical library of hundreds of 
selective 5-HT1A agonists. These provided ample material to explore and compare in vitro signalling 
properties. It became apparent that wide-ranging differences could be identified in the agonist 
properties of these 
compounds and, in particular, 
of F15599, a drug that can be 
considered as a prototypical 5-
HT1A biased agonist with 
preferential post-synaptic 
cortical 5-HT1A activity. The 
rest of this chapter is devoted 
to describing the studies I 
directed on this compound, in 
comparison with other 
serotonergic ligands. 
Distinct pharmacological targeting of pre- and post-synaptic 5-HT1A receptors.  
F15599 is a potent, selective and high efficacy agonist at 5-HT1A receptors [88]. Chemically-
related compounds include befiradol (F13640) and F13714 (137-139), but not 8-OH-DPAT or buspirone 
(Fig. 3.2) so F15599 marks a break with older azapirone partial agonists. Detailed studies comparing 
F15599 and F13714 showed that they differ markedly in their in vitro signaling profiles and in their in 
vivo properties at sub-populations of 5-HT1A receptors. Thus, although F15599, F13714, 8-OH-DPAT 
and 5-HT all behaved as efficacious agonists in tests of G-protein activation, adenylyl cyclase 
Figure 3.2: Chemical structures of 5-HT1A receptor agonists.  
F15599 and F13714 are chemically-related but distinct from 5-HT, 
8-OH-DPAT or buspirone. 
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inhibition, ERK1/2 phosphorylation and receptor internalization, the order of potency for stimulation 
of these responses was specific to each agonist (Table 3.1). F15599 showed marked potency for 
ERK1/2 phosphorylation (EC50 ~15 nM) but lower potency for other responses (EC50 100 to 350 nM), 
whereas 5-HT preferentially elicited adenylyl cyclase inhibition [88]. Each agonist exhibited its own 
“signaling fingerprint”, possibly because of agonist-directed coupling of 5-HT1A receptors to different 
G-protein subtypes. Indeed, 5-HT activated both Gαi and Gαo over a similar concentration range, 
whereas F15599 activated Gαi more potently and more efficaciously than Gαo, and F13714 and 
8-OH-DPAT exhibited intermediate profiles [88]. Given that 5-HT1A receptors couple to different 
G-protein subtypes depending on brain area 
(110)
, this suggests that biased agonists can, de facto, 
preferentially target certain brain regions and functional responses.  
Table 3.1: Order of potency of agonists for  5-HT1A receptor signalling 
pERK: ERK1/2 phosphorylation; G-protein: total G-protein activation; Internal.: receptor internalization; cAMP: 
inhibition of adenylyl cyclase. Each agonist displayed a distinct order of potency for these responses.  
Adapted from [88]. 
Agonist 1
st 
response  2
nd
 response  3
rd
 response  4
th
 response 
        
F15599 pERK >> G-protein > Internal. > cAMP 
F13714 pERK ≥ Internal. = G-protein ≥ cAMP 
(+)8-OH-DPAT pERK >> cAMP > Internal. ≥ G-protein 
5-HT cAMP ≥ G-protein > pERK > Internal. 
 
However, caution is desirable when extrapolating from in vitro effects to in vivo functional 
responses because cross-talk may render receptor-level biased agonism redundant in more 
integrated systems (1,129). In the case of F15599, I directed a series of studies [88,93,94,95,97] that 
demonstrated that its distinctive “signaling fingerprint” translates to a distinctive preferential 
activation of post-synaptic (mainly cortical) 5-HT1A receptors, with less influence on pre-synaptic 
5-HT1A receptors. In contrast, F13714 exhibits an opposite preference, with more pronounced 
activation of 5-HT1A autoreceptors and less potent activity at cortical receptors. The findings 
supporting this assertion are summarized below. 
Firstly, in rat electrophysiological tests, F15599 stimulated frontal cortex pyramidal cell 
electrical activity at low doses (MED 0.2 µg/kg i.v.), whereas much higher doses were necessary to 
inhibit raphe neuron firing (MED 8.2 µg/kg i.v.) [94]. Both of these effects were antagonized by 
WAY100635. The electrophysiological profile of F15599 is not shared by other 5-HT1A agonists, such 
as 8-OH-DPAT, befiradol or repinotan [102](140-142).  
Secondly, in microdialysis studies, F15599 stimulated dopamine release in rat frontal cortex 
at low doses (ED50 0.03 mg/kg i.p.). This effect, associated with beneficial properties on mood and 
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cognitive parameters, was 5-HT1A-specific, being reversed by WAY100635 [94]
(140,143)
. In contrast, 
F15599 inhibited hippocampal serotonin release at doses that were about an order of magnitude 
higher (ED50 0.24 mg/kg i.p.) [94] a profile of activity not shared by other 5-HT1A agonists, such as 
F13714 or befiradol [94,97,102]. In addition, when F15599 was chronically administered by mini-
pump, no desensitization of pre-synaptic 5-HT1A receptors was observed except at very high doses 
(20 mg/kg/day for 14 days) whereas a low dose of F13714 was sufficient to rapidly achieve this 
effect (2.5 mg/kg/day for 3 days) [67](144). 
Thirdly, a preferential post-synaptic action of F15599 is supported by ex vivo studies of 
expression of the immediate early gene, c-Fos. The latter provides a marker of neuronal activation 
state and, in the case of F15599, was markedly stimulated in frontal cortex but very little or not at all 
in median or dorsal raphe [88]. In contrast, F13714 showed an opposite profile, strongly stimulating 
c-Fos expression in dorsal raphe, to an extent that exceeded that in frontal cortex (145). 
Fourthly, in ex vivo studies, F15599 stimulated extra-cellular signal regulated kinase (ERK1/2) 
phosphorylation in rat frontal cortex (a response controlled by post-synaptic 5-HT1A receptors) and 
inhibited it in hippocampus (a response controlled by pre-synaptic receptors) at similar doses [88]. In 
contrast, F13714 and befiradol were markedly more potent for stimulation of ERK1/2 
phosphorylation in hippocampus, reflecting a preferential pre-synaptic action (125). These data 
suggest that pronounced ERK1/2 phosphorylation may underlie the preferential cortical activity of 
F15599, an interpretation that is consistent with the compound’s potent activation of ERK1/2 
phosphorylation in cellular tests in vitro, as discussed above [88]. 
Interestingly, deficits in ERK phosphorylation are associated with depressive states and are 
reversed by chronic SSRI administration 
(146-148)
, suggesting that the potent ERK phosphorylation-
inducing activity of F15599 could underlie a favourable antidepressant profile (see below). 
Effects of post-synaptic 5-HT1A receptor activation in models of mood and cognition. 
The biased agonism of F15599 at post-synaptic cortical 5-HT1A receptors translates to a 
superior behavioral profile in models of mood and cognition. Thus, F15599 potently and completely 
reversed immobility in the rat forced swim test (FST), a classical model of antidepressant-like 
activity. It is worth underlining the fact that current antidepressants only exhibit partial activity in 
this test and require repeated administration to induce marked reduction in immobility behaviour. In 
contrast, F15599 (and F13714) achieved maximal efficacy (i.e. normalization of behaviour) upon 
acute treatment, consistent with a rapid and extensive antidepressant-like profile of action. 
In a separate series of experiements, F15599 inhibited shock-induced ultrasonic vocalization 
(USV) in rat, a measure of anti-stress / anxiolytic activity [97] (149). Notably, the potency of F15599 in 
both these tests (FST and USV) is as great as that of its congener, F13714, despite the fact that the 
latter has over 30-fold higher affinity in in vitro binding experiments (0.01 nM for F13714 versus 3.4 
nM for F15599) [88]. The marked in vivo potency of F15599 suggests that preferential activation of 
cortical 5-HT1A receptors accentuated beneficial effects on mood parameters.  
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On the basis of clinical data showing that adjunctive treatment with 5-HT1A partial agonists 
improves the cognitive state of schizophrenics 
(143)
, F15599 was tested in rodent models of cognitive 
impairment induced by the non-competitive N-methyl-D-aspartic acid (NMDA) receptor antagonist, 
phencyclidine (PCP). Indeed, NMDA receptor hypo-function, particularly in cortical regions, is 
considered to underlie aspects of negative symptomatology and cognitive deficits in schizophrenia 
(150-152)
. F15599 significantly attenuated PCP-induced deficits of cognitive flexibility in an operant 
conditioning reversal learning test in rat [95]. In comparison, F13714 failed to reverse the PCP-
induced deficit and, in fact, tended to accentuate it [95]. This observation is likely related to 
F13714’s preferential pre-synaptic 5-HT1A agonism, potently inhibiting serotonin release [67]. Indeed, 
reversal learning is known to require functional serotonergic transmission in frontal cortex (153,154) as 
well as functional D2 receptors 
(155)
 suggesting that F15599 is able to re-establish normal functioning 
in this brain region by its preferential activity at cortical 5-HT1A receptors at doses that elicit 
dopamine release therein without suppressing serotonergic neurotransmission [94]. In another test 
of PCP-induced cognitive deficits, F15599 improved performance of rats in a hole-board test, 
significantly improving working and reference memory scores [95], possibly by opposing the release 
of glutamate elicited in frontal cortex by NMDA receptor blockade (156,157). In contrast, F13714 
disrupted performance when tested alone and tended to further accentuate PCP-induced deficits 
[95]. Finally, in an extensive study of the role of 5-HT1A agonism on PCP-disrupted novel object 
recognition in rat, F15599 markedly improved the discrimination index, as did another efficacious 
agonist, tandospirone, whereas the partial agonist, buspirone, did not (158).  
In animal tests related to side-effects, F15599 exhibited a superior profile compared to 
Figure 3.3: Concept of a post-synaptic-preferential cortical 5-HT1A receptors biased agonist.  
Such an agonist would be expected to exhibit antidepressant properties and be beneficial against cognitive 
deficits with only modest impact on thermoregulation or cholinergic function. Notably, avoiding activation 
of 5-HT1A autoreceptors should reduce the delay of therapeutic onset of antidepressant efficacy. 
 
 
 
D.Sc. Thesis  Chapter 3 
  
Part A: Page 42 of 206  
F13714. Thus, F15599 exhibited little propensity to elicit forepaw treading or flat body posture [97], 
which are elements of serotonin behavioral syndrome commonly observed with 5-HT1A receptor 
agonists (159,160). F15599 only elicited these responses at doses that were 30- to 60-fold higher than 
those that suppress immobility in the forced swim test [97]. Further, at “antidepressant” doses, 
F15599 did not impair working memory in the delayed non-matching to position (DNMTP) test, did 
not interfere with attentional performance in the 5-choice serial reaction time test (5CSRTT) and did 
not disrupt pre-pulse inhibition of startle response [95]. In contrast, F13714 potently elicited these 
side-effects at doses similar to those active in the forced swim test. The superior profile of F15599 
could be related to preferential occupancy of subpopulations of 5-HT1A receptors. Indeed, using 
[3H]WAY100635 as a radiotracer, F15599 occupied mouse cortical and hippocampal 5-HT1A receptors 
in vivo nearly as potently as F13714 [97], despite the fact that the latter has greater affinity in vitro 
(Table 3) [88]. Further, in a positron emission tomography (PET) imaging study, [18F]F15599 
preferentially labeled rat cortical, rather than hippocampal, 5-HT1A receptors, even though the latter 
brain region expresses higher levels of receptors [93]. In cat, [
18
F]F15599 preferentially labeled 
cingulate cortex 5-HT1A receptors, and labeling was not observed in hippocampus. This unique 
regional distribution of labeling differs sharply from that observed with antagonist radioligands such 
as [18F]MPPF (161) or [O-methyl-11C]WAY-100635 (162) which label all 5-HT1A receptors in different brain 
regions. These observations support the notion that [18F]F15599 preferentially interacts with specific 
subpopulations of 5-HT1A receptors in brain, possibly depending on their coupling to specific 
G-protein subtypes. Two additional comments should be made: firstly, [18F]F15599 also labeled 
mid-brain raphe 5-HT1A receptors in cat [93] as did [
18F]F13714 [103]. Thus, in this species, the 
distinct pre- / post-synaptic activation of 5-HT1A receptors observed in rat was not reflected in the 
distribution of receptor labelling. It will therefore be interesting to compare these radiotracers in 
higher species: ongoing autoradiography experiments in post-mortem human brain (Uni. of Lyon, 
France) and PET experiments in non-human primate (New Haven, MA) will provide clarification of 
this issue. Secondly, F15599 may distinguish different populations of 5-HT1A receptors within cortical 
tissue – an assertion based on microinjection studies in the frontal cortex where agonists were 
locally administered: whereas F13714 and 8-OH-DPAT showed conventional monophasic dose-
response relationships for inhibition of immobility in the forced swim test, F15599 yielded a biphasic 
dose-response curve (163). F15599 may, possibly, distinguish cortical 5-HT1A receptors expressed on 
pyramidal cells from those expressed on GABAergic interneurons (102,164). 
3.4 Conclusions and perspectives. 
5-HT1A receptors are attractive targets for pharmacotherapy, in view of their localization as 
autoreceptors controlling serotonergic transmission and as post-synaptic receptors in brain regions 
controlling mood, movement, cognition and pain. However, current drugs acting as 5-HT1A agonists 
may be sub-optimal in their profile of activity, because they indiscriminately activate 5-HT1A 
receptors in those brain regions that mediate side-effects as well as in those that are responsible for 
therapeutic actions. Some attempts to circumvent this difficulty have been made with recent drugs. 
For example, SB-649915-B is a serotonin reuptake inhibitor (SRI) and 5-HT1A antagonist 
(165,166) aiming 
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to avoid feed-back inhibition of serotonin release by blocking the activation of 5-HT1A autoreceptors 
(104,167)
. However, whilst antidepressant efficacy may be enhanced by 5-HT1A autoreceptor 
antagonism, it ils likely to be hindered by antagonism of post-synaptic 5-HT1A receptors 
(38,168). 
Vilazodone, LuAA21004 and VN2222 exemplify another approach: they act as SRIs whilst retaining 
partial agonist activity at 5-HT1A receptors 
(142,169,170)
. Indeed, pindolol, which has been extensively 
tested in depressed patients in combination with SRIs, is a partial agonist at 5-HT1A receptors [41]
(104)
. 
However, a partial agonist strategy risks only partially achieving its objectives: is the agonism 
sufficiently modest to ensure blockade of 5-HT1A autoreceptors? Is the agonism of sufficient 
magnitude to avoid blocking post-synaptic 5-HT1A receptors?  
The studies conducted in my laboratory demonstrated that subpopulations of cortical 5-HT1A 
receptors may be pharmacologically targeted by biased (or “functionally selective”) agonists, such as 
F15599, that possess specific intracellular “signaling fingerprints”, possibly via preferential Gαi 
G-protein subtype activation and/or potent ERK1/2 activation. These observations were the first to 
demonstrate the feasibility of preferential targeting of cortical 5-HT1A receptors and open the path to 
(hopefully) accelerated onset of therapeutic efficacy in depression and attenuated cognitive 
impairments in schizophrenia. In addition, preferential targeting of cortical 5-HT1A receptors may 
increase the therapeutic margin with respect to side-effects that arise from the activation of other 
5-HT1A receptors sub-populations. Taken together, the studies I directed provided evidence that the 
activity of 5-HT1A receptor agonists at distinct pre- and post-synaptic sub-populations of 5-HT1A 
receptors should be considered when selecting drugs that influence serotonergic neurotransmission. 
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4. Serotonin 5-HT1A receptor activation and 
psychotic disorders 
 
4.1 Key points  
 The influence of 5-HT1A receptor activation in schizophrenia and in the profile of action of 
antipsychotic drugs constituted a major part of the author’s research: over a third of the present 
thesis’ publications are related to this field.  
 The prototypical atypical antipsychotic, clozapine, was discovered to possess partial agonist 
activity at 5-HT1A receptors [4]. This activity likely underlies some aspects of its “atypical” 
therapeutic profile and was further characterized in subsequent studies [19,39,52,56,58,63,80].  
 Novel antipsychotic drug candidates, notably F15063, were discovered and characterized. These 
drugs, which combine accentuated 5-HT1A receptor agonist properties with D2 antagonism or 
inverse agonism [70], exhibited superior profiles of activity in experimental models of positive 
symptoms, negative symptoms and cognitive deficits of schizophrenia 
[14,52,71,72,73,74,80,83,86,92].  
 Extensive comparative studies were carried out on reference antipsychotics possessing dual 
5-HT1A/D2 properties. These studies showed that, in general, drugs targeting these receptors 
exhibited a broader profile of therapeutic-like activity in models of schizophrenia than older 
atypical or first generation antipsychotics [58,60,62,66,76,77,81] 
 Antipsychotic drugs possessing dual 5-HT1A agonism and D2 antagonism / partial agonism were 
shown to display strongly reduced EPS liability [59,65,72,76,90] and more benign neuroendocrine 
impact [64,83]. 
4.2 Background to the author’s work 
Since the serendipitous discovery of the first antipsychotic agent, chlorpromazine (24), the clinical 
treatment of schizophrenia has been based on compounds which are capable of blocking D2 
receptors, a property which currently remains fundamental in the clinical management of psychosis 
(171-173) although other mechanisms, including activation of metabotropic glutamate (mGluR2/3) 
receptors (174,175), activation of muscarinic M1/M4 receptors (176,177) and indirect activation of NMDA 
receptors by inhibition of glycine transporters (178-180) may offer alternative avenues to achieve 
antipsychotic efficacy independently of direct dopaminergic antagonism.  
’Typical’ antipsychotics such as chlorpromazine and haloperidol are effective in controlling the 
positive symptoms of schizophrenia. However they are essentially ineffective against negative 
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symptoms and exhibit a marked propensity to induce ‘Parkinson’s-like’ neuromuscular disturbances 
(akathisia, dystonia and tardive dyskinesia) known collectively as the extrapyramidal syndrome (EPS). 
’Atypical’ antipsychotic agents, such as clozapine, risperidone, olanzapine, ziprasidone, sertindole 
and aripiprazole, interact at multiple serotonergic and adrenergic receptors in addition to D2-like 
receptors, and were originally known as ‘atypical’ due to their lowered EPS liability and improved 
capacity to alleviate (but not abolish) negative and cognitive symptoms 
(181-183)
. Their fundamental 
pharmacological activity is posited to emerge from the combined interaction at D2 and serotonergic 
receptors. Indeed, antagonism of 5-HT2A receptors is a feature of clozapine, risperidone, olanzapine, 
sertindole and ziprasidone 
(184-187)
 and the 5-HT2A/2C antagonist, ritanserin, potentiated the clinical 
efficacy of risperidone on negative symptoms (188). Nevertheless, a substantial proportion of 
schizophrenic patients fail to respond adequately to existing medications and continue to exhibit 
impairments in social functioning and cognitive performance, as well as persistent and/or recurrent 
psychotic episodes. In addition, both conventional and atypical antipsychotic agents may be 
associated with cardiac arrhythmias 
(189-191)
, and some antipsychotics, such as clozapine and 
olanzapine, induce marked weight gain and metabolic dysfunction linked to diabetes 
(192,193)
. These 
considerations highlight the need for antipsychotic agents that display both wider therapeutic 
activities along with an improved security profile.  
Serotonin 5-HT1A receptor activation: a mechanism for improved antipsychotic action 
In view of the limitations associated with many antipsychotic therapies, attention has been 
increasingly given to the concept of a ‘pharmacological cocktail’ approach (194-196). This strategy 
targets pharmacological properties necessary for the desired therapeutic benefits (actions against 
positive, negative and cognitive symptoms) whilst attempting to avoid interaction(s) with sites 
responsible for side effects, such as antagonism of serotonin 5-HT2C or histaminergic H1 receptors, 
associated with weight gain, or blockade of muscarinic receptors, associated with autonomic side 
effects and memory disturbances (197). A promising means of achieving this is to combine, in the 
same molecule, agonist properties at 5-HT1A receptors with antagonist (or partial agonist) properties 
at D2 receptors [75,96,101] 
(47,198,199). Indeed, multiple observations have attracted attention to 5-
HT1A receptors as a key target in the treatment of schizophrenia. 
First, 5-HT1A receptor activation plays an important role in stimulating dopamine (DA) release in 
frontal cortex [6,60] (200-203) and  recent receptor knock-out (KO) and chemical knock-down 
experiments in mice showed that 5-HT1A, but not 5-HT2A, receptor activation is required for cortical 
DA release by antipsychotics (101). In fact, antagonism of 5-HT2A receptors in frontal cortex indirectly 
elicits activation of 5-HT1A receptors 
(204) and risperidone and olanzapine, which do not directly 
interact with 5-HT1A receptors, increase frontal cortex DA release partly via activation of 5-HT1A sites 
(204). Furthermore, in microdialysis experiments, synergism between 5-HT2A blockade and 5-HT1A 
receptor activation has been demonstrated: cortical DA release is increased when a 5-HT2A receptor 
antagonist (which is inactive by itself) is co-administered with a threshold dose of a 5-HT1A receptor 
agonist (204). Taken together, these results suggested that activation of 5-HT1A receptors is a crucial 
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element in the neurochemical mechanism of action of atypical antipsychotics and may alleviate a 
deficiency in dopaminergic neurotransmission in frontocortical regions of schizophrenic patients. 
Amelioration of this 'hypofrontality' had been associated with improvement in negative and 
cognitive symptoms of schizophrenia 
(205,206)
.  
Second, numerous laboratories, including mine, have demonstrated anti-cataleptic properties of 
5-HT1A agonists in rodents, indicating that activation of 5-HT1A receptors should reduce EPS induced 
by D2 receptor blockade [59,65] 
(207-209). The extent to which 5-HT1A agonists are able to reverse 
neuroleptic-induced catalepsy is dependent on the level of efficacy of the ligand: relatively high 
efficacy activation, for example by the prototypical agonist, 8-OH-DPAT, is necessary to completely 
abolish neuroleptic-induced catalepsy [59,65] 
(210-212)
. Interestingly, interactions between 5-HT1A and 
5-HT2A receptors may underlie predisposition to catalepsy 
(213)
, further illustrating the close functional 
relationship between these two targets.  
Third, 5-HT1A receptor density had been shown to be modified in schizophrenics, with most studies 
reporting up-regulation, as determined by post-mortem investigations of receptor expression in 
frontal cortex and other brain regions 
(214-217)
. 5-HT1A receptor expression may increase as a 
compensatory mechanism subsequent to hypoactivation of this site, a deficiency that could be 
remedied by administration of 5-HT1A receptor agonists. Further, 5-HT1A receptor activation 
hyperpolarizes cortical pyramidal neurons (50,218,219) and may thus attenuate dysfunctional 
glutamatergic function in schizophrenia by opposing the increase in glutamate release induced by 
NMDA receptor blockade (220,221). Such regulation of NMDA receptor function may thus help to re-
establish normal cortical activity. 
Fourth, the atypical antipsychotic, clozapine, which displays improved capacity to treat negative 
symptoms with minimal liability for EPS, exhibits partial agonist properties at 5-HT1A receptors in 
various in vitro models of receptor transduction, as first demonstrated in my laboratory in 1996 [4] 
and subsequently confirmed in a multiplicity of studies [44,63,56,80]. Both the elevation of DA 
release in frontal cortex and the anti-cataleptic properties of clozapine in rats are partially mediated 
by 5-HT1A receptors 
(201,222) and the anxiolytic-like activity of clozapine in an ultrasonic vocalization 
test in rat, is blocked by WAY100635, a selective 5-HT1A receptor antagonist 
(223)
, further supporting a 
role of 5-HT1A receptors in the mechanism of action of clozapine.  
Fifth, exploratory clinical trials have shown that buspirone and tandospirone, which act as partial 
agonists at 5-HT1A receptors 
(32,224), substantially ameliorate cognitive and negative symptom scores 
and reduce the incidence of extrapyramidal symptoms in haloperidol-treated schizophrenic patients 
(225-229). The fact that beneficial effects are seen when a 5-HT1A partial agonist is administered to 
schizophrenic patients provides compelling clinical support for the rationale of combining D2 
antagonism with 5-HT1A receptor agonism in novel antipsychotics.  
Finally, recent clinical studies have shown that schizophrenic patients expressing the C(-1019)G 
polymorphism of the gene coding for the 5-HT1A receptor exhibit negative symptoms and cognitive 
deficit that are resistant to treatment with antipsychotics (115-118). As discussed in Chapter 2, the 
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C(-1019)G polymorphism is located in the promoter region of the 5-HT1A receptor gene and elicits 
hypoactivity of cortical 5-HT1A receptors and is associated with mood deficits 
(119,120)
. These findings 
provide powerful support for the contention that regulating 5-HT1A receptor activity is an important 
element in successful management of schizophrenia. 
4.3 Contribution of author’s work  
In view of the extensive evidence supporting an important role for 5-HT1A receptors in the control of 
the negative symptoms and cognitive deficits of schizophrenia, it is not suprising that numerous 
pharmaceutical companies have proposed drug candidates that combine 5-HTA agonism with D2 
antagonism or partial agonism (Fig. 4.1). However, despite extensive interest in compounds of this 
type, few direct comparative studies have been reported, with publications often describing results 
on only one or two compounds [for example, see publications on SSR181507 
(230)
, cariprazine 
(231)
 or 
adoprazine (232)]. This raises a considerable difficulty in evaluating the relative merits and limitations 
of these drugs, since experimental conditions can vary considerably between laboratories. One of 
the objectives of my work was to carry out systematic comparative studies under uniform conditions 
in order to interpret the role of different receptor targets in the effects of novel antipsychotic 
candidates. A key finding of these studies is that relatively modest changes in the balance of D2 
antagonism versus 5-HT1A receptor activation translate to markedly divergent profiles of activity in 
neurochemical and behavioural tests of antipsychotic-like activity. My work led to the notion that an 
appropriate balance of D2 and 5-HT1A receptor properties is necessary in order to achieve optimal 
Figure 4.1: Timeline of the rise of interest in 5-HT1A receptors as targets for antipsychotics.  
Early interest in 5-HT1A receptors centered on their role in attenuating EPS but subsequent studies extended 
this to negative symptoms and cognitive deficits. The author’s work drew attention to the 5-HT1A agonist 
properties of clozapine and other atypical antipsychotics. Here, landmark research studies are shown in black; 
exploratory drugs are shown in red; commercialized antipsychotics are shown in magenta. 
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antipsychotic activity. The rest of this Chapter is devoted to describing the comparative studies that I 
directed to elucidate this issue, which is relevant to the ongoing efforts to identify and develop 
antipsychotics that activate 5-HT1A receptors. Indeed, in addition to clozapine, ziprasidone and 
nemonapride, the more recent antipsychotics, aripiprazole and perospirone, also exhibit partial 
agonist properties at 5-HT1A receptors in a variety of in vitro assays [15,56,63,64,80] 
(233-236)
. Other 
compounds have undergone extensive clinical trials, including bifeprunox [75] 
(237)
, lurasidone 
(48)
 and 
cariprazine (231,238). Further, early-stage 5-HT1A/D2 compounds such as adoprazine (SLV313; 
(232), 
SSR181507 
(230)
 and F15063, a development candidate identified in my laboratory [71], have been 
extensively characterized at a pharmacological level and provide useful comparators for assessing 
the influence of combined targeting of 5-HT1A and D2 receptors.  
Binding affinity of recent antipsychotics at D2 and 5-HT1A receptors in vitro  
I carried out a ligand binding and in vitro functional activity comparison of a series of commercialized 
and potential antipsychotics [56], showing that they differed widely in their balance of affinity and 
agonist properties at 5-HT1A receptors. As a follow-up, I carried out a much broader investigation of 
the binding profiles of 22 antipsychotics at 8 native brain and 18 cloned human receptors (239). As 
expected, conventional antipsychotics such as haloperidol exhibited robust affinity for D2-like 
receptors and little or no affinity for 5-HT1A receptors. Atypical ‘multi-receptor’ antipsychotics such 
as clozapine, olanzapine, risperidone and ziprasidone, were notable for their accentuated 5-HT2A and 
5-HT2C receptor affinity. These antipsychotics also interacted potently with diverse other receptors, 
including α1 and α2 adrenergic, muscarinic M1 and histaminergic H1 receptors, some of which are 
associated with side-effects such as sedation, weight gain and metabolic disturbances. These data 
are consistent with previous comparative studies of antipsychotic affinity profiles (240-242). 
In contrast, some recent compounds exhibited comparatively simple receptor profiles with 
decreased affinity at 5-HT2A and 5-HT2C receptors, and low affinity at adrenergic, M1 and H1R 
receptors (Fig. 4.2). This clearly marks a departure from the principle that had guided the selection 
of atypical antipsychotics, i.e., more potent interaction at 5-HT2A than at D2 receptors and broad 
antagonism of monoamine receptors, as described above. Instead, recent antipsychotics exhibit 
affinity at 5-HT1A receptors close to their affinity at D2 receptors. Thus the “selectively non-selective” 
profile typified by bifeprunox, adoprazine and F15063 [56,75,101] (194), as well as that reported for 
cariprazine and lurasidone (48,231), should avoid a number of undesirable effects associated with 
current antipsychotics, whilst retaining desired pharmacological actions (242-244). Nonetheless, 
differences are apparent among these compounds. For example, aripiprazole and bifeprunox have 
about 10-fold higher affinity at D2 receptors than at 5-HT1A [56,75], whereas adoprazine and 
SSR-181507 possess 5 to 10-fold higher affinity at 5-HT1A than at D2 receptors [56,101]. Thus, the 
balance of D2 and 5-HT1A receptor properties for these compounds varies substantially and the 
question of an “optimal balance” remains open, pending the availability of further clinical data drugs 
(Fig. 4.4).  
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Agonist efficacy of recent antipsychotics at D2 and 5-HT1A receptors in vitro  
The level of agonist efficacy at 5-HT1A and D2 receptors is a key element influencing activity of the 
compounds in models of antipsychotic action. Some recent compounds such as aripiprazole, 
bifeprunox and SSR181507 exhibit different levels of partial agonism at D2 receptors 
(245)
, as do other 
recently-reported compounds such as cariprazine (231) and PF-217830 [70] (246). The rationale for 
partial agonism at D2 receptors, although attractive (EPS reduction, “stabilization” of DA 
transmission, avoidance of hyper-prolactinaemia) is complex. For example, bifeprunox, which 
exhibits marked partial agonist activity at D2 receptors exceeding that of aripiprazole [70,75] 
(247,248)
 
did not achieve satisfactory antipsychotic efficacy in Phase III clinical trials and failed to win FDA 
regulatory approval. Thus it appears that D2 receptor partial agonism should, at most, remain very 
modest and not exceed that of aripiprazole, which has demonstrated antipsychotic efficacy (249,250).  
In our studies, a number of recent antipsychotics were compared in several tests of signal 
transduction at 5-HT1A receptors, including G-protein activation, adenylyl cyclase inhibition, 
extracellular regulated kinase (ERK1/2) phosphorylation and receptor internalization [56,63,64,80]. 
In general, the drugs behaved as partial agonists in all of these tests, but distinct responses were 
observed in some cases. For example, in G-protein activation ([35S]GTPγS binding) experiments, all 
the compounds exhibited agonist efficacy of about 40 to 60%, similar to that of buspirone [56,64]. 
Similarly, in the receptor internalization test, all the compounds exhibited low efficacy [80]. In 
contrast, in tests of ERK1/2 phosphorylation, clozapine exhibited modest efficacy (<30%) which was 
about half that of either other antipsychotics or buspirone [63]. F15063 was more active than the 
other compounds tested, with efficacy higher than that of buspirone and approaching that of 
8-OH-DPAT [71]. The results from the adenylyl cyclase test were markedly distinct: ziprasidone, 
Figure 4.2: Binding profiles of established and novel antipsychotics.  
Whereas haloperidol exhibits potent and relatively selective antagonism at D2 receptors, the atypical 
antipsychotics such as clozapine, olanzapine and risperidone, exhibit multi-receptor profiles. More recent 
drugs, such as aripiprazole and cariprazine, show preferential interactions at D2 and 5-HT1A receptors. 
Adapted from [101]. 
 
Note: for copyright reasons, this Figure is omitted from the public access version of the thesis. 
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adoprazine and F15063 showed high efficacy whereas bifeprunox was less active [56]. Taken 
together, these data show that recent antipsychotics exhibit various levels of partial agonism at 
5-HT1A receptors and this affects their balance of pharmacological properties in relation to 
agonism/antagonism at D2 receptors. These data also indicate that agonist efficacy can be highly 
dependent on the in vitro efficacy system considered. Indeed, some agonists preferentially activate 
specific signaling pathways, a phenomenon known as “functional selectivity” or “biased agonism” 
(127,251). Thus, aripiprazole has been reported to exhibit functional selectivity at dopamine D2 
receptors, at which it exhibited distinctive signaling properties for adenylyl cyclase inhibition, ERK1/2 
phosphorylation and receptor internalization 
(252,253)
. In addition, aripiprazole may also act as a biased 
agonist at 5-HT1A receptors, i.e., it preferentially elicited DA release in frontal cortex (via locally-
expressed 5-HT1A receptors) at low doses whereas higher doses are necessary to inhibit serotonin 
release (via raphe-localized 5-HT1A receptors) 
(254). These differences likely arise from distinct signal 
transduction properties of 
5-HT1A receptors in different 
brain regions [99] 
(110,112)
. Thus, 
some differences between 
novel antipsychotics may arise 
from their potential 
“functional selectivity” at 
5-HT1A receptor 
subpopulations (e.g. in frontal 
cortex), that mediate some of 
the therapeutic properties of 
atypical antipsychotics. 
Preferential pharmacological 
targeting of post-synaptic 
cortical 5-HT1A receptors has 
recently been demonstrated 
in my laboratory using a 
selective 5-HT1A receptor 
“biased agonist”, F15599, as 
described in Chapter 3 
[88,94,99]. 
Activity in rodent models of positive symptoms of schizophrenia  
In view of the complexity and multifactorial nature of schizophrenia, I believed strongly that no 
single experimental procedure in a non-human species can be considered to model the pathology. At 
best, different tests may model individual symptoms of the illness and an assessment of the 
therapeutic usefulness of putative antipsychotics may be assessed by profiling their activity in a 
palette of diverse types of experiments (for review see (255). In the case of the positive symptoms of 
Figure 4.3: Agonist efficacy of antipsychotics at 5-HT1A receptors.  
Antipsychotics were tested in a variety of in vitro signal transduction 
models and in different cellular environments. Like clozapine, recent 
antipsychotics act as partial agonists at this receptor.  
Adapted from [56,63,71,80]. 
 
Note: for copyright reasons, this Figure is omitted from the public 
access version of the thesis. 
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schizophrenia, procedures include pharmacological reversal of stereotyped behaviors or hyper-
locomotion elicited by the DA releasers, methylphenidate and amphetamine, DA agonists such as 
apomorphine, or non-competitive NMDA receptor antagonists such as phencyclidine, ketamine or 
MK-801. Inhibition of conditioned avoidance behavior and reversal of apomorphine-induced pre-
pulse inhibition (PPI) deficits are also widely used. All of these procedures are sensitive to D2 
receptor antagonists and are therefore suitable for comparing drugs possessing combined D2 and 5-
HT1A properties. In an extensive comparison of the activity of twelve established and novel putative 
antipsychotics [65,66,72,76,77], the compounds were active in most of the above tests, but some 
important differences emerged. For example, haloperidol was potently active in all of the tests over 
similar dose ranges. In contrast, clozapine and other atypical antipsychotics exhibited a broader 
variability of active doses among tests, probably reflecting their lower affinity at D2 receptors. In 
particular, the total reversal (“normalization”) of stereotyped behaviors induced by methylphenidate 
required high doses of clozapine and was not achieved with ziprasidone [76]. In the case of 
antipsychotics possessing 5-HT1A and D2 properties, aripiprazole and the other D2 partial agonists 
displayed somewhat variable active dose ranges. Indeed, aripiprazole, like another D2 receptor 
partial agonist, SSR181507, was active in most tests but failed to normalize methylphenidate-
induced behaviors [65,76]. Thus, this test may be particularly stringent in identifying high-potency D2 
receptor antagonists, as well as differentiate “true” antagonists from partial agonists. These 
observations underlined the importance of potent D2 receptor antagonism to achieve “incisive” 
antipsychotic-like properties. Consistent with this interpretation, the potency of the antipsychotics 
to inhibit apomorphine-induced climbing in mouse correlated closely with their in vitro affinity at D2 
receptors and with central occupancy of D2 receptors [68]. In a further test of antipsychotic-like 
activity, haloperidol and risperidone reversed PPI deficits induced by apomorphine in rat [66], a 
model of gating deficits observed in schizophrenics 
(256)
 and consistent with previous findings 
(257,258)
. 
The activity of antipsychotics in this test is related to D2 receptor antagonism 
(259) but may be 
outweighed by excessive 5-HT1A receptor agonist properties. Consequently, 5-HT1A / D2 compounds 
exhibited a variety of profiles, depending on their balance of properties at these sites. Aripiprazole, 
which acts as a partial agonist at both D2 and 5-HT1A receptors was poorly active in this test [66,77], 
although another study reported somewhat discrepant data (260). Adoprazine and SSR181507 failed 
to reverse apomorphine-induced PPI deficits, due to excessive 5-HT1A agonist actions, as 
demonstrated by the fact that activity was restored by pre-administration of a selective 5-HT1A 
receptor antagonist [66,77]. In addition, adoprazine and SSR181507 elicited deficits of basal PPI, at 
least at some doses. This is attributable to their marked agonism at 5-HT1A receptors: the deficit 
elicited by SSR181507 was reversed when animals were pre-treated with WAY100635 [77]. In a 
study from another laboratory, the deficit elicited by the efficacious 5-HT1A receptor agonist, 8-OH-
DPAT, was attenuated by administration of the partial agonist, buspirone, or D2 receptor antagonists 
such as haloperidol and raclopride (261), supporting the concept of a “balance” of activity between 5-
HT1A receptor activation and D2 receptor blockade. Thus, whilst F15063 exhibits substantial 5-HT1A 
receptor agonism, it nevertheless reversed apomorphine-induced PPI deficits, likely due to its 
concomitant potent D2 receptor antagonism [72]. It should be noted that, contrary to observations 
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in rats, 5-HT1A receptor activation does not impair but increases PPI in mice 
(262)
, so caution is 
necessary when extrapolating from these data to other species. 
Activity in rodent models of negative symptoms and cognitive deficits of schizophrenia  
Negative symptoms of schizophrenia, including blunted affect, impoverished speech and social 
withdrawal, are poorly treated by many current antipsychotics. I therefore carried out a comparative 
microdialysis study of the effects of eleven antipsychotics on a surrogate neurochemical marker of 
efficacy against negative symptoms, i.e., increased DA levels in the frontal cortex of rat [60], a brain 
region that is relevant to the control of mood and cognition. Clozapine and other atypical 
antipsychotics, but not haloperidol, increased frontal cortex levels of DA [60,86]. Neither aripiprazole 
nor bifeprunox increased DA levels in these studies, although others have reported that aripiprazole 
elicited a modest increase in DA levels over a narrow dose range 
(263,264)
. These data suggest that 
aripiprazole and bifeprunox may have a limited capacity to alleviate cognitive deficits or negative 
symptoms that arise from impaired frontocortical dopaminergic neurotransmission. Indeed, it 
appears that by activating inhibitory pre-synaptic VTA-located D2 receptors controlling DA release 
(265), the D2 receptor partial agonist properties of these compounds predominate in this 
neurochemical paradigm. In contrast, the putative 5-HT1A/D2 antipsychotics, adoprazine, SSR181507 
and F15063, robustly increased DA release in frontal cortex of rat [60,86]. This effect was mediated 
by 5-HT1A receptor agonism, as demonstrated by its reversal by the selective 5-HT1A receptor 
antagonist, WAY100635.  
Another neurochemical means of investigating the 5-HT1A agonist properties of antipsychotics is to 
examine their inhibition of serotonin release, a response controlled by activation of 5-HT1A 
autoreceptors. In a comparative microdialysis study, serotonin levels in ventral hippocampus were 
not significantly modified by ziprasidone or aripiprazole, indicating that their 5-HT1A agonist 
properties are modest [60]. In contrast, bifeprunox, adoprazine, SSR181507 and F15063 robustly 
reduced serotonin levels [60,86], consistent with accentuated agonist efficacy at 5-HT1A receptors. 
However, generalized reductions of serotonin release are unlikely to be beneficial in schizophrenia. 
Indeed, animals with impaired serotonin transmission can exhibit deficits in tests of cognitive 
flexibility (see (266) and discussion below) and, in mice that lack pre-synaptic serotonergic markers, 
atypical antipsychotics fail to oppose PCP-induced PPI deficits (267). In addition, the antipsychotic-like 
activity (assessed by inhibition of MK-801-induced hyper-locomotion) of M100907 is lost in 
serotonin-depleted mice (268), suggesting that serotonergic neurotransmission must be maintained to 
achieve therapeutic efficacy with atypical antipsychotics. These considerations suggest that it may 
be preferable to select antipsychotics that do not substantially inhibit serotonin levels.  
A behavioural model of the negative symptoms of schizophrenia is the measure of PCP-induced 
social interaction deficits, which resemble the social withdrawal observed in schizophrenia patients. 
In a comparative study of nine antipsychotics [62], both haloperidol and clozapine failed to show 
significant activity over a three-day treatment period. However, clozapine has been reported to 
require three weeks of treatment in order to attenuate the PCP-induced deficit (269). In contrast, 
aripiprazole, SSR181507 and F15063 showed substantial activity in this model, attenuating PCP-
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induced deficits within 3 days at low doses [62,73]. In each case, the attenuating effects of these 
drugs were blocked by pre-administration of a 5-HT1A antagonist [62,73], consistent with other 
reports on SSR181507 (230) and aripiprazole (270). It is interesting that adoprazine and the selective 
5-HT1A receptor agonist, 8-OH-DPAT, did not alleviate PCP-induced social interaction deficits, 
indicating that the balance of D2 antagonist/partial agonist and 5-HT1A receptor agonist properties is 
critical to activity in this test [62]. Nevertheless, in a separate study 
(230)
 the selective 5-HT1A agonist, 
8-OH-DPAT, was able to reverse PCP-induced social interaction deficits, possibly reflecting 
methodological differences and underlining the necessity for comparative studies under uniform 
experimental conditions.   
In experiments designed to investigate the effects of antipsychotics on cognitive parameters, several 
recent 5-HT1A/D2 antipsychotics were compared in a reversal learning task, a model of cognitive 
flexibility. In this test, PCP impairs re-acquisition of an operant conditioning task, and the atypical 
antipsychotic clozapine tended to reduce deficits, although it required 4 to 5 days of treatment 
before this became apparent [73] 
(271)
. In contrast, the attenuation of PCP-induced deficits with 
SSR181507 and F15063 was detected from the first day [73] 
(271)
. Consistent with these observations, 
5,7-dihydroxytryptamine lesions of pre-frontal cortex serotonergic transmission in marmosets 
impaired cognitive flexibility (266), an effect which is neurochemically specific, as demonstrated by the 
fact that depletion of frontal cortex DA did not elicit a similar effect (154). These observations suggest 
that activation of cortical 5-HT1A receptors may be beneficial in maintaining cognitive flexibility and 
Figure 4.4: Concept of “balance”when targeting both D2 and 5-HT1A receptors  
Antipsychotics that exhibit potent D2 receptor antagonism, such as haloperidol (lower left), possess marked 
side-effects (indicated in red). Combining D2 antagonism or partial agonism with 5-HT1A agonism, as in the 
case of clozapine or aripiprazole, brings significant benefits, but a suitable balance needs to be achieved. 
For example, bifeprunox lacks sufficient antipsychotic efficacy due to excessive D2 partial agonism. 
Buspirone is anxiolytic but lacks adequate D2 antagonism. Figure adapted from [96]. 
 
Note: for copyright reasons, this Figure is omitted from the public access version of the thesis. 
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that this underlies the capacity of adoprazine and F15063 to attenuate reversal learning deficits 
induced by NMDA hypofunction. Indeed, these compounds have only weak affinity for other 5-HT 
receptors, such as 5-HT2A and 5-HT6 [71,75] 
(232) and exemplify the concept of “selectively non-
selective” antipsychotics targeted at 5-HT1A / D2 receptors. 
Taken together, the results obtained in my laboratory provided consistent evidence of the 
importance of the balance between 5-HT1A agonist and D2 antagonist properties in order to achieve 
desired neurochemical profile. Although several recent antipsychotics interact at a variety of targets 
other than D2 and 5-HT1A, it seems clear that agonist properties at 5-HT1A receptors provide benefits 
in tests of negative symptoms and cognitive deficits related to schizophrenia. 
Activity in models of extrapyramidal symptom liability and side effects 
The classic animal model for assessing EPS liability in rodents is catalepsy, although this is essentially 
a model of rigidity, rather than akathisia or tardive dyskinesia 
(255)
. Haloperidol, risperidone, 
olanzapine and ziprasidone all induce catalepsy to various degrees, whereas clozapine, which is a 
low-potency D2 antagonist, only induces slight catalepsy at high doses 
(184,222). A comparative study 
showed that, unlike conventional or atypical antipsychotics, D2/5-HT1A drugs were essentially free of 
catalepsy in rodents [65,76]. This was true of the D2 receptor partial agonists aripiprazole, 
bifeprunox and SSR181507, but also of the potent D2 receptor antagonists, adoprazine and F15063 
[65,76,72]. Their freedom from catalepsy induction is remarkable, in view of the high affinity of 
these compounds at D2 receptors in vitro and their marked in vivo D2 receptor antagonism observed 
in a range of tests including normalization of methylphenidate-induced stereotypies [76] (see 
above). In addition, in the case of  typical and atypical antipsychotics, high levels of D2 receptor 
occupancy are associated with EPS induction (184,272,273) and it is therefore striking that adoprazine and 
F15063 are free of catalepsy induction even at doses that completely occupy D2 receptors [68]. The 
absence of catalepsy with recent antipsychotics is at least partially due to their 5-HT1A agonist 
properties, both in rat and mouse. Indeed, when 5-HT1A receptors are blocked by prior antagonist 
treatment, a robust catalepsy is then unmasked [59] (274). These data emphasize the role of 5-HT1A 
activation in the low EPS liability of new generation antipsychotics [65]. In addition to rodent studies, 
we carried out a comparative study of the acute influence of thirteen antipsychotics on behavior of 
non-human primates [90]. In Cynomolgous monkeys, haloperidol produced potent dystonia-like 
rigidity and unusual postures at low doses. Clozapine exhibited little rigidity but elicited sedation-like 
behavior. In contrast, aripiprazole and other 5-HT1A agonists/D2 receptor partial agonists (bifeprunox 
and SSR181507) induced very little motor disturbance. Other compounds (adoprazine, F15063), 
which act as 5-HT1A agonists and D2 antagonists, exhibited an intermediate profile, once again 
suggesting that the balance of 5-HT1A and D2 receptor properties plays an important role. 
It should be noted that all of the drugs interfered with cognitive function in operant conditioning 
tasks, when administered at higher doses. Thus, in rat, the compounds decreased accuracy of 
responding in a 5-choice serial reaction time task (5CSRTT), a test that requires sustained attention 
in order to gain  food reinforcement (275). The decrease in accuracy cannot to be due to catalepsy 
induction and may be due to a slowing in responding and/or sedative effect of the compounds. 
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Indeed, decreased performance in the 5CSRTT coincided, in most cases, with decreases in 
spontaneous locomotion, consistent with a general reduction in motor activity [76].  
Antipsychotics with pronounced D2 antagonism increase prolactin levels by blocking pituitary D2 
receptors that tonically inhibit prolactin release. I therefore undertook a comparative study of the 
neuroendocrine effects of antipsychotics in rats [64] 
(276)
. Clozapine only increased prolactin levels at 
high doses (40 mg/kg) reflecting its low affinity at D2 receptors, whereas haloperidol and risperidone 
did so at low doses, consistent with their potent antagonism of D2 receptors. Recent antipsychotics 
that, like haloperidol, act as antagonists at D2 receptors, including adoprazine and F15063, also 
increased plasma prolactin levels [64,72]. In contrast, antipsychotics possessing partial agonism at D2 
receptors, such as aripiprazole, bifeprunox and SSR181507, elicited only small increases in prolactin 
levels [64] 
(276)
, likely because they maintain a low level of activation of pituitary D2 receptors.  
A serious side-effect of some current antipsychotics such as clozapine and olanzapine is their 
detrimental impact on metabolism and body mass, with concomitant induction of diabetic disorders, 
commonly referred to as “metabolic syndrome” 
(192,193)
. I therefore compared the effects of 
antipsychotics on plasma glucose levels in rats [83]. Upon acute administration, clozapine and 
olanzapine elicited substantial increases in plasma glucose levels, whereas drugs such as aripiprazole, 
ziprasidone and bifeprunox, which are not associated with metabolic dysfunction in humans, did not. 
These results are consistent with the reduced interaction by these antipsychotics with receptors 
associated with metabolic regulation, including 5-HT2C and histamine H1 receptors 
(277-279)
. However, 
differences were also apparent among recent 5-HT1A / D2 compounds. Thus, SSR181507 and 
adoprazine elicited increases in plasma glucose whereas F15063 did not [83]. It is possible that these 
differences may be related to the 5-HT1A / D2 balance of these compounds. Indeed, SSR181507 and 
adoprazine also elicited increases in corticosterone release, likely due to their substantial 5-HT1A 
agonism [83]. In contrast, F15063 has predominant D2 antagonist properties and did not elicit 
corticosterone release [72]. These observations emphasize, once again, the importance of 
considering the balance of 5-HT1A / D2 properties in the profile of novel antipsychotics.  
4.4 Conclusions and perspectives. 
Whilst a variety of recent antipsychotic drugs share the general property of interacting at both 5-
HT1A and D2 receptors, the extensive pharmacological comparisons that I directed revealed that the 
“balance” of D2 and 5-HT1A properties profoundly influences their pharmacological profile [96,101]. 
Thus, insufficient 5-HT1A agonism versus D2 receptor antagonism would yield an antipsychotic that 
induces EPS and is likely to be less effective against negative and cognitive symptoms (cf. 
haloperidol). In contrast, insufficient D2 antagonism versus 5-HT1A agonism (as in the case of 
buspirone) would yield a compound that lacks robust antipsychotic action and may cause a 
serotonin syndrome, at least in rodents. Taken together, the observations indicated that 
antipsychotics exhibiting an appropriate combination of D2 / 5-HT1A properties may possess 
improved efficacy against negative symptoms and cognitive deficits of schizophrenia. Further, these 
drugs may be expected to have low EPS liability and little propensity to induce side-effects such as 
metabolic dysfunction or weight gain.    
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5. Serotonin 5-HT1B and 5-HT1D receptors 
5.1 Key points 
 Many of the drugs that were characterized over the course of the author’s research interacted at 
several serotonin receptors. The signalling of 5-HT1B, 5-HT1D, 5-HT2A, 5-HT2B and 5-HT2C receptors 
was therefore investigated as this can substantially influence CNS responses. 
 5-HT1B and 5-HT1D receptors were found to exhibit marked differences in constitutive activity for 
activation of coupled G-proteins [25,31,34]. This constitutive activity was blocked by some, but 
not all, antipsychotics [37].  
 Serotonin was discovered to exhibit ‘protean’ agonism at 5-HT1B receptors: under high sodium ion 
conditions, 5-HT stimulated G-protein activation but under low sodium ion conditions it inhibited 
basal activation [53].  
 Using 5-HT1D receptors expressed in CHO cells, I developed a technique to detect and quantify 
constitutive activity without using inverse agonists. The methodology relied on isotopic dilution 
of [35S]GTPγS binding with unlabelled GTPγS [34]. 
 Despite prominent constitutive activity in vitro, and the availability of selective inverse agonists, 
tests of 5-HT1B / 5-HT1D receptor activation in vivo and ex vivo did not detect corresponding 
constitutive activation [25]. 
5.2 Background to author’s work 
Classical theories of G-protein-coupled receptor (GPCR) activation assume that functional responses 
are induced by the action of agonists at otherwise quiescent receptors (280). Accordingly, the 
induction of an active state of the receptor, capable of stimulating signal transduction pathways, was 
considered to depend upon the presence of an agonist. Antagonists were thought to exert no effects 
themselves on the state of receptor activation, and merely interfere with the actions of agonists. 
However, during the 1970s and 1980s, several observations suggested that certain “antagonists” 
may act in a fashion opposite to agonists. One early observation was that lesions of dopaminergic 
pathways and dopaminergic antagonists can induce additive effects on striatal levels of acetylcholine 
(281), suggesting that some antagonists could have an effect of their own, in addition to blocking the 
action of endogenous dopamine. Nevertheless, it could not be formally excluded that antagonists 
might be blocking the actions of residual pools of dopamine. Another study reported that agonists 
had higher affinity for [3H]dopamine-labelled dopamine receptors whereas antagonists had greater 
affinity for [3H]haloperidol-labelled sites (282). Further, at muscarinic receptors labelled with 
[3H]quinuclidyl benzylate, antagonists had higher affinity for receptors uncoupled from G-proteins 
(283). This led to the proposal by Costa and Herz that certain antagonists act as “inverse agonists” at 
δ-opioid receptors endogenously expressed by NG108-15 cells (284). Indeed, whereas the agonist, 
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DADLE, increased GTPase activity at these δ-opioid receptors, the “antagonist,” ICI174864, inhibited 
basal activity. Crucially, both actions were blocked by a “neutral” antagonist (cf. a simplified model 
of receptor coupling in Fig. 2.2). Although agonists and antagonists are classically considered to 
down- and up-regulate receptors, respectively, the above observations led to the suggestion that 
“inverse agonist” rather than “antagonist” properties may favor receptor up-regulation in vitro 
and/or in vivo 
(285)
. Subsequent studies employing homogeneous populations of recombinant 
receptors in heterologous expression systems free of endogenous agonist underpinned the concept 
of “negative intrinsic efficacy” and “inverse agonism” 
(286,287)
. Thus, many types of wild-type GPCRs 
have been observed to display an agonist-independent constitutive activation of intracellular 
transduction mechanisms inhibited by inverse agonists. In contrast, genuinely “neutral” antagonists 
are considered to block the actions of both agonists and inverse agonists, without themselves 
altering activity. Gradually, a more sophisticated model of G-protein coupling emerged (the Cubic 
Ternary Complex model) in which multiple states of receptor / G-protein interaction were identified, 
depending on the constitutive activity of the receptor and its interaction with bound ligands and/or 
G-protein (see Fig. 5.1). Such a model instructed my thinking about the function of serotonin 
receptors, which exhibit substantial constitutive activity and for which both agonists and inverse 
agonists can be identified (see next section). 
 
Figure 5.1: The Cubic Ternary Complex Model of receptor-G-protein coupling. 
The model represents ligand (L), receptor (R), and G protein (G) interactions. Association of L and R is 
represented from top to bottom, R and G interactions from front to back, and the conversion of inactive and 
active R states from left to right. The dynamics of  G-protein activation are represented as red dashed lines. 
Reproduced from 
(2)
. 
Note: for copyright reasons, this Figure is omitted from the public access version of the thesis. 
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5.3 Contribution of author’s work  
5-HT1B receptors: in vitro constitutive activity and R:G ratios 
Serotonin 5-HT1B autoreceptors on serotonergic neuronal terminals modulate serotonin release both 
in the central nervous system 
(288)
 [25] and in the periphery, including the dura matter. Consequently, 
an understanding of mechanisms of signal transduction at 5-HT1B receptors is relevant to the 
treatment of affective and cardiovascular disorders and to the management of migraine [13] 
(289,290)
. 
In vitro, 5-HT1B receptors couple to inhibition of adenylyl cyclase 
(291), a response which is abolished 
by pre-treatment with Bordetella pertussis toxin (PTX). This toxin ADP-ribosylates Gα subunits of the 
Gi/o family, indicating coupling of 5-HT1B receptors to this family of G proteins.  
In view of the importance of 5-HT1B receptors, I decided to apply a similar approach to these sites as I 
had used for 5-HT1A receptors (Chapter 2). Thus, a [
35
S]GTPγS binding study at 5-HT1B receptors 
expressed in CHO cells demonstrated robust activation of G-proteins by agonists, and also revealed 
that 5-HT1B receptors exhibit marked constitutive activity for G-protein activation [31]. In agreement 
with previous studies 
(292,293)
, several compounds were shown to act as inverse agonist at this 
receptor, including methiothepin and the selective 5-HT1B ligand, SB224,289 [31] as well as some 
antipsychotics [37]. In addition, an investigation was carried out of influence of receptor density on 
the activation of intracellular G-proteins using two cell membrane preparations (referred to as 
RGhigh and RGlow) that exhibited either a high or a low ratio of receptor expression to G-protein 
expression, determined in saturation binding experiments. Importantly, RGhigh and RGlow 
membranes differed in their functional responses. Firstly, the stimulation attained with 5-HT was 
markedly higher in RGhigh membranes than in RGlow membranes, probably reflecting a faster rate 
of G-protein 'cycling' due to the greater availability of 5-HT1B receptors per G-protein 
(294,295)
. 
Secondly, the relative efficacies of the partial agonists, BMS181,101 and L775,606, were also 
increased in RGhigh membranes vs. RGlow membranes. The present data differ from those for 
5-HT1A receptors expressed in CHO cells [10] where the potency of 5-HT, but not its efficacy, was 
increased by an augmentation of R:G stoichiometry: the reverse was true for 5-HT1B receptors. One 
factor potentially implicated is that the R:G ratio of RGlow membranes (~0.3) was substantially less 
than its counterpart in CHO-h5-HT1A cell membranes (1.4) [10]. Thus, CHO-h5-HT1B RGlow 
membranes may not have attained a 'ceiling' whereby, for example, the number of available 
G-proteins was limiting, as may have been the case in studies of CHO-h5-HT1A RGlow cell membranes 
[10] and cannabinoid CB1 receptors (296). Thirdly, in RGlow membranes, the inhibitory effects of the 
inverse agonist, methiothepin, was modest, whereas in RGhigh membranes about 40 % of basal 
[35S]-GTPγS binding was inhibited by SB224,289 and methiothepin. These data are reminiscent of 
observations at CHO-h5-HT1A cell membranes showing that an increase in R:G ratio augmented the 
negative efficacy of the inverse agonist, spiperone [10]. The most likely explanation is that inverse 
agonists stabilise G-protein-coupled (as well as uncoupled) receptors in inactive conformation(s) [10] 
(297). This reduces the pool of G-proteins available for activation by non-inverse agonist-occupied 
receptors. The present data therefore provide evidence that receptor:G-protein stoichiometry is an 
important factor in detecting inverse agonism at 5-HT1B receptor-coupled G-proteins.  
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5-HT1B receptors: constitutive activity and “protean” agonism at G-protein subtypes 
The study described above [31] and other studies of the influence of serotonergic ligands on 
G-protein activation by 5-HT1B receptors 
(77,292,293)
 used techniques which measured ‘overall’ G-
protein activation, without distinguishing the precise G-protein subtype(s) involved. However, 5-HT1B 
receptors can couple to several Gα subtypes, including members of the Gαi/o family and Gα15 
subunits 
(86,298,299)
. In fact, reconstitution of 5-HT1B receptors expressed in Sf9 cells with different 
purified Gαi subunits increased the affinity of agonists, indicating coupling to these G-protein 
subtypes (86). Compared with Gαi2 and GαO, the Gαi3 subtype induced the greatest increase in 
agonist affinity, suggesting preferential coupling of 5-HT1B receptors to this G-protein. In view of 
these observations, I decided to employ an antibody-capture technique coupled to scintillation 
proximity assay (SPA) detection 
(91)
 [45,46] to characterise Gαi3 subunit activation by recombinant 
human 5-HT1B receptors stably expressed in CHO cells [31]. The latter express Gαi3 subunits 
(92,300,301)
 
but only low levels of Gαo and Gαi1 
(92,301)
. I had previously applied a similar methodology to the 
study of 5-HT1A receptor coupling to G-proteins [46] (Chapter 2). 
Agonist-induced activation of Gαi3 subunits exhibited interesting differences from that of ‘total’ 
G-protein activation determined by classical [35S]GTPγS binding filtration assays [31,34] (77,293). Firstly, 
although BMS181,101 behaved as an efficacious agonist (Emax 85%) in conventional [
35
S]GTPγS 
binding experiments, its efficacy for Gαi3 activation was accentuated, consistently exceeding that of 
5-HT. Secondly, S18127 behaved as ‘neutral’ antagonist in [35S]GTPγS binding [34], whereas it 
exhibited modest partial agonist properties for Gαi3 activation. Thirdly, the potencies of the agonists 
for Gαi3 activation were markedly greater than for ‘total’ G protein activation [53]. Thus, the profile 
of action of 5-HT1B receptor ligands for Gαi3 subunit activation may differ from that of other 
G-protein subtypes, and classical G protein activation assays may mask these differences by yielding 
a composite response of multiple G proteins. In contrast to the actions of agonists, it is interesting to 
note that the negative efficacies of inverse agonists for inhibition of Gαi3 activation corresponded 
closely to those reported previously by classical methods. This suggests that a major proportion of 
the constitutive activity in CHO-h5-HT1B cell membranes may be mediated by Gαi3 subunits.  
We investigated the detection of constitutive activity under different conditions of sodium ion 
availability [53]. Indeed, NaCl influences receptor conformation, favouring a change from a G-protein 
coupled to an uncoupled state, reducing the affinity of agonists (302). Further, NaCl reduces basal 
G-protein activation in membranes of cells expressing GPCRs (67,303,304). However, few studies have 
examined the influence of NaCl on specific G protein subtypes (305). In our study, NaCl concentration 
was inversely related to basal Gαi3 activation and the inverse agonist, methiothepin failed to inhibit 
[35S]GTPγS binding in the presence 300mM NaCl, when constitutive activity was, it seems, totally 
suppressed [53]. These data are reminiscent of studies at 5-HT1A receptors, where inverse agonist 
properties of certain ligands could only be observed in the absence of NaCl (98). However, a striking 
result concerned the influence of 5-HT on Gαi3 activation. Whereas, under standard conditions 
(100mM NaCl), 5-HT exhibited robust stimulation of [35S]GTPγS binding to Gαi3 subunits, at low NaCl 
concentrations (10mM), 5-HT inhibited Gαi3  activation [53]. Hence, under the latter conditions, 
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5-HT behaved as an inverse agonist, reversing basal [
35
S]GTPγS binding in a manner similar to that of 
methiothepin (Fig. 5.2). This behaviour is consistent with the concept of a protean agonist 
(97)
, by 
which ligands can exhibit either agonist or inverse agonist properties depending on the ‘receptor 
tone’. When the latter is low (i.e. little constitutive G protein activation), the agonist properties of 
the ligand (in this case 5-HT) are observed. In contrast, when receptor tone is high (i.e. a high level of 
constitutive activity) the ligand stabilises the receptor in a conformation which is less able to activate 
G-proteins than the free, non-ligand-occupied, receptor. Indeed, it is noteworthy that, over a wide 
range of NaCl concentrations (10 to 100mM), saturating levels of 5-HT induced a similar degree of 
Gαi3 labelling, either by stimulating or inhibiting [
35
S]GTPγS binding from basal levels.  
Previous reports had described the protean agonist properties of secretin at constitutively active 
mutants of secretin receptor 
(306)
 and of levomedetomidine and the dexefaroxan analogue, 
RX831003, at α2A receptors 
(307,308)
. However, our study was the first to demonstrate that the 
endogenous agonist, 5-HT, can exhibit protean agonism at non-mutant 5-HT1B receptors. These data 
raise the intriguing possibility that agonist signalling at 5-HT1B receptors may vary markedly 
depending on NaCl concentration. It would be interesting to investigate whether these actions of 
NaCl are due to its reported allosteric regulation of a conserved aspartate residue in the intracellular 
end of the putative 2nd transmembrane segment of the receptor. Mutation of this residue in 
noradrenalin α2 receptors abolished the ability of Na+ to modulate receptor-ligand interactions (302).  
 
5-HT1D receptors: quantification of its prominent constitutive activity in vitro 
Despite progress in defining the actions of agonists and inverse agonists at different receptor targets 
in vitro, several obstacles hinder the detection and quantification of constitutive activity. Firstly, the 
presence of constitutive activity has often been inferred when ligands (inverse agonists) inhibit basal 
activity in the absence of an endogenous ligand. However, if such inverse agonists are not available, 
the potential presence of constitutive activity cannot be verified. Hence, it is desirable to be able to 
use a procedure permitting the detection and quantification of constitutive activity independently of 
the use of inverse agonists. Secondly, the efficacy of agonists is expressed relative to that of a 'full' 
Figure. 5.2: Influence of NaCl on 5-HT1B receptor-mediated activation of Gai3 subunits.  
Adapted from [53].   
 
Note: for copyright reasons, this Figure is omitted from the public access version of the thesis. 
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agonist (generally the endogenous neurotransmitter). However, in the case of inverse agonists, the 
existence of an 'endogenous ligand' remains speculative for many GPCRs and the maximal negative 
efficacy that may be attained is often unclear. Indeed, there is still no consensus as to how the 
efficacies of inverse agonists, relative to an actual or theoretical 'full inverse agonist', should be 
defined.  
5-HT1D receptors exhibit marked constitutive activity and several inverse agonists have been 
identified at this site [37] 
(292,309,310)
. Further, 5-HT1D receptors are of potential importance as 
inhibitory receptors on serotonergic cell bodies in the raphe nuclei, suggesting that inverse agonist 
properties at 5-HT1D receptors may be relevant to the treatment of affective disorders and of 
migraine [25]. In a novel approach, I investigate constitutive G-protein activation directly by 
analysing homologous inhibition of [
35
S]GTPγS binding by unlabelled GTPγS. Such binding isotherms 
detect high affinity (HA) and low affinity (LA) binding components. Although it had been shown that 
HA binding may be modulated by agonists (311), the actions of inverse agonists on HA binding had not 
been investigated. The investigations I conducted showed that analysis of HA sites yields information 
concerning the presence and degree of constitutive activity at CHO-h5 HT1D receptors [34]. 
The agonist, 5-HT, increased the amount of HA [35S]GTPγS binding. Conversely, the inverse agonists, 
methiothepin and, to a lesser degree, SB224289, decreased the number of HA binding sites. Neither 
5-HT nor the inverse agonists markedly influenced LA [
35
S]GTPγS binding sites [31,34], suggesting 
that the latter are not related to 5-HT1D receptor/G-protein coupling events. Further, LA (but not HA) 
sites were detected in membranes of control, non-transfected CHO cells, indicating that LA binding 
does not require the presence of h5-HT1D receptors and are probably related to the spontaneous 
turnover of GTP/GDP by Gα subunits in CHO cell membranes. These observations indicate that HA, 
but not LA, [
35
S]GTPγS binding observed under basal conditions reflects the constitutive activation of 
G-proteins by h5-HT1D receptors [34]. Three components may, therefore, be distinguished in GTPγS 
versus [
35
S]GTPγS binding isotherms (Fig. 5.3): (i) LA sites, which may reflect endogenous GTP/GDP 
exchange of G-proteins; (ii) receptor-dependent G-protein activation observed in the absence of 
receptor ligands, which provides a measure of the constitutive activity of the receptor and which can 
be inhibited by inverse agonists; and (iii) agonist-dependent activation of G-proteins.  
Several issues arise from this model. Firstly, it appears that 5-HT1D receptors display a high degree of 
constitutive activity with marked [35S]GTPγS binding induced by the receptor itself in the absence of 
agonist. Correspondingly, the agonist, 5-HT, only increased [35S]GTPγS binding to 129% relative to 
basal values (=100%) an observation in accordance with the modest stimulation induced by 5-HT 
that had been observed in other studies of [35S]GTPγS binding at 5-HT1D receptors expressed in CHO 
cells (77,293). Indeed, if 5-HT1D receptors predominantly exist in a state which is constitutively active, 
agonists may only induce a small additional stimulation of G-protein activation (312-314). In 
comparison, at receptor subtypes which display a lower degree of constitutive activity, 5-HT induced 
219% and 240% increases in [35S]GTPγS binding in the case of 5-HT1B receptors 
(293) [31] and 230% in 
the case of 5-HT1A receptors [19]. 
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Secondly, endogenous constitutive activity may be detected without the need for inverse agonists. 
Indeed, biphasic inhibition of basal [
35
S]GTPγS binding by GTPγS is observed for 5-HT1A and 5-HT1B 
receptors, systems in which inverse agonists have been detected [10,31] (77). Another research group 
subsequently applied the same methodology to the study histamine H3 receptors reporting similar 
data 
(315)
. In contrast, at D2, D3 and D4 receptors, inhibition of basal [
35
S]GTPγS binding by GTPγS only 
revealed LA sites and, under these conditions, we detected no inverse agonists [12,20]. Thus, 
biphasic inhibition of basal [35S]GTPγS binding by GTPS may indicate the presence of constitutive G-
protein activation at a variety of GPCRs and, hence, the possibility of observing inverse agonist 
actions.  
Thirdly, quantification of 
constitutive activity enables the 
definition of a ‘full inverse 
agonist’: i.e. a ligand that totally 
abolishes constitutive activity (i.e. 
HA binding sites). Methiothepin 
and SB224,289 suppressed 77% 
and 33% of HA sites, respectively, 
compared with 56% and 22% of 
‘overall’ (i.e. HA+LA) basal 
[
35
S]GTPγS binding [34]. The ratio 
between the ‘overall’ percentage 
of inhibition and ‘corrected’ values 
(with LA sites subtracted) may 
vary as a function of the degree of 
constitutive activity, receptor 
expression levels and G-protein 
subtype activated [10,31]. Such 
factors may contribute to the wide 
variations in negative efficacies reported for inhibition of [35S]GTPγS binding by methiothepin at 
5-HT1D receptors: 70% 
(77), 28% (310) and 56% [34]. Expressing negative efficacy as a proportion of 
observed HA [35S]GTPγS binding may, thus, facilitate comparisons of inverse agonist efficacy 
between different expression systems. In summary, the methodology that I developed showed that 
[35S]GTPγS versus GTPγS inhibition isotherms can be employed to characterise constitutive activity at 
5-HT1D receptors in the absence of inverse agonist ligands. It would be of interest to apply the 
present approach to cerebral and other native populations of GPCRs (see perspectives). 
5.4 Conclusions and perspectives. 
The studies described above indicate that 5-HT1B and 5-HT1D receptors are capable of eliciting 
substantial constitutive activity in cellular recombinant tests. However, constitutive activation is not 
Figure 5.3: Determination of constitutive G-protein activity  
The use of isotopic dilution of [
35
S]GTPγS binding identifies three 
components (i) LA sites, which may reflect endogenous GTP/GDP 
exchange of G-proteins; (ii) receptor-dependent G-protein 
activation observed in the absence of receptor ligands, which 
provides a measure of the constitutive activity of the receptor and 
which can be inhibited by inverse agonists; and (iii) agonist-
dependent activation of G-proteins. Adapted from [34].   
 
Note: for copyright reasons, this Figure is omitted from the public 
access version of the thesis. 
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easily detected in various native systems, as we found when we carried out an additional series of 
experiments (functional [
35
S]GTPγS autoradiography on rat brain tissue sections; microdialysis 
studies of 5-HT release in frontal cortex; measures of core temperature [25]). In each case, 5-HT1B / 
5-HT1D receptor agonists elicited the expected effects (increased [
35
S]GTPγS binding, decreased 5-HT 
release and lowered core temperature) but the selective 5-HT1B / 5-HT1D receptor inverse agonist, 
SB224289, did not exert the opposite effects (i.e. it did not inhibit basal [
35
S]GTPγS binding, did not 
increase 5-HT release or body temperature). In fact, SB224289 appeared to possess “neutral” 
antagonist properties in these tests, similar to another compound, S18127, which appeared 
“neutral” in in vitro measures [25,37,53]. In other words, when tested on native tissue systems, the 
inverse agonists could not be distinguished from neutral antagonists. 
Several reasons may explain the absence of inverse agonist actions in vivo. Firstly, SB224289 may act 
as an inverse agonist at recombinant human 5-HT1B/5-HT1D receptors but not at native rat and guinea 
pig receptors. However, in a comparison of recombinant guinea pig and human 5-HT1B receptors 
(316), 
SB224289 acted as inverse agonists in both cases. Secondly, agonist and inverse agonist efficacy 
depends on receptor and G-protein expression levels, as discussed above [10,31]. These may be too 
low at native 5-HT1B receptors to permit inverse agonist actions to be detected. Thirdly, the 
techniques may not have been sufficiently sensitive to detect modest inverse agonist actions in vivo. 
In particular, this may be the case for [35S]GTPγS autoradiography, in which actions of SB224289 
upon 5-HT1B coupled G-proteins might be diluted by other pools of G-proteins. Fourthly, for inverse 
agonism to be detected, the receptor must be present in a constitutively active state and, ideally, 
endogenous agonist(s) should not be present. However, in vivo, 5-HT is spontaneously released both 
at the dendritic and terminal level suggesting that 5-HT is available to pre- and postsynaptic 
receptors. Thus, spontaneous release of 5-HT may impede the detection of inverse agonist actions. 
In conclusion, although extensive in vitro data, partly generated in my laboratory [25,31,37,53], 
supports the existence of 5-HT1B and 5-HT1D receptor constitutive activity, this still lacks in vivo 
correlates. It should be noted that constitutive activation of another serotonin receptor subtype 
(5-HT2C) has been documented 
(317). It is the author’s opinion that the demonstration of in vivo 
constitutive activity at 5-HT1B/1D receptors will require novel technical strategies and/or specific 
experimental conditions. These may include, for example, the use of transgenic mice overexpressing 
5-HT1B or 5-HT1D receptors in order to increase basal activation signals. In addition, it may be useful 
to test rodents that are 5-HT-depleted, allowing potential inverse agonist effects to be detected in 
the absence of concurrent agonist activation.  
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6. Serotonin 5-HT2A, 5-HT2B and 5-HT2C 
receptors 
6.1 Key points  
 Agonists at 5-HT2A, 5-HT2B and 5-HT2C receptors exhibited functional selectivity: some were more 
potent and efficacious for activation of Gαq G-proteins, whereas others were more potent for 
activation of calcium release [84].  
 5-HT2B antagonism was shown to be relevant to antipsychotic activity, inhibiting amphetamine-
induced nucleus accumbens dopamine release in microdialysis experiments and opposing 
amphetamine-induced locomotion in rat [98]. 
 G-protein activation by 5-HT2C receptors was characterised using a novel methodology (antibody-
capture associated with scintillation proximity assay). 5-HT2C receptors were found to display 
“promiscuous” coupling to both Gαi3 and Gαq/11 G-proteins [40,45]. 
 The novel antidepressant, agomelatine (Valdoxan®) was found to display antagonist properties at 
5-HT2C and 5-HT2B receptors [51].  
 At 5-HT2B and 5-HT2C receptors, a novel rapid methodology was developed to determine in vitro 
agonism, based on depletion of [
3
H]phosphatidylinositol by phospholipase-C, rather than on 
synthesis of [3H]inositol triphosphate, which is a more resource-intensive procedure [26,32,47]. 
6.2 Background to the author’s work 
The serotonin 5-HT2 receptor family includes three receptor subtypes (5-HT2A, 5-HT2B and 5-HT2C), 
which are expressed throughout the mammalian brain (318,319). During the last three decades, much 
attention has been devoted to the role of 5-HT2A and 5-HT2C receptors and they are considered as 
promising targets for improved treatments of neuropsychiatric disorders related to monoamine 
neuron dysfunctions (318,320,321).  In particular, the marked affinity and antagonist properties of 
atypical antipsychotics such as clozapine at 5-HT2A sites may permit control of psychotic symptoms in 
the relative absence of extrapyramidal side-effects (318,322). Clozapine and other antipsychotics also 
display high affinity for closely-related 5 HT2C receptors 
(318,323,324), blockade of which exerts a tonic, 
inhibitory influence upon ascending dopaminergic pathways: correspondingly, by enhancing 
dopamine release in frontal cortex, 5-HT2C antagonist properties may counteract the "hypofrontality" 
which contributes to the deficit symptoms of schizophrenia (325,326). 5-HT2C receptor antagonists have 
also been reported to manifest anxiolytic properties (327,328).  
In contrast, relatively few studies have focused on the role of central 5-HT2B receptors in the control 
of DA neuron activity. Some early electrophysiological and microdialysis studies in rats (325) indicated 
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that 5-HT2B did not influence dopaminergic neuronal firing or dopamine release. On the other hand, a 
study in mice 
(329)
, reported that central 5-HT2B receptors modulate accumbal DA release induced by 
3,4-methylenedioxymethamphetamine (MDMA), suggesting that they do, in fact, influence 
dopaminergic function.  
The three 5-HT2 receptors show high homology in their primary and secondary structure 
(319,330,331) 
and are mainly coupled via Gq/11 G-proteins to phospholipase C (PLC) 
(332-335)
. Activation of PLC 
elevates cytosolic levels of inositol phosphates, and subsequently increases levels of intracellular 
calcium, two major parameters that have been exploited for characterization of drug efficacy at 
5-HT2 receptor subtypes 
(336)
. Furthermore, previous studies have shown that both 5-HT2A and 5-HT2C 
receptors can couple independently to PLC and phospholipase A2 (PLA2) and that the relative 
efficacy of the agonists at these receptors can differ depending upon whether phosphatidylinositol 
hydrolysis or arachidonic acid release is measured 
(333,337,338)
. Biased agonism, or functional 
selectivity, has also been reported for 5-HT2C receptors coupled to PLC versus ERK 1/2 
phosphorylation where the rank order of relative efficacy of DOI and quipazine was reversed 
(339)
. 
Although the precise nature of G-proteins involved in these transduction pathways remains to be 
elucidated, 5-HT2C receptors are known to interact with other G-proteins than Gαq/11, notably Gαi3 
and Gα13, depending also on the nature of 5-HT2C receptor editing [45] 
(340-342)
. 
6.3 Contribution of author’s work 
5-HT2A receptors and biased agonism 
Although serotonin 5-HT2A receptors are thought to be a primary target of some hallucinogen 
compounds such as LSD and DOI(343), not all 5-HT2A receptor agonists elicit hallucinations. This 
discrepancy may be related to the capacity of the agonists to stimulate signalling via different 
intracellular pathways (128), a hypothesis supported by the fact that functional selectivity was 
observed for a series of compounds for 5-HT2A and 5-HT2C receptor-mediated PLC and PLA2 activation 
(337,338). In my laboratory, a series of hallucinogenic and non-hallucinogenic compounds showed 
differential preference for the activation of specific cellular signalling responses [84]. Indeed, at 
5-HT2A receptors, lisuride, bromocriptine, LSD and, to a lesser extent, pergolide preferentially 
induced activation of Gαq/11 proteins while the other agonists more potently elicited for Ca2+ 
release. Moreover, a similar tendency was also observed at 5-HT2B and 5-HT2C-VSV receptors [84]. 
These observations are unlikely to be accounted for by “strength of signal” dependent on receptor 
reserve. Indeed, lisuride was more potent than mCPP to induce Gαq/11 protein activation at 5-HT2A 
receptor while the opposite result was observed for induction of Ca2+ signalling. Furthermore, both 
compounds behaved as partial agonists at both pathways, suggesting that a contribution of receptor 
reserve is unlikely (Fig. 6.1). In contrast, these results are highly suggestive of the existence of 
agonist-specific receptor states that preferentially engage distinct cellular pathways. Evidence for 
ligand-specific preferential activation of PLC, PLA2 and phospholipase D by 5-HT2 receptors have 
been presented repeatedly in vitro (128,337) and more recently in vivo for 5-HT2A 
(132,344). In NIH-3T3 
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cells, LSD also induced weak 5-HT2C receptor coupling to Ca
2+
 response whereas efficient activation of 
PLC pathway was observed 
(345)
, in accordance with our results. 
A concern in the interpretation of these data was the nature of the different pathways examined, i.e. 
activation of Gαq/11 proteins and of Ca
2+
 signalling. These pathways are closely linked to each other, 
such that Ca
2+
 mobilization can be considered as a downstream consequence of Gαq/11 activation 
and subsequent PLC stimulation. However, the pharmacological differences between these two 
responses observed in our experiments suggest that that Gαq/11 signalling is not the only element 
controlling the strength of Ca
2+
 signalling. One possible interpretation is that 5-HT2A receptors couple 
to different G-proteins in CHO cell lines and that the propensity to activate these different G-
proteins varies according to the 
agonist tested. Indeed, 5-HT2C 
receptors couple to Gα13 and 
Gαi3, as well as to Gαq/11 
(346,347)
[45], and some 5-HT2A 
intracellular signalling involves 
pertussis toxin-sensitive G-
proteins (338,348). Thus, the 
differential signalling reported 
herein may be the result of the 
agonist-specific activation of a 
combination of distinct 
G-proteins.  
This interpretation is consistent 
with the observation that Gαq 
protein KO mice displayed a 
decreased DOI-induced head-
twitch response, supporting a key 
role for this G-protein in 
hallucinogenic drug effects (349). 
We likewise observed that DOI 
was a potent and efficacious 
agonist at 5-HT2A receptor-coupled 
Gαq/11 proteins, a property 
which was shared also by LSD, 
pergolide and bromocriptine 
whereas lisuride was less 
efficacious. Pergolide and, to a 
lesser degree, bromocriptine have 
been reported to induce 
Figure. 6.1: 5-HT2A receptor biased agonists.  
h5-HT2A receptors coupled to Gq/11 activation (□) and Ca
2+
 
release (■). Reproduced from [84].   
 
Note: for copyright reasons, this Figure is omitted from the public 
access version of the thesis. 
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hallucinations in Parkinsonian patients 
(350-352)
. However, lisuride, which is generally considered to be 
non-hallucinogenic in human 
(343)
, as well as LSD, bromocriptine and pergolide exhibited a high 
propensity to stimulate Gαq/11 proteins in comparison with Ca2+ mobilization. Thus, our results 
tentatively suggested that differences in hallucinogenic properties between these compounds may 
not be simply related to a higher efficacy and potency to stimulate Gαq/11 proteins versus Ca
2+
 
mobilization, but that a threshold of efficacy at 5-HT2A receptor may be of importance. 
5-HT2B receptors and dopamine release in rat 
In 2008, data was published indicating that 5-HT2B receptors modulate the increase in accumbal DA 
release induced by 3,4-methylenedioxymethamphetamine (MDMA) 
(329)
. This landmark study was 
the first to report that central 5-HT2B receptors had a role in the control of CNS dopamine release. At 
that time, I was working on compounds that had antagonist properties at 5-HT2 receptors, including 
5-HT2B [47], so I decided to investigate the influence of 5-HT2B receptors on DA release in rat using in 
vivo microdialysis. In this study [98], the selective 5-HT2B receptor antagonists, LY266097 or 
RS127445 significantly decreased Nucleus Accumbens (NAc) DA outflow. Both compounds possess 
high (subnanomolar) affinity for 5-HT2B receptors, and at least 100-fold selectivity over numerous 
other receptors (353,354). Thus, given that the 5-HT2B antagonists were administered at very low doses, 
it was concluded that their effects result from selective blockade of 5-HT2B receptors. This was 
supported by previous microdialysis studies showing that basal DA outflow in the striatum and the 
NAc is unaltered by selective antagonism of 5-HT2A, 5-HT3 or 5-HT4 receptors 
(355-357)
, and increased 
by 5-HT2C antagonism 
(317). Therefore the pattern of response to 5-HT2B antagonists in rat was 
different to that observed previously for other receptors (358). In co-treatment experiments, 
LY266097 significantly attenuated amphetamine-induced dopamine release in the NAc, thus showing 
that 5-HT2B receptor blockade attenuates the effects of this psychostimulant. In addition, LY266097 
was tested in behavioural experiments, at the same dose as that used in microdialysis experiments, 
and significantly reduced amphetamine-induced hyperlocomotion, whilst not affecting spontaneous 
locomotor activity. Locomotor activity is a behavioral response classically associated with increased 
DA function in the NAc (359). Thus, our data suggested that reduction of amphetamine-induced 
hyperlocomotion by a 5-HT2B receptor antagonist results from the ability of the latter to reduce 
accumbal DA outflow.  
From a therapeutic point of view, our findings suggest that central 5-HT2B receptors constitute a new 
pharmacological target for improved treatment of neuropsychiatric disorders resulting from DA 
neuron dysfunction, such as schizophrenia, depression or drug addiction. In this regard, the ability of 
5-HT2B receptor antagonists to achieve a selective reduction of mesoaccumbens DA hyperactivity 
without altering nigrostriatal DA, could avoid the side-effects induced by long term DAergic 
treatments which are currently available (i.e. neuroleptic-induced extrapyramidal symptoms 
including tardive diskynesias or levodopa-induced psychosis) (360). Interestingly, several atypical 
antipsychotic drugs, such as aripiprazole and cariprazine, have been shown to possess high affinity 
and potent antagonist properties at 5-HT2B receptors, which could contribute to their advantageous 
therapeutic properties (244,361). It is also interesting to speculate whether 5-HT2B receptor antagonism 
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plays a role in the therapeutic properties of the antidepressant, agomelatine, which was investigated 
in my laboratory. Agomelatine possesses melatonin agonist activity and 5-HT2C antagonist properties 
[51] which are considered important for its clinical efficacy, despite being of only low potency (pKi = 
6.15). However, agomelatine also acted as a 5-HT2B receptor antagonist with an affinity (pKi = 6.59) 
which is about 3-fold greater than at 5-HT2C receptors [51]. In the light of the findings described 
above, it would be interesting to determine whether such properties are relevant to agomelatine’s 
profile of action. 
5-HT2C receptors and promiscuous coupling to Gαi and Gαq/11 
5-HT2C receptors play a major role in the etiology and treatment of affective disorders, anxious 
states, schizophrenia, and Parkinson’s disease 
(334,362)
. They are coupled to phospholipase C (PLC), the 
activity of which is classically determined by quantification of levels of inositol phosphate and/or 
intracellular calcium 
(323,333)
 [26,32,47]. In addition to PLC, 5-HT2C receptors control other transduction 
systems including cGMP formation, adenylyl cyclase, and phospholipase A2 (PLA2) (333,363,364). Several 
isoforms of 5-HT2C receptors, which arise from differential extents of RNA editing, are differentially 
coupled to PLC as revealed by differing efficacies and potencies of agonists; furthermore, the 
nonedited INI isoform of 5-HT2C receptors exhibits constitutive activity 
(317,345,365)
. 
5-HT2C receptor agonists can differentially stimulate PLC compared with PLA2 activity and cGMP 
production 
(333,366)
. This suggests that agonists can induce different receptor conformations, 
preferentially engaging specific effector pathways. In fact, although 5-HT2C receptors are classically 
considered to couple to Gαq, 5-HT2C receptors interact with PTX-sensitive Gαi/o proteins controlling 
DNA synthesis and proliferation (367), adenylyl cyclase activity (363), and membrane currents in 
Xenopus laevis oocytes 
(368)
. Moreover, direct coupling of 5-HT2C receptors to Gαi1 and Gαo was 
shown by an antisense strategy (369). Finally, in a cell line expressing high levels of 5-HT2C receptors, 
5-HT stimulated [
35
S]GTPγS binding to Gαi proteins 
(341)
. 
In our laboratory, we characterized the coupling of 5-HT2C receptors expressed in CHO cells using 
[35S]GTPγS binding as an index of “total” G-protein activation, i.e. a measure that is composed of the 
effects of all the G-protein subtypes involved [45]. An indication of their identity was gained by pre-
treating the cells with pertussis toxin (PTX). 5-HT-mediated [35S]GTPγS binding was sensitive to PTX, 
resulting in a decrease in [35S]GTPγS binding and an increase in pEC50. This demonstrates the 
involvement of Gαi/o proteins, but PTX did not completely abolish [35S]GTPγS binding, indicating that 
5-HT also stimulated PTX-insensitive G proteins, such as Gαq/11. In comparison, PTX did not affect 
the potency or efficacy of LSD and lisuride, suggesting that these ligands mainly activated PTX-
insensitive G-proteins coupled to 5-HT2C receptors. Therefore, these data suggested that some 5-HT2C 
receptor agonists can signal preferentially through Gαq/11 and/or Gαi G-proteins. To confirm this 
hypothesis, we used an antibody capture assay together with a detection technique employing anti-
IgG–coated scintillation proximity assay (SPA) beads, as originally described by (90,91) and applied to 
5-HT1A and 5-HT1B receptors [46,53,69]. This technique permitted measurement of the stimulation of 
Gαq/11 and Gαi3 proteins in response to 5-HT2C receptor activation by different agonists [45].  
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LSD behaved as a full agonist for Gαq/11 activation but only as a weak partial agonist at Gαi3. 
Previous studies in HEK293 cells had likewise shown that LSD is more efficacious at Gαq (inositol 
generation) than at Gαi/o ([35S]GTPγS binding) (341). However, in our study, 5-HT, RO600175 and DOI 
more potently activated Gαq/11 than Gαi3 [45], whereas differential activation was not apparent in 
another study 
(341)
. One possibility that could have accounted for these divergent results was the 
presence of receptor reserve in the cell line we used. Indeed, coupling of GPCRs to distinct G-
proteins was known to be influenced by the presence of receptor reserve (370,371), and we had 
previously shown that the CHO-h5-HT2C cell line used in these experiments displayed substantial 
receptor reserve for activation of PLC, 
using an innovative rapid experimental 
procedure based on measuring 
depletion of membrane-bound 
[
3
H]phosphatidylinositols [26,32,47]. 
We therefore examined this issue by 
carrying out receptor inactivation 
experiments using the alkylating agent, 
EEDQ. These showed that extensive 
receptor reserve was present in the cell 
line for 5-HT2C receptor-mediated 
activation of Gαq/11 but not for Gαi3 
G-proteins. Indeed, the efficacies of 
5-HT, Ro600175 and DOI for Gαq/11 
activation were not reduced by EEDQ 
pre-treatment, even though the 
number of 5-HT2C receptors was 
diminished 7-fold. In contrast to 
Gαq/11 activation, EEDQ treatment 
markedly diminished the efficacy of all 
agonists for 5-HT2C receptor-mediated 
Gαi3 activation. Thus, in the present 
system, potential agonist-directed 
trafficking by LSD and DOI must take 
into account the large receptor 
reserve. It was concluded that the 
markedly higher efficacy of the partial 
agonists, DOI and LSD, at Gαq/11 
compared with Gαi3 (observed in the 
absence of EEDQ) was associated with 
the more efficient coupling of 5-HT2C 
receptors to Gαq/11 versus Gαi3.  
Figure 6.2: 5-HT2C receptor-mediated Gq/11 and Gi3 
protein activation.  
Agonist concentration-response curves at Gq/11 (left-hand 
panels) and Gi3 (right-hand panels) from membrane 
preparation of CHO–h5-HT2C cells. [
35
S]GTPgS binding is 
expressed as a percent of maximal stimulation with 5-HT 
(100%) under three conditions: control (), EEDQ-treated for 
60 minutes () and EEDQ-treated for 90 minutes (). 
Reproduced from [45]. 
Note: for copyright reasons, this Figure is omitted from the 
public access version of the thesis. 
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Thus, LSD, DOI and lisuride express their “functional selectivity” properties only under certain 
conditions of receptor reserve. This conclusion is similar to that reached for α2A-adrenoceptor 
coupling to adenylyl cyclase via Gαi and Gαs (370) and raises the question of whether receptor reserve 
exists for Gαq/11 and/or Gαi3 in physiological systems. In this context, it should be noted that 
coupling to Gαi3 was observed herein even after extensive EEDQ treatment, reducing receptor 
expression to about 2 pmol/mg. In rat choroid plexus neurons, 5-HT2C expression levels (for a 
mixture of cell types) is also in the pmol/mg range (372) suggesting that the present data in CHO cells 
are relevant to central populations of 5-HT2C receptors.  
To summarise, our data demonstrated that 5-HT2C receptors (VSV isoform) couple to both Gαq/11 
and Gαi3 in CHO cells and that these G-proteins subtypes are recruited in an agonist and receptor 
reserve-dependent manner. The differential influence of agonists upon G-protein coupling at 5-HT2C 
receptors may be relevant to their functional profiles in vivo. 
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7. Dopamine D2, D3 and D4 receptors 
7.1 Key points  
 Antagonism of dopamine D2 receptors is fundamental for antipsychotic activity and, in 
conjunction with 5-HT1A receptor activation, was the basis for a drug discovery program directed 
by the author and discussed in Chapter 4. However, dopamine D3 and D4 receptor subtypes may 
also contribute to the activity of antipsychotics. The author carried out studies that characterized 
the function of these receptors and identified novel selective ligands. 
 The in vitro signal transduction pathways elicited by D2 and D3 receptors were compared and 
shown to differ both at the G-protein level [20] and on down-stream responses (ERK 
phosphorylation) [23]. These receptors signal through different G-proteins and kinase cascades. 
The pharmacology of D2 receptor signalling was examined at GIRK channels [70]. 
 D4 receptors were shown to be tightly coupled to G-proteins and to GIRK currents, but most 
available agonists only displayed modest efficacy [12,82]. Notably, some agonists showed higher 
efficacy for one response whereas others had an opposite profile, suggesting functional 
selectivity. D4 receptors were also discovered to be “promiscuous”, being activated by adrenaline 
and noradrenaline, as well as dopamine [7].  
 The pharmacology of D3 receptors was investigated using novel selective as radiotracers: 
[
3
H]S14297 [3] and [
3
H]S33084 [30]. S33084 was also characterised in vitro and in vivo [29,33]. 
Another D3 antagonist, S33138, was characterized and later taken into clinical trials as an 
antipsychotic [79]. A highly-selective D4 receptor antagonist, S18126, was characterized [18]. 
 The relative contributions of D2, D3 and D4 receptor activation was compared in tests of penile 
erection in rats [87], agonist-induced emesis in dogs [85], and apomorphine-induced rotations in 
rats with unilateral 6-OH-DA lesions of nigro-striatal pathway [42]. 
7.2 Background to author’s work 
Dopamine D2 and D3 receptors 
Dopaminergic neurotransmission is mediated by 5 receptor subtypes (D1 to D5) which are grouped 
into 2 receptor families. D1-like receptors include the D1 and D5 subtypes, whereas D2 -like receptors 
include the D2, D3 and D4 subtypes. D2 and D3 receptors, in particular, display marked sequence 
homology and pharmacological similarity in their in vitro ligand binding profiles (373,374). However, D3 
receptors may be distinguished from D2 receptors by several factors. D3 receptors are concentrated 
in limbic rather than striatal brain regions (375). Further, they mediate stimulation, rather than 
inhibition, of c-fos expression in striatal neurones (376,377), and inhibition, rather than stimulation, of 
locomotor activity in rats (378). In addition, whereas D2 receptors couple efficiently to second 
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messenger systems, markedly inhibiting adenylyl cyclase activity, such responses proved elusive and 
complex for D3 receptors 
(379,380)
. Indeed, D3 receptors were found to couple selectively to inhibition 
of adenylyl cyclase type V, but not type I or VI, and only weakly to type II (381,382). In vitro studies of 
agonist efficacy at D3 receptors therefore employed other measures of receptor activation, including 
medium acidification 
(383)
, and stimulation of mitogenesis 
(376,384)
. However, these approaches 
measure responses 'downstream' of the receptor in the intracellular activation cascade and the 
relevance of an increase in mitogenesis for post-mitotic central nervous system neurones is unclear. 
In contrast, measuring receptor-mediated G-protein activation by stimulation of [
35
S]GTPγS binding 
directly reflects ligand binding events at the receptor itself. Thus, I adopted this strategy to 
investigate the functional properties of human D3 receptors (see below).  
The extracellular signal-regulated kinases, ERK1 and ERK2, also known as mitogen-activated protein 
kinases (MAPK), are involved in the control of cell growth and differentiation by growth factors 
(385,386). In the case of dopamine receptors, D2 receptors expressed in C6 glioma cells had been found 
to stimulate ERK1/2 and thymidine incorporation via the Ras protein 
(387)
 and, when expressed in 
CHO cells, D2 receptors activated ERK1/2 via PI3-kinase 
(388)
. D4 receptors expressed in SK-N-MC 
human neuroblastoma cells stimulate a pathway involving Ras activation via Shc/Grb2/Sos complex 
and the tyrosine kinase Src 
(389)
. In contrast to D2 and D4 receptors, little comparative information 
was available concerning D3 receptors, although they were known to stimulate expression of the 
immediate early gene, c-fos, in cultured neurones 
(376)
, and mediate stimulation of mitogenesis 
(376,384)
. These data suggested that D3 receptors may couple to serine/threonine kinase pathways and 
activate ERK1/2, but the demonstration of such coupling had not, as yet, been documented. 
Dopamine D4 receptors 
Although many antipsychotics antagonise D2/3 receptors, they also bind with high affinity to D4 
receptors (390). In humans, D4 receptors are upregulated in schizophrenics, independently of their 
antipsychotic treatment, suggesting that the changes are disorder-related (391). Interest was 
stimulated by the observation that clozapine has somewhat higher affinity at D4 receptors than for 
D2 or D3 receptors 
(392), suggesting that aspects of clozapine’s ‘atypical’ profile may be attributed to 
actions at D4 receptors, notably insofar as concerns cognitive function. Indeed, D4 receptors had 
been shown to be preferentially localised in brain regions that are implicated in regulation of 
cognition, including the hippocampus and frontal cortex (393-397). In addition, electrophysiological 
studies demonstrated that D4 receptor activation influences the electrical activity of prefrontal 
cortex (PFC) neurons: NMDA receptor currents are decreased and NMDA receptor internalisation 
favoured (398). It is interesting that D4 receptor blockade has protective properties on cultured 
hippocampal neurons (399) whereas D4 receptor activation reduces oxidative stress-induced in rat 
cortical neurons and hippocampus-derived cells (400,401). Thus, an intermediate degree of partial 
agonist activity may provide a beneficial influence on preservation of neuronal integrity. Further 
observations support this hypothesis: in rodents, D4 receptor activation is implicated in memory 
consolidation (402), short-term social memory (403) and increased exploratory activity (404), and reduced 
D4 receptor expression is associated with attentional deficits (405). In contrast, in tests of cognition in 
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primates, D4 receptor antagonists opposed the deficits in frontal cortex-dependent working memory 
tasks induced by stress 
(406)
 or chronic treatment with PCP 
(407)
. The D4 receptor antagonist, L745870, 
had differential effects in rats with high versus low basal memory performance, suggesting that 
optimal responses may be obtained with a partial agonist 
(408)
. D4 receptor activation is also relevant 
to the treatment of sexual dysfunction, a frequently-reported side-effect of antipsychotic treatment 
that can seriously influence treatment outcome in schizophrenia patients 
(409,410)
. Compounds 
possessing D4 agonist properties, such as ABT724 and flibanserin (a compound also possessing 5-HT1A 
receptor agonist activity), were clinically evaluated for attenuation of sexual dysfunction 
(411,412)
.  
Taken together, these observations suggested that a modest level of D4 receptor activation may be a 
desirable property for novel antipsychotic agents with improved efficacy against negative and 
cognitive symptoms of schizophrenia. However, there was a lack of studies providing a comparative 
analysis of the in vitro efficacy at DA D4 receptors of established and novel antipsychotics.  
7.3 Contribution of author’s work 
D2 and D3 Receptor coupling to G-proteins 
I compared the G-protein coupling of dopamine D3 receptors with that of D2 receptors expressed in a 
common CHO cell environment. Although both D3 and D2 receptors mediated stimulation of 
[35S]GTPgS binding, a detailed investigation of the coupling of these receptor subtypes identified 
marked differences between D3 and D2 sites [20].  
First, despite an 11-fold difference in receptor expression level (15 pmol/mg for D3 vs only 1,4 
pmol/mg for D2 receptors), the dopamine-elicited increase in [
35S]GTPγS binding by D3 receptors 
(1.6-fold) was less than that observed at D2 receptors (2.5-fold). This striking difference was further 
underlined by the observation that partial inactivation of D3 receptors using the alkylating agent, 
EEDQ, markedly reduced the stimulation of [35S]GTPγS binding induced by dopamine, indicating that 
high receptor expression levels are necessary to observed measurable activation of G-proteins by D3 
receptors. However, when Furchgott analysis was undertaken, a hyperbolic occupancy/response plot 
was obtained, indicating the presence of marked D3 receptor reserve for stimulation of [
35S]GTPγS 
binding by dopamine. Thus the limited stimulation of [35S]GTPγS binding to CHO-hD3 membranes 
appears to be a property of D3 receptors themselves and not due to insufficient intrinsic efficacy of 
dopamine. In addition, the modest stimulation at D3 receptors was not a consequence of augmented 
basal [35S]GTPγS binding, because basal [35S]GTPγS binding was unaffected by receptor inactivation. 
Further, the low fold-stimulation in CHO-hD3 membranes was unlikely to be due to a global lack of 
activatable G-proteins: the amount (Bmax) of dopamine-activated G-proteins in CHO-hD3 cell 
membranes was about 3-fold higher than that in CHO-hD2 cell membranes. Taken together, these 
data suggested that, unlike D2 receptors, D3 receptors are poorly capable of inducing the 
conformational changes necessary for G-protein activation (413), perhaps due to a slower rate of 
G-protein coupling/uncoupling at D3 receptors or, alternatively, to interaction with different 
G-protein subtypes at D3 vs D2 receptors, a possibility suggested by subsequent experiments. 
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Indeed, G-protein activation by dopamine at D3 receptors was PTX-sensitive, implicating Gαi/o 
G-proteins similar to the known PTX sensitivity of D2 receptors 
(414,415)
. However, marked differences 
were observed between D3 and D2 receptors in antibody tests. Thus, dopamine-stimulated 
[
35
S]GTPγS binding at hD3 and hD2 receptors was inhibited by an antiserum that recognizes the three 
Gαi subunits (Gαi1/i2/i3) and, more weakly, Gαo subunits. This antiserum inhibited dopamine-
stimulated [
35
S]GTPγS binding to CHO-hD3 membranes more strongly than to CHO-hD2 membranes 
(67 % vs 40 % inhibition). The greater effect at D3 receptors suggested that D3 may couple to both 
Gαi and Gαo proteins whereas D2 receptors may preferentially couple to members of the Gαi protein 
family. This is consistent with a study which found that an attenuation of D2 receptor-mediated 
inhibition of adenylyl cyclase by pretreatment with anti-Gαi1/i2 but not by anti-Gαo antibodies (416).  
 An interaction of D3 receptors with a G-protein other than Gαi or Gαo is suggested by the 
observation that, when CHO-hD3 cells were treated with PTX, there remained a residual capacity of 
dopamine to stimulate [35S]GTPγS binding, consistent with the inhibition of dopamine-dependent 
[
35
S]GTPγS binding at D3 (but not hD2) receptors by anti-Gαq/11 antibodies. Thus, these data suggest 
that D3 receptors in the present CHO-hD3 cell line may interact with Gαq/11 [20]. Although a previous 
study of D3 receptors expressed in CHO cells did not find such an effect 
(379), that may have been due 
to a 50-fold lower D3 expression level (0.3 vs 15 pmol/mg in the cells used here). 
 In conclusion, this study characterized, for the first time, G-protein coupling at D3 receptors 
using a functional test. The data suggested that the coupling of D3 receptors to G-proteins is less 
efficacious than that at D2 receptors. In addition, unlike D2 receptors, D3 receptors appeared to 
couple to G-proteins other than Gαi, such as Gαo and/or Gαq/11 proteins. 
D3 Receptor activation of ERK pathway 
Both dopamine D2 and D4 receptor subtypes were known to stimulate ERK1/2 in cultured cells 
(388,389) 
but it was not known whether dopamine D3 receptors also activate this pathway and, if so, by which 
intracellular signaling mechanisms. This was therefore the focus of a study undertaken in my 
research group [23]. We found that, in CHO cells stably transfected with D3 receptors (CHO-hD3), DA 
stimulated ERK1/2 phosphorylation in a time-dependent manner with a peak of activation occurring 
at 5 min and a rapid return to the basal level. The activation was specifically mediated by D3 
receptors, because haloperidol and the selective D3 receptor antagonist, GR218,231, blocked DA-
mediated but not FGF-induced stimulation of ERK1/2 phosphorylation. Further, the preferential D3 
agonists, (+)7-OH-DPAT and PD128,907, like DA, triggered ERK1/2  activation. It is interesting that 
stimulation was similar for the three agonists whereas both (+)7-OH-DPAT and PD128,907 exhibit 
partial agonist properties for G-protein activation in CHO-hD3 cell membranes [20]. This difference 
suggests possible signal amplification at the level of kinase cascade following G-protein activation 
and ERK1/2 phosphorylation may, thus, more readily detect weak agonist actions.  
PTX-treatment of CHO-hD3 cells abolished ERK1/2 stimulation by DA, (+)7-OH-DPAT and PD128,907, 
suggesting the exclusive involvement of Gi and/or Go proteins, analogous to that reported for D2 
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receptors 
(388)
. As in other studies 
(417)
, inhibition of MEK (located just upstream of ERK) by the 
specific inhibitor, PD98059, abolished ERK1/2 activity in CHO-hD3 cells. Further investigation 
revealed distinctive features in the activation of the ERK1/2 cascade by D3 receptors versus D2, D4 
receptors and other GPCRs. Inhibitors of tyrosine kinase activity (genistein and lavendustin A), did 
not reduce DA-induced ERK1/2 activation. In contrast, inhibitors of protein kinase C (PKC; Ro31-8220 
and Gö6983), blocked DA-induced ERK1/2 activation. However, ERK1/2 activation was insensitive to 
PKC downregulation by phorbol esters, indicating the involvement of an ‘atypical’ PKC. Futhermore 
ERK1/2 activation involved phosphatidylinositol 3-kinase (PI 3-kinase) inasmuch as its inhibition by 
LY294002 and wortmannin reduced DA-induced ERK1/2 activation.  
In conclusion, this work demonstrated that D3 receptors activate ERK1/2 activity. Although the 
ERK1/2 activation pathway bore similarities to other previously-characterised GPCRs (such as 
dopamine D2 receptors) a distinctive pattern of intracellular kinase cascade activation was observed. 
Thus, D3 receptor-mediated ERK1/2 phosphorylation involves the activation of PI 3-kinase and 
‘atypical’ PKC. These findings raised the possibility that ERK1/2 stimulation may be relevant to 
regulation of cellular events such as neuronal plasticity, morphological differentiation and synaptic 
transmission. Subsequent studies by other authors provided substantiation for this hypothesis 
(418,419)
. 
D4 Receptor coupling to G-proteins 
In vitro profiling of antipsychotics at D4 receptors  
Although D4 receptors had been the object of considerable interest because of their potential role in 
cognition and psychosis, the drugs used to investigate their function were only characterized in 
somewhat scattered reports using different methodologies that were not easily cross-interpreted. 
For example, one study estimated agonist efficacies at D4.4 receptors (4-repeat splice variant, the 
most common allele in human) by comparing their affinities at different receptor states (420). Other 
studies investigated agonist/antagonist activity at D4 receptors by adenylyl cyclase determinations 
but only few compounds were compared in each study (421-423) and systematic comparisons of agonist 
efficacies and antagonist potencies were lacking. The study I conducted was the first to address this 
issue by evaluation of a series of 33 dopaminergic ligands, including the principal anti-Parkinson’s 
disease drugs and antipsychotics, using competition binding and [35S]GTPγS binding to membranes of 
CHO cells transfected with the D4.4 receptor [12] 
(424). High concentrations of GDP (3 M), NaCl (100 
mM) and MgCl2 (3 mM) were found to be necessary to optimize the ratio of agonist-induced over 
basal [35S]GTPγS binding. In addition, CHO-D4.4 cells displayed a high ratio of dopamine-activated 
G-proteins to receptors, indicating the absence of 'spare receptors' and enabling partial agonist 
activity to be defined. In accordance with previous studies (421,425) the antipsychotics, clozapine and 
haloperidol, as well as other antipsychotics, exhibited antagonist properties, with Kb values that 
corresponded closely to respective Ki values. None of the antipsychotic drugs tested exhibited any 
intrinsic agonist activity, indicating that they acted as 'neutral' or 'silent' antagonists in this study 
[12].  
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Several years later, I undertook a further study comparing over 30 dopaminergic drugs by [
35
S]GTPγS 
binding and by activation of G-protein-regulated inwardly-rectifying potassium (GIRK) currents in 
Xenopus oocytes [82]. As expected, the selective D4 receptor agonists, ABT724, CP226269, 
PD168077 and Ro-10-5824 modestly stimulated [
35
S]GTPγS binding, whereas the antagonists, 
L745870 and RBI257 did not. In contrast, antipsychotics exhibited wide variety of efficacy at D4 
receptors. However, the observed levels of agonism were highly dependent on experimental 
conditions. Thus, when a higher concentration of sodium (100 mM) was used in the incubation 
buffers, Emax values for G-protein activation were decreased and a loss of potency was seen for 
most agonists. This is consistent with the influence of NaCl on opposing D4 receptor / G-protein 
coupling [12] (426) and raises the issue of the most physiologically-relevant conditions in which to 
undertake in vitro studies, as discussed previously for 5-HT1B receptor coupling to Gαi3 subunits [53] 
(see Chapter 5). Whilst physiological extra-cellular sodium concentrations are in the 100 mM range, 
heterotrimeric G-proteins that are located at the intracellular face of plasma membranes where NaCl 
concentrations are much lower (approximately 10 mM), except under neuronal depolarisation 
conditions, when sodium influx transiently increases intracellular NaCl levels. Therefore, a low NaCl 
concentration may be more “physiological” when measuring G-protein activation. In any case, these 
data raised the question of the amount of receptor activation that is relevant to receptor activation 
under physiological conditions in vivo. Although the precise receptor densities and G-protein 
subtypes encountered by D4 receptors in their neuronal microenvironments are still unknown, even 
modest in vitro partial agonism may translate to measurable in vivo effects. This is supported by the 
observation that apomorphine and ABT724 (Emax 47 and 36%, respectively, [82]) facilitated sexual 
activity in rodents 
(427)
. Further, PD168077 (Emax 39 %) stimulated extracellular regulated kinase 
(ERK) phosphorylation in the paraventricular nucleus, a region associated with sexual behaviour (428). 
Compounds such as bifeprunox, sarizotan, SLV313 and F15063 that possess partial agonist 
properties (Emax 13 – 32%) may therefore also be expected to influence D4 activity under 
physiological conditions. Indeed, F15063 and SLV313 reversed scopolamine-induced memory deficits 
in a rat social recognition paradigm [73](429), an action that is blocked by pre-treatment with 
L745,870. Thus, D4 receptor activation by F15063 and SLV313 appears responsible for their activity in 
a model of cholinergic deficit, a finding in accordance with the known pro-cholinergic action of 
SLV313 in neurochemical measures (232). 
In general, the compounds that activated [35S]GTPγS binding to CHO-hD4.4 membranes also increased 
GIRK channel currents in the Xenopus oocytes [82], demonstrating that they are capable of 
regulating both of these transduction systems linked to D4 receptors 
(430). However, whereas 
[35S]GTPγS binding experiments measure activation of G-protein Gα subunits, GIRK channel currents 
provide measures of Gβγ subunit activation (431) and some drugs exhibited preferential efficacy for 
one transduction system versus the other. For example, sarizotan exhibited substantial partial 
agonist efficacy for [35S]GTPγS binding (Emax = 32%), greater than that observed with the selective 
agonist, CP226289 (Emax = 23%). In contrast, sarizotan was less efficacious for activation of GIRK 
currents (Emax <40%) than CP226289 (Emax ~70%). These data suggest that CP226289 may 
preferentially exert its agonist properties via GIRK channels whereas sarizotan may predominantly 
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influence other G-protein activation pathways. Such observations suggested that some “biased 
agonism” may be occurring at D4 receptors, as has been observed at other receptors (see Chapter 3 
for discussion of biased agonism at 5-HT1A receptors).  
In summary, the studies I conducted [12,82] underline the importance of comparative information 
using a library of reference compounds in order to ‘calibrate’ in vitro functional responses. It is 
interesting to note that several recent drugs, such as bifeprunox, SLV313, F15063 and aripiprazole, 
exhibit marked partial agonist activity. It may therefore be supposed that this will translate in vivo to 
detectable physiological activity, particularly in regards to cognitive profile (see Introduction) and/or 
influence on sexual dysfunction.  
“Promiscuous” coupling of D4 receptors to adrenaline and noradrenaline 
Receptors are usually classified according to their endogenous neurotransmitter, with the 
assumption that other neurotransmitters have little, if any, capacity to activate the receptor. 
However, preliminary evidence had been reported that dopaminergic receptors may also exhibit 
high affinity for other neurotransmitters (432-434). I found this to be an intriguing concept because it 
runs contrary to usual assumptions of receptor selectivity and signaling. When I investigated the 
issue at D4 receptors, I found that, remarkably, noradrenaline and adrenaline, like dopamine, bound 
to D4 receptors with high affinity [7]. In fact, 
the high-affinity components (KH) of the 
biphasic competition binding curves were in 
the nanomolar range (3 to 12 nM; see Fig. 7.1). 
These KH values are similar to the affinitites of 
noradrenaline and adrenaline at 1- 2- and -
adrenoceptors 
(435)
, suggesting that D4 
receptors are concurrently activated under 
physiological conditions. Nanomolar KH values 
were also observed for a further D4 receptor 
isoform (D4.2) and in a different expression 
system (baculovirus-infected Sf9 cells), 
providing further support for the assertion that 
high affinity for noradrenaline and adrenaline 
is an intrinsic characteristic of D4 receptors. In 
contrast, D2 receptors exhibited low affinity for 
noradrenaline and adrenaline, indicating that 
high affinity for these neurotransmitters is not 
a general property of dopaminergic receptors 
[7].  
 The biphasic competition isotherms of 
adrenaline and noradrenaline at D4 receptors 
Figure 7.1: Binding and G-protein activation by 
adrenaline and noradrenaline at D4 receptors.  
The upper panel shows the binding isotherms of 5 
endogenous agonists at dopamine D4.4 receptors. 
The lower panel shows the effects of these agonists 
on G-protein activation. Adapted from [7]. 
Note: for copyright reasons, this Figure is omitted 
from the public access version of the thesis. 
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suggested the presence of two G-protein-coupling states of the receptor. Indeed, an increase in KH 
values was observed in the presence of GppNHp, consistent with a change from a high agonist 
affinity (G-protein coupled) to a low agonist affinity (uncoupled) conformation of the receptor (see 
Chapter 2 and Fig. 2.2). In G-protein activation experiments ([
35
S]GTPγS binding), noradrenaline and 
adrenaline, like dopamine, acted as agonists (Fig. 7.1). It is interesting that noradrenaline and 
adrenaline are less potent than dopamine in stimulating [
35
S]GTPγS binding and it is interesting to 
speculate whether they may promote coupling of the D4 receptor to different G-protein populations. 
In any case, stimulation of [
35
S]GTPγS binding by noradrenaline was specifically mediated by D4 
receptors, since the selective antagonist, L745,870, as well as spiperone, haloperidol and clozapine, 
completely antagonised it. In contrast, noradrenaline-induced [35S]GTPγS binding was not inhibited 
by antagonists at dopamine D2/D3, D1/D5 receptors or α1-, α2- and β-adrenoceptors [7]. 
Conclusions and perspectives. 
In addition to dopamine, adrenaline and noradrenaline also potently bind D4 receptors (but not D2 
receptors). Like dopamine, adrenaline and noradrenaline also act as agonists, stimulating D4 
receptor-mediated [
35
S]GTPgS binding [7]. These observations are consistent with similar ones 
published almost concurrently by another laboratory (436) and with subsequent data reported by a 
third research group 
(426)
. A later study extended these data by demonstrating that the “promiscuity” 
of D4 receptors is also observed for activation of GIRK channels in Xenopus oocytes 
(437). Taken 
together, these observations strongly suggest that D4 receptors mediate some of the physiological 
actions of noradrenaline and adrenaline. For example, D4 receptors are found in hippocampus and 
spinal cord (393,438), which receive noradrenergic, but little dopaminergic, innervation (439). Similarly, 
mRNA encoding D4 receptors is detected in retina, adrenal chromaffin cells, heart and kidney 
(440,441), 
tissues rich in noradrenaline and adrenaline.  
D.Sc. Thesis  Chapter 8 
  
Part A: Page 79 of 206  
8. Noradrenergic α2 receptors 
8.1 Key points  
 Noradrenergic α2 receptors are important targets in the control of movement disorders such as 
Parkinson’s disease but little systematic characterisation of the in vitro binding profiles of anti-
parkinsonian drugs was available. 
 The author conducted the first multiparametric study of anti-Parkinson’s disease agents with 
differing profiles of action at α2 and other monoamine receptors. This extensive study compared 
14 drugs, including the principal clinically-employed pharmacotherapeutics, in ligand binding tests 
at 21 receptors [48]. 
 The effects of 14 antiparkinsonian agents were examined in signal transduction tests in vitro at 14 
targets, including 6 serotonergic (5-HT1A, 5-HT1B, 5-HT1D, 5-HT2A, 5-HT2B, 5-HT2C), 4 dopaminergic 
(D2S, D2L, D3, D4), and 4 noradrenergic (α1, α2A, α2B, α2C) receptors [49,50]. 
 The clinical anti-Parkinson’s disease drug, piribedil, which was previously thought to act 
essentially through dopaminergic mechanisms, was shown to possess α2 receptor antagonism in 
vitro and in vivo [38]. The alpha2 properties were of a similar magnitude as the dopaminergic 
properties of piribedil. 
 Commonly-used α2 antagonists often lack of selectivity with regards to serotonin 5-HT1A 
receptors. This was revealed using in vitro binding and signal transduction studies [17] and in in 
vivo studies of anti-cataleptic influence [55]. 
8.2 Background to author’s work 
In Parkinson’s disease, the progressive degeneration of nigrostriatal dopaminergic pathways is 
associated with diverse motor symptoms, including rigidity, tremor, bradykinesia, and postural 
instability (442). In addition, patients exhibit sensory and cognitive/attentional deficits together with 
depressed mood and chronic pain (19,443,444). Despite increasing interest in neuroprotective strategies, 
Parkinson’s disease is principally treated by administration of the dopamine (DA) precursor 
L-dihydroxyphenylalanine (L-DOPA) (445). However, L-DOPA displays variable pharmacokinetics, elicits 
dyskinesias and autonomic side effects, poorly improves certain motor symptoms, is largely 
ineffective against cognitive and mood deficits, and loses efficacy upon prolonged administration (20). 
Abrupt transitions between “on” and “off” phases are particularly distressing to patients (22). 
These observations encouraged efforts to identify non-dopaminergic strategies for relief of 
Parkinson’s disease: one possibility was to target adrenergic mechanisms because parkinsonian 
patients show a loss of locus ceruleus-localized adrenergic neurons (446-448). This depletion of 
noradrenaline is seen notably in the motor cortex, in limbic structures such as the nucleus 
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accumbens, and in the spinal cord and aggravates deficits in the control of motor behavior, mood, 
cognition, and attention 
(23,446)
. α2A receptors are implicated in the functional roles of adrenergic 
pathways and elicit activation of signaling (G-protein activation) in regions such as amygdala and 
lateral septum [28]. α2A receptors are also implicated in the inhibition of frontocortical and, possibly, 
subcortical dopaminergic pathways as well as corticolimbic serotonergic projections 
(1,447)
. 
Modulation of noradrenergic transmission by α2A receptors has, therefore, well-established and 
broad effects on control of motor behavior, mood, and cognition [27](447,449-451). 
In this context, α2 receptor antagonists potentiate induction of rotation by dopaminergic agonists in 
rats bearing unilateral lesions of the substantia nigra 
(447,450-452)
. They also enhance the ability of 
dopaminergic agonists to alleviate perturbation of motor functions provoked by reserpine and 
haloperidol 
(446)
 (although some α2 receptor antagonists also exhibit 5-HT1A agonist properties 
[17,55]). Moreover, α2 receptor antagonists facilitate antiparkinsonian actions of L-DOPA in this 
model while suppressing its dyskinetic side effects (446,453). Furthermore, in primates, α2 receptor 
antagonists attenuate motor symptoms elicited by the neurotoxin 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP) 
(454,455)
, whereas lesions of the locus ceruleus exacerbate pathological 
changes and delay recovery (450). On a clinical level, small-scale clinical studies in parkinsonian 
patients had suggested a modest improvement upon administration of α2 receptor antagonists 
(456,457). Moreover, coadministration of idazoxan improves L-DOPA-elicited dyskinesia in PD 
patients
(458,459)
. 
These observations indicate that a deficiency of adrenergic transmission may contribute to motor, 
cognitive, and/or emotional symptoms of Parkinson’s disease, and blockade of α2 autoreceptors 
may be favourable for its treatment. This might be achieved by adjunctive use of α2 receptor 
antagonists with L-DOPA or dopaminergic agonists 
(23,446)
. Alternatively, α2 receptor antagonist and 
D2 agonist properties might be incorporated into a single molecule, such as piribedi [38]. The latter is 
an antiparkinsonian drug from Servier laboratories, where I was working at the time of the studies 
described in the present chapter. However, studies of the adrenergic properties of antiparkinsonian 
drugs had been restricted to a few ligands at poorly-characterized native sites and knowledge of the 
comparative agonist/antagonist profiles of antiparkinson agents was fragmentary. 
8.3 Contribution of author’s work  
The above considerations led me to believe that (i) whereas psychopharmacologists had for many 
years carried out highly detailed analysis of the receptor profiles of antipsychotics (see Chapter 4), 
such analyses of antiparkinsonian drugs were conspicuously absent; (ii) a careful investigation of 
available antiparkinsonian drugs, particularly in relation to their α2 adrenergic properties, could 
provide a rational basis from which to interpret in vivo animal data and clinical observations; 
(iii) a comparative study of antiparkinsonian drugs should examine different chemical classes of 
drugs and carry out both affinity and efficacy (agonist / antagonist) measures.  
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The studies that I undertook evaluated the actions of 14 dopaminergic agonists (antiparkinson 
agents) at multiple classes of monoaminergic receptors. In addition, actions at muscarinic M1 sites 
and histamine H1 sites were evaluated in light of their role in the control of motor behavior, 
attention, mood, and cognition 
(460-462)
 and the alterations in histaminergic and cholinergic 
transmission that had been reported in Parkinson’s disease 
(463,464)
. The strategy adopted was as 
follows. First, using competition binding assays, we determined drug affinities at recombinant, stably 
transfected, human receptors as well as at rat α2D and at native H1 receptors. Second, to analyse the 
extensive database of drug profiles, data were subjected to principle components analysis (PCA) and 
drugs were classified by hierarchical (cluster) analysis in accordance with their overall homology [48]. 
This multivariate approach to drug comparisons had the advantage of permitting identification of 
patterns that are not necesserily revealed by visual inspection or drug-by-drug/receptor-by-receptor 
comparisons (465,466). Third, efficacies of antiparkinson agents were determined at the majority of 
monoaminergic receptor subtypes incorporated into these multivariate analyses [48,50]. 
Cluster analysis of drug homology for receptor affinities. 
Although multivariate techniques had been used for evaluation of biochemical abnormalities in 
schizophrenia (467) and characterization of drug pharmacokinetic profiles (465), this was their first 
utilization for characterization of drug/receptor binding. Multivariate strategies simultaneously 
analyse the entire database, permitting hypothesis-free exploration of overall affinity profiles. 
Although the experimenter still needs to select both the drugs and the variables to be measured, 
substantial databases such as the one that was generated in my laboratory, decrease the risk that an 
involuntary “bias” may distort analyses. Comparisons of the overall affinity profiles of drugs provide 
a framework for interpretation of their contrasting functional profiles in vivo. For example, 
comparisons of the profiles of established drugs with those of novel compounds could provide 
information on the latter’s possible  therapeutic potential. However, multivariate analyses assume 
that drugs behave in an identical manner at different receptor types. This is appropriate for 
structure-activity relationships focusing on drug affinity (pKi values) but neglects potential 
differences in efficacy. In other words, the multivariate analysis did not take into account the fact 
that some compounds possess agonist or antagonist properties. I therefore addressed this important 
issue in separate investigations of G-protein activation and other intracellular responses [49,50]. 
Ideally, an integrated measure would be available that reflects both affinity and efficacy, but there is 
not yet an accepted parameter that can be used for a multivariate analysis.  
From the dendrogram of overall drug homology generated by analysis of the database, several drug 
clusters were observed (Fig. 8.1). The most striking separation between drugs was at the first 
“node”, which yielded two major subdivisions. The first major group comprised quinpirole, 
quinelorane, ropinirole, pramipexole, piribedil, and talipexole, whereas the second comprised 
lisuride, terguride, roxindole, bromocriptine, cabergoline, pergolide, TL99, and apomorphine. These 
drugs displayed low affinities for multiple classes of 5-HT receptor, and low affinities for D5 
compared with D2S/D2L receptors. Drugs in this first cluster also showed low affinity for D1 and H1 
receptors and negligible affinity for α1 and α2 receptors, although this feature was also seen in 
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certain drugs in the second major cluster. Within the first group, similarity was apparent between 
quinpirole and, and between ropinirole and pramipexole, which comprised two closely related 
subclusters. The other two agents, piribedil and talipexole, could be distinguished by their more 
pronounced affinities at noradrenergic α2A, α2C and α1 receptors. Within the second major 
subdivision, lisuride and terguride revealed high affinities at all sites, notably at α1, α2, 5-HT2A and 
5-HT2C receptors and all subtypes of dopamine receptor. Roxindole and bromocriptine constituted a 
closely related subcluster showing a similar overall pattern of affinities, notably sharing high affinity 
for α1 receptors. An additional pair of ligands displaying similar receptor binding profiles was formed 
by cabergoline and pergolide, with the former showing higher affinities at most sites. Both revealed 
low affinities for H1 receptors and α1 and α2 receptors. The final couple of closely-related drugs was 
TL99 and apomorphine, which showed less pronounced affinities at most sites than other drugs.  
Noradrenergic α2 receptors.  
When the antiparkinsonian compounds were compared in functional tests of receptor activation, 
striking differences in drug efficacies were seen at α2 receptor subtypes [49]. In analogy to piribedil 
[38], lisuride, bromocriptine, and apomorphine displayed antagonist properties, observations 
amplifying functional studies of isolated organs and hippocampal NA release in rats (468,469). In line 
with their high affinities for α2 receptors [48], roxindole and two further ergot-related ligands, 
terguride and cabergoline, also manifested potentα2 receptor antagonist properties [22]. In 
contrast, in line with previous in vivo studies atα2 receptors in rodents (470,471), TL99 displayed 
agonist, and talipexole partial agonist, properties at α2A, α2B and α2C receptors. In vivo studies in 
rodents had revealed agonist actions of pergolide at central α2 receptors (472) and particularly 
Figure 8.1: Cluster analysis of receptor affinity of anti-Parkinson’s disease drugs.  
The analysis is based on 294 values of binding affinity (pKi) at 21 receptors. The distance between two 
individual drugs is inversely proportional to their pharmacological homology. In broad terms, three 
different drug classes were identified: those with selective affinity for dopamine D2-like receptgors (shown 
in magenta), those with combined α2 and D2 properties (black) and those with mixed D2, serotonergic and 
adrenergic properties (blue). Figure adapted from [48]. 
Note: for copyright reasons, this Figure is omitted from the public access version of the thesis. 
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pronounced agonist properties at α2B receptors were observed here [49]. These contrasting actions 
of antiparkinson agents are of considerable significance in light of evidence that blockade of α2 
receptors improves motor performance, cognitive function, and perhaps mood in Parkinson’s 
disease 
(23,446)
. In contrast, α2 receptor agonists interfere with antiparkinsonian actions 
(451,473,474)
. 
Indeed, talipexole-induced stereotypy in rats (which reflects agonist properties at striatal D2 
receptors) is only apparent upon prevention of its α2 receptor agonist properties by 
coadministration of idazoxan (470) and it only elicits rotation in unilateral SNPC-lesioned rats upon 
cotreatment withα2 receptor antagonists 
(475)
. The overall picture that emerges from these studies 
is that currently-used antiparkinsonian drugs display a widely-diverging palette of mechanisms of 
action which, in some cases appears to be far from optimised. One drug that displays a distinctive 
and somewhat more attractive pharmacological profile is piribedil, as discussed below. 
Table 8.1: Agonist efficacies of antiparkinsonian drugs.  
Information is based on data from cloned human receptors  [38,49,50]. 
 Dopaminergic Adrenergic Serotonin 5-HT1 Serotonin 5-HT2 
Ligand D2 D3 D4 α1A α2A 1A 1B 1D 2A 2B 2C 
Quinpirole ++++ ++ ++ 0 0 + 0 0 0 0 0 
Quinelorane ++++ ++ ++ 0  0 0 0 0 0 0 
Ropinirole +++ ++ ++ 0 0 + 0 0 0 0 0 
Pramipexole ++++ ++ + 0 ++ + 0 0 0 0 0 
Piribedil ++ ++ 0   0 0 0 0 0 0 
Talipexole ++ ++ + 0 ++ 0 0 0 0 0 0 
Lisuride + + +   +++ ++ ++ ++  ++ 
Terguride + +    ++ + ++ ++   
Roxindole  + +   ++ +     
Bromocriptine +++ ++    ++ ++ ++ ++  ++ 
Cabergoline +++ ++ +   +++ +++ ++ +++ +++ +++ 
Pergolide +++ ++ + 0 + ++ +++ ++ +++ +++ ++ 
TL 99 ++ +++ ++ 0 +++ 0 0 0 0 0 0 
Apomorphine +++ ++ + 0  + 0 +    
Piribedil as a dual dopamine D2 and α2 adrenergic anti-parkinsonian agent.  
The studies I carried out indicated that, although piribedil is not a potent agent, its affinity at α2A and 
α2C receptors was comparable to its affinity at D2 receptors [38]. This suggests that at therapeutically 
relevant doses activating D2 receptors, piribedil also occupies α2A and α2C sites, actions that likely 
contribute to its functional profile. Although certain other antiparkinsonian agents also interact with 
α2 receptors [48,49], piribedil behaves essentially as an antagonist, whereas some compounds, such 
as talipexole, are efficacious agonists [49](470,476), a property that is lilely to limit their clinical efficacy. 
In contrast, selecting compounds that exhibit α2 receptor antagonism in addition to D2 receptor 
agonism may represent a promising strategy for improved management of Parkinson’s disease. Even 
if post-synaptic α2 receptors are simultaneously antagonized, favorable actions should be mediated 
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via colocalized, post-synaptic α1 and β adrenergic receptors 
(452)
[38,49]. Correspondingly, in contrast 
to talipexole, piribedil was found to reinforce corticolimbic adrenergic and cholinergic transmission, 
actions contributing to its favorable influence upon cognitive function and mood (477-481). Moreover, 
apart from mild affinity at 5-HT1A sites, piribedil was devoid of activity at multiple serotonergic 
receptors [48,50]. In contrast, other agents, such as bromocriptine, pergolide, and cabergoline, acted 
as potent agonists at 5-HT2A and 5-HT2C receptors, which likely underlies their propensity to elicit 
psychotic side-effects in Parkinsonian patients [48,50].  
8.1 Conclusions and perspectives. 
The comprehensive analysis that I conducted of the binding profiles of antiparkinson agents revealed 
marked and unexpected heterogeneity [48]. The latter extended beyond binding affinities to 
remarkable diversity in agonist / antagonist actions identified in accompanying efficacy studies 
[49,50]. In particular, this work demonstrated that some antiparkinsonian drugs exhibit marked 
affinity at α1 and α2 adrenergic receptors. Whereas talipexole behaves as an agonist at α2 receptors 
(470)
, piribedil showed antagonist properties [38].  
It is interesting that, in the decade since these studies were published, new research on the use of 
α2 receptor antagonists in treatment of Parkinson’s disease has been limited (a couple of dozen 
references found in PubMed in response to the keywords “alpha2” and “parkinsons”). Nevertheless, 
a selective α2 antagonist, fipamezole, was found to decrease L-DOPA-induced dyskinesias without 
interfering with antiparkinsonian properties 
(482)
 and recent publications suggest that interest in 
noradrenergic strategies for pharmacotherapy of Parkinson’s disease may be increasing (23,446). In 
particular, piribedil constitutes a possible “prototype” anti-PD drug that differs structurally from 
imidazolines (such as idazoxan), alkaloids (such as yohimbine) and other prototypical antagonists, 
but shares their antagonist properties at α2 receptors [38].  
In conclusion, the study of anti-PD drugs carried out in my laboratory and the characterization of 
piribedil’s α2 receptor antagonism contributed to advancing concepts that provide a basis for novel 
drug discovery programs for the treatment of Parkinson’s disease. 
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Reference no. 1 
Biochem J. 1992 Aug 1;285 ( Pt 3):933-8. 
High-level stable expression of recombinant 5-HT1A  
5-hydroxytryptamine receptors in Chinese hamster ovary cells.  
Newman-Tancredi A, Wootton R, Strange PG. 
Biological Laboratory, The University, Canterbury, Kent, U.K. 
The human 5-hydroxytryptamine 5-HT1A receptor gene was transfected into Chinese hamster ovary 
cells. A series of recombinant monoclonal cell lines expressing the receptor were isolated and the 
properties of one cell line that expressed receptors at a high level (2.8 pmol/mg) were studied in 
detail. In ligand binding assays with the selective 5-HT1A receptor agonist 2-(NN-di[
3H]propylamino)-
8-hydroxy-1,2,3,4-tetrahydronaphthalene ([
3
H]8-OH-DPAT) only a single class of saturable high-
affinity binding sites was detected, with a pharmacological profile in competition experiments 
essentially identical to that of the 5-HT1A receptor of bovine hippocampus. [
3
H]8-OH-DPAT binding to 
the recombinant cell membranes was inhibited by GTP, showing that the receptors in the 
transfected cells couple to G-proteins. A series of 5-hydroxytryptamine agonists inhibited forskolin-
stimulated adenylate cyclase activity in the cells and, despite the high level of receptor expression, 
their apparent efficacies were similar to those observed for inhibition of adenylate cyclase in brain. 
This recombinant cell line provides a complete model system for studying the 5-HT1A receptor and its 
transmembrane signalling system. The recombinant cells can also be grown in suspension culture for 
long periods but, whereas 5-HT1A receptor numbers and receptor regulation by guanine nucleotides 
are maintained in suspension-grown cells, the inhibition of adenylate cyclase by the 5-HT1A receptor 
is gradually lost. 
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Biochem Pharmacol. 1993 Mar 9;45(5):1003-9. 
Characterization of recombinant human serotonin 5 -HT1A receptors 
expressed in Chinese hamster ovary cells. [ 3H]spiperone discriminates 
between the G-protein-coupled and -uncoupled forms. 
Sundaram H, Newman-Tancredi A, Strange PG. 
Biological Laboratory, The University, Canterbury, Kent, U.K. 
5-HT1A serotonin (5-hydroxytryptamine) receptors have been characterized by ligand binding in a 
recombinant Chinese Hamster Ovary cell line expressing the human receptor gene. The agonist 
ligand [
3
H]2-(N,N-dipropylamino)-8-hydroxy-1,2,3,4-tetrahydronaphthalene ([
3
H]8-OH-DPAT) and the 
antagonist [
3
H]spiperone were used. For both radioligands the binding sites labelled have the 
properties of 5-HT1A receptors and most antagonists show roughly equal affinities for the receptors 
labelled by either [
3
H]8-OH-DPAT or [
3
H]spiperone. Agonists, however, show higher affinities for the 
sites labelled by [
3
H]8-OH-DPAT and the antagonist spiperone conversely shows a higher affinity for 
the sites labelled by [3H]spiperone. Whereas [3H]8-OH-DPAT binding is inhibited by guanosine 
triphosphate (GTP) the binding of [3H]spiperone is increased by GTP. A model is proposed for the 
results whereby [
3
H]8-OH-DPAT labels a form of the receptor coupled to a G-protein and 
[
3
H]spiperone labels a form of the receptor uncoupled from G-proteins (or possibly coupled to a 
different G-protein). 
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Neuropharmacology. 1995 Dec;34(12):1693-6. 
[3H](+)S 14297: a novel, selective radioligand at cloned human 
dopamine D3 receptors. 
Newman-Tancredi A, Audinot V, Jacques V, Peglion JL, Millan MJ. 
Institut de Recherches Servier, Department of Psychopharmacology, Croissy-sur-Seine, France. 
The selective dopamine D3 receptor antagonist [
3
H](+)S 14297 ((+)-[7-(N,N-dipropylamino)-5,6,7,8-
tetrahydro-naphtho(2,3b)dihydro,2,3- furane]), labelled to high specific activity (145 Ci/mmol), 
bound to cloned human dopamine D3 receptors but displayed negligible binding to cloned human D2 
receptors. [3H](+)S 14297 exhibited rapid association and dissociation, high affinity saturable binding 
(Kd = 7.0 nM) and a competition binding profile highly correlated with that of [125I]iodosulpride 
(r=0.98). 
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Neuropharmacology. 1996 Jan;35(1):119-21. 
Clozapine is a partial agonist at cloned, human serotonin 5-HT1A  
receptors. 
Newman-Tancredi A, Chaput C, Verriele L, Millan MJ. 
Institut de Recherches Servier, Department of Psychopharmacology, Croissy-sur-Seine, France. 
Clozapine exhibited 10-fold higher affinity than haloperidol for human 5-HT1A receptors expressed in 
Chinese Hamster Ovary cells (CHO-h5-HT1A) (Kis = 160 and 1910 nM respectively). Whereas 
haloperidol did not alter the basal binding of [
35
S]GTP gama S to CHO-h5HT1A membranes, clozapine 
stimulated it with an EC50 of 2320 nM and an efficacy of 49% (compared to 5-HT). The stimulation 
was antagonized by the selective 5-HT1A receptor antagonist, WAY100635 (1 nM). 
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Eur J Pharmacol. 1996 Jun 20;307(1):107-11. 
S 15535 and WAY100635 antagonise 5-HT-stimulated [35S]GTPgammaS 
binding at cloned human 5-HT1A  receptors. 
Newman-Tancredi A, Chaput C, Verrièle L, Millan MJ. 
Institut de Recherches Servier, Department of Psychopharmacology, Croissy-sur-Seine, France. 
In Chinese hamster ovary (CHO) cells expressing cloned human 5-HT1A receptors, S15535 (4-
(benzodioxan-5-yl)1-(indan-2-yl)piperazine) exhibited high affinity (Ki = 0.79 nM), similar to that of 
5-HT (0.61 nM), (+/-)-8-hydroxy-3-(di-n-propylamino)tetralin ((+/-)-8-OH-DPAT; 0.58 nM) and N-{2-
[4-(2-methoxyphenyl)-1-piperazinyl]ethyl}-N- (2-pyridinyl)cyclo-hexanecarboxamide (WAY100635; 
0.56 nM). In these cells, 5-HT stimulated [
35
S]GTPγS binding 3-fold (EC50 = 15 nM) whereas (+/-)-8-
OH-DPAT exhibited 73% efficacy relative to 5-HT (EC50 = 6.0 nM). WAY100635 completely blocked 5-
HT- and (+/-)-8-OH-DPAT-stimulated [
35
S]GTPγS binding. Likewise, S15535 antagonised 5-HT-
stimulated [35S]GTP gamma S binding, reducing it to 30.1% of control values. S 15535 (100 nM) also 
shifted the 5-HT and (+/-)-8-OH-DPAT stimulation curves to the right, to EC50 values of 870 and 313 
nM, respectively. However, unlike WAY100635, which by itself did not stimulate [35S]GTPγS binding, 
S15535 alone increased it by 34.7% relative to 5-HT (EC50 = 5.8 nM). In conclusion, S15535 
antagonises the stimulation of 5-HT1A receptors by 5-HT, whilst itself exerting weak partial agonist 
activity at these sites. 
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J Pharmacol Exp Ther. 1997 Mar;280(3):1241-9. 
Interactions of (+)- and (-)-8- and 7-hydroxy-2-(di-n-
propylamino)tetralin at human (h)D3, hD2 and h serotonin1A receptors 
and their modulation of the activity of serotoninergic and dopaminergic 
neurones in rats. 
Lejeune F, Newman-Tancredi A, Audinot V, Millan MJ. 
Institut de Recherches Servier, Department of Psychopharmacology, Croissy-sur-Seine, France. 
The aminotetralins, 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) and 7-OH-DPAT behave as 
preferential agonists at serotonin 5-HT1A and dopamine D3 and D2 receptors, respectively. In our 
study, we evaluated the influence of their (+)- and (-) isomers on the electrical activity of 
serotoninergic neurones of the dorsal raphe nucleus (DRN), which bear 5-HT1A autoreceptors, and of 
dopaminergic neurones of the ventral tegmental area (VTA), which possess inhibitory D3 and D2 
receptors. These actions were compared to their in vitro interactions with cloned, human (h)5-HT1A, 
hD3 and hD2 receptors. In binding studies, racemic 8-OH-DPAT showed 100-fold selectivity for 
h5-HT1A vs. hD2 and hD3 receptors and there was little difference between its (+)- and (-)-isomers 
either in terms of their potency at 5-HT1A receptors or of their selectivity at 5-HT1A vs hD2/hD3 sites. 
Nevertheless, the (+)-isomer was markedly more efficacious than its (-)-counterpart in stimulating 
the binding of guanosine 5'-O-(3-[35S]thiotriphosphate) ([35S]-GTPgammaS) at h5-HT1A receptors, a 
measure of coupling to G-proteins; 90 vs. 57% maximal stimulation respectively, relative to 5-HT = 
100%. Also the (+)-isomer was ca. 3-fold more potent than the (-)-isomer in inhibiting the firing rate 
of DRN neurones. These actions were abolished by the 5-HT1A antagonist, (-)-tertatolol, but 
unaffected by the hD2/hD3 antagonist, haloperidol. Whereas (+)-8-OH-DPAT stimulated VTA neurone 
firing with a bell-shaped dose response curve, the (-)-isomer only inhibited VTA firing. The (+)-
isomer-induced stimulation was blocked by (-)-tertatolol but not haloperidol, whereas the (-)-
isomer-induced inhibition was abolished by haloperidol and unaffected by (-)-tertatolol. In contrast 
to 8-OH-DPAT, the (+)- and (-)isomers of 7-OH-DPAT showed marked stereoselectivity inasmuch as 
the latter bound with 20-fold less potency than the former at hD3 and, at higher concentrations, hD2 
receptors. Correspondingly, (+)-7-OH-DPAT was 20-fold more potent than (-)-7-OH-DPAT in reducing 
VTA firing. Concerning 5-HT1A receptors, the (+)-isomer showed 20-fold lower affinity than at hD3 
receptors and, accordingly, it inhibited DRN firing at 20-fold higher doses than for inhibition of VTA 
firing. (-)-7-OH-DPAT showed even less (5-fold) selectivity for hD3 vs. 5-HT1A sites and for inhibition of 
VTA vs. DRN firing. The inhibition of VTA and DRN neurone firing by (+)-7-OH-DPAT was abolished by 
haloperidol and (-)-tertatolol, respectively. Finally, in line with this inhibition of DRN firing, both (+)- 
and (-)-7-OH-DPAT showed substantial efficacy ([35S]-GTPgammaS binding, 76 and 53%, respectively) 
at h5-HT1A receptors. In conclusion, for these substituted aminotetralins, stereospecificity is a more 
marked feature of interactions at hD3 (and hD2) than at h5-HT1A receptors and is more pronounced 
for 7- as compared to 8-OH-DPAT. Neither (+)- nor (-)-7-OH-DPAT show substantial selectivity for hD3 
vs. 5-HT1A receptors and their inhibition of the firing of VTA as compared to DRN neurones is 
mediated by hD3/hD2 and 5-HT1A receptors, respectively. Finally, VTA neurones are stimulated by (+)-
8-OH-DPAT via 5-HT1A receptors and inhibited by (-)-8-OH-DPAT via hD3 and/or hD2 receptors. 
D.Sc. Thesis  Publication Abstracts 
 
Part B: Page 92 of 206 
Reference no. 7 
Eur J Pharmacol. 1997 Jan 29;319(2-3):379-83. 
Noradrenaline and adrenaline are high affinity agonists at dopamine  D4 
receptors. 
Newman-Tancredi A, Audinot-Bouchez V, Gobert A, Millan MJ. 
Institut de Recherches Servier, Department of Psychopharmacology, Croissy-sur-Seine, France. 
The activity of monoamine neurotransmitters was examined at dopamine D4 receptors. In 
competition binding with [3H]spiperone, noradrenaline and adrenaline exhibited a high affinity 
binding component (KH = 12.1 nM and 5.0 nM, respectively), similar to that of dopamine (KH = 2.6 
nM), whereas serotonin (5-hydroxytryptamine, 5-HT) and histamine had low affinity (Ki > 1000 nM). 
Noradrenaline and adrenaline acted as agonists at dopamine D4 receptors, stimulating receptor-
mediated [
35
S]guanylyl-gamma-thiotriphosphate ([
35
S]GTPgammaS) binding (EC50 = 7.8 and 5.8 
microM, respectively, versus 0.1 microM for dopamine). The dopamine D4 receptor-selective ligand, 
3-(4-[4-chlorophenyl]piperazin-1-yl)methyl-1H-pyrrolo[2,3b]-pyridi ne (L745,870) and the 
dopaminergic antagonists, spiperone, haloperidol and clozapine, inhibited noradrenaline-stimulated 
[35S]GTPgammaS binding whereas alpha1-, alpha2- and beta-adrenoceptor antagonists did not. 
These results indicate that dopamine D4 receptors are activated by noradrenaline and adrenaline, 
although at 50-100-fold higher concentrations than dopamine. 
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Br J Pharmacol. 1997 Mar;120(5):737-9. 
Inhibition of the constitutive activity of human 5-HT1A  receptors by the 
inverse agonist, spiperone but not the neutral antagonist, WAY100635. 
Newman-Tancredi A, Conte C, Chaput C, Spedding M, Millan MJ. 
Institut de Recherches Servier, Department of Psychopharmacology, Croissy-sur-Seine, France. 
At recombinant human 5-hydroxytryptamine (5-HT) 5-HT1A receptors expressed in Chinese hamster 
ovary cells (CHO-5-HT1A), 5-carboxamidotryptamine (5-CT), acted as a full agonist (relative to 5-HT = 
100%) for stimulation of receptor-mediated [
35
S]GTPgammaS (guanylyl-5'-[gamma-thio]-
tryphosphate) binding. In contrast, spiperone inhibited basal [35S]GTPgammaS binding by 30.2% (IC50 
= 55.5 nM) in CHO-5-HT1A membranes but not in control untransfected membranes. The antagonist, 
N-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-N-(2-pyridinyl)-cyclohexane-carboxamide 
(WAY100635), blocked both 5-CT-induced stimulation and spiperone-induced inhibition of 
[35S]GTPgammaS binding without itself modifying [35S]GTPgammaS binding. It is concluded that, in 
this heterologous expression system, 5-HT1A receptors display 'constitutive' activation of G-proteins 
and that spiperone displays inverse agonist activity whereas WAY100635 acts as a 'neutral' 
antagonist at this site. 
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J Pharmacol Exp Ther. 1997 Jul;282(1):132-47. 
S 15535, a novel benzodioxopiperazine ligand of serotonin (5 -HT)1A 
receptors: I. Interaction with cloned human (h) 5-HT1A, dopamine 
hD2/hD3 and h alpha2A-adrenergic receptors in relation to modulation 
of cortical monoamine release and activity in models of potential 
antidepressant activity. 
Millan MJ, Newman-Tancredi A, Rivet JM, Brocco M, Lacroix P, Audinot V, Cistarelli L, Gobert A. 
Institut de Recherches Servier, Psychopharmacology Department, Croissy-sur-Seine, France. 
The novel, potential anxiolytic, S 15535 (4-(benzodioxan-5-yl)1-(indan-2-yl)piperazine), is an agonist 
and antagonist (weak partial agonist) at pre- and postsynaptic serotonin 5-HT1A receptors, 
respectively. Herein, we characterized its influence on dialysate levels of 5-HT, dopamine (DA) and 
NAD simultaneously determined in single samples of the frontal cortex (FCX) of freely moving rats, 
and compared its activity in several other models of potential antidepressant (AD) properties with 
those of the 5-HT reuptake inhibitor (SSRI), fluoxetine. S 15535 displayed high affinity at cloned 
human (h) 5-HT1A receptors (Ki = 0.7 nM) and >250-fold lower affinity at cloned hD2 (400 nM), hD3 
(248 nM) and h alpha2A-adrenergic (AR) (190 nM) receptors. S 15535 (0.08-5.0 mg/kg s.c.) markedly 
and dose-dependently suppressed dialysate levels of 5-HT in the FCX, nucleus accumbens and 
striatum of freely moving rats, whereas fluoxetine (10.0 mg/kg s.c.) elevated levels of 5-HT in each 
structure. In contrast to 5-HT, dialysate levels of DA and NAD in the FCX were dose-dependently 
increased by S 15535, and this effect was mimicked by fluoxetine. The influence of S 15535 and 
fluoxetine on FCX levels of DA was regionally specific inasmuch as dialysate levels of DA in the 
accumbens and striatum were not modified. The selective 5-HT1A antagonist, WAY100635 (N-[2-[4-
(2-methoxyphenyl)-1-piperazinyl]ethyl]-N-(2-pyridinyl) cyclohexanecarboxamide (0.16) transiently 
elicited a slight increase in cortical levels of 5-HT, an action opposite to that of S 15535. Further, in 
the presence of WAY100635 (0.16), the influence of S 15535 (0.63) on cortical levels of 5-HT, DA and 
NAD was markedly attenuated. Upon chronic administration of S 15535 or fluoxetine (10.0 mg/kg 
s.c. daily for 14 days, in each case), there was no significant alteration in the density of beta-AR 
receptors in the FCX. However, in contrast to fluoxetine, S 15535 elicited a significant (25%) decrease 
in the density (Bmax) of 5-HT2A receptors labeled by [
3H]ketanserin in the cortex; there was no 
alteration in Kd. In a learned helplessness paradigm in rats, S 15535 (0.63-40.0 mg/kg p.o.) markedly 
reduced escape deficits on each of three consecutive days of testing. Fluoxetine (2.0-8.0 mg/kg i.p.) 
was also active in each session, but presented a biphasic dose-response curve. Finally, under the 
conditions used, neither S 15535 (0.63-10.0) nor fluoxetine (0.63-10.0) decreased immobility time in 
the forced swim test. In conclusion, S 15535 is a selective ligand of cloned, h5-HT1A receptors. Its 
agonist actions at 5-HT1A autoreceptors underlie its ability to decrease extracellular levels of 5-HT in 
the FCX, and likely contribute to the increase in extracellular levels of DA and NAD evoked by S 
15535 in this structure. Further, S 15535 is active in several other, although not all, models of 
potential AD activity. Thus, although S 15535 is under development as an anxiolytic agent, a further 
characterization of its putative AD actions would be of interest. 
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Neuropharmacology. 1997 Apr-May;36(4-5):451-9. 
Agonist and inverse agonist efficacy at human recombinant serotonin 
5-HT1A  receptors as a function of receptor:G-protein stoichiometry. 
Newman-Tancredi A, Conte C, Chaput C, Verrièle L, Millan MJ. 
Institut de Recherches Servier, Department of Psychopharmacology, Croissy-sur-Seine, France. 
Membrane preparations were made from Chinese Hamster Ovary (CHO) cells expressing 1.6 and 4.2 
pmol/mg of recombinant human 5-HT1A receptors, as determined by saturation binding with the 
selective antagonist, [
3
H]S 15535 ([
3
H]4-(benzodioxan-5-yl)]-(indan-2-yl)piperazine). There was no 
change in the number of G-proteins activated by the full agonist, serotonin (5-HT; approximately 1.1 
pmol/mg in each preparation, measured by [
35
S]GTPgammaS saturation binding), therefore 
increasing the receptor:G-protein ratio from approximately 1.4:1 (RGlow) to approximately 4:1 
(RGhigh). Agonist efficacy was measured by stimulation of [
35
S]GTPgammaS binding. The 
serotonergic agonist, eltoprazine, behaved as a partial agonist (Emax = 52.7%) at RGlow membranes 
but virtually as a full agonist (Emax = 93.2%) at RGhigh membranes, relative to 5-HT (= 100%). The 
latter exhibited a two-fold shift to the left in its concentration-response curve in RGhigh compared 
to RGlow membranes (P < 0.01). WAY100635 (N-2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl-N-(2-
pyridinyl) -cyclo-hexane-carboxamide), did not alter [
35
S]GTPgammaS binding from basal levels in 
either membrane preparation. In contrast, spiperone displayed inverse agonist activity, decreasing 
[
35
S]GTPgammaS binding from basal levels by 17% in RGlow membranes but by 28% in RGhigh 
membranes. These data indicate that an increased receptor:G-protein ratio (i) augments the potency 
of full agonists, (ii) increases the efficacy of partial agonists and (iii) increases the negative efficacy of 
inverse agonists at recombinant human 5-HT1A receptors. Furthermore, these data suggest that 
spiperone induces, or stabilises, a G-protein-coupled, but inactive conformation of the receptor. 
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Eur J Pharmacol. 1997 May 30;327(2-3):247-56. 
Binding profile of the novel 5-HT1B/1D receptor antagonist, 
[3H]GR125,743, in guinea-pig brain: a comparison with  
[3H]5-carboxamidotryptamine. 
Audinot V, Lochon S, Newman-Tancredi A, Lavielle G, Millan MJ. 
Institut de Recherches Servier, Department of Psychopharmacology, Croissy-sur-Seine, France. 
Native brain 5-HT1B/1D) receptors were studied using the novel antagonist, [
3
H]GR125,743 (N-[4-
methoxy-3-(4-methylpiperazin-1-yl)phenyl]-3-methyl-4-(4-pyri dyl)benzamide). In guinea-pig striatal 
membranes, [
3
H]GR125,743 displayed rapid association (t1/2 = 4.5 min), high (90%) specific binding 
and high affinity (Kd = 0.29 nM), although Bmax values (fmol/mg protein) varied according to brain 
region-striatum: 199; frontal cortex: 89; hippocampus: 79; cerebellum: 26. In frontal cortex, the 
B(max) determined with [
3
H]5-CT ([
3
H]carboxamidotryptamine) was significantly higher (178; 
P<0.05), suggesting that it also labels other binding sites. In striatal membranes, 
guanylylimidodiphosphate (GppNHp) inhibited [3H]5-CT but not [3H]GR125,743 binding, suggesting 
that the latter has antagonist properties. Nevertheless, in competition binding experiments, the pKi 
values obtained with [
3
H]GR125,743 and [
3
H]5-CT for 20 serotonergic ligands, including L694,247 (2-
[5-[3-(4-methylsulphonylamino)benzyl-1,2,4-oxadiazol-5-yl ]-1H-indole-3-yl]ethylamine), GR46,611 
(3-[3-(2-dimethylamino-ethyl)-1H-indol-6-yl]-N-(4-methoxybenzyl)acrylami de), sumatriptan and 
alniditan, were highly correlated (r = 0.99). Ketanserin and ritanserin showed low affinity for 
[3H]GR125,743 binding to guinea-pig striatal sites (Ki = 12600 and 369 nM), suggesting that 5-HT1B 
(rather than 5-HT1D) receptors are predominantly labelled in this tissue. The present data indicate 
that [3H]GR125,743 is a useful tool for studying native 5-HT1B/1D receptors. 
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J Pharmacol Exp Ther. 1997 Jul;282(1):181-91. 
[35S]Guanosine-5'-O-(3-thio)triphosphate binding as a measure of 
efficacy at human recombinant dopamine D4.4 receptors: actions of 
antiparkinsonian and antipsychotic agents.  
Newman-Tancredi A, Audinot V, Chaput C, Verrièle L, Millan MJ. 
Institut de Recherches Servier, Department of Psychopharmacology, Croissy-sur-Seine, France. 
Recombinant human dopamine D4.4 receptor-mediated G protein activation was characterized in 
membranes of transfected mammalian (Chinese hamster ovary) cells by the use of [
35
S]guanosine-5'-
O-(3-thio)triphosphate ([
35
S]GTPgammaS) binding. An initial series of experiments defined the 
conditions (3 microM GDP, 100 mM NaCl, 3 mM MgCl2) under which optimal stimulation (2.2-fold 
increase in specific [
35
S]GTPgammaS binding) was achieved with the endogenous agonist dopamine. 
The number of dopamine-activated G-proteins in Chinese hamster ovary-D4.4 membranes was 
determined through [
35
S]GTPgammaS isotopic dilution saturation binding, yielding a Bmax value of 
2.29 pmol/mg. This compared with a D4.4 receptor Bmax value of 1.40 pmol/mg determined by 
[
3
H]spiperone saturation binding, indicating that 1 or 2 G-proteins were activated per D4.4 receptor 
and that there were few or no "spare receptors" in this cell line. Under these conditions, the efficacy 
for stimulation of [35S]GTPgammaS binding at D4.4 receptors of 12 dopaminergic agonists was 
determined. Several antiparkinsonian drugs, including ropinirole, quinerolane and lisuride, exhibited 
agonist activity at D4.4 receptors (Emax = 74.3%, 72.4% and 32.2%, respectively, compared with 
dopamine = 100%). The EC50 values for agonist stimulation of [
35
S]GTPgammaS binding correlated 
well with the inhibition constants derived from competition binding with [3H]spiperone (r = +.99). 
However, other antiparkinsonian drugs (bromocriptine, L-DOPA and terguride) showed low affinity 
and/or were devoid of agonist activity at D4.4 receptors. The potency at D4.4 receptors of the novel, 
selective D4.4 receptor antagonist L 745,870 was determined, indicating that it has high affinity (Ki = 
1.99 nM) without detectable agonist activity. Furthermore, L745,870 completely inhibited 
dopamine-stimulated [35S]GTPgammaS binding with a Kb value of 1.07 nM. The action of an 
additional 20 chemically diverse dopaminergic ligands, including clozapine, ziprasidone, sertindole, 
olanzapine and several other "atypical" antipsychotics, in advanced development was investigated. 
Each of these ligands shifted the dopamine stimulation curve to the right in a parallel manner 
consistent with competitive antagonism at this site and yielding Kb values (32.6, 22.4, 17.2 and 26.5 
nM, respectively) that agreed closely with their Ki values (38.0, 14.9, 18.5 and 26.1 nM). In contrast, 
raclopride and seroquel exhibited low affinity at D4.4 receptors (Ki > 1000 nM). Other compounds 
that showed antagonist activity at D4.4 receptors included the 5-hydroxytryptamine2A receptor 
antagonist fananserin (RP62203), the sigma ligand BMY14,802 and the D3 receptor antagonist 
GR103,691. In conclusion, dopamine D4.4 receptor activity is unlikely to be an important factor in the 
clinical effectiveness of antiparkinsonian drugs, although low agonist efficacy at D4.4 receptors might 
be associated with a lesser incidence of side effects. Furthermore, antagonist activity at D4.4 
receptors is a common property of many typical and atypical antipsychotic agents. 
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Naunyn Schmiedebergs Arch Pharmacol. 1997 Jun;355(6):682-8. 
Agonist activity of antimigraine drugs at recombinant human 5-HT1A  
receptors: potential implications for prophylactic and acute therapy.  
Newman-Tancredi A, Conte C, Chaput C, Verrièle L, Audinot-Bouchez V, Lochon S, Lavielle G, Millan 
MJ. 
Department of Psychopharmacology, Institut de Recherches Servier, Croissy-sur-Seine, France. 
The actions of several serotonergic ligands in use or under development for the treatment of 
migraine headaches were examined at recombinant human 5-HT1A receptors stably expressed in 
Chinese Hamster Ovary cells. Affinities (Kis) at this site were determined in competition binding 
experiments with [
3
H]8-OH-DPAT ([
3
H](+/-)8-hydroxy-N,N-dipropylaminotetralin), whilst agonist 
efficacy was measured by stimulation of [
35
S]GTPgammaS (guanylyl-5'-[gamma[
35
S]thio]-
triphosphate) binding. Of the prophylactic antimigraine drugs tested, methysergide and lisuride 
behaved as efficacious agonists (Emax > or = 90% relative to 5-HT) whereas pitozifen and 
(-)propranolol acted as a partial agonist (60%) and an antagonist, respectively. This suggests that 
there is no correlation between agonism at 5-HT1A receptors and prophylactic antimigraine action. In 
contrast, serotonin, dihydroergotamine, sumatriptan, naratriptan and alniditan, which are effective 
in acute interruption of migraine attacks, each displayed high efficacy (Emax = 100, 100, 92.6, 79.3, 
79.1% respectively) and marked affinity (Ki = 18.7, 0.6, 127, 26.4 and 3.0 nM respectively) at 5-HT1A 
receptors. EC50 values for agonist stimulation of [
35
S]GTPgammaS binding correlated with respective 
Ki values at 5-HT1A receptors (r = 0.93) and the stimulation of [
35S]GTPgammaS binding by these 
compounds was antagonised by the selective 5-HT1A antagonist WAY100635 (N-{2-[4-(2-
methoxyphenyl)-1-piperazinyl]ethyl}-N-(2-pyridinyl) cyclo-hexanecarboxamide; 100 nM). These data 
suggest that agonism at 5-HT1A receptors may be involved in some actions of drugs used in acute 
antimigraine therapy. In comparison with the above compounds, novel ligands targeted at 5-HT1B/1D 
receptors, such as GR125,743 (N-[4-methoxy-3-(4-methyl-piperazin-1-yl)phenyl] -3-methyl-4-(4-
pyridyl)benzamide) and GR127,935 (N-[4-methoxy-3-(4-methylpiperazin-1-yl)-phenyl]-2'-methyl-4'-
(5-m ethyl-1, 2,4-oxadiazol-3-yl)-biphenyl-4-carboxamide), only weakly activated [35S]GTPgammaS 
binding (32.4 and 32.1% efficacy) and displayed moderate affinity at 5-HT1A receptors (Kis 53.1 and 
49.8 nM) suggesting that they constitute useful tools to differentiate 5-HT1A and 5-HT1B/1D receptor-
mediated actions. In conclusion, the present data indicates that several antimigraine agents exhibit 
marked 5-HT1A receptor activity and that although this is unlikely to be important for prophylactic 
action it may be relevant to the ancilliary properties of drugs used for acute migraine treatment. 
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J Pharmacol Exp Ther. 1998 Sep;286(3):1341-55. 
S 16924 ((R)-2-[1-[2-(2,3-dihydro-benzo[1,4] dioxin-5-Yloxy)-ethyl]-
pyrrolidin-3yl]-1-(4-fluoro-phenyl)-ethanone), a novel, potential 
antipsychotic with marked serotonin (5-HT)1A agonist properties: I. 
Receptorial and neurochemical profile in comparison with clozapine and 
haloperidol. 
Millan MJ, Gobert A, Newman-Tancredi A, Audinot V, Lejeune F, Rivet JM, Cussac D, Nicolas JP, 
Muller O, Lavielle G. 
Institut de Recherches Servier, Department of Psychopharmacology, Croissy-sur-Seine, France. 
S 16924 showed a pattern of interaction at multiple (>20) native, rodent and cloned, human (h) 
monoaminergic receptors similar to that of clozapine and different to that of haloperidol. Notably, 
like clozapine, the affinity of S 16924 for hD2 and hD3 receptors was modest, and it showed 5-fold 
higher affinity for hD4 receptors. At each of these sites, using a [
35S]GTPgammaS binding procedure, 
S 16924, clozapine and haloperidol behaved as antagonists. In distinction to haloperidol, S 16924 
shared the marked affinity of clozapine for h5-HT2A and h5-HT2C receptors. However, an important 
difference to clozapine (and haloperidol) was the high affinity of S 16924 for h5-HT1A receptors. At 
these sites, using a [35S]GTPgammaS binding model, both S 16924 and clozapine behaved as partial 
agonists, whereas haloperidol was inactive. In vivo, the agonist properties of S 16924 at 5-HT1A 
autoreceptors were revealed by its ability to potently inhibit the firing of raphe-localized 
serotoninergic neurones, an action reversed by the selective 5-HT1A receptor antagonist, 
WAY100635. In contrast, clozapine and haloperidol only weakly inhibited raphe firing, and their 
actions were resistant to WAY100635. Similarly, S 16924 more potently inhibited striatal turnover of 
5-HT than either clozapine or haloperidol. Reflecting its modest affinity for D2 (and D3) 
autoreceptors, S 16924 only weakly blocked the inhibitory influence of the dopaminergic agonist, 
apomorphine, upon the firing rate of ventrotegmental area-localized dopaminergic neurones. 
Further, S 16924 only weakly increased striatal, mesolimbic and mesocortical turnover of dopamine 
(DA). Clozapine was, similarly, weakly active in these models, whereas haloperidol, in line with its 
higher affinity at D2 (and D3) receptors, was potently active. In the frontal cortex (FCX) of freely 
moving rats, S 16924 dose-dependently reduced dialysate levels of 5-HT, whereas those of DA and 
NAD were dose-dependently increased in the same samples. In contrast, although S 16924 also 
suppressed 5-HT levels in the striatum and nucleus accumbens, DA levels therein were unaffected. 
Clozapine mimicked this selective increase in DA levels in the FCX as compared to striatum and 
accumbens. In contrast, haloperidol modestly increased DA levels in the FCX, striatum and 
accumbens to the same extent. In distinction to S 16924, clozapine and haloperidol exerted little 
influence upon 5-HT levels. Finally, the influence of S 16924 upon FCX levels of 5-HT, DA (and NAD) 
was attenuated by WAY100635. In conclusion, S 16924 possesses a profile of interaction at multiple 
monoaminergic receptors comparable to that of clozapine and distinct to that of haloperidol. In 
addition, S 16924 is a potent, partial agonist at 5-HT1A receptors. Correspondingly, acute 
administration of S 16924 decreases cerebral serotoninergic transmission and selectively reinforces 
frontocortical as compared to subcortical dopaminergic transmission. In line with these actions, S 
16924 shows a distinctive profile of activity in functional (behavioral) models of potential 
antipsychotic activity (companion paper). 
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Neuropsychopharmacology. 1998 May;18(5):395-8. 
Agonist and antagonist actions of (-)pindolol at recombinant, human 
serotonin1A (5-HT1A) receptors. 
Newman-Tancredi A, Chaput C, Gavaudan S, Verrièle L, Millan MJ. 
Department of Psychopharmacology, Institut de Recherches Servier, Paris, France. 
It has been proposed that the arylalkylamine, (-)pindolol, potentiates the therapeutic action of 
antidepressant drugs in humans by blockade of 5-HT1A autoreceptors. Its interactions at human 
5-HT1A receptors have not, however, been directly characterized. Herein, we demonstrate that 
(-)pindolol exhibits nanomolar affinity at human 5-HT1A receptors expressed in Chinese Hamster 
Ovary cells (CHO-h5-HT1A; Ki = 6.4 nmol/L). In a functional test of receptor-mediated G-protein 
activation (stimulation of [
35
S]GTPgammaS binding) (-)pindolol displays an efficacy of 20.3% relative 
to the endogenous agonist, 5-HT (= 100%). (-)Pindolol also antagonizes 5-HT (100 nmol/L)-stimulated 
[35S]GTPgammaS binding, reducing it to 19.8% of control binding. These data indicate that (-)pindolol 
acts as a (weak) partial agonist at CHO-h5-HT1A receptors and that it blocks the action of 5-HT at 
these sites. 
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Naunyn Schmiedebergs Arch Pharmacol. 1998 Mar;357(3):205-17. 
Labelling of recombinant human and native rat serotonin 5-HT1A  
receptors by a novel, selective radioligand, [3H]S 15535: definition of its 
binding profile using agonists, antagonists and inverse agonists.  
Newman-Tancredi A, Verrièle L, Chaput C, Millan MJ. 
Department of Psychopharmacology, Institut de Recherches Servier, Paris, France. 
The novel benzodioxopiperazine, 5-HT1A receptor weak partial agonist, S 15535 (4-(benzodioxan-5-
yl)1-(indan-2-yl)piperazine) bound with high affinity and selectivity to membranes of Chinese 
Hamster Ovary cells stably expressing the human (h) 5-HT1A receptor (Ki = 0.6 nM versus [
3
H]8-
hydroxy-dipropylamino-tetralin, [
3
H]8-OH-DPAT): its affinity at h5-HT1A receptors was more than 70-
fold higher than its affinity at > 50 other binding sites. S 15535 was tritiated to high specific activity 
(50 Ci/mmol) and its binding profile characterised. At 22 degrees C, [
3
H]S 15535 associated and 
dissociated from h5-HT1A receptors with half-times of 2.9 and 5.0 min, respectively, yielding a Kd 
estimate of 3.6 nM. In saturation binding experiments, [3H]S 15535 displayed a Bmax value for 
h5-HT1A receptors (1630 fmol/mg), higher than that obtained with the agonist [
3H]8-OH-DPAT (1023 
pmol/mg). Guanylyl imidodiphosphate (GppNHp, 100 microM) reduced the binding of [
3
H]S 15535 by 
only 25% compared with 79% for [
3
H]8-OH-DPAT at h5-HT1A receptors. [
3
H]S 15535 also showed high 
affinity, saturable binding to rat hippocampal membranes (Bmax = 820 fmol/mg versus 647 fmol/mg 
for [
3
H]8-OH-DPAT). For both h5-HT1A and rat 5-HT1A receptors, the Ki values for competition binding 
of 15 serotonergic ligands with [3H]S 15535 was highly correlated with that of [3H]8-OH-DPAT. 
However, important differences were also observed. The agonist, 5-hydroxytryptamine (5-HT), 
displayed biphasic competition curves with [3H]S 15535 but not with [3H]8-OH-DPAT at h5-HT1A 
receptors. Similarly, the 'antagonists', spiperone, methiothepin and (+)butaclamol, showed biphasic 
competition isotherms versus [3H]S 15535 but not [3H]8-OH-DPAT. When [3H]S 15535 competition 
binding experiments were carried out in the presence of GppNHp (100 microM) the 5-HT and 8-OH-
DPAT competition curves shifted to the right, whereas the spiperone and methiothepin competition 
curves shifted to the left. In contrast, in the presence of GppNHp, the competition isotherms for N-
[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-N-(2-pyridinyl)cyclo-h exanecarboxamide (WAY100635) 
were not altered. Taken together, these data show that (i) [3H]S 15535 is a highly selective 5-HT1A 
receptor ligand which labels both G-protein-coupled and uncoupled 5-HT1A receptors, (ii) 
antagonists, such as WAY100635, which yield monophasic isotherms in competition with both 
[3H]agonists and [3H]antagonists, are not sensitive to the G-protein coupling state of the receptor, 
but (iii) spiperone and methiothepin behaved as inverse agonists, their competition isotherms with 
[3H]S 15535 being modulated in an opposite manner to those of agonists. 
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Naunyn Schmiedebergs Arch Pharmacol. 1998 Aug;358(2):197-206. 
Actions of alpha2 adrenoceptor ligands at alpha 2A and 5-HT1A  receptors: 
the antagonist, atipamezole, and the agonist, dexmedetomidine, are 
highly selective for alpha 2A adrenoceptors. 
Newman-Tancredi A, Nicolas JP, Audinot V, Gavaudan S, Verrièle L, Touzard M, Chaput C, Richard N, 
Millan MJ. 
Department of Psychopharmacology, Institut de Recherches Servier, Paris, France. 
This study examined the activity of chemically diverse alpha2 adrenoceptor ligands at recombinant 
human (h) and native rat (r) alpha2A adrenoceptors compared with 5-HT1A receptors. First, in 
competition binding experiments at h alpha2A and h5-HT1A receptors expressed in CHO cells, several 
compounds, including the antagonists 1-(2-pyrimidinyl)piperazine (1-PP), (+/-)-idazoxan, benalfocin 
(SKF 86466), yohimbine and RX 821,002, displayed preference for h alpha2A versus h5-HT1A receptors 
of only 1.4-, 3.6-, 4-, 10- and 11-fold, respectively (based on differences in pKi values). Clonidine, 
brimonidine (UK 14304), the benzopyrrolidine fluparoxan and the guanidines guanfacine and 
guanabenz exhibited intermediate selectivity (22- to 31-fold) for h alpha2A receptors. Only the 
antagonist atipamezole and the agonist dexmedetomidine (DMT) displayed high preference for 
alpha2 adrenoceptors (1290- and 91-fold, respectively). Second, the compounds were tested for 
their ability to induce h5-HT1A receptor-mediated G-protein activation, as indicated by the 
stimulation of [35S]GTPgammaS binding. All except atipamezole and RX 821,002 exhibited agonist 
activity, with potencies which correlated with their affinity for h5-HT1A receptors. Relative efficacies 
(Emax values) were 25-35% for guanabenz, guanfacine, WB 4101 and benalfocin, 50-65% for 1-PP, 
(+/-)-idazoxan and clonidine, and over 70% for fluparoxan, oxymetazoline and yohimbine (relative to 
5-HT = 100%). Yohimbine-induced [35S]GTPgammaS binding was inhibited by the selective 5-HT1A 
receptor antagonist WAY100635. In contrast, RX 821,002 was the only ligand which exhibited 
antagonist activity at h5-HT1A receptors, inhibiting 5-HT-stimulated [
35S]GTPgammaS binding. 
Atipamezole, which exhibited negligeable affinity for 5-HT1A receptors, was inactive. Third, the 
affinities for r alpha2A differed considerably from the affinities for h alpha2A receptors whereas the 
affinities for r5-HT1A differed much less from the affinities for h5-HT1A receptors. This affected 
markedly the affinity ratios of certain compounds. For example, (+/-)-idazoxan was only 3.6-fold 
selective for h alpha2A versus h5-HT1A but 51-fold selective for r alpha2A versus r5-HT1A receptors. 
Conversely, yohimbine was tenfold selective for h alpha2A versus h5-HT1A adrenoceptors but 4.2-fold 
selective for r alpha2A versus r5-HT1A receptors. Nevertheless, both atipamezole and DMT were highly 
selective for both rat and human alpha2A versus rat or human 5-HT1A receptors. In conclusion, these 
data indicate that: (1) the agonist DMT and the antagonist atipamezole are the ligands of choice to 
distinguish alpha2-mediated from 5-HT1A-mediated actions, whilst several of the other compounds 
show only low or modest selectivity for alpha2A over 5-HT1A receptors; (2) caution should be 
exercised in experimental and clinical interpretation of the actions of traditionally employed alpha2 
ligands, such as clonidine, yohimbine and (+/-)-idazoxan, which exhibit marked agonist activity at 5-
HT1A receptors. 
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J Pharmacol Exp Ther. 1998 Oct;287(1):167-86. 
S 18126 ([2-[4-(2,3-dihydrobenzo[1,4]dioxin-6-yl)piperazin-1-yl 
methyl]indan-2-yl]), a potent, selective and competitive antagonist at 
dopamine D4 receptors: an in vitro  and in vivo comparison with L 
745,870 (3-(4-[4-chlorophenyl]piperazin-1-yl)methyl-1H-pyrrolo[2, 
3b]pyridine) and raclopride. 
Millan MJ, Newman-Tancredi A, Brocco M, Gobert A, Lejeune F, Audinot V, Rivet JM, Schreiber R, 
Dekeyne A, Spedding M, Nicolas JP, Peglion JL. 
Department of Psychopharmacology, Institut de Recherches Servier, Paris, France. 
The novel benzoindane S 18126 possessed > 100-fold higher affinity at cloned, human (h) D4 (Ki = 2.4 
nM) vs. hD2 (738 nM), hD3 (2840 nM), hD1 (> 3000 nM) and hD5 (> 3000 nM) receptors and about 50 
other sites, except sigma1 receptors (1.6 nM). L 745,870 similarly showed selectivity for hD4 (2.5 nM) 
vs. hD2 (905 nM) and hD3 (> 3000 nM) receptors. In contrast, raclopride displayed low affinity at hD4 
(> 3000 nM) vs. hD2 (1.1 nM) and hD3 receptors (1.4 nM). Stimulation of [
35S]-GTPgammaS binding at 
hD4 receptors by dopamine (DA) was blocked by S 18126 and L 745,870 with Kb values of 2.2 and 1.0 
nM, respectively, whereas raclopride (> 1000 nM) was inactive. In contrast, raclopride inhibited 
stimulation of [35S]-GTPgammaS binding at hD2 sites by DA with a Kb of 1.4 nM, whereas S 18126 (> 
1000 nM) and L 745,870 (> 1000 nM) were inactive. As concerns presynaptic dopaminergic 
receptors, raclopride (0.01-0.05 mg/kg s.c. ) markedly enhanced DA synthesis in mesocortical, 
mesolimbic and nigrostriatal dopaminergic pathways. In contrast, even high doses (2. 5-40.0 mg/kg 
s.c.) of S 18126 and L 745,870 were only weakly active. Similarly, raclopride (0.016 mg/kg i.v.) 
abolished inhibition of the firing rate of ventrotegmental dopaminergic neurons by apomorphine, 
whereas even high doses (0.5 mg/kg i.v.) of S 18126 and L 745,870 were only weakly active. As 
regards postsynaptic dopaminergic receptors, raclopride potently (0.01-0.3 mg/kg s.c.) reduced 
rotation elicited by quinpirole in rats with unilateral lesions of the substantia nigra, antagonized 
induction of hypothermia by PD 128, 907, blocked amphetamine-induced hyperlocomotion and was 
effective in six further models of potential antipsychotic activity. In contrast, S 18126 and L 745,870 
were only weakly active in these models (5.0-> 40.0 mg/kg s.c.). In six models of extrapyramidal and 
motor symptoms, such as induction of catalepsy, raclopride was likewise potently active (0.01-2.0 
mg/kg s.c.) whereas S 18126 and L 745,870 were only weakly active (10.0-80.0 mg/kg s.c.). In freely 
moving rats, raclopride (0.16 mg/kg s.c.) increased levels of DA by + 55% in dialysates of the frontal 
cortex. However, it also increased levels of DA in the accumbens and striatum by 70% and 75%, 
respectively. In contrast to raclopride, at a dose of 0.16 mg/kg s.c. , neither S 18126 nor L 745,870 
modified frontal cortex levels of DA. However, at a high dose (40.0 mg/kg s.c.), S 18126 increased 
dialysate levels of DA (+ 85%) and noradrenaline (+ 100%), but not serotonin (+ 10%), in frontal 
cortex without affecting DA levels in accumbens (+ 10%) and striatum (+ 10%). In conclusion, S 
18126 and L 745,870 behave as potent and selective antagonists of cloned, hD4 vs. other 
dopaminergic receptor types in vitro. However, their in vivo effects at high doses probably reflect 
residual antagonist actions at D2 (or D3) receptors. Selective blockade of D4 receptors was thus 
associated neither with a modification of dopaminergic transmission nor with antipsychotic 
(antiproductive) or extrapyramidal properties. The functional effects of selective D4 receptor 
blockade remain to be established. 
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Eur J Pharmacol. 1998 Aug 21;355(2-3):245-56. 
Agonist and antagonist actions of antipsychotic agents at 5-HT1A  
receptors: a [35S]GTPgammaS binding study. 
Newman-Tancredi A, Gavaudan S, Conte C, Chaput C, Touzard M, Verrièle L, Audinot V, Millan MJ. 
Department of Psychopharmacology, Institut de Recherches Servier, Paris, France. 
Recombinant human (h) 5-HT1A receptor-mediated G-protein activation was characterised in 
membranes of transfected Chinese hamster ovary (CHO) cells by use of guanosine-5'-O-(3-[35S]thio)-
triphosphate ([
35
S]GTPgammaS binding). The potency and efficacy of 21 5-HT receptor agonists and 
antagonists was determined. The agonists, 5-CT (carboxamidotryptamine) and flesinoxan displayed 
high affinity (subnanomolar Ki values) and high efficacy (Emax > 90%, relative to 5-HT = 100%). In 
contrast, ipsapirone, zalospirone and buspirone displayed partial agonist activity. EC50s for agonist 
stimulation of [
35
S]GTPgammaS binding correlated well with Ki values from competition binding 
(r=+0.99). Among the compounds tested for antagonist activity, methiothepin and (+)butaclamol 
exhibited 'inverse agonist' behaviour, inhibiting basal [35S]GTPgammaS binding. The actions of 17 
antipsychotic agents were investigated. Clozapine and several putatively 'atypical' antipsychotic 
agents, including ziprasidone, quetiapine and tiospirone, exhibited partial agonist activity and 
marked affinity at h5-HT1A receptors, similar to their affinity at hD2 dopamine receptors. In contrast, 
risperidone and sertindole displayed low affinity at h5-HT1A receptors and behaved as 'neutral' 
antagonists, inhibiting 5-HT-stimulated [
35
S]GTPgammaS binding. Likewise the 'typical' neuroleptics, 
haloperidol, pimozide, raclopride and chlorpromazine exhibited relatively low affinity and 'neutral' 
antagonist activity at h5-HT1A receptors with Ki values which correlated with their respective Kb 
values. The present data show that (i) [35S]GTPgammaS binding is an effective method to evaluate 
the efficacy and potency of agonists and antagonists at recombinant human 5-HT1A receptors. (ii) 
Like clozapine, several putatively 'atypical' antipsychotic drugs display balanced serotonin 
h5-HT1A/dopamine hD2 receptor affinity and partial agonist activity at h5-HT1A receptors. (iii) Several 
'typical' and some putatively 'atypical' antipsychotic agents displayed antagonist properties at 
h5-HT1A sites with generally much lower affinity than at hD2 dopamine receptors. It is suggested that 
agonist activity at 5-HT1A receptors may be of utility for certain antipsychotic agents. 
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Mol Pharmacol. 1999 Mar;55(3):564-74. 
G protein activation by human dopamine D3 receptors in high-expressing 
Chinese hamster ovary cells: A guanosine-5'-O-(3-[35S]thio)- 
triphosphate binding and antibody study.  
Newman-Tancredi A, Cussac D, Audinot V, Pasteau V, Gavaudan S, Millan MJ. 
Department of Psychopharmacology, Institut de Recherches Servier, Paris, France. 
Despite extensive study, the G-protein coupling of dopamine D3 receptors is poorly understood. In 
this study, we used guanosine-5'-O-(3-[
35
S]thio)-triphosphate ([
35
S]GTPgammaS) binding to 
investigate the activation of G-proteins coupled to human (h) D3 receptors stably expressed in 
Chinese hamster ovary (CHO) cells. Although the receptor expression level was high (15 pmol/mg), 
dopamine only stimulated G protein activation by 1.6-fold. This was despite the presence of marked 
receptor reserve for dopamine, as revealed by Furchgott analysis after irreversible hD3 receptor 
inactivation with the alkylating agent, EEDQ (N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline). 
Thus, half-maximal stimulation of [35S]-GTPgammaS binding required only 11.8% receptor 
occupation of hD3 sites. In contrast, although the hD2(short) receptor expression level in another 
CHO cell line was 11-fold lower, stimulation by dopamine was higher (2.5-fold). G-protein activation 
was increased at hD3 and, less potently, at hD2 receptors by the preferential D3 agonists, PD 128,907 
[(+)-(4aR,10bR)-3,4,4a, 10b-tetrahydro-4-propyl-2H,5H- [1]benzopyrano[4,3-b]-1, 4-oxazin-9-ol] and 
(+)-7-OH-DPAT (7-hydroxy-2-(di-n-propylamino)tetralin). Furthermore, the selective D3 antagonists, S 
14297 ((+)-[7-(N, N-dipropylamino)-5,6,7, 8-tetrahydro-naphtho(2,3b)dihydro-2,3-furane]) and GR 
218,231 (2(R, S)-(dipropylamino)-6-(4-methoxyphenylsulfonylmethyl)-1,2,3,4- 
tetrahydronaphtalene), blocked dopamine-stimulated [35S]GTPgammaS binding more potently at hD3 
than at hD2 sites. Antibodies against Galphai/alphao reduced dopamine-induced G-protein activation 
at both CHO-hD3 and -hD2 membranes, whereas GalphaS antibodies had no effect at either site. In 
contrast, incubation with anti-Galphaq/alpha11 antibodies, which did not affect dopamine-induced 
G-protein activation at hD2 receptors, attenuated hD3-induced G protein activation. These data 
suggest that hD3 receptors may couple to Galphaq/alpha11 and would be consistent with the 
observation that pertussis toxin pretreatment, which inactivates only Gi/o proteins, only 
submaximally (80%) blocked dopamine-stimulated [35S]GTPgammaS binding in CHO-hD3 cells. Taken 
together, the present data indicate that 1) hD3 receptors functionally couple to G protein activation 
in CHO cells, 2) hD3 receptors activate G-proteins less effectively than hD2 receptors, and 3) hD3 
receptors may couple to different G-protein subtypes than hD2 receptors, including nonpertussis 
sensitive Gq/11 proteins. 
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Eur J Neurosci. 1999 Dec;11(12):4419-32. 
Contrasting mechanisms of action and sensitivity to antipsychotics of 
phencyclidine versus amphetamine: importance of nucleus accumbens 
5-HT2A  sites for PCP-induced locomotion in the rat.  
Millan MJ, Brocco M, Gobert A, Joly F, Bervoets K, Rivet J, Newman-Tancredi A, Audinot V, Maurel S. 
Department of Psychopharmacology, Institut de Recherches Servier, Paris, France. 
In the present study, the comparative mechanisms of action of phencyclidine (PCP) and 
amphetamine were addressed employing the parameter of locomotion in rats. PCP-induced 
locomotion (PLOC) was potently blocked by the selective serotonin 5-HT2A vs. D2 antagonists, 
SR46349, MDL100,907, ritanserin and fananserin, which barely affected amphetamine-induced 
locomotion (ALOC). In contrast, the selective D2 vs. 5-HT2A antagonists, eticlopride, raclopride and 
amisulpride, preferentially inhibited ALOC vs. PLOC. The potency of these drugs and 12 
multireceptorial antipsychotics in inhibiting PLOC vs. ALOC correlated significantly with affinities at 
5-HT2A vs. D2 receptors, respectively. Amphetamine and PCP both dose dependently increased 
dialysate levels of dopamine (DA) and 5-HT in the nucleus accumbens, striatum and frontal cortex 
(FCX) of freely moving rats, but PCP was proportionally more effective than amphetamine in 
elevating levels of 5-HT vs. DA in the accumbens. Further, whereas microinjection of PCP into the 
accumbens elicited locomotion, its introduction into the striatum or FCX was ineffective. The action 
of intra-accumbens PCP, but not intra-accumbens amphetamine, was abolished by SR46349 and 
clozapine. Parachloroamphetamine, which depleted accumbens pools of 5-HT but not DA, likewise 
abolished PLOC without affecting ALOC. In contrast, intra-accumbens 6-hydroxydopamine (6-OHDA), 
which depleted DA but not 5-HT, abolished ALOC but only partially attenuated PLOC. In conclusion, 
PLOC involves (indirect) activation of accumbens-localized 5-HT2A receptors by 5-HT. PLOC is, 
correspondingly, more potently blocked than ALOC by antipsychotics displaying marked affinity at 
5-HT2A receptors. 
D.Sc. Thesis  Publication Abstracts 
 
Part B: Page 107 of 206 
Reference no. 22 
Naunyn Schmiedebergs Arch Pharmacol. 1999 Jun;359(6):447-53. 
Actions of roxindole at recombinant human dopamine  D2, D3 and D4 and 
serotonin 5-HT1A, 5-HT1B  and 5-HT1D  receptors. 
Newman-Tancredi A, Cussac D, Audinot V, Millan MJ. 
Department of Psychopharmacology, Institut de Recherches Servier, Croissy (Paris), France  
Roxindole is a potential antidepressant agent. The present study determined its affinity and agonist 
efficacy at recombinant human (h) dopamine hD2, hD3 and hD4 and serotonin (5-HT) h5-HT1A, h5-HT1B 
and h5-HT1D receptors. Roxindole exhibited high affinity at hD3 as well as at hD2 (short isoform) and 
hD4 (4-repeat isoform) receptors (pKi values 8.93, 8.55 and 8.23, respectively). Further, it displayed 
high affinity at hS-HT1A receptors (pKi = 9.42) but modest affinity at 5-HT1B and 5-HT1D receptors (pKi 
values 6.00 and 7.05, respectively). In [
35
S]GTPgammaS binding experiments, roxindole was >20-fold 
more potent in stimulating [
35
S]GTPgammaS binding at hD3 than at hD2 or hD4 receptors (pEC50 = 
9.23 vs. 7.88 and 7.69). However, whereas roxindole exhibited partial agonist activity at hD3 and hD4 
sites (Emax = 30.0% and 35.1%, respectively, relative to dopamine = 100%), it only weakly activated 
hD2 receptors (Emax = 10.5%). Roxindole potently blocked dopamine-stimulated [
35S]GTPgammaS 
binding at hD2 receptors (pKB = 9.05). In comparison, the dopamine receptor agonist, (-)quinpirole, 
acted as a partial agonist at hD3 and hD4 sites (Emax = 67.4% and 66.3%, respectively) but surpassed 
the efficacy of dopamine at hD2 receptors (Emax = 132%). At h5-HT1A receptors, roxindole behaved 
as a high affinity (pKi = 9.42) partial agonist (Emax = 59.6%, relative to 5-HT = 100%), whereas 
(-)quinpirole had negligible activity. The selective 5-HT1A antagonist, WAY100635, blocked roxindole 
(100 nM)-stimulated [
35
S]GTPgammaS binding at h5-HT1A receptors in a concentration-dependent 
manner (pKB = 9.28). Roxindole only weakly stimulated [
35S]GTPgammaS binding at 5-HT1B and 5-HT1D 
receptors (Emax = 27.1% and 13.7%). The present data suggest that roxindole activates mainly D3 vs. 
D2 or D4 receptors and 5-HT1A vs. 5-HT1B or 5-HT1D receptors. Activation of D3 and/or 5-HT1A receptors 
may thus contribute to its potential antidepressant properties. 
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Mol Pharmacol. 1999 Nov;56(5):1025-30. 
Human dopamine D3 receptors mediate mitogen-activated protein kinase 
activation via a phosphatidylinositol 3-kinase and an atypical protein 
kinase C-dependent mechanism. 
Cussac D, Newman-Tancredi A, Pasteau V, Millan MJ. 
Department of Psychopharmacology, Institut de Recherches Servier, Croissy (Paris), France. 
The mitogen-activated protein kinase (MAPK) cascade is stimulated by both receptor tyrosine 
kinases and G protein-coupled receptors. We show that recombinant human dopamine D3 receptors 
expressed in Chinese hamster ovary cells transiently activate MAPK via pertussis toxin-sensitive Gi 
and/or Go proteins. The involvement of D3 receptors was confirmed by use of the D3 agonists 
PD128,907 and (+)-7-hydroxy-2-dipropylaminotetralin, which mimicked the response to dopamine 
(DA). Furthermore, haloperidol and the selective D3 receptor antagonists S 14297 and GR 218,231 
attenuated DA-induced MAPK activation; however, when tested alone, S 14297 weakly stimulated 
MAPK activity, suggesting partial agonist activity. The transduction mechanisms by which hD3 
receptors activate MAPK were explored with specific kinase inhibitors. Genistein and lavendustin A, 
inhibitors of tyrosine kinase activity, did not reduce DA-induced MAPK activation. In contrast, PD 
98059, an inhibitor of MAPK kinase, and Ro 31-8220 and Gö 6983, inhibitors of protein kinase C 
(PKC), blocked DA-induced MAPK activation. However, MAPK activation was insensitive to PKC 
down-regulation by phorbol esters, indicating the involvement of an "atypical" PKC. Furthermore, 
MAPK activation involved phosphatidylinositol 3-kinase inasmuch as its inhibition by LY 294002 and 
wortmannin reduced DA-induced MAPK activation. In conclusion, this study demonstrates that 
stimulation of hD3 receptors activates MAPK. This action is mediated via an atypical isoform of PKC, 
possibly involving cross-talk with products of phosphatidylinositol 3-kinase activation. 
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Eur J Pharmacol. 1999 Nov 19;384(2-3):111-21. 
The 5HT1A receptor ligand, S15535, antagonises G-protein activation: a 
[35S]GTPgammaS and [3H]S15535 autoradiography study. 
Newman-Tancredi A, Rivet J, Chaput C, Touzard M, Verrièle L, Millan MJ. 
Department of Psychopharmacology, Institut de Recherches Servier, Croissy (Paris), France. 
4-(Benzodioxan-5-yl)1-(indan-2-yl)piperazine (S15535) is a highly selective ligand at 5-HT1A receptors. 
The present study compared its autoradiographic labelling of rat brain sections with its functional 
actions, visualised by guanylyl-5'-[gamma-thio]-triphosphate ([
35
S]GTPgammaS) autoradiography, 
which affords a measure of G-protein activation. [3H]S15535 binding was highest in hippocampus, 
frontal cortex, entorhinal cortex, lateral septum, interpeduncular nucleus and dorsal raphe, 
consistent with specific labelling of 5-HT1A receptors. In functional studies, S15535 (10 microM) did 
not markedly stimulate G-protein activation in any brain region, but abolished the activation induced 
by the selective 5-HT1A agonist, (+)-8-hydroxy-dipropyl-aminotetralin ((+)-8-OH-DPAT, 1 microM), in 
structures enriched in [3H]S15535 labelling. S15535 did not block 5-HT-stimulated activation in 
caudate nucleus or substantia nigra, regions where (+)-8-OH-DPAT was ineffective and [3H]S15535 
binding was absent. Interestingly, S15535 attenuated (+)-8-OH-DPAT and 5-HT-stimulated G-protein 
activation in dorsal raphe, a region in which S15535 is known to exhibit agonist properties in vivo 
[Lejeune, F., Millan, M.J., 1998. Induction of burst firing in ventral tegmental area dopaminergic 
neurons by activation of serotonin 5-HT1A receptors: WAY100635-reversible actions of the highly 
selective ligands, flesinoxan and S15535. Synapse 30, 172-180.]. The present data show that (i) 
[
3
H]S15535 labels pre- and post-synaptic populations of 5-HT1A sites in rat brain sections, (ii) S15535 
exhibits antagonist properties at post-synaptic 5-HT1A receptors in corticolimbic regions, and (iii) 
S15535 also attenuates agonist-stimulated G-protein activation at raphe-localised 5-HT1A receptors. 
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Neuropsychopharmacology. 1999 Aug;21(2 Suppl):61S-67S. 
Inverse agonists and serotonergic transmission: from recombinant, 
human serotonin 5-HT1B  receptors to G-protein coupling and function in 
corticolimbic structures in vivo. 
Millan MJ, Gobert A, Audinot V, Dekeyne A, Newman-Tancredi A. 
Department of Psychopharmacology, Institut de Recherches Servier, Croissy (Paris), France. 
The concept of inverse agonism, whereby "antagonists" exert actions opposite to those of agonists 
at constitutively active receptors, has been documented both at receptor-modulated ion channels as 
well as at G-protein-coupled receptors (GPCR) in recombinant expression systems. However, it 
remains unclear whether physiologically or therapeutically relevant inverse agonists actions at 
GPCRs occur in the CNS in vivo. The present overview discusses our recent observations concerning 
5-HT1B receptors, and focuses on the relationship between actions at heterologous Chinese hamster 
ovary (CHO) expression systems compared with native CNS populations of receptors. To this end, we 
have exploited several novel and selective ligands, notably the inverse agonist and neutral 
antagonist at 5-HT1B receptors, SB224,289 and S18127, respectively. Like 5-HT itself, the agonist, 
GR46611, markedly increases the binding of [35S]GTPgamma S binding to h5-HT1B receptors 
expressed in CHO cells, while the "antagonist", GR127,935, modestly stimulates binding suggesting 
partial agonist properties. However, SB224,289 markedly suppresses binding at these sites. S18127, 
which does not alter [
35
S]GTPgammaS binding alone, abolishes the actions of both GR46611 and 
SB224,289. Nevertheless, in quantitative autoradiographical studies, S18127 and SB224,289 cannot 
be distinguished as concerns modulation of [35S]GTPgamma S binding at substantia nigra and 
caudate nucleus-localized 5-HT1B receptors, inasmuch as they each block the action of the 5-HT1B 
agonist, CP93129, yet fail to modify binding alone. Further, S18217 and SB224,289, as well as 
GR127,935, all abolish the inhibitory influence of GR46611 upon dialysis levels of 5-HT in the frontal 
cortex of freely moving rats without themselves modifying release. Moreover, they all block the 
hypothermic actions of GR46611 without themselves modifying core temperature. Thus, differences 
in intrinsic activity of S18127, SB224,289 and GR127,935 seen at cloned, h5-HT1B receptors cannot be 
detected in vivo. Most notably, no evidence for opposite actions of the inverse agonist, SB224,289, 
as compared to 5-HT1B agonists is apparent. These data suggest that in vitro observations of inverse 
agonist actions cannot necessarily be extrapolated to intact systems in vivo. 
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Naunyn Schmiedebergs Arch Pharmacol. 2000 Feb;361(2):221-3. 
An innovative method for rapid characterisation of phospholipase C 
activity: SB242,084 competitively antagonises 5-HT2C  receptor-mediated 
[3H]phosphatidylinositol depletion.  
Cussac D, Newman-Tancredi A, Quentric Y, Millan MJ. 
Psychopharmacology Department, Institut de Recherches Servier, Croissy-sur-Seine (Paris), France. 
6-chloro-5-methyl-1-[6-(2-methylpyridin-3-yloxy) pyridin-3-ylcarbamoyl] indoline (SB242,084) is a 
novel, selective 5-HT2C receptor antagonist, but its actions at these sites have been little 
characterised at the cellular level. We employed a rapid and innovative approach to investigate its 
functional activity at phospholipase C (PLC)-coupled human 5-HT2C receptors expressed in CHO cells. 
PLC activity was determined as a decrease in the [3H]phosphatidylinositol ([3H]PI) content of cell 
membranes. Serotonin (5-HT) stimulated [
3
H]PI depletion (pEC50=8.74), and SB242,084, like 
mesulergine, completely reversed this action of 5-HT (pKB=9.25 and 9.01, respectively). Further, in 
Schild analysis, SB242,084 behaved as a high affinity competitive antagonist, inducing a parallel, 
rightward displacement of the 5-HT stimulation isotherm without loss of maximum efficacy. The pA2 
of 9.50 was similar to its binding affinity (pKi=9.38). SB242,084 also displayed antagonist properties 
when PLC activity was examined by conventional determination of [
3
H]inositol phosphate 
generation. Employing this parameter, the potency of SB242,084 (pKB=9.21) and that of mesulergine 
(pKB=9.06) closely resembled those determined by [
3
H]PI depletion. In conclusion, determination of 
[3H]PI depletion constitutes a useful and novel technique to characterise agonist and antagonist 
properties of ligands at PLC-coupled receptors. 
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J Pharmacol Exp Ther. 2000 Jan;292(1):38-53. 
S18327 (1-[2-[4-(6-fluoro-1, 2-benzisoxazol-3-yl)piperid-1-yl]ethyl]3-
phenyl imidazolin-2-one), a novel, potential antipsychotic displaying 
marked antagonist properties at alpha(1)- and alpha(2)-adrenergic 
receptors: I. Receptorial, neurochemical, and electrophysiological 
profile. 
Millan MJ, Gobert A, Newman-Tancredi A, Lejeune F, Cussac D, Rivet JM, Audinot V, Adhumeau A, 
Brocco M, Nicolas JP, Boutin JA, Despaux N, Peglion JL. 
Psychopharmacology Department, Institut de Recherches Servier, Croissy-sur-Seine (Paris), France. 
S18327 displayed modest affinity for human (h)D2 and hD3 receptors and high affinity for hD4 
receptors. At each, S18327 antagonized stimulation of [
35
S]guanosine-5'-O-(3-thio)triphosphate 
binding by dopamine (DA). It also blocked activation of mitogen-activated protein kinase at hD3 
receptors. The affinity of S18327 at hD1 and hD5 sites was modest. S18327 showed pronounced 
affinity for human serotonin h5-HT2A receptors and human alpha1A-adrenergic receptors (hARs), at 
which it antagonized increases in intracellular Ca2+ concentration levels elicited by 5-HT and 
norepinephrine (NE), respectively. S18327 presented significant affinity for halpha2A-ARs and 
antagonized NE-induced [
35
S]guanosine-5'-O-(3-thio)triphosphate binding both at these sites and at 
alpha2-ARs in rat amygdala. Reflecting blockade of alpha2-autoreceptors, S18327 enhanced firing of 
adrenergic neurons in locus ceruleus, accelerated hippocampal synthesis of NE, and increased 
dialysate levels of NE in hippocampus, accumbens, and frontal cortex. S18327 abolished inhibition of 
ventrotegmental area-localized dopaminergic neurons by apomorphine. However, S18327 alone did 
not affect their activity and only modestly enhanced cerebral turnover of DA and dialysate levels of 
DA in striatum and accumbens. In contrast, S18327 markedly increased dialysate levels of DA in 
frontal cortex, an action abolished by the selective alpha2-AR agonist, S18616. Finally, S18327 
reduced synthesis and dialysate levels of 5-HT in striatum and suppressed firing of dorsal raphe-
localized serotonergic neurons, an action attenuated by the alpha1-AR agonist cirazoline. In 
conclusion, S18327 possesses marked antagonist activity at alpha1-ARs and D4 and 5-HT2A receptors 
and less potent antagonist activity at alpha2-ARs and D1 and D2 receptors. Antagonism by S18327 of 
alpha2-ARs enhances adrenergic transmission and reinforces frontocortical dopaminergic 
transmission, whereas blockade of alpha1-ARs inhibits dorsal raphe-derived serotonergic pathways. 
As further described in the accompanying paper, this profile of activity may contribute to the 
potential antipsychotic properties of S18327. 
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Neuropharmacology. 2000 Apr 3;39(6):1111-3. 
[35S]-GTPgammaS autoradiography reveals alpha(2) adrenoceptor -
mediated G-protein activation in amygdala and lateral septum.  
Newman-Tancredi A, Chaput C, Touzard M, Millan MJ. 
Psychopharmacology Department, Institut de Recherches Servier, Croissy-sur-Seine (Paris), France. 
Alpha2-adrenoceptor-mediated G-protein activation was examined by [
35
S]-GTPgammaS 
autoradiography. In alpha2-adrenoceptor-rich regions (amygdala, lateral septum), noradrenaline 
stimulated [
35
S]-GTPgammaS binding. These actions were abolished by the selective alpha2 
antagonist, atipamezole. Conversely, in caudate nucleus, which expresses few alpha2 receptors, 
noradrenaline-induced stimulation was not inhibited by atipamezole, suggesting that it is not 
mediated by alpha2-adrenoceptors. 
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Eur J Pharmacol. 2000 Apr 7;394(1):47-50. 
The novel antagonist, S33084, and GR218,231 interact selectively with 
cloned and native, rat dopamine D3 receptors as compared with native, 
rat dopamine D2 receptors. 
Cussac D, Newman-Tancredi A, Sezgin L, Millan MJ. 
Psychopharmacology Department, Institut de Recherches Servier, Croissy-sur-Seine (Paris), France. 
The novel benzopyranopyrrole, S33084 ((3aR,9bS)-N[4-(8-cyano-1,3a,4, 9b-tetrahydro-
3
H-
benzopyrano[3,4-c]pyrrole-2-yl)-butyl] (4-phenyl)benzamide)), and the aminotetralin derivative, 
GR218,231 (2(R,S)-(di-n-propylamino)-6-(4-methoxyphenylsulfonylmethyl)-1,2,3 , 4-tetrahydro 
naphthalene), displayed high affinity at cloned, rat dopamine D3 receptors (pK(i)s of 8.72 and 8.67, 
respectively), as well as dopamine D3 receptors in rat olfactory tubercle (8.62 and 8.94, respectively). 
In contrast, they showed low affinities at striatal dopamine D2 receptors (6.82 and 6.64, 
respectively). Unlike S33084 and GR218,231, the arylpiperazine, L741,626 (4-(4-chlorophenyl)-1-(1H-
indol-3-ylmethyl)piperidin-4-ol), showed lower affinity for cloned (6.46) and native (6.92) dopamine 
D3 receptors than for striatal dopamine D2 receptors (7.52). S33084, GR218,231 and L741,626 should 
prove useful tools for exploration of the functional roles of dopamine D3 vs. dopamine D2 receptors. 
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Naunyn Schmiedebergs Arch Pharmacol. 2000 May;361(5):569-72. 
[3H]S33084: a novel, selective and potent radioligand at cloned, human 
dopamine D3 receptors. 
Cussac D, Newman-Tancredi A, Sezgin L, Millan MJ. 
Psychopharmacology Department, Institut de Recherches Servier, Croissy-sur-Seine Paris, France. 
The novel, selective dopamine D3 receptor antagonist, S33084 [(3aR,9bS)-N[4-(8-cyano- 1,3a,4,9b-
tetrahydro-3H-benzopyrano[3,4-c]pyrrole-2-yl)-butyl] (4-phenyl)benzamide], was tritium-labelled to 
59 Ci/mmol specific activity. Determination of association and dissociation rate constants at 
recombinant, human (h) D3 receptors stably expressed in Chinese hamster ovary (CHO) cells yielded 
a Kd value (0.16 nM) comparable to that observed in saturation binding experiments (0.17 nM). The 
competition binding profile of [
3
H]S33084 with diverse D3 receptor agonists and antagonists 
correlated highly (0.99) with that of [
3
H]spiperone. In conclusion, [
3
H]S33084 is a highly potent and 
selective radioligand at dopamine D3 receptors, which should be of considerable use for their 
characterisation. 
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Mol Pharmacol. 2000 Nov;58(5):1042-9. 
Inverse agonism and constitutive activity as functional c orrelates of 
serotonin h5-HT1B  receptor/G-protein stoichiometry. 
Newman-Tancredi A, Audinot V, Moreira C, Verrièle L, Millan MJ. 
Psychopharmacology Department, Institut de Recherches Servier, Croissy-sur-Seine (Paris), France.  
This study evaluated the influence of receptor/G-protein (R:G) stoichiometry on constitutive activity 
and the efficacy of agonists, partial agonists, and inverse agonists at human (h) 
5-hydroxytryphamine1B (5-HT1B) receptors. Two Chinese hamster ovary cell lines were used; they 
expressed 8.5 versus 0.4 pmol h5-HT1B receptors/mg (determined by [
3H]GR125,743 saturation 
analysis) and 3.0 versus 1.5 pmol receptor-activated G-proteins/mg [determined by guanosine-5'-O-
(3-[
35
S]thio)-triphosphate ([
35
S]GTPgammaS) isotopic dilution], respectively. Thus, they displayed R:G 
ratios of approximately 3.0 (RGhigh) and approximately 0.3 (RGlow), respectively. In competition-
binding experiments, the agonists, 5-HT and sumatriptan, displayed fewer high-affinity (HA)-binding 
sites and the partial agonists, BMS181, 101 and L775,606, displayed decreased affinity in RGhigh 
versus RGlow membranes. In contrast, the inverse agonists, SB224,289 and, to a lesser extent, 
methiothepin, showed increased affinity. In G-protein activation experiments, both basal and 5-HT-
activated [
35
S]GTPgammaS binding were higher in RGhigh than in RGlow membranes. Constitutive 
activity (determined by inhibition of basal [35S]GTPgammaS binding with GTPgammaS in the absence 
of receptor ligands) was more pronounced in RGhigh versus RGlow membranes, as revealed by the 
>5-fold greater proportion of HA sites. Correspondingly, the negative efficacy of inverse agonists was 
strikingly augmented, inasmuch as they suppressed approximately two-thirds of HA [
35
S]GTPgammaS 
binding in RGhigh membranes, but only approximately one-third in RGlow membranes. 
Furthermore, the efficacy of partial agonists was greater at RGhigh versus RGlow membranes, as 
estimated by their ability to enhance [35S]GTPgammaS binding. In conclusion, an increase in R:G 
ratios at h5-HT1B receptors was associated with an increase in relative efficacy of partial agonists and, 
most notably, an increase in both constitutive G-protein activation and negative efficacy of inverse 
agonists. 
D.Sc. Thesis  Publication Abstracts 
 
Part B: Page 117 of 206 
Reference no. 32 
Naunyn Schmiedebergs Arch Pharmacol. 2000 May;361(5):549-54. 
Antagonist properties of the novel antipsychotic, S16924, at cloned, 
human serotonin 5-HT2C  receptors: a parallel phosphatidylinositol and 
calcium accumulation comparison with clozapine and haloperidol.  
Cussac D, Newman-Tancredi A, Nicolas JP, Boutin JA, Millan MJ. 
Institut de Recherches Servier, Psychopharmacology Department, Croissy-sur-Seine, France. 
The novel benzopyranopyrrolidine and potential antipsychotic, S16924 ((+)-2-[[1-[2-(2,3-
dihydrobenzo[ 1,4] dioxin-5-yloxy)-ethyl]-pyrrolidin-3yl]]-1-(4-fluoro-ph enyl)-ethanone), displays 
marked affinity for serotonin (5-HT)1A, 5-HT2A and dopamine D2 receptors. Herein, we show that it 
also possesses high affinity for the cloned, INI isoform of h5-HT2C receptors (pKi=8.28) stably 
expressed in CHO cells. Similarly, clozapine (8.04) was a potent ligand, whereas haloperidol (<6.0) 
showed low affinity. As demonstrated by fura2-detection, S16924 concentration-dependently 
abolished (pKb=7.93) the 5HT-induced elevation in intracellular levels of Ca
2+
 ([Ca
2+
]i) in a CHO cell 
line stably expressing the INI isoform of 5-HT2C receptors. Further, as determined by depletion of 
membrane-bound levels of pre-labelled [3H]phosphatidylinositols ([3H]PI), S16924 concentration-
dependently, surmountably and competitively blocked the activation of phospholipase C by 5-HT. 
This action was expressed with a pA2 of 7.89 according to Schild analysis. Clozapine likewise 
inhibited 5-HT-induced alterations in [Ca2+]i and [3H]PI levels with pKbs of 7.43 and 7.84, 
respectively, whereas haloperidol was inactive (<5.0 in each case). Applied alone, S 16924, clozapine 
and haloperidol modified levels of neither [Ca2+]i nor [3H]PI. In conclusion, in analogy to clozapine, 
and in contrast to haloperidol, S16924 behaves as a potent and competitive antagonist at h5-HT2C 
receptors, the blockade of which may contribute to its distinctive functional profile of activity. 
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J Pharmacol Exp Ther. 2000 Jun;293(3):1048-62. 
S33084, a novel, potent, selective, and competitive antagonist at 
dopamine D3-receptors: I. Receptorial, electrophysiological and 
neurochemical profile compared with GR218,231 and L741,626.  
Millan MJ, Gobert A, Newman-Tancredi A, Lejeune F, Cussac D, Rivet JM, Audinot V, Dubuffet T, 
Lavielle G. 
Institut de Recherches Servier, Psychopharmacology Department, Croissy-sur-Seine, France. 
The benzopyranopyrrole S33084 displayed pronounced affinity (pKi = 9.6) for cloned human hD3-
receptors, and >100-fold lower affinity for hD2 and all other receptors (>30) examined. S33084 
concentration dependently, potently, and competitively (pA2 = 9.7) antagonized dopamine (DA)-
induced [35S]guanosine-5'-O-(3-thio)triphosphate (GTPgammaS) binding at hD3-receptors. It also 
concentration dependently abolished stimulation by DA of hD3-receptor-coupled mitogen-activated 
protein kinase. Administered alone, S33084 did not modify dialysate levels of DA in the frontal 
cortex, nucleus accumbens, or striatum of freely moving rats, nor the firing rate of ventrotegmental 
dopaminergic cell bodies. Furthermore, it had minimal effect on DA turnover in mesocortical, 
mesolimbic, and nigrostriatal projection regions. However, S33084 dose dependently blocked the 
suppressive influence of the preferential D3-agonist PD128,907 on frontocortical release of DA. 
Furthermore, it likewise antagonized the inhibitory influence of PD128,907 on the electrical activity 
of ventrotegmental dopaminergic neurons. Although less potent than S33084, GR218,231 likewise 
behaved as a selective hD3- versus hD2-receptor antagonist and its neurochemical and 
electrophysiological profiles were similar. In contrast, L741,626 was a preferential antagonist at hD2 
versus hD3 sites. In vivo, on administration alone, L741,626 increased frontocortical, mesolimbic, and 
(more potently) striatal DA release, enhanced the firing rate of dopaminergic perikarya, and 
accelerated cerebral DA synthesis. It also blocked the actions of PD128,907. In conclusion, S33084 is 
a novel, potent, selective, and competitive antagonist at hD3-receptors. Although GR218,231 
behaves similarly, L741,626 is a preferential D2-receptor antagonist. DA D2- but not D3-(auto) 
receptors tonically inhibit ascending dopaminergic pathways, although the latter may contribute to 
phasic suppression of DA release in frontal cortex. 
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Neuropharmacology. 2001;40(1):57-64. 
Constitutive activity at serotonin 5-HT1D  receptors: detection by 
homologous GTPgammaS versus [ 35S]-GTPgammaS binding isotherms. 
Audinot V, Newman-Tancredi A, Millan MJ. 
Institut de Recherches Servier, Psychopharmacology Department, Croissy-sur-Seine, France. 
Although many G-protein-coupled receptors (GPCRs) may display constitutive activity, their 
detection has, to date, depended on the use of inverse agonists. The present study exploited a novel 
procedure to investigate constitutive activity at recombinant human (h) serotonin (5-HT) 5-HT1D 
receptors stably expressed in Chinese hamster ovary (CHO) cells. 5-HT modestly stimulated 
guanosine-5'-O-(3-[
35
S]thio)-triphosphate ([
35
S]-GTPgammaS) binding to CHO-h5-HT1D membranes 
whereas methiothepin and the 5-HT1B/1D-selective ligand, SB224,289, exerted robust inhibition of 
basal [
35
S]-GTPgammaS binding (inverse agonism). These actions were specific inasmuch as they 
were reversed by the novel, selective 5-HT1B/1D ligand, S18127. Constitutive activity was investigated 
by homologous inhibition of [35S]-GTPgammaS binding to CHO-h5-HT1D membranes with unlabelled 
GTPgammaS. Under 'basal' conditions (absence of receptor ligand), biphasic isotherms were 
observed. Most (80%) [35S]-GTPgammaS binding sites were in the high affinity (HA) versus low 
affinity (LA) component of the isotherms. HA binding was augmented by 5-HT (to 155%; relative to 
basal values=100%), but decreased by methiothepin (to 23%) and by SB224,289 (to 67%). In 
contrast, LA binding was not altered. Further, membranes of untransfected CHO cells exhibited only 
LA binding sites, indicating that the latter are not related to h5-HT1D receptor-G-protein coupling. 
Thus, at 5-HT1D receptors expressed in this CHO cell line, HA binding detected in homologous 
inhibition experiments (GTPgammaS versus [35S]-GTPgammaS) under basal conditions provides a 
measure of constitutive G-protein activation. Thus, it is suggested that for h5-HT1D receptors and, 
possibly, other GPCRs, inverse agonists will be detectable by [35S]-GTPgammaS binding if a HA 
component is present under basal conditions. 
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Br J Pharmacol. 2001 Jan;132(2):518-24. 
Differential modulation by GTPgammaS of agonist and inverse agonist 
binding to h5-HT1A  receptors revealed by [3H]WAY100635. 
Newman-Tancredi A, Verrièle L, Millan MJ. 
Institut de Recherches Servier, Psychopharmacology Department, Croissy-sur-Seine, France. 
1. The interaction of serotonergic ligands at human (h) 5-HT1A receptors expressed in Chinese 
hamster ovary cells was examined with the selective 'neutral' 5-HT1A antagonist [
3H]WAY100635. Its 
binding was saturable (KD=0.056 nM) with a Bmax (3.65 pmol/mg) significantly higher than that of 
two other selective 5-HT1A radioligands: the partial agonist, [
3H]S15535 (2.77 pmol/mg) and the 
agonist, [
3
H]8-OH-DPAT (2.02 pmol/mg).  
2. The influence of GTPgammaS (100 microM) on the binding affinity of 15 serotonergic agonists, 
partial agonists, antagonists and inverse agonists was investigated in competition binding 
experiments with [3H]WAY100635.  
3. Agonists, including 5-HT, 8-OH-DPAT and buspirone, displayed biphasic isotherms which shifted to 
the right in the presence of GTPgammaS. In contrast, isotherms of the inverse agonists, 
methiothepin, (+)butaclamol and spiperone, were shifted to the left in the presence of GTPgammaS. 
Unlabelled WAY100635 was the only ligand that was unaffected by GTPgammaS, consistent with 
'neutral' antagonist properties.  
4. The magnitude of affinity changes induced by GTPgammaS for 13 ligands was highly correlated 
(r=0.98) with their efficacy (positive and negative) previously determined by [35S]GTPgammaS 
binding.  
5. In contrast, the napthylpiperazine derivative and high efficacy agonist, S14506, displayed only a 
modest GTPgammaS shift, in accordance with previous indications of 'atypical' binding properties of 
this ligand. A further full agonist, S14671, which is chemically closely-related to S14506, also 
displayed a minimal GTPgammaS shift, underpinning this observation.  
6. In conclusion, [3H]WAY100635 constitutes a useful neutral antagonist radioligand for the 
characterization of drug actions at h5-HT1A receptors. GTPgammaS-induced affinity changes of 
agonist and inverse agonist competition isotherms generally correlate well with ligand efficacy, with 
the notable exception of two chemically-similar agents, S14506 and S14671, which are efficacious 
agonists, yet relatively insensitive to h5-HT1A receptor/G-protein coupling changes. 
D.Sc. Thesis  Publication Abstracts 
 
Part B: Page 121 of 206 
Reference no. 36 
Naunyn Schmiedebergs Arch Pharmacol. 2001 Apr;363(4):391-8. 
Pindolol antagonises G-protein activation at both pre- and postsynaptic 
serotonin 5-HT1A  receptors: a GTPgammaS autoradiography study.  
Newman-Tancredi A, Chaput C, Touzard M, Millan MJ. 
Department of Psychopharmacology, Institut de Recherches Servier, Croissy-sur-Seine Paris, France. 
The arylalkylamine, pindolol, may potentiate the clinical actions of antidepressant agents. Although 
it is thought to act via blockade of 5-HT1A autoreceptors, its efficacy at these sites remains 
controversial. Herein, we evaluated the actions of pindolol at 5-HT1A autoreceptors and specific 
populations of postsynaptic 5-HT1A receptors employing [
35S]GTPgammaS autoradiography, a 
measure of receptor-mediated G-protein activation. Both 8-OH-DPAT (1 microM) and 5-HT (10 
microM) elicited a pronounced increase in [
35
S]GTPyS binding in the dorsal raphe nucleus, which 
contains serotonergic cell bodies bearing 5-HT1A autoreceptors. Pindolol abolished their actions. In 
the dentate gyrus, lateral septum and entorhinal cortex, structures enriched in postsynaptic 5-HT1A 
receptors, 8-OH-DPAT (1 microM) and 5-HT (10 microM) also elicited a marked increase in 
[35S]GTPgammaS binding which was likewise blocked by pindolol. The antagonism of 5-HT-induced 
[35S]GTPgammaS labelling in the dentate gyrus was shown to be concentration-dependent, yielding a 
pIC50 of 5.82. Pindolol did not, itself, affect [
35
S]GTPgammaS binding in any brain region examined. In 
conclusion, these data suggest that, as characterised by [35S]GTPgammaS autoradiography, and 
compared with 5-HT and 8-OH-DPAT, pindolol possesses low efficacy at both pre- and postsynaptic 
5-HT1A receptors. 
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Neuropsychopharmacology. 2001 Sep;25(3):410-22. 
Inverse agonist properties of  antipsychotic agents at cloned, human (h) 
serotonin 5-HT1B  and h5-HT1D  receptors. 
Audinot V, Newman-Tancredi A, Cussac D, Millan MJ. 
Molecular and Cellular Pharmacology Dept., Institut de Recherches Servier, Croissy-sur-Seine, 
France. 
The actions of diverse antipsychotics at cloned h5-HT1B and h5-HT1D receptors were examined 
employing [
3
H]GR125,743 and [
35
S]-GTPgammaS for determination of affinities and efficacies, 
respectively. Compared with hD2 receptors, haloperidol, chlorpromazine and olanzapine showed 
markedly (>100-fold) lower affinity for h5-HT1D and h5-HT1B receptors at which they expressed 
inverse agonist properties. Clozapine, risperidone and ocaperidone likewise behaved as inverse 
agonists at h5-HT1B and h5-HT1D receptors but their affinities were only approximately 10-fold lower 
than at hD2 receptors. Moreover, ziprasidone, S16924 and ORG5222 interacted at h5-HT1B and 
h5-HT1D receptors with affinities similar to hD2 sites. While S16924 and ORG5222 were inverse 
agonists at h5-HT1B and h5-HT1D sites, ziprasidone was an inverse agonist at h5-HT1D receptors yet a 
partial agonist at h5-HT1B receptors. These actions of antipsychotics were abolished by the selective, 
neutral antagonist, S18127. In conclusion, with the exception of ziprasidone, all antipsychotics were 
inverse agonists at h5-HT1B and h5-HT1D receptors, although they differed markedly in their potency 
at these sites as compared to hD2 receptors. 
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J Pharmacol Exp Ther. 2001 Jun;297(3):876-87. 
Antiparkinsonian agent piribedil displays antagonist properties at 
native, rat, and cloned, human alpha2-adrenoceptors: cellular and 
functional characterization. 
Millan MJ, Cussac D, Milligan G, Carr C, Audinot V, Gobert A, Lejeune F, Rivet JM, Brocco M, 
Duqueyroix D, Nicolas JP, Boutin JA, Newman-Tancredi A. 
Department of Psychopharmacology, Institut de Recherches Servier, Croissy-sur-Seine, France.  
Compared with cloned, human (h)D2 receptors (pKi = 6.9), the antiparkinsonian agent piribedil 
showed comparable affinity for halpha2A- (7.1) and halpha2C- (7.2) adrenoceptors (ARs), whereas its 
affinity for halpha2B-ARs was less marked (6.5). At halpha2A- and halpha2C-ARs, piribedil 
antagonized induction of [35S]guanosine-5'-O-(3-thio)triphosphate (GTPgammaS) binding by 
norepinephrine (NE) with pKb values of 6.5 and 6.9, respectively. Furthermore, Schild analysis of the 
actions of piribedil at halpha2A-ARs indicated competitive antagonism, yielding a pA2 of 6.5. At a 
porcine alpha2A-AR-Gi1alpha-Cys351C (wild-type) fusion protein, piribedil competitively abolished 
(pA2 = 6.5) GTPase activity induced by epinephrine. However, at a alpha2A-AR-Gi1alpha-Cys351I 
(mutant) fusion protein of amplified sensitivity, although still acting as a competitive antagonist (pA2 
= 6.2) of epinephrine, piribedil itself manifested weak partial agonist properties. Similarly, piribedil 
weakly induced mitogen-activated protein kinase phosphorylation via wild-type halpha2A-ARs, 
although attenuating its phosphorylation by NE. As demonstrated by functional [
35
S]GTPgammaS 
autoradiography in rats, piribedil antagonized activation by NE of alpha2-ARs in cortex, amygdala, 
and septum. Antagonist properties were also expressed in a dose-dependent enhancement of the 
firing rate of adrenergic neurons in locus ceruleus (0.125-4.0 mg/kg i.v.). Furthermore, piribedil (2.5-
4.0 mg/kg s.c.) accelerated hippocampal NE synthesis, elevated dialysis levels of NE in hippocampus 
and frontal cortex, and blocked hypnotic-sedative properties of the alpha2-AR agonist xylazine. 
Finally, piribedil showed only modest affinity for rat alpha1-ARs (5.9) and weakly antagonized NE-
induced activation of phospholipase C via halpha1A-ARs (pKb = 5.6). In conclusion, piribedil displays 
essentially antagonist properties at cloned, human and cerebral, rat alpha2-ARs. Blockade of alpha2-
ARs may, thus, contribute to its clinical antiparkinsonian profile. 
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Eur J Pharmacol. 2001 Oct 5;428(2):177-84. 
Efficacy of antipsychotic agents at human 5-HT1A  receptors determined 
by [3H]WAY100635 binding affinity ratios: relationship to efficacy for G-
protein activation. 
Newman-Tancredi A, Verrièle L, Touzard M, Millan MJ. 
Department of Psychopharmacology, Institut de Recherches Servier, Croissy-sur-Seine, Paris, France.  
5-HT1A receptors are implicated in the aetiology of schizophrenia. Herein, the influence of 15 
antipsychotics on the binding of the selective 'neutral' antagonist, [
3
H]WAY100635 ([
3
H]N-[2-[4-(2-
methoxyphenyl)-1-piperazinyl]ethyl]-N-(2-pyridinyl)-cyclo-hexanecarboxamide), was examined at 
human 5-HT1A receptors expressed in Chinese Hamster Ovary cells. In competition binding 
experiments, 5-HT displayed biphasic isotherms which were shifted to the right in the presence of 
the G-protein uncoupling agent, GTPgammaS (100 microM). In analogy, the isotherms of 
ziprasidone, quetiapine and S16924 (((R-2-[1-[2-(2,3-dihydro-benzo[1,4]dioxin-5-yloxy)-ethyl]-
pyrrolidin-3yl]-1-(4-fluoro-phenyl)-ethanone), were displaced to the right by GTPgammaS, consistent 
with agonist actions. Binding of several other antipsychotics, such as ocaperidone, olanzapine and 
risperidone, was little influenced by GTPgammaS. Isotherms of the neuroleptics, haloperidol, 
chlorpromazine and thioridazine were shifted to the left in the presence of GTPgammaS, suggesting 
inverse agonist properties. For most ligands, the magnitude of affinity changes induced by 
GTPgammaS (alteration in pKi values) correlated well with their previously determined efficacies in 
[35S]GTPgammaS binding studies [Eur. J. Pharmacol. 355 (1998) 245]. In contrast, the affinity of the 
'atypical' antipsychotic agent, clozapine, which is a known partial agonist at 5-HT1A receptors, was 
less influenced by GTPgammaS. When the ratio of high-/low-affinity values was plotted against 
efficacy, hyperbolic isotherms were obtained, consistent with a modified ternary complex model 
which assumes that receptors can adopt active conformations in the absence of agonist. In 
conclusion, modulation of [3H]WAY100635 binding by GTPgammaS differentiated agonist vs. inverse 
agonist properties of antipsychotics at 5-HT1A receptors. These may contribute to differing profiles of 
antipsychotic activity. 
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Psychopharmacology (Berl). 2001 Jun;156(1):58-62. 
The "selective" dopamine D1 receptor antagonist, SCH23390, is a potent 
and high efficacy agonist at cloned human serotonin 2C receptors. 
Millan MJ, Newman-Tancredi A, Quentric Y, Cussac D. 
Institut de Recherches Servier, Psychopharmacology Department, Paris, France. 
RATIONALE: The benzazepine and "selective" dopamine D1 receptor antagonist, SCH23390 [(R)-(+)-
8-chloro-2,3,4,5-tetrahydro-3-methyl-5-phenyl-1H-benzazepine-7-ol], shows significant affinity at 
native serotonin (5-HT)2C receptors. 
OBJECTIVES: We examined its functional actions at cloned human (h)5-HT2C receptors (VSV isoform) 
stably expressed in CHO cells. 
METHODS: Since 5-HT2C receptors are positively coupled to phospholipase C (PLC), their activation 
was determined by depletion of membrane-bound pools of pre-labelled [
3
H]phosphotidylinositol 
([3H]PI). 
RESULTS: SCH23390 showed high affinity (Ki, 9.3 nM) at h5-HT2C sites and depleted [
3H]PI with an 
EC50 of 2.6 nM. Its efficacy was equivalent to that of 5-HT. [
3
H]PI depletion elicited by SCH23390 was 
concentration-dependently abolished by the selective 5-HT2C antagonist, SB242,084, with a KB of 
0.55 nM. Further, in the presence of a fixed concentration of SB242,084 (10 nM), the concentration-
response curve for SCH23390 was shifted to the right without loss of maximal effect, yielding a KB of 
0.57 nM. 
CONCLUSIONS: SCH23390 is a potent and high efficacy agonist at h5-HT2C receptors. Activation of 
5-HT2C receptors by SCH23390 may contribute to its functional properties both in animals and in 
humans. 
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Eur J Pharmacol. 2001 Jul 13;424(1):13-7. 
Agonist properties of pindolol at h5-HT1A  receptors coupled to mitogen-
activated protein kinase. 
Millan MJ, Newman-Tancredi A, Duqueyroix D, Cussac D. 
Psychopharmacology Department, Institut de Recherches Servier, Croissy-sur-Seine, France.  
At h5-HT1A receptors, stably transfected into Chinese Hamster Ovary Cells (CHO-h5-HT1A), the 
selective 5-HT1A receptor agonist, (+)8-hydroxy-dipropyl-amino-tetralin, ((+)8-OH-DPAT), transiently 
activated mitogen-activated protein kinase (MAPK) with a pEC50 of 8.5. The arylalkylamine, (-)-
pindolol, also behaved as an agonist with a maximal effect of 57% relative to (+)8-OH-DPAT (100%), 
and with a pEC50 of 7.2. The selective 5-HT(1A) receptor antagonist, N-[2-[4-(2-methoxyphenyl)-1-
piperazinyl]ethyl]-N-(2-pyridinyl)cyclo-hexane carboxamide (WAY100635), blocked (+)8-OH-DPAT- 
and (-)-pindolol-induced MAPK activation with pK(B)s of 9.7 and 9.9, respectively, whereas the 
selective 5-HT(1B) receptor antagonist, 1'-Methyl-5-[2'-methyl-4'-(5-methyl-1,2,4-oxadiazol-3-
yl)biphenyl-4-ylcarbonyl]-2,3,6,7-tetrahydro-5H-spiro[furo[2,3-f]indole-3,4'-piperidine] (SB224,289) 
was inactive. Pertussis toxin blocked the actions of (+)8-OH-DPAT and (-)-pindolol demonstrating 
implication of G(i)/G(o) proteins. Thus, stimulation of MAPK provides an intracellular marker and 
signal for expression of the agonist actions of (-)-pindolol at h5-HT1A receptors. 
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Brain Res. 2001 Nov 30;920(1-2):41-54. 
Dopamine D2 receptor-mediated G-protein activation in rat striatum: 
functional autoradiography and influence of unilateral  6-
hydroxydopamine lesions of the substantia nigra.  
Newman-Tancredi A, Cussac D, Brocco M, Rivet JM, Chaput C, Touzard M, Pasteau V, Millan MJ. 
Department of Psychopharmacology, Institut de Recherches Servier, Croissy-sur-Seine, Paris, France.  
Unilateral 6-hydroxydopamine (6-OHDA) lesions of substantia nigra pars compacta (SNPC) neurons in 
rats induce behavioural hypersensitivity to dopaminergic agonists. However, the role of specific 
dopamine receptors is unclear, and potential alterations in their transduction mechanisms remain to 
be evaluated. The present study addressed these issues employing the dopaminergic agonist, 
quinelorane, which efficaciously stimulated G-protein activation (as assessed by [35S]GTPgammaS 
binding) at cloned hD2 (and hD3) receptors. At rat striatal membranes, dopamine stimulated 
[
35
S]GTPgammaS binding by 1.9-fold over basal, but its actions were only partially reversed by the 
selective D2/D3 receptor antagonist, raclopride, indicating the involvement of other receptor 
subtypes. In contrast, quinelorane-induced stimulation (48% of the effect of dopamine) was 
abolished by raclopride, and by the D2 receptor antagonist, L741,626. Further, novel antagonists 
selective for D3 and D4 receptors, S33084 and S18126, respectively, blocked the actions of 
quinelorane at concentrations corresponding to their affinities for D2 receptors. Quinelorane 
potently induced contralateral rotation in unilaterally 6-OHDA-lesioned rats, an effect abolished by 
raclopride and L741,626, but not by D3 and D4 receptor-selective doses of S33084 and S18126, 
respectively. In functional ([
35
S]GTPgammaS) autoradiography experiments, quinelorane stimulated 
G-protein activation in caudate putamen and, to a lesser extent, in nucleus accumbens and cingulate 
cortex of naive rats. In unilaterally SNPC-lesioned rats, quinelorane-induced G-protein activation in 
the caudate putamen on the non-lesioned side was similar to that seen in naive animals 
(approximately 50% stimulation), but significantly greater on the lesioned side (approximately 80%). 
This increase was both pharmacologically and regionally specific since it was reversed by raclopride, 
and was not observed in nucleus accumbens or cingulate cortex. In conclusion, the present data 
indicate that, in rat striatum, the actions of quinelorane are mediated primarily by D2 receptors, and 
suggest that behavioural hypersensitivity to this agonist, induced by unilateral SNPC lesions, is 
associated with an increase in D2, but not D3 or D4, receptor-mediated G-protein activation. 
D.Sc. Thesis  Publication Abstracts 
 
Part B: Page 128 of 206 
Reference no. 43 
Pharmacol Biochem Behav. 2002 Apr;71(4):589-98. 
Specific labelling of serotonin 5-HT1B  receptors in rat frontal cortex with 
the novel, phenylpiperazine derivative, [ 3H]GR125,743. A 
pharmacological characterization.  
Millan MJ, Newman-Tancredi A, Lochon S, Touzard M, Aubry S, Audinot V. 
Psychopharmacology Department, Institut de Recherches Servier, Croissy/Seine, Paris, France.  
Although several tritiated agonists have been used for radiolabelling serotonin 
(5-hydroxytryptamine, 5-HT1B receptors in rats, data with a selective, radiolabelled antagonist have 
not been presented. Inasmuch as [3H]GR125,743 specifically labels cloned, human and native guinea 
pig 5-HT1B receptors and has been employed for characterization of cerebral 5-HT1B receptor in the 
latter species [Eur. J. Pharmacol. 327 (1997) 247.], the present study evaluated its utility for 
characterization of native, cerebral 5-HT1B sites in the rat. In homogenates of frontal cortex, 
[3H]GR125,743 (0.8 nM) showed rapid association (t1/2=3.4 min), >90% specific binding and high 
affinity (Kd=0.6 nM) for a homogeneous population of receptors with a density (Bmax) of 160 
fmol/mg protein. In competition binding studies, affinities were determined for 15 chemically 
diverse 5-HT1B agonists, including 2-[5-[3-(4-methylsulphonylamino)benzyl-1,2,4-oxadiazol-5-yl]-1H-
indole-3-yl]ethylamine (L694,247; pK(i), 10.4), 5-carboxamidotryptamine (5-CT; 9.7), 3-[3-(2-
dimethylamino-ethyl)-1H-indol-6-yl]-N-(4-methoxybenzyl)acrylamide (GR46,611; 9.6), 5-methoxy-3-
(1,2,5,6-tetrahydro-4-pyridinyl)-1H-indole (RU24,969; 9.5), dihydroergotamine (DHE; 8.6), 5-H-
pyrrolo[3,2-b]pyridin-5-one,1,4-dihydro-3-(1,2,3,6-tetrahydro-4-pyridinyl (CP93,129; 8.4), anpirtoline 
(7.9), sumatriptan (7.4), 1-[2-(3-fluorophenyl)ethyl]-4-[3-[5-(1,2,4-triazol-4-yl)-1H-indol-3-
yl]propyl]piperazine (L775,606; 6.4) and (minus sign)-1(S)-[2-[4-(4-methoxyphenyl)piperazin-1-
yl]ethyl]-N-methyl-3,4-dihydro-1H-2-benzopyran-6-carboxamide (PNU109,291; <5.0). Similarly, 
affinities were established for 13 chemically diverse antagonists, including N-[4-methoxy-3-(4-
methylpiperazin-1-yl)phenyl]-3-methyl-4-(4-pyridyl)benzamide (GR125,743; pK(i), 9.1), (-
)cyanopindolol (9.0), (-)-tertatolol (8.2), N-(4-methoxy-3-(4-methylpiperazin-1-yl)phenyl]-2'-methyl-
4'-(5-methyl-1,2,4-oxadiozol-3-yl)biphenyl-4-carboxamide (GR127,935; 8.2), N-[3-(1,4-benzodioxan-
5-yl)piperidin-4-yl]N-(indan-2yl)amine (S18127; 7.9), metergoline (7.8), (-)-pindolol (7.6), 1'-methyl-
5-[2'-methyl-4'-(5-methyl-1,2,4-oxadiazol-3-yl)-biphenyl-4-ylcarbonyl]-2,3,6,7-tetrahydro-5H-
spiro[furo[2,3-f]indole-3,4'-piperidine] (SB224,289; 7.5) and ketanserin (<5.0). These rank orders of 
affinity correspond to the binding profile of 5-HT1B) rather than 5-HT1D receptors. The low affinities of 
L775,066 and PNU109,291 versus L694,247 should be noted, as well as the low affinity of ketanserin 
as compared to SB224,289. Finally, in line with species differences, the affinities of several ligands 
including CP93,129, RU24,969, (-)-pindolol and (-)-propanolol in rat 5-HT1B sites were markedly 
different to guinea pig 5-HT1B sites labelled with [
3H]GR125,743. In conclusion, [3H]GR125,743 is an 
appropriate tool for the radiolabelling of native, rat 5-HT1B receptors and permitted determination of 
the affinities of an extensive series of ligands at these sites. 
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Psychopharmacology (Berl). 2002 Jul;162(2):168-77. Epub 2002 Apr 30. 
Stimulation by antipsychotic agents of mitogen-activated protein kinase 
(MAPK) coupled to cloned, human (h)serotonin 5-HT1A  receptors. 
Cussac D, Duqueyroix D, Newman-Tancredi A, Millan MJ. 
Institut de Recherches Servier, Psychopharmacology Department, Croissy-sur-Seine, France. 
RATIONALE: There is evidence that serotonergic mechanisms contribute to the functional profiles of 
antipsychotic drugs, several of which display affinity for human (h)5-HT1A receptors. 
OBJECTIVE: Here, we compared the interaction of several antipsychotic agents at h5-HT1A receptors 
employing mitogen-activated protein kinase (MAPK), an intracellular marker. 
METHODS: The influence of antipsychotics on MAPK phosphorylation was quantified in Chinese 
hamster ovary (CHO) cells stably transfected with h5-HT1A receptors by use of a highly selective 
antibody. 
RESULTS: The novel antipsychotic agent, S16924, concentration-dependently (pEC50, 8.10) 
stimulated the phosphorylation of MAPK. Its maximal effect (96%) was similar to that of the 
prototypical 5-HT1A agonist, (+)8-OH-DPAT (pEC50, 8.54) (defined as 100%). The selective 5-HT1A 
receptor antagonist WAY100635, which was inactive alone, abolished stimulation of MAPK by 
S16924 with a pKb of 9.66. This stimulatory influence of S16924 on MAPK was potently mimicked by 
the benzoisoxazole, antipsychotic ziprasidone (pEC50, 7.25; 93%). The atypical antipsychotic 
clozapine also activated MAPK, albeit with lower potency and efficacy (pEC50, 5.43 and 43%). These 
actions of ziprasidone and clozapine were also blocked by WAY100635. Evaluated at a single, high 
concentration, several other antipsychotics stimulated MAPK phosphorylation with variable efficacy: 
quetiapine (75%), ocaperidone (74%), tiospirone (57%), olanzapine (54%) and risperidone (21%). In 
all cases, their actions were abolished by WAY100635. In contrast, haloperidol, thioridazine and 
sertindole did not stimulate MAPK. 
CONCLUSIONS: Antipsychotics display contrasting efficacies in modulating MAPK phosphorylation at 
h5-HT1A receptors, ranging from high (e.g. S16924 and ziprasidone), via intermediate (e.g. clozapine) 
to low (e.g. haloperidol). Differential modulation of 5-HT1A receptor-coupled MAPK may contribute 
to their contrasting functional profiles. 
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Mol Pharmacol. 2002 Sep;62(3):578-89. 
Differential activation of Gq/11 and Gi3 proteins at  
5-hydroxytryptamine2C receptors revealed by antibody capture assays: 
influence of receptor reserve and relationship to agonist -directed 
trafficking. 
Cussac D, Newman-Tancredi A, Duqueyroix D, Pasteau V, Millan MJ. 
Institut de Recherches Servier, Psychopharmacology Department, Croissy-sur-Seine, Paris, France.  
As determined by a guanosine 5'-O-(3-[
35
S]thio)triphosphate ([
35
S]GTPgammaS) binding assay, which 
does not distinguish G protein subtypes, 5-hydroxytryptamine (5-HT) and 2(S)- 1-(6-chloro-5-fluoro-
1H-indol-1-yl)-2-propanamine fumarate (Ro600175) behaved as full agonists at human 5-HT2C 
(h5-HT2C) receptors (VSV isoform) stably expressed in Chinese hamster ovary (CHO) cells, whereas 1-
2,5-dimethoxy-4-iodophenyl-2-aminopropane (DOI), d-lysergic acid diethylamide (LSD), and lisuride 
exhibited partial agonist properties. After treatment with pertussis toxin to uncouple 5-HT2C 
receptors from Gi/Go but not Gq/11, DOI and LSD were as efficacious as 5-HT and Ro600175 in 
stimulating [35S]GTPgammaS binding, whereas lisuride still exhibited low efficacy (40%). 
Correspondingly, in a scintillation proximity assay employing specific antibodies against Gq/11, 5-HT, 
Ro600175, DOI, and LSD behaved as high-efficacy agonists, whereas lisuride showed efficacy of 36%. 
In contrast, when employing a specific antibody recognizing Gi3, DOI and LSD were less efficacious 
(80 and 30%, respectively) than 5-HT and Ro600175, and lisuride was inactive. Agonist actions were 
specifically mediated by h5-HT2C receptors inasmuch as the selective 5-HT2C antagonist SB242,084 
blocked [
35
S]GTPgammaS binding at both Gq/11 and Gi3. Agonist potency for stimulation of Gi3 was 
~6- to 8-fold less than for Gq/11, indicating that the latter was preferentially engaged by h5-HT2C 
receptors. Inactivation of h5-HT2C receptors with the alkylating agent N-ethoxycarbonyl-2-ethoxy-
1,2-dihydroquinoline did not modify the efficacy of 5-HT, Ro600175, and DOI at Gq/11, whereas 
their efficacies were substantially reduced at Gi3, indicating a greater receptor reserve for the 
former. Finally, the preferential activation of Gq/11 versus Gi3 by DOI, LSD, and lisuride was 
diminished in the presence of lower receptor number. In conclusion, h5-HT2C receptors couple to 
both Gq/11 and Gi3 in CHO cells, and efficacy for G protein subtype activation is both ligand- and 
receptor reserve-dependent. 
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Mol Pharmacol. 2002 Sep;62(3):590-601. 
Antibody capture assay reveals bell-shaped concentration-response 
isotherms for h5-HT1A  receptor-mediated Galpha(i3) activation: 
conformational selection by high-efficacy agonists, and relationship to 
trafficking of receptor signaling.  
Newman-Tancredi A, Cussac D, Marini L, Millan MJ. 
Department of Psychopharmacology, Institut de Recherches Servier, Croissy-sur-Seine, France. 
Although serotonin 5-HT1A receptors couple to several Gi/o G-protein subtypes, little is known 
concerning their differential activation patterns. In this study, in membranes of Chinese hamster 
ovary cells expressing h5-hydroxytryptamine1A receptors (CHO-h5-HT1A), isotherms of 5-HT-
stimulated guanosine-5'-O-(3-[
35
S]thio)-triphosphate ([
35
S]GTPgammaS) binding were biphasic, 
suggesting coupling to multiple G-protein subtypes. The high potency component was abolished by 
preincubation with an antibody recognizing Galpha(i3) subunits and was resistant to induction of 
[35S]GTPgammaS dissociation by unlabeled GTPgammaS, thus yielding a bell-shaped concentration-
response isotherm. To directly investigate Galpha(i3) activation, we adopted an antibody-
capture/scintillation proximity assay. 5-HT and other high-efficacy agonists yielded bell-shaped 
[
35
S]GTPgammaS binding isotherms, with peaks at nanomolar concentrations. As drug 
concentrations increased, Galpha(i3) stimulation progressively returned to basal values. In contrast, 
the partial agonists (-)-pindolol and 4-(benzodioxan-5-yl)1-(indan-2-yl)piperazine (S15535) displayed 
sigmoidal stimulation isotherms, whereas spiperone and other inverse agonists sigmoidally inhibited 
[
35
S]GTPgammaS binding. Agonist-induced stimulation and inverse agonist-induced inhibition of 
Galpha(i3) activation were i) abolished by pretreatment of CHO-h5-HT1A cells with pertussis toxin; ii) 
reversed by the selective 5-HT1A antagonist (N-[2-[4-(2-methoxy-phenyl)-1-piperazinyl]ethyl]-N-(2-
pyridinyl)-cyclohexane-carboxamide) fumarate (WAY100635), and iii) absent in nontransfected CHO 
cell membranes. 5-HT isotherms could be modified by altering sodium concentration; only 
stimulatory actions were observed at 300mM NaCl, whereas only inhibitory actions were seen at 10 
mM NaCl. Furthermore, bell-shaped isotherms were not detected at short incubation times, 
suggesting time-dependent changes in receptor/Galpha(i3) coupling. Taken together, these data 
show that low but not high concentrations of high-efficacy 5-HT1A agonists direct receptor signaling 
to Galpha(i3). In contrast, partial agonists favor h5-HT1A receptor signaling to Galpha(i3) over a wide 
concentration range, whereas inverse agonists inhibit constitutive Galpha(i3) activation. 
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Characterization of phospholipase C activity at h 5-HT2C  compared with 
h5-HT2B  receptors: influence of novel ligands upon membrane -bound 
levels of [3H]phosphatidylinositols.  
Cussac D, Newman-Tancredi A, Quentric Y, Carpentier N, Poissonnet G, Parmentier JG, Goldstein S, 
Millan MJ. 
Department of Psychopharmacology, Institut de Recherches Servier, Croissy-Sur-Seine, France.  
Employing a novel, rapid and sensitive method for evaluation of phospholipase C (PLC) activity, the 
present study characterized the actions of diverse agonists and antagonists at human (h)5-HT2C 
receptors expressed in Chinese Hamster Ovary (CHO) cells. In addition, affinities and efficacies at 
these sites were compared with those obtained at h5-HT2B receptors.5-HT elicited a robust and rapid 
reduction in levels of the pre-labelled, membrane-bound substrate of PLC, [
3
H]phosphatidylinositols 
([
3
H]PI). The time-course of [
3
H]PI depletion paralleled that of [
3
H]inositol phosphate ([
3
H]IP) 
accumulation, as determined by conventional anion exchange chromatography. Inactivation of 
h5-HT2C receptors with the alkylating agent, N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline 
(EEDQ), revealed a large receptor reserve, with half-maximal PLC activation induced by a 
concentration of 5-HT occupying only 5% of sites. In analogy to 5-HT ( Emax=100%), DOI, MK212 and 
mCPP, as well as the novel ligands, Ro600332, Ro600175 and BW723C86, showed "full" efficacy at 
h5-HT2C sites. Their efficacies were similar at h5-HT2B sites, with the exception of mCPP and MK212, 
which acted as partial agonists. Further, lisuride and Ro600869 behaved as partial agonists and 
antagonists at h5-HT2C and h5-HT2B receptors, respectively. As concerns functional selectivity 
(potency for induction of [3H]PI depletion), only Ro600175 preferentially activated h5-HT2B sites. In 
contrast, Ro600332 preferentially activated h5-HT2C receptors. Amongst antagonists, RS102221 and 
SB242084 displayed a marked preference for h5-HT2C sites, whereas LY266097, S33526 and 
SB204741 behaved as selective antagonists at h5-HT2B receptors. At both h5-HT2C and h5-HT2B 
receptors, antagonist potency (pKb) and binding affinity (pKi) were highly correlated. In conclusion, 
this rapid and innovative method for determination of PLC activity permitted characterization of an 
extensive range of novel ligands at h5-HT2C receptors. Although several antagonists clearly 
differentiated h5-HT2C from h5-HT2B receptors under these conditions, highly selective agonists 
remain to be identified. 
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Differential actions of antiparkinson agents at multiple classes of 
monoaminergic receptor. I. A multivariate analysis of the binding 
profiles of 14 drugs at 21 native and cloned human receptor subtypes.  
Millan MJ, Maiofiss L, Cussac D, Audinot V, Boutin JA, Newman-Tancredi A. 
Department of Psychopharmacology, Institut de Recherches Servier, Croissy-sur-Seine, Paris, France.  
Because little comparative information is available concerning receptor profiles of antiparkinson 
drugs, affinities of 14 agents were determined at diverse receptors implicated in the etiology and/or 
treatment of Parkinson's disease: human (h)D1, hD2S, hD2L, hD3, hD4, and hD5 receptors; human 
5-hydroxytryptamine 5-HT1A, h5-HT1B, h5-HT1D,  h5-HT2A, h5-HT2B, and h5-HT2C receptors; halpha1A-, 
halpha1B-, halpha1D-, halpha2A-, halpha2B-, halpha2C-, rat alpha2D-, hbeta1-, and hbeta2-
adrenoceptors (ARs); and native histamine1 receptors. A correlation matrix (294 pKi values) 
demonstrated substantial "covariance". Correspondingly, principal components analysis revealed 
that axis 1, which accounted for 76% variance, was associated with the majority of receptor types: 
drugs displaying overall high versus modest affinities migrated at opposite extremities. Axis 2 (7% of 
variance) differentiated drugs with high affinity for hD4 and H1 receptors versus halpha1-AR 
subtypes. Five percent of variance was attributable to axis 3, which distinguished drugs with marked 
affinity for hbeta1- and hbeta2-ARs versus hD5 and 5-HT2A receptors. Hierarchical (cluster) analysis of 
global homology generated a dendrogram differentiating two major groups possessing low versus 
high affinity, respectively, for multiple serotonergic and hD5 receptors. Within the first group, 
quinpirole, quinerolane, ropinirole, and pramipexole interacted principally with hD2, hD3, and hD4 
receptors, whereas piribedil and talipexole recognized dopaminergic receptors and halpha2-ARs. 
Within the second group, lisuride and terguride manifested high affinities for all sites, with 
roxindole/bromocriptine, cabergoline/pergolide, and 6,7-dihydroxy-N,N-dimethyl-2-ammotetralin 
(TL99)/apomorphine comprising three additional subclusters of closely related ligands. In conclusion, 
an innovative multivariate analysis revealed marked heterogeneity in binding profiles of 
antiparkinson agents. Actions at sites other than hD2 receptors likely participate in their (contrasting) 
functional profiles. 
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Differential actions of antiparkinson agents at multiple classes of 
monoaminergic receptor. II. Agonist and antagonist properties at 
subtypes of dopamine D2-like receptor and alpha1/alpha2-adrenoceptor. 
Newman-Tancredi A, Cussac D, Audinot V, Nicolas JP, De Ceuninck F, Boutin JA, Millan MJ. 
Department of Psychopharmacology, Institut de Recherches Servier, Croissy-sur-Seine, Paris, France. 
The accompanying multivariate analysis of the binding profiles of antiparkinson agents revealed 
contrasting patterns of affinities at diverse classes of monoaminergic receptor. Herein, we 
characterized efficacies at human (h)D2S, hD2L, hD3, and hD4.4 receptors and at halpha2A-, halpha2B-, 
halpha2C-, and halpha1A-adrenoceptors (ARs). As determined by guanosine 5'-O-(3-
[35S]thio)triphosphate ([35S]GTPgammaS) binding, no ligand displayed "full" efficacy relative to 
dopamine (100%) at all "D2-like" sites. However, at hD2S receptors quinpirole, pramipexole, 
ropinirole, quinerolane, pergolide, and cabergoline were as efficacious as dopamine (Emax 100%); 
TL99, talipexole, and apomorphine were highly efficacious (79-92%); piribedil, lisuride, 
bromocriptine, and terguride showed intermediate efficacy (40-55%); and roxindole displayed low 
efficacy (11%). For all drugs, efficacies were lower at hD2L receptors, with terguride and roxindole 
acting as antagonists. At hD3 receptors, efficacies ranged from 33% (roxindole) to 94% (TL99), 
whereas, for hD4 receptors, highest efficacies (approximately 70%) were seen for quinerolane, 
quinpirole, and TL99, whereas piribedil and terguride behaved as antagonists and bromocriptine was 
inactive. Although efficacies at hD2S versus hD2L sites were highly correlated (r = 0.79), they 
correlated only modestly to hD3/hD4 sites (r = 0.44-0.59). In [
35
S]GTPgammaS studies of halpha2A-
ARs, TL99 (108%), pramipexole (52%), talipexole (51%), pergolide (31%), apomorphine (16%), and 
quinerolane (11%) were agonists and ropinirole and roxindole were inactive, whereas piribedil and 
other agents were antagonists. Similar findings were obtained at halpha2B- and halpha2C-ARs. Using 
[3H]phosphatidylinositol depletion, roxindole, bromocriptine, lisuride, and terguride displayed potent 
antagonist properties at halpha1A-ARs. In conclusion, antiparkinson agents display diverse agonist 
and antagonist properties at multiple subtypes of D2-like receptor and alpha1/alpha2-AR, actions, 
which likely contribute to their contrasting functional profiles. 
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Differential actions of antiparkinson agents at multipl e classes of 
monoaminergic receptor. III. Agonist and antagonist properties at 
serotonin, 5-HT1 and 5-HT2, receptor subtypes. 
Newman-Tancredi A, Cussac D, Quentric Y, Touzard M, Verrièle L, Carpentier N, Millan MJ. 
Department of Psychopharmacology, Institut de Recherches Servier, Croissy-sur-Seine, Paris, France. 
Although certain antiparkinson agents interact with serotonin (5-HT) receptors, little information is 
available concerning functional actions. Herein, we characterized efficacies of apomorphine, 
bromocriptine, cabergoline, lisuride, piribedil, pergolide, roxindole, and terguride at human 
(h)5-HT1A, h5-HT1B, and h5-HT1D receptors [guanosine 5'-O-(3-[
35
S]thio)triphosphate 
([35S]GTPgammaS) binding], and at h5-HT2A, h5-HT2B, and h5-HT2C receptors (depletion of membrane-
bound [
3
H]phosphatydilinositol). All drugs stimulated h5-HT1A receptors with efficacies (compared 
with 5-HT, 100%) ranging from modest (apomorphine, 35%) to high (cabergoline, 93%). At h5-HT1B 
receptors, efficacies varied from mild (terguride, 37%) to marked (cabergoline, 102%) and potencies 
were modest (pEC50 values of 5.8-7.6): h5-HT1D sites were activated with a similar range of efficacies 
and greater potency (7.1-8.5). Piribedil and apomorphine were inactive at h5-HT1B and h5-HT1D 
receptors. At h5-HT2A receptors, terguride, lisuride, bromocriptine, cabergoline, and pergolide 
displayed potent (7.6-8.8) agonist properties (49-103%), whereas apomorphine and roxindole were 
antagonists and piribedil was inactive. Only pergolide (113%/8.2) and cabergoline (123%/8.6) 
displayed pronounced agonist properties at h5-HT2B receptors. At 5-HT2C receptors, lisuride, 
bromocriptine, pergolide, and cabergoline were efficacious (75-96%) agonists, apomorphine and 
terguride were antagonists, and piribedil was inactive. MDL100,907 and SB242,084, selective 
antagonists at 5-HT2A and 5-HT2C receptors, respectively, abolished these actions of pergolide, 
cabergoline, and bromocriptine. In conclusion, antiparkinson agents display markedly different 
patterns of agonist and antagonist properties at multiple 5-HT receptor subtypes. Although all show 
modest (agonist) activity at 5-HT1A sites, their contrasting actions at 5-HT2A and 5-HT2C sites may be of 
particular significance to their functional profiles in vivo. 
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The novel melatonin agonist agomelatine (S20098) is an antagonist at 
5-hydroxytryptamine2C receptors, blockade of which enhances the 
activity of frontocortical dopaminergic and adrenergic pathways. 
Millan MJ, Gobert A, Lejeune F, Dekeyne A, Newman-Tancredi A, Pasteau V, Rivet JM, Cussac D. 
Department of Psychopharmacology, Institut de Recherches Servier, Croissy-sur-Seine, France.  
Agomelatine (S20098) displayed pKi values of 6.4 and 6.2 at native (porcine) and cloned, human 
(h)5-hydroxytryptamine 5-HT2C receptors, respectively. It also interacted with h5-HT2B receptors (6.6), 
whereas it showed low affinity at native (rat)/cloned, human 5-HT2A (<5.0/5.3) and 5-HT1A (<5.0/5.2) 
receptors, and negligible (<5.0) affinity for other 5-HT receptors. In antibody capture/scintillation 
proximity assays, agomelatine concentration dependently and competitively abolished h5-HT2C 
receptor-mediated activation of Gq/11 and Gi3 (pA2 values of 6.0 and 6.1). As measured by 
[
3
H]phosphatidylinositol depletion, agomelatine abolished activation of phospholipase C by h5-HT2C 
(pKB value of 6.1) and h5-HT2B (pKB value of 6.6) receptors. In vivo, it dose dependently blocked 
induction of penile erections by the 5-HT2C agonists (S)-2-(6-chloro-5-fluoroindol-1-yl)-1-
methylethylamine (Ro60,0175) and 1-methyl-2-(5,8,8-trimethyl-8H-3-aza-cyclopenta[a]inden-3-yl) 
ethylamine (Ro60,0332). Furthermore, agomelatine dose dependently enhanced dialysis levels of 
dopamine in frontal cortex of freely moving rats, whereas they were unaffected in nucleus 
accumbens and striatum. Although the electrical activity of ventrotegmental dopaminergic neurons 
was unaffected agomelatine, it abolished their inhibition by Ro60,0175. Extracellular levels of 
noradrenaline in frontal cortex were also dose dependently enhanced by agomelatine in parallel 
with an acceleration in the firing rate of adrenergic cell bodies in the locus coeruleus. These 
increases in noradrenaline and dopamine levels were unaffected by the selective melatonin 
antagonist N-[2-(5-ethyl-benzo[b]thien-3-yl)ethyl] acetamide (S22153) and likely flect blockade of 5-
HT2C receptors inhibitory to frontocortical dopaminergic and adrenergic pathways. Correspondingly, 
distinction to agomelatine, melatonin showed negligible activity 5-HT2C receptors and failed to 
modify the activity of adrenergic and dopaminergic pathways. In conclusion, in contrast to 
melatonin, agomelatine behaves as an antagonist at 5-HT2B and 5-HT2C receptors: blockade of the 
latter reinforces frontocortical adrenergic and dopaminergic transmission. 
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Comparison of hippocampal G protein activation by 5-HT1A  receptor 
agonists and the atypical antipsychotics clozapine and S16924.  
Newman-Tancredi A, Rivet JM, Cussac D, Touzard M, Chaput C, Marini L, Millan MJ. 
Dept. of Psychopharmacology, Institut de Recherches Servier, Croissy-sur-Seine, France. 
This study employed [
35
S]guanosine 5'- O-(3-thiotriphosphate) ([
35
S]GTPgammaS) binding to compare 
the actions of antipsychotic agents known to stimulate cloned, human 5-HT1A receptors with those of 
reference agonists at postsynaptic 5-HT(1A) receptors. In rat hippocampal membranes, the following 
order of efficacy was observed (maximum efficacy, Emax, values relative to 5-HT=100): (+)8-OH-
DPAT (85), flesinoxan (62), eltoprazine (60), S14506 (59), S16924 (48), buspirone (41), S15535 (22), 
clozapine (22), ziprasidone (21), pindolol (7), p-MPPI (0), WAY100635 (0), spiperone (0). Despite 
differences in species and tissue source, the efficacy and potency (pEC50) of agonists (with the 
exception of clozapine) correlated well with those determined previously at human 5-HT1A receptors 
expressed in Chinese hamster ovary (CHO) cells. In contrast, clozapine was more potent at 
hippocampal membranes. The selective antagonists p-MPPI and WAY100635 abolished stimulation 
of binding by (+)8-OH-DPAT, clozapine and S16924 (p-MPPI), indicating that these actions were 
mediated specifically by 5-HT1A receptors. Clozapine and S16924 also attenuated 5-HT- and (+)8-OH-
DPAT-stimulated [35S]GTPgammaS binding, consistent with partial agonist properties. In 
[
35
S]GTPgammaS autoradiographic studies, 5-HT-induced stimulation, mediated through 5-HT1A 
receptors, was more potent in the septum (pEC50 approximately 6.5) than in the dentate gyrus of the 
hippocampus (pEC50 approximately 5) suggesting potential differences in coupling efficiency or 
G-protein expression. Though clozapine (30 and 100 microM) did not enhance [35S]GTPgammaS 
labelling in any structure, S16924 (10 micro M) modestly increased [
35
S]GTPgammaS labelling in the 
dentate gyrus. On the other hand, both these antipsychotic agents attenuated 5-HT (10 microM)-
stimulated [35S]GTPgammaS binding in the dentate gyrus and septum. In conclusion, clozapine, 
S16924 and ziprasidone act as partial agonists for G protein activation at postsynaptic 5-HT1A 
receptors in the hippocampus. These data support a role of postsynaptic 5-HT1A receptors in the 
functional profiles of certain antipsychotic agents. 
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Br J Pharmacol. 2003 Mar;138(6):1077-84. 
h5-HT1B  receptor-mediated constitutive Galphai3-protein activation in 
stably transfected Chinese hamster ovary cells: an anti body capture 
assay reveals protean efficacy of 5-HT. 
Newman-Tancredi A, Cussac D, Marini L, Touzard M, Millan MJ. 
Department of Psychopharmacology, Institut de Recherches Servier, Croissy-sur-Seine, France. 
1. Serotonin 5-HT1B receptors couple to G-proteins of the Gi/o family. However, their activation of 
specific G-protein subtypes is poorly characterised. Using an innovative antibody capture/guanosine-
5'-0-(3-[
35
S]thio)-triphosphate ([
35
S]GTPgammaS) binding strategy, we characterised Galpha(i3) 
subunit activation by h5-HT1B receptors stably expressed in Chinese hamster ovary (CHO) cells.  
2. The agonists, 5-HT, alniditan and BMS181,101, stimulated Galpha(i3), whereas methiothepin and 
SB224,289 behaved as inverse agonists. The selective 5-HT1B receptor ligand, S18127, modestly 
stimulated Galpha(i3) and reversed the actions of both 5-HT and methiothepin. S18127 (1 micro M) 
also produced parallel, dextral shifts of the 5-HT and methiothepin isotherms.  
3. Isotopic dilution experiments ([
35
S]GTPgammaS versus GTPgammaS) revealed high-affinity 
[35S]GTPgammaS binding to Galpha(i3) subunits in the absence of receptor ligands indicating 
constitutive activity. High-affinity [35S]GTPgammaS binding was increased 2.8-fold by 5-HT with an 
increase in the affinity of GTPgammaS for Galpha(i3) subunits. In contrast, methiothepin halved the 
number of high-affinity binding sites and decreased their affinity.  
4. h5-HT1B receptor-mediated Galpha(i3) subunit activation was dependent on the concentration of 
NaCl. At 300 mM, 5-HT stimulated [
35
S]GTPgammaS binding, basal Galpha(i3) activation was low and 
methiothepin was inactive. In contrast, at 10 mM NaCl, basal activity was enhanced and the inverse 
agonist activity of methiothepin was accentuated. Under these conditions, 5-HT decreased 
Galpha(i3) activation.  
5. In conclusion, at h5-HT1B receptors expressed in CHO cells: (i) inverse agonist induced inhibition of 
Galpha(i3), and its reversal by S18127, reveals constitutive activation of this Galpha subunit; (ii) 
constitutive Galpha(i3) activation can be quantified by isotopic dilution [35S]GTPgammaS binding and 
(iii) decreasing NaCl concentrations enhances Galpha(i3) activation and leads to protean agonist 
properties of 5-HT: that is a switch to inhibition of Galpha(i3). 
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International Congress Series, 2003 August; 1249:101-117 
“Inverse agonism”. Proceedings of the Esteve Foundation Symposium X 
Differential ligand efficacy at h5-HT1A  receptor-coupled G-protein 
subtypes: a commentary  
Newman-Tancredi A  
Institut de Recherche Pierre Fabre, Neurobiology 2 Division, Castres, France 
Activation of heterotrimeric G-protein involves the exchange by α subunits of GDP for GTP. The 
binding of the hydrolysis-resistant GTP analogue, guanosine-5′-O-(3-[
35
S]thio)-triphosphate 
([35S]GTPγS), provides a measure of agonist, antagonist and inverse agonist actions at G-protein-
coupled receptors. However, classical [
35
S]GTPγS binding methods do not distinguish among the 
subtypes of G-proteins activated. This is a limitation in view of (i) promiscuity of receptor coupling to 
multiple families of G-proteins, and (ii) the differential influence of ligands on distinct signal 
transduction pathways. A recent development of [35S]GTPγS binding methodology employing 
antibody capture and scintillation proximity assays (SPA) permits the targeting of specific Gα 
subtypes in both recombinant and native tissues. When applied to human serotonin1A receptor 
(h5-HT1A) expressed in Chinese hamster ovary (CHO) cells, this methodology revealed surprising 
patterns of Gαi3 subunit activation. For example, low but not high concentrations of high-efficacy 
h5-HT1A agonists direct receptor signalling to Gαi3. In contrast, partial agonists favour h5-HT1A 
receptor signalling to Gαi3 over a wide concentration range. Further, alterations in buffer sodium 
concentration reversed these actions of agonists: stimulation of Gαi3 activation was observed at 
high sodium concentration, but inhibition was observed at low sodium concentration, suggestive of 
protean efficacy, i.e. a switch from positive to negative efficacy dependent on receptor tone. These 
results indicate that complex changes in both magnitude and direction of response to receptor 
ligands can occur for specific G-protein subtypes. Interestingly, the inverse agonist, spiperone, 
inhibited constitutive h5-HT1A receptor-mediated Gαi3 activation under all conditions tested, 
consistent with the hypothesis that it selectively stabilises distinct receptor conformation(s). Further, 
whereas classical [35S]GTPγS binding assays in CHO cell membranes failed to demonstrate negative 
efficacy for the neuroleptic, haloperidol, this compound exhibited robust inverse agonism for the 
activation of Gαi3 subunits. These data suggest that haloperidol may selectively inhibit constitutive 
activation of this G-protein subtype and, thus, exhibit inverse agonist-mediated trafficking of 
receptor signalling. 
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Psychopharmacology (Berl). 2005 Feb;177(4):373-80. Epub 2004 Sep 24. 
Anticataleptic properties of alpha2 adrenergic antagonists in the 
crossed leg position and bar tests: differential mediation by 5-HT1A  
receptor activation. 
Kleven MS, Assié MB, Cosi C, Barret-Grévoz C, Newman-Tancredi A. 
Neurobiology II, Centre de Recherche Pierre Fabre, 17 Avenue Jean Moulin, F-81106 Castres, France. 
RATIONALE: Recent studies suggest that alpha2 adrenoceptor blockade may improve the 
antipsychotic-like effects of neuroleptics and attenuate dopamine D2 receptor antagonist-induced 
catalepsy. However, several alpha2 adrenergic antagonists also display serotonin 5-HT1A receptor 
agonist activity, which may contribute to anticataleptic actions. 
OBJECTIVES: In this study, we examined a series of alpha2 adrenergic antagonists to determine the 
role of activity at serotonin 5-HT1A receptors in their anticataleptic effects. 
METHODS: Catalepsy in rats induced by the antipsychotic haloperidol (2.5 mg/kg, SC) was measured 
using the cross-legged position (CLP) and bar tests. The compounds examined in this study, in 
decreasing rank order of alpha2 adrenergic versus 5-HT1A receptor selectivity, were atipamezole, 
methoxy-idazoxan (RX821002), efaroxan, idazoxan, and yohimbine. Antagonism studies were 
conducted using the selective 5-HT1A receptor antagonist N-[2-[4-(2-methoxyphenyl)-1-
piperazinyl]ethyl]-N-(2-pyridinyl) cyclohexanecarboxamide dihydrochloride (WAY100635). 
RESULTS: Idazoxan, efaroxan, and yohimbine significantly attenuated the cataleptic effects of 
haloperidol (2.5 mg/kg, SC) in the CLP test and the actions of their highest doses were significantly 
blocked by pre-treatment with WAY100635 (0.63 mg/kg, SC). In contrast to the other compounds, 
methoxy-idazoxan was ineffective in the CLP test. Atipamezole exhibited anticataleptic effects in the 
bar and CLP tests which were not blocked by WAY100635. Similarly, the anticataleptic effects of 
methoxy-idazoxan and idazoxan in the bar test were not blocked by WAY100635. 
CONCLUSIONS: Serotonin 5-HT1A receptors play a prominent role in anticataleptic effects of certain 
alpha2 adrenergic antagonists in the CLP test, whereas alpha2-adrenergic mechanisms are likely to 
be primarily responsible for the anticataleptic effects of these ligands in the bar test. 
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Int J Neuropsychopharmacol. 2005 Sep;8(3):341-56. Epub 2005 Feb 11. 
Novel antipsychotics activate recombinant human and native rat 
serotonin 5-HT1A  receptors: affinity, efficacy and potential implications 
for treatment of schizophrenia.  
Newman-Tancredi A, Assié MB, Leduc N, Ormière AM, Danty N, Cosi C. 
Division of Neurobiology 2, Centre de Recherche Pierre Fabre, Castres, France.  
Serotonin 5-HT1A receptors are promising targets in the management of schizophrenia but little 
information exists about affinity and efficacy of novel antipsychotics at these sites. We addressed 
this issue by comparing binding affinity at 5-HT1A receptors with dopamine rD2 receptors, which are 
important targets for antipsychotic drug action. Agonist efficacy at 5-HT1A receptors was determined 
for G-protein activation and adenylyl cyclase activity. Whereas haloperidol, thioridazine, risperidone 
and olanzapine did not interact with 5-HT1A receptors, other antipsychotic agents exhibited agonist 
properties at these sites. Emax values (% effect induced by 10 microM of 5-HT) for G-protein 
activation at rat brain 5-HT1A receptors: sarizotan (66.5), bifeprunox (35.9), SSR181507 (25.8), 
nemonapride (25.7), ziprasidone (20.6), SLV313 (19), aripiprazole (15), tiospirone (8.9). These data 
were highly correlated with results obtained at recombinant human 5-HT1A receptors in 
determinations of G-protein activation and inhibition of forskolin-stimulated adenylyl cyclase. In 
binding-affinity determinations, the antipsychotics exhibited diverse properties at r5-HT1A receptors: 
sarizotan (pKi=8.65), SLV313 (8.64), SSR181507 (8.53), nemonapride (8.35), ziprasidone (8.30), 
tiospirone (8.22), aripiprazole (7.42), bifeprunox (7.19) and clozapine (6.31). The affinity ratios of the 
ligands at 5-HT1A vs. D2 receptors also varied widely: ziprasidone, SSR181507 and SLV313 had similar 
affinities whereas aripiprazole, nemonapride and bifeprunox were more potent at D2 than 5-HT1A 
receptors. Taken together, these data indicate that aripiprazole has low efficacy and modest affinity 
at 5-HT1A receptors, whereas bifeprunox has low affinity but high efficacy. In contrast, SSR181507 
has intermediate efficacy but high affinity, and is likely to have more prominent 5-HT1A receptor 
agonist properties. Thus, the contribution of 5-HT1A receptor activation to the pharmacological 
profile of action of the antipsychotics will depend on the relative 5-HT1A/D2 affinities and on 5-HT1A 
agonist efficacy of the drugs. 
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J Pharmacol Exp Ther. 2005 Mar;312(3):1034-42. Epub 2004 Nov 4. 
Dual, hyperalgesic, and analgesic effects of the high -efficacy 5-
hydroxytryptamine 1A (5-HT1A) agonist F13640 [(3-chloro-4-fluoro-
phenyl)-[4-fluoro-4-{[(5-methyl-pyridin-2-ylmethyl)-amino]-
methyl}piperidin-1-yl]methanone, fumaric acid salt]: relationship with 
5-HT1A  receptor occupancy and kinetic parameters.  
Bardin L, Assié MB, Pélissou M, Royer-Urios I, Newman-Tancredi A, Ribet JP, Sautel F, Koek W, 
Colpaert FC. 
Department of General Pharmacology, Centre de Recherche Pierre Fabre, Castres, France. 
The aim of the present study was to establish the relationship between the plasma and brain 
concentration-time profiles of F13640 [(3-chloro-4-fluoro-phenyl)-[4-fluoro-4-{[(5-methyl-pyridin-2-
ylmethyl)-amino]-methyl}piperidin-1-yl]methanone, fumaric acid salt] after acute administration and 
both its hyper- and hypoanalgesic effects in rats. The maximal plasma concentration (C(max)) of 
F13640 after i.p. administration of 0.63 mg/kg was obtained at 15 min and decreased to half its 
maximal value after about 1 h. The amount of F 13640 collected by means of in vivo microdialysis in 
hippocampal dialysates could be measured reliably after 0.63 and 2.5 mg/kg, reached its maximum 
at about 1 h, and fell to half of its maximal value at about 3 h. 5-Hydroxytryptamine 1A (5-HT1A) 
receptor occupancy was estimated by ex vivo binding in rat brain sections. F13640 inhibited 
[3H]8-hydroxy-2-[di-n-propylamino] tetralin binding ex vivo in rat hippocampus, entorhinal cortex, 
and frontal cortex (ED50, 0.34 mg/kg i.p.). Maximal inhibition was reached at approximately 30 min 
after 0.63 mg/kg F 13640 and fell to half of its value after about 4 to 8 h. After injection (15 min) in 
the paw pressure test, F 13640 (0.63 mg/kg i.p.) induced an initial hyperalgesia that was followed 4 h 
later by a paradoxical analgesia that lasted until 8 h. In contrast, in the formalin test, F 13640 
inhibited pain behaviors until 4 h after drug administration. F 13640 also produced elements of the 
5-HT syndrome that lasted up to 4 h after administration. These results demonstrate that F 13640 
induces hyperalgesia and/or analgesia with a time course that parallels the occupancy of 5-HT1A 
receptors and the presence of the compound in blood and brain. 
D.Sc. Thesis  Publication Abstracts 
 
Part B: Page 143 of 206 
Reference no. 58 
Brain Res. 2005 May 10;1043(1-2):32-41. 
Clozapine, ziprasidone and aripiprazole but not haloperidol protect 
against kainic acid-induced lesion of the striatum in mice, in vivo: role of 
5-HT1A  receptor activation. 
Cosi C, Waget A, Rollet K, Tesori V, Newman-Tancredi A. 
Division de Neurobiologie II, Centre de Recherche Pierre Fabre, Castres, France.  
Excessive activation of non-NMDA receptors, AMPA and kainate, contributes to neuronal 
degeneration in acute and progressive pathologies, possibly including schizophrenia. Because 5-HT1A 
receptor agonists have neuroprotective properties (e.g., against NMDA-induced neurotoxicity), we 
compared the effects of the antipsychotics, clozapine, ziprasidone and aripiprazole, that are partial 
agonists at 5-HT1A receptor, with those of haloperidol, which is devoid of 5-HT1A agonist properties, 
on kainic acid (KA)-induced striatal lesion volumes, in C57Bl/6N mice. The involvement of 5-HT1A 
receptors was determined by antagonist studies with WAY100635, and data were compared with 
those obtained using the potent and high efficacy 5-HT1A receptor agonist, F13714. Intra-striatal KA 
lesioning and measurement of lesion volumes using cresyl violet staining were carried out at 48 h 
after surgery. F13714, antipsychotics or vehicle were administered ip twice, 30 min before and 3 ½  h 
after KA injection. WAY100635 (0.63 mg/kg) or vehicle were given sc 30 min before each drug 
injection. Clozapine (2 x 10 mg/kg), ziprasidone (2 x 20 mg/kg) and aripiprazole (2 x 10 mg/kg) 
decreased lesion volume by 61%, 59% and 73%, respectively. WAY100635 antagonized the effect of 
ziprasidone and of aripiprazole but only slightly attenuated that of clozapine. In contrast, haloperidol 
(2 x 0.16 mg/kg) did not affect KA-induced lesion volume. F13714 dose-dependently decreased 
lesion volume. The 61% decrease of lesion volume obtained with F13714 (2 x 0.63 mg/kg) was 
antagonized by WAY100635. WAY100635 alone did not affect lesion volume. These results show 
that 5-HT1A receptor activation protects against KA-induced striatal lesions and indicate that some 
atypical antipsychotic agents with 5-HT1A agonist properties may protect against excitotoxic injury, in 
vivo. 
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Neuropharmacology. 2005 Aug;49(2):135-43. Epub 2005 Apr 1. 
Novel antipsychotic agents with 5-HT1A  agonist properties: role of 5-HT1A  
receptor activation in attenuation of catalepsy induction in rats.  
Kleven MS, Barret-Grévoz C, Bruins Slot L, Newman-Tancredi A. 
Pierre Fabre Research Centre, Neurobiology 2 Division, Castres, France. 
Compounds possessing 5-HT1A agonist properties attenuate catalepsy induced by D2 receptor 
blockade. Here we examined the role of 5-HT1A receptor agonism in the reduced cataleptogenic 
potential of several novel antipsychotic agents in the crossed leg position (CLP) and the bar catalepsy 
tests in rats. When administered alone, ziprasidone produced marked catalepsy, whereas 
aripiprazole, bifeprunox, SLV313, SSR181507 and sarizotan did not. However, when 5-HT1A receptors 
were blocked with the selective antagonist, WAY100635 (0.63 mg/kg, SC), robust cataleptogenic 
properties of SLV313, bifeprunox and sarizotan were unmasked and the catalepsy induced by 
ziprasidone was accentuated. In contrast, only modest catalepsy was induced by aripiprazole and 
SSR181507, even following a higher dose of WAY100635 (2.5 mg/kg). This suggests that these 
compounds possess other anti-cataleptic properties, such as partial agonism at dopamine D2 
receptors. The capacity to reverse neuroleptic-induced catalepsy was investigated in interaction 
studies with haloperidol (2.5 mg/kg, SC). Whereas ziprasidone and aripiprazole did not markedly 
reduce the effects of haloperidol, SLV313 and sarizotan attenuated CLP catalepsy. In contrast, 
SSR181507 and bifeprunox potently inhibited both CLP and bar catalepsy. Taken together, these 
data show that 5-HT1A receptor activation reduces the cataleptogenic potential of novel 
antipsychotic agents but indicate marked diversity in the contribution of 5-HT1A and/or other 
mechanisms to the profiles of the drugs. 
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J Pharmacol Exp Ther. 2005 Oct;315(1):265-72. Epub 2005 Jun 29. 
Contrasting contribution of 5-hydroxytryptamine 1A receptor activation 
to neurochemical profile of novel antipsychotics: frontocortical 
dopamine and hippocampal serotonin release in rat brain.  
Assié MB, Ravailhe V, Faucillon V, Newman-Tancredi A. 
Centre de Recherche Pierre Fabre, Castres, France.  
Several novel antipsychotics, such as aripiprazole, bifeprunox, SSR181507 [(3-exo)-8-benzoyl-N-
(((2S)7-chloro-2,3-dihydro-1,4-benzodioxin-1-yl)methyl)-8-azabicyclo(3.2.1)octane-3-methanamine], 
and SLV313 [1-(2,3-dihydro-benzo[1,4]dioxin-5-yl)-4-[5-(4-fluorophenyl)-pyridin-3-ylmethyl]-
piperazine], activate serotonin 5-hydroxytryptamine (5-HT)1A receptors. Such activity is associated 
with enhanced treatment of negative symptoms and cognitive deficits, which may be mediated by 
modulation of cerebral dopamine and serotonin levels. We employed microdialysis coupled to high 
pressure liquid chromatography with electrochemical detection to examine 5-HT1A receptor 
activation in the modulation of extracellular dopamine in medial prefrontal cortex and serotonin in 
hippocampus of freely moving rats. The above compounds were compared with drugs that have less 
interaction with 5-HT1A receptors (clozapine, nemonapride, ziprasidone, olanzapine, risperidone, and 
haloperidol). Hippocampal 5-HT was decreased by bifeprunox, SSR181507, SLV313, sarizotan, and 
nemonapride, effects similar to those seen with the 5-HT1A agonist, (+)-8-hydroxy-2-(di-n-
propylamino)tetralin [(+)8-OH-DPAT], consistent with activation of 5-HT1A autoreceptors. These 
decreases were reversed by the selective 5-HT1A antagonist, WAY100635 [N-[2-[4-(2-
methoxyphenyl)-1-piperazinyl]ethyl]-N-(2-pyridinyl)cyclohexanecarboxamide]. In contrast, 
haloperidol, risperidone, clozapine, olanzapine, ziprasidone, and aripiprazole did not significantly 
modify hippocampal serotonin levels. In medial prefrontal cortex, dopamine levels were increased 
by SSR181507, SLV313, sarizotan, and (+)8-OH-DPAT. These effects were reversed by WAY100635, 
indicating mediation by 5-HT1A receptors. In contrast, the increases in dopamine levels induced by 
clozapine, risperidone, olanzapine, and ziprasidone were not blocked by WAY100635, consistent 
with predominant influence of other mechanisms in the actions of these drugs. Haloperidol, 
nemonapride, and the D2 partial agonists, aripiprazole and bifeprunox, did not significantly alter 
dopamine release. Taken together, these data demonstrate the diverse contribution of 5-HT1A 
receptor activation to the profile of antipsychotics and suggest that novel drugs selectively targeting 
D2 and 5-HT1A receptors may present distinctive therapeutic properties. 
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Neuropharmacology. 2005 Dec;49(7):963-76. Epub 2005 Jun 17. 
Differential ion current activation by human 5-HT1A  receptors in 
Xenopus oocytes: evidence for agonist-directed trafficking of receptor 
signalling. 
Heusler P, Pauwels PJ, Wurch T, Newman-Tancredi A, Tytgat J, Colpaert FC, Cussac D. 
Centre de Recherche Pierre Fabre, 17, Avenue Jean Moulin, F-81106 Castres Cedex, France.  
The subject of the present study was the functional and pharmacological characterization of human 
5-HT1A receptor regulation of ion channels in Xenopus oocytes. Activation of the heterologously 
expressed human 5-HT1A receptor induced two distinct currents in Xenopus oocytes, consisting of a 
smooth inward current (Ismooth) and an oscillatory calcium-activated chloride current, I(ClCa). 5-HT1A 
receptor coupling to both ionic responses as well as to co-expressed inward rectifier potassium 
(GIRK) channels was pharmacologically characterized using 5-HT1A receptor agonists. The relative 
order of efficacy for activation of GIRK current was 5-HT ~ F 13714 ~ L694,247 ~ LY228,729 > 
flesinoxan ~ (+/-)8-OH-DPAT. In contrast, flesinoxan and (+/-)8-OH-DPAT typically failed to activate 
I(ClCa). The other ligands behaved as full or partial agonists, exhibiting an efficacy rank order of 5-HT 
~ L694,247 > F 13714 ~ LY228,729. The pharmacological profile of Ismooth activation was completely 
distinct: flesinoxan and F 13714 were inactive and rather exhibited an inhibition of this current. 
I(smooth) was activated by the other agonists with an efficacy order of L 694,247 > 5-HT ~ LY 
228,729 > (+/-)8-OH-DPAT. Moreover, activation of I(smooth) was not affected by application of 
pertussis toxin or the non-hydrolyzable GDP-analogue, guanosine-5'-O-(2-thio)-diphosphate 
(GDPbetaS), suggesting a GTP binding protein-independent pathway. Together, these results suggest 
the existence of distinct and agonist-specific signalling states of this receptor. 
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Neuropharmacology. 2005 Dec;49(7):996-1006. Epub 2005 Jul 11. 
Effects of novel antipsychotics with mixed D2 antagonist/5-HT1A  agonist 
properties on PCP-induced social interaction deficits in the rat.  
Bruins Slot LA, Kleven MS, Newman-Tancredi A. 
Department of Cellular and Molecular Biology, Centre de Recherche Pierre Fabre, Castres, France.  
Considerable interest has arisen in identifying antipsychotic agents with improved efficacy against 
negative symptoms, such as social withdrawal. In rats, a social interaction deficit can be induced by 
the NMDA antagonist phencyclidine (PCP). Here, we examined the effects of antipsychotics, 
reported to exert dual 5-HT1A/D2 actions, on PCP-induced social interaction deficits. Drugs were 
administered daily for 3 days in combination with either vehicle or PCP (2.5mg/kg, SC) and social 
interaction was measured on the last day of drug treatment. Pairs of unfamiliar rats receiving the 
same treatment were placed in a large open field for 10 min and the number of social behaviors 
were scored. The results indicate that: (1) PCP significantly reduced social interaction by over 50% 
compared with vehicle-treated controls; (2) haloperidol (0.0025-0.16 mg/kg, SC) and clozapine (0.04-
10mg/kg, IP) did not reverse PCP-induced social interaction deficits; (3) the substituted benzamide 
remoxipride reversed PCP-induced deficits at 0.63 and 2.5mg/kg (4) the 5-HT1A agonist 8-OH-DPAT 
was inactive (at 0.01-0.63 mg/kg, SC); (5) among compounds reported to exert dual 5-HT1A/D2 
actions, SSR181507 (at 0.16 mg/kg, SC) and aripiprazole (at 0.04 and 0.16 mg/kg, IP), but not 
ziprasidone (0.04-2.5mg/kg, IP), SLV313 (0.0025-0.16 mg/kg, SC) or bifeprunox (0.01-0.63 mg/kg, IP), 
significantly reversed PCP-induced social interaction deficits; and (6) the 5-HT1A receptor antagonist 
WAY100635 blocked the effects of SSR181507 and aripiprazole. These findings indicate that the 
balance of activity at 5-HT1A and D2 receptors profoundly influences the activity of antipsychotics in 
this model of social withdrawal, and their potential benefit on at least some of the negative 
symptoms of schizophrenia. 
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Eur J Pharmacol. 2006 Mar 18;534(1-3):63-70. Epub 2006 Feb 21. 
Differential profile of antipsychotics at serotonin 5-HT1A  and dopamine 
D2S receptors coupled to extracellular signal-regulated kinase. 
Bruins Slot LA, De Vries L, Newman-Tancredi A, Cussac D. 
Department of Cellular and Molecular Biology, Centre de Recherche Pierre Fabre, Castres, France.  
The effects of antipsychotics targeting dopamine D2 and serotonin 5-HT1A receptors were compared 
with conventional antipsychotics on phosphorylation of Extracellular signal-Regulated Kinase 1/2 
(ERK 1/2) in CHO cell lines stably expressing either the human serotonin 5-HT1A or human dopamine 
D2S receptor. All antipsychotics except haloperidol and olanzapine exhibited agonist properties at 
serotonin 5-HT1A receptors. Emax values (% effect of 10 microM 5-HT) were: bifeprunox (74), 
SSR181507 (73), SLV313 (72), aripiprazole (60), ziprasidone (56), clozapine (33). At dopamine D2S 
receptors, partial agonist activity (% effect of 10 microM dopamine) was observed for bifeprunox 
(76), SSR181507 (66) and aripiprazole (59). Other antipsychotics attenuated dopamine-induced ERK 
phosphorylation, with pKB values of : SLV313 (8.5), haloperidol (8.1), olanzapine (7.8), ziprasidone 
(7.7), and clozapine (6.4). Amongst the dopamine D2/serotonin 5-HT1A receptor compounds, 
aripiprazole acts as a partial dopamine D2S and serotonin 5-HT1A receptor agonist. SSR181507 and 
bifeprunox possess a profile of action similar to each other, efficaciously stimulating both serotonin 
5-HT1A and dopamine D2S receptors. In contrast, SLV313, also an efficacious serotonin 5-HT1A receptor 
agonist, acted as a high potency dopamine D2 receptor antagonist. Thus, antipsychotics display 
varying efficacies at serotonin 5-HT1A and dopamine D2S receptors which may play a major role in 
their differential functional profiles in blocking the diverse symptoms of schizophrenia. 
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Eur J Pharmacol. 2006 Mar 27;535(1-3):135-44. Epub 2006 Mar 22. 
Partial agonist properties of the antipsychotics SSR181507, aripiprazole 
and bifeprunox at dopamine D2 receptors: G protein activation and 
prolactin release. 
Cosi C, Carilla-Durand E, Assié MB, Ormiere AM, Maraval M, Leduc N, Newman-Tancredi A. 
Division de Neurobiologie I, Centre de Recherche Pierre Fabre, Castres, France. 
Dopamine D2 receptor antagonists induce hyperprolactinemia depending on the extent of D2 
receptor blockade. We compared the effects of the new antipsychotic agents SSR181507 ((3-exo)-8-
benzoyl-N-[[(2s)7-chloro-2,3-dihydro-1,4-benzodioxin-1-yl]methyl]-8-azabicyclo[3.2.1]octane-3-
methanamine monohydrochloride), bifeprunox (DU127090: 1-(2-Oxo-benzoxazolin-7-yl)-4-(3-
biphenyl)methylpiperazinemesylate) and SLV313 (1-(2,3-dihydro-benzo[1,4]dioxin-5-yl)-4-[5-(4-
fluorophenyl)-pyridin-3-ylmethyl]-piperazine) with those of aripiprazole (7-{4-[4-(2,3-
dichlorophenyl)-1-piperazinyl]-butyloxy)-3,4-dihydro-2(1 H)-quinolinone), clozapine and haloperidol, 
on functional measures of dopamine D2 receptor activity in vitro and in vivo: [
35S]-GTPgammaS 
binding to membranes from Sf9 insect cells expressing human dopamine D2 Long (hD2L) receptors, 
and serum prolactin levels in the rat. All compounds antagonized apomorphine-induced G protein 
activation at dopamine hD2L receptors. Antagonist potencies of aripiprazole, bifeprunox and SLV313 
were similar to haloperidol (pKB = 9.12), whereas SSR181507 (8.16) and clozapine (7.35) were less 
potent. Haloperidol, SLV313 and clozapine were silent antagonists but SSR181507, bifeprunox and 
aripiprazole stimulated [35S]-GTPgammaS binding by 17.5%, 26.3% and 25.6%, respectively, relative 
to 100 microM apomorphine (Emax = 100%). pEC50s were: SSR181507, 8.08; bifeprunox, 8.97; 
aripiprazole, 8.56. These effects were antagonized by raclopride. Following oral administration in 
vivo, the drugs increased prolactin release to different extents. SLV313 and haloperidol potently 
(ED50 0.12 and 0.22 mg/kg p.o., respectively) stimulated prolactin release up to 86 and 83 ng/ml. 
Aripiprazole potently (ED50 0.66 mg/kg p.o.) but partially (32 ng/ml) induced prolactin release. 
SSR181507 (ED50 4.9 mg/kg p.o.) also partially (23 ng/ml) enhanced prolactin release. Bifeprunox 
only weakly increased prolactin at high doses (13 ng/ml at 40 mg/kg) and clozapine only affected 
prolactin at the highest dose tested (41 ng/ml at 40 mg/kg). Prolactin levels of the corresponding 
vehicle-treated animals were <4.3 ng/ml. These data show that (1) SSR181507, aripiprazole and 
bifeprunox, but not SLV313, are partial agonists at dopamine hD2L receptors in vitro; (2) SSR181507, 
bifeprunox and aripiprazole exhibit reduced prolactin release in vivo compared with drugs that are 
neutral antagonists at dopamine D2 receptors. 
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Neuropsychopharmacology. 2006 Sep;31(9):1869-79. Epub 2005 Oct 19. 
Antipsychotic-like vs cataleptogenic actions in mice of novel 
antipsychotics having D2 antagonist and 5-HT1A  agonist properties. 
Bardin L, Kleven MS, Barret-Grévoz C, Depoortère R, Newman-Tancredi A. 
Division of Neurobiology 2, Centre de Recherche Pierre Fabre, Castres, France.  
A new generation of proven or potential antipsychotics, including aripiprazole, bifeprunox, 
SSR181507 and SLV313, exhibit agonist actions at serotonin 5-HT1A receptors, but little comparative 
data are available on their pharmacological profiles. Here, we compared in mice the in vivo 
antipsychotic-like vs cataleptogenic activities of these compounds with those of drugs that exhibit 
little interaction at 5-HT1A receptors, such as haloperidol, olanzapine and risperidone. All the drugs 
dose-dependently reduced apomorphine-induced climbing or sniffing and, with the exception of 
ziprasidone, produced complete suppression of these responses. In the bar catalepsy test, when 
administered alone, haloperidol, olanzapine and risperidone produced marked catalepsy, whereas, 
at doses up to 40 mg/kg, aripiprazole, SLV313, SSR181507, and sarizotan produced little or no 
catalepsy. The latter compounds, therefore, displayed a large separation between doses with 
'antipsychotic-like' and those with cataleptogenic actions. When 5-HT1A receptors were blocked by 
pretreatment with WAY100635 (2.5 mg/kg, s.c.), cataleptogenic properties of SSR181507 and 
sarizotan were unmasked, and the catalepsy induced by bifeprunox was enhanced. In the case of 
aripiprazole and SLV313, although WAY100635 produced upward shifts in their dose-response, the 
magnitude of catalepsy appeared to reach an asymptotic plateau, suggesting that other mechanisms 
may be involved in their low cataleptogenic liability. The present data confirm that 5-HT1A receptor 
activation reduces or even completely prevents the cataleptogenic potential of novel antipsychotic 
agents. Further, they indicate that the balance of affinity and/or efficacy between D2 and 5-HT1A 
receptors profoundly influences their pharmacological activities, and will likely impact their 
therapeutic profiles. 
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Neuropsychopharmacology. 2006 Sep;31(9):1900-9. Epub 2006 Jan 18. 
Actions of novel antipsychotic agents on apomorphine -induced PPI 
disruption: influence of combined serotonin 5-HT1A  receptor activation 
and dopamine D2 receptor blockade. 
Auclair AL, Kleven MS, Besnard J, Depoortère R, Newman-Tancredi A. 
Division of Neurobiology 2, Centre de Recherche Pierre Fabre, Castres, France.  
The dopamine D1/D2 agonist apomorphine (0.63 mg/kg) disrupted prepulse inhibition (PPI) of 
acoustic startle in rats, a model of sensorimotor gating deficits observed in schizophrenia. All current 
antipsychotics, which antagonize D2 receptors, prevent this apomorphine-induced deficit. A novel 
class of antipsychotics possesses, in addition to D2 antagonist property, various levels of 5-HT1A 
agonist activity. Considering that the latter itself produces PPI deficits, it appeared necessary to 
assess the potential of this novel class of antipsychotics to reverse apomorphine-PPI deficits. Potent 
D2 antagonists, like haloperidol (0.63-2.5 mg/kg), risperidone (0.63-10 mg/kg), and olanzapine (0.63-
40 mg/kg) prevented apomorphine PPI disruption. The atypical antipsychotics, clozapine (40 mg/kg), 
nemonapride (0.01-2.5 mg/kg), ziprasidone (10 mg/kg), and aripiprazole (0.01 and 10 mg/kg), which 
all exhibit 5-HT1A agonist properties, reversed PPI deficits at some doses only, whereas the anti-
dyskinetic agent sarizotan (0.16-10 mg/kg), an efficacious 5-HT1A agonist, did not. New generation 
antipsychotics with marked 5-HT1A agonist properties, such as SLV313 and SSR181507 (0.0025-10 
mg/kg and 0.16-10 mg/kg, respectively) did not reverse these deficits whereas bifeprunox (0.04-2.5 
mg/kg) did. To reveal the contribution of 5-HT1A agonist properties in the lack of effects of SLV313 
and SSR181507, we pretreated rats with the 5-HT1A antagonist WAY100635 (0.63 mg/kg). Under 
these conditions, significant reversal of PPI deficit was observed, indicating that D2 antagonist 
properties of SLV313 and SSR181507 are now sufficient to overcome the disruptive effects of 
apomorphine. To summarize, antipsychotics possessing agonist efficacy at 5-HT1A receptors exhibit 
diverse profiles against apomorphine-induced PPI deficits, depending on the balance between D2 
and 5-HT1A activities, suggesting that they may display distinct activity on some aspects of gating 
deficits in schizophrenic patients. 
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Br J Pharmacol. 2006 Sep;149(2):170-8. Epub 2006 Aug 14. 
Rapid desensitization of somatodendritic  5-HT1A  receptors by chronic 
administration of the high-efficacy 5-HT1A  agonist, F13714: a 
microdialysis study in the rat.  
Assié MB, Lomenech H, Ravailhe V, Faucillon V, Newman-Tancredi A. 
Centre de Recherche Pierre Fabre, Castres Cedex, France.  
BACKGROUND AND PURPOSE: Desensitization of somatodendritic 5-HT1A receptors is involved in the 
mechanism of action of several antidepressants, but the rapidity of this effect and the amount of 
agonist stimulation needed are unclear. We evaluated the capacity of the high-efficacy 5-HT1A 
agonist, F13714 (3-chloro-4-fluorophenyl-(4-fluoro-4-{[(5-methyl-6-methylamino-pyridin-2-
ylmethyl)-amino]-methyl}-piperidin-1-yl-methanone) and of the partial agonist, flesinoxan, to 
desensitize somatodendritic 5-HT1A receptors involved in the control of 5-HT release. 
EXPERIMENTAL APPROACH: Intracerebral microdialysis in the hippocampus of freely moving rats was 
used to examine the acute and chronic effects of the two compounds (administered by osmotic 
pumps for 3, 7 or 14 days) on extracellular 5-HT levels, measured by HPLC with electrochemical 
detection. 
KEY RESULTS: When given acutely, F13714, flesinoxan and the low-efficacy 5-HT1A agonist, buspirone, 
dose-dependently decreased extracellular 5-HT concentrations (ED50 values: 0.04, 0.77 and 5.6 
mg/kg, respectively). The selective 5-HT1A antagonist WAY100635 inhibited the effects of the three 
compounds. F13714 (2.5 mg/kg per day for 3, 7 or 14 days and 0.63 mg/kg for 7 days) significantly 
attenuated the inhibition of 5-HT release induced by buspirone (10 mg/kg). In contrast, flesinoxan 
(10 mg/kg per day) failed to alter the response to buspirone at any of the treatment durations. 
CONCLUSIONS AND IMPLICATIONS: Rat somatodendritic 5-HT1A receptors controlling hippocampal 
5-HT release were rapidly desensitized by chronic activation with a high-efficacy 5-HT1A agonist, but 
not by chronic activation with a partial agonist. Thus, rapid 5-HT1A autoreceptor desensitization by 
high-efficacy agonists may accelerate the onset of the therapeutic effects of antidepressants. 
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Naunyn Schmiedebergs Arch Pharmacol. 2006 Sep;373(6):441-50. Epub 2006 Sep 1. 
In vivo occupancy of dopamine D2 receptors by antipsychotic drugs and 
novel compounds in the mouse striatum and olfactory tubercles.  
Assié MB, Dominguez H, Consul-Denjean N, Newman-Tancredi A. 
Neurobiology II, Centre de Recherche Pierre Fabre, Castres, France.  
Interaction with dopamine D2-like receptors plays a major role in the therapeutic effects of 
antipsychotic drugs. We examined in vivo dopamine D2 receptor occupancy of various established 
and potential antipsychotics in mouse striatum and olfactory tubercles 1 h after administration of 
the compound, using [3H]nemonapride as a ligand. All the compounds reduced in vivo binding of 
[
3
H]nemonapride in the striatum. When administered systemically, conventional antipsychotics, D2 
antagonists, nemonapride (ID50: 0.034 mg/kg), eticlopride (0.047), haloperidol (0.11) and raclopride 
(0.11) potently inhibited [
3
H]nemonapride binding. The 'atypical' antipsychotics, risperidone (0.18), 
ziprasidone (0.38), aripiprazole (1.6), olanzapine (0.99), and clozapine (11.1) were less potent for 
occupying D2-like receptors. New compounds, displaying marked agonism at 5-HT1A receptors in 
addition to D2 receptor affinity, exhibited varying D2 receptor occupancy: bifeprunox (0.25), SLV313 
(0.78), SSR181507 (1.6) and sarizotan (6.7). ID50 values for inhibition of [
3H]nemonapride binding in 
the striatum correlated with those in the olfactory tubercles (r=0.95, P<0.0001). These values also 
correlated with previously-reported in vitro affinity of the compounds at rat D2 receptors (r=0.85, 
P=0.0001) and with inhibition of apomorphine-induced climbing in mice (r=0.79 P=0.0005). In 
contrast, there was no significant correlation between ID50 values herein and previously-reported 
ED50 values for catalepsy in mice. These data indicate that: (1) there is no difference in D2 receptor 
occupancy in limbic versus striatal regions between most classical and atypical or potential 
antipsychotics; and (2) high occupancy of D2 receptors can be dissociated from catalepsy, if the drugs 
also activate 5-HT1A receptors. Taken together, these data support the strategy of simultaneously 
targeting D2 receptor blockade and 5-HT1A receptor activation for new antipsychotics. 
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Mol Pharmacol. 2007 Mar;71(3):638-43. Epub 2006 Dec 13. 
Native rat hippocampal 5-HT1A  receptors show constitutive activity.  
Martel JC, Ormière AM, Leduc N, Assié MB, Cussac D, Newman-Tancredi A. 
Department of Neurobiology 2, Institut de Recherche Pierre Fabre, France.  
Previous studies have shown that human 5-hydroxytryptamine (5-HT)1A receptors stably expressed in 
transfected cell lines show constitutive G-protein activity, as revealed by the inhibitory effect of 
inverse agonists, such as spiperone, on basal guanosine-5'-O-(3-[
35
S]thio)-triphosphate 
([35S]GTPgammaS) binding. In the present study, we evaluated the constitutive activity of native rat 
5-HT1A receptors in hippocampal membranes. Using anti-Galphao-antibody capture coupled to 
scintillation proximity assay under low sodium (30 mM) conditions, we observed high basal 
[35S]GTPgammaS binding to Galphao subunits (defined as 100%). Under these conditions, 5-HT and 
the prototypic selective 5-HT1A agonist (+)8-hydroxy-2-(di-n-propylamino)tetralin [(+)-8-OH-DPAT] 
both stimulated [
35
S]GTPgammaS binding to Galphao to a similar extent, raising binding to 
approximately 130% of basal with pEC50 values of 7.91 and 7.87, respectively. The 5-HT1A-selective 
neutral antagonist [O-methyl-3H]-N-(2-(4-(2-methoxyphenyl)-1-piperazinyl)ethyl)-N-(2-
pyridinyl)cyclohexanecarboxamide trihydrochloride (WAY100635) could block these effects in a 
competitive manner with pKb values (5-HT, 9.57; (+)-8-OH-DPAT, 9.52) that are consistent with its 
pKi value at r5-HT1A receptors (9.33). In this native receptor system, spiperone and methiothepin 
reduced basal [35S]GTPgammaS binding to Galphao in a concentration-dependent manner to 90% of 
basal with pIC50 values of 7.37 and 7.98, respectively. The inhibition of basal [
35S]GTPgammaS binding 
induced by maximally effective concentrations of spiperone (10 microM) or methiothepin (1 
microM) was antagonized by WAY100635 in a concentration-dependent manner (pKB, 9.52 and 8.87, 
respectively), thus indicating that this inverse agonism was mediated by 5-HT1A receptors. These data 
provide the first demonstration that native rat serotonin 5-HT1A receptors can exhibit constitutive 
activity in vitro. 
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Neuropharmacology. 2007 Mar;52(4):1106-13. Epub 2007 Jan 19. 
Differential agonist and inverse agonist profile of antipsychotics at  D2L 
receptors coupled to GIRK potassium channels.  
Heusler P, Newman-Tancredi A, Castro-Fernandez A, Cussac D. 
Cellular and Molecular Biology Department, Pierre Fabre Research Center, Castres, France.  
The D2 dopaminergic receptor represents a major target of antipsychotic drugs. Using the coupling of 
the human D2long (hD2L) receptor to G protein-coupled inward rectifier potassium (GIRK) channels in 
Xenopus laevis oocytes, we examined the activity of antipsychotic agents of different classes - 
typical, atypical, and a "new generation" of compounds, exhibiting a preferential D2 and 5-HT1A 
receptor profile. When the hD2L receptor was coexpressed with GIRK channels, a series of reference 
compounds exhibited full agonist (dopamine, and quinpirole), partial agonist (apomorphine, (-)3-
PPP, and (+)-UH232) or inverse agonist (raclopride, and L741626) properties. Sarizotan exhibited 
only very weak partial agonist action. At higher levels of receptor cRNA injected per oocyte, both 
partial agonist activity and inverse agonist properties were generally more pronounced. The inverse 
agonist action of L741626 was reversed by interaction with sarizotan, thus confirming the 
constitutive activity of wild-type hD2L receptors in the oocyte expression system. When antipsychotic 
agents were tested for their actions at the hD2L receptor, typical (haloperidol) as well as atypical 
(nemonapride, ziprasidone, and clozapine) compounds acted as inverse agonists. In contrast, among 
D2/5-HT1A antipsychotics, only SLV313 and F15063 behaved as inverse agonists, whilst the other 
members of this group (bifeprunox, SSR181507 and the recently marketed antipsychotic, 
aripiprazole) exhibited partial agonist properties. Thus, the X. laevis oocyte expression system 
highlights markedly different activity of antipsychotics at the hD2L receptor. These differential 
properties may translate to distinct therapeutic potential of these compounds. 
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F15063, a potential antipsychotic with D2/D3 antagonist, 5-HT1A  agonist 
and D4 partial agonist properties. I. In vitro  receptor affinity and efficacy 
profile. 
Newman-Tancredi A, Assié MB, Martel JC, Cosi C, Slot LB, Palmier C, Rauly-Lestienne I, Colpaert F, 
Vacher B, Cussac D. 
Division of Neurobiology 2, Centre de Recherche Pierre Fabre, Castres, France.  
BACKGROUND AND PURPOSE: Combining 5-HT1A receptor activation with dopamine D2/D3 receptor 
blockade should improve negative symptoms and cognitive deficits in schizophrenia. We describe 
the in vitro profile of F15063 (N-[(2,2-dimethyl-2,3-dihydro-benzofuran-7-yloxy)ethyl]-3-(cyclopent-
1-enyl)-benzylamine). 
EXPERIMENTAL APPROACH: F15063 was characterised in tests of binding affinity and in cellular 
models of signal transduction at monoamine receptors. 
KEY RESULTS: Affinities (receptor and pKi values) of F15063 were: rD2 9.38; hD2L 9.44; hD2S 9.25; hD3 
8.95; hD4 8.81; h5-HT1A 8.37. F15063 had little affinity (40-fold lower than D2) at other targets. 
F15063 antagonised dopamine-activated G-protein activation at hD2, rD2 and hD3 receptors with 
potency (pKB) values 9.19, 8.29 and 8.74 in [
35S]GTPgammaS binding experiments) similar to 
haloperidol. F15063 did not exhibit any hD2 receptor agonism, even in tests of ERK1/2 
phosphorylation and G-protein activation in cells with high receptor expression. In contrast, like 
(+/-)8-OH-DPAT, F15063 efficaciously activated h5-HT1A (Emax 70%, pEC50 7.57) and r5-HT1A receptors 
(52%, 7.95) in tests of [35S]GTPgammaS binding, cAMP accumulation (90%, 7.12) and ERK1/2 
phosphorylation (93%, 7.13). F15063 acted as a partial agonist for [35S]GTPgammaS binding at hD4 
(29%, 8.15) and h5-HT1D receptors (35%, 7.68). In [
35S]GTPgammaS autoradiography, F15063 
activated G-proteins in hippocampus, cortex and septum (regions enriched in 5-HT1A receptors), but 
antagonised quinelorane-induced activation of D2/D3 receptors in striatum.  
CONCLUSIONS and IMPLICATIONS: F15063 antagonised dopamine D2/D3 receptors, a property 
underlying its antipsychotic-like activity, whereas activation of 5-HT1A and D4 receptors mediated its 
actions in models of negative symptoms and cognitive deficits of schizophrenia (see companion 
papers). 
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Br J Pharmacol. 2007 May;151(2):253-65. Epub 2007 Mar 20. 
F15063, a compound with D2/D3 antagonist, 5-HT1A  agonist and D4 
partial agonist properties. II. Activity in models of positive symptoms of 
schizophrenia. 
Depoortère R, Bardin L, Auclair AL, Kleven MS, Prinssen E, Colpaert F, Vacher B, Newman-Tancredi 
A. 
Division of Neurobiology 2, Centre de Recherche Pierre Fabre, Castres, France.  
BACKGROUND AND PURPOSE: F15063 is a high affinity D2/D3 antagonist, D4 partial agonist, and high 
efficacy 5-HT1A agonist, with little affinity (40-fold lower than for D2 receptors) at other central 
targets. Here, the profile of F15063 was evaluated in models of positive symptoms of schizophrenia 
and motor side-effects. 
EXPERIMENTAL APPROACH: Rodent behavioural tests were based on reversal of hyperactivity 
induced by psychostimulants and on measures of induction of catalepsy and 'serotonin syndrome'. 
KEY RESULTS: F15063 potently (ED50s: 0.23 to 1.10 mg/kg i.p.) reversed methylphenidate-induced 
stereotyped behaviors, blocked d-amphetamine and ketamine hyperlocomotion, attenuated 
apomorphine-induced prepulse inhibition (PPI) deficits, and was active in the conditioned avoidance 
test. In mice, it reversed apomorphine-induced climbing (ED50=0.30 mg/kg i.p.). F15063, owing to its 
5-HT1A agonism, did not produce (ED50>40 mg/kg i.p.) catalepsy in rats and mice, a behavior 
predictive of occurrence of extra-pyramidal syndrome (EPS) in man. This absence of cataleptogenic 
activity was maintained upon sub-chronic treatment of rats for 5 days at 40 mg/kg p.o. Furthermore, 
F15063 did not induce the 'serotonin syndrome' in rats (flat body posture and forepaw treading: ED50 
>32 mg/kg i.p.). 
CONCLUSIONS AND IMPLICATIONS: F15063 conformed to the profile of an atypical antipsychotic, 
with potent actions in models of hyperdopaminergic activity but without inducing catalepsy. These 
data suggest that F15063 may display potent antipsychotic actions with low EPS liability. This profile 
is complemented by a favourable profile in rodent models of negative symptoms and cognitive 
deficits of schizophrenia (companion paper). 
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F15063, a compound with D2/D3 antagonist, 5-HT1A  agonist and D4 
partial agonist properties. III. Activity in models of cognit ion and 
negative symptoms. 
Depoortère R, Auclair AL, Bardin L, Bruins Slot L, Kleven MS, Colpaert F, Vacher B, Newman-Tancredi A. 
Division of Neurobiology 2, Centre de Recherche Pierre Fabre, Castres, France.  
BACKGROUND AND PURPOSE: The D2/D3 receptor antagonist, D4 receptor partial agonist, and high 
efficacy 5-HT1A receptor agonist F15063 was shown to be highly efficacious and potent in rodent 
models of activity against positive symptoms of schizophrenia. However F15063 induced neither 
catalepsy nor the 'serotonin syndrome'. Here, we evaluated its profile in rat models predictive of 
efficacy against negative symptoms/cognitive deficits of schizophrenia. 
EXPERIMENTAL APPROACH: F15063, given i.p., was assessed in models of behavioural deficits 
induced by interference with the NMDA/glutamatergic (phencyclidine: PCP) or cholinergic 
(scopolamine) systems. 
KEY RESULTS: Through 5-HT1A activation, F15063 partially alleviated (MED: 0.04 mg/kg) PCP-induced 
social interaction deficit between two adult rats, without effect by itself, underlining its potential to 
combat negative symptoms. At doses above 0.16 mg/kg, F15063 reduced interaction by itself. 
F15063 (0.16 mg/kg)) selectively re-established PCP-impaired 'cognitive flexibility' in a reversal 
learning task, suggesting potential against adaptability deficits. F15063 (0.04-0.63 mg/kg) also 
reversed scopolamine-induced amnesia in a juvenile-adult rat social recognition test, indicative of a 
pro-cholinergic influence. Activity in this latter test is consistent with its D4 partial agonism, as it was 
blocked by the D4 antagonist L745,870. Finally, F15063 up to 40 mg/kg did not disrupt basal prepulse 
inhibition of startle reflex in rats, a marker of sensorimotor gating. 
CONCLUSIONS AND IMPLICATIONS: The balance of D2/D3, D4 and 5-HT1A receptor interactions of 
F15063 yields a promising profile of activity in models of cognitive deficits and negative symptoms of 
schizophrenia. 
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Naunyn Schmiedebergs Arch Pharmacol. 2007 Jun;375(4):241-50. Epub 2007 Apr 24. 
F15063, a potential antipsychotic with dopamine D2/D3 antagonist, 
5-HT1A  agonist and D4 partial agonist properties: (IV) duration of brain  
D2-like receptor occupancy and antipsychotic-like activity versus plasma 
concentration in mice. 
Assié MB, Bardin L, Auclair A, Consul-Denjean N, Sautel F, Depoortère R, Newman-Tancredi A. 
Centre de Recherche Pierre Fabre, 17 Avenue Jean Moulin, 81106 Castres Cedex, France.  
F15063 (N-[(2,2-dimethyl-2,3-dihydro-benzofuran-7-yloxy)ethyl]-3-(cyclopent-1-enyl)-benzylamine 
fumarate salt) is a novel potential antipsychotic with dopamine D2/D3 blocking properties and 
agonist activity at 5-HT1A and D4 receptors. The pertinent parameter for pharmacological activity of 
antipsychotics appears to be central D2-like receptor occupancy. However, its duration is not 
necessarily correlated with drug plasma levels, on which clinical dosing regimens are often based. 
Thus, we compared in mice the duration of actions of F15063 and haloperidol to (1) inhibit 
apomorphine-induced climbing and sniffing (behavioural measures of D2-like receptor antagonism) 
and (2) occupy D2-like receptors in vivo in the striatum and olfactory tubercles (inhibition of 
[
3
H]nemonapride binding). Finally, we measured plasma levels of F15063. D2-like receptor occupancy 
in the striatum remained elevated at 1, 4 and 8 h postadministration, with both F15063 (ID50: 7.1, 3.6 
and 16.5 mg/kg p.o., respectively) and the typical antipsychotic, haloperidol (ID50: 1.4, 0.52 and 0.53 
mg/kg p.o., respectively). This was paralleled by a protracted inhibition of apomorphine-induced 
climbing (ED50: 0.9, 2.8 and 3.6 mg/kg p.o., and 0.21, 0.37 and 0.87 mg/kg p.o., respectively, for 
F15063 and haloperidol). In contrast, after administration of 10 mg/kg p.o. of F15063, its plasma 
levels decreased rapidly: 15.2, 2.1 and 0.6 ng/ml, 1, 4 and 8 h after administration, respectively. A 
similar pattern of results was observed when F15063 and haloperidol were administered i.p. and s.c., 
respectively. To summarise, the time-course of D2-like receptor occupancy and inhibition of 
apomorphine-climbing (and sniffing) behaviours was similarly long lasting with F15063 and 
haloperidol. In addition, the durations of action of F15063 and haloperidol in a behavioural model of 
antipsychotic-like activity were closely correlated to their occupancy of central D2-like receptors, and 
much longer than their presence in plasma. 
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Neuropharmacological profile of bifeprunox: merits and limitations in 
comparison with other third-generation antipsychotics.  
Newman-Tancredi A, Cussac D, Depoortere R. 
Division of Neurobiology 2, Centre de Recherche Pierre Fabre, Castres, France.  
Schizophrenia is characterized by a range of positive and negative symptoms, and cognitive deficits. 
While positive symptoms respond to current antipsychotic agents, negative symptoms and cognitive 
deficits are often resistant to pharmacopea. Thus research is now focused on developing third-
generation antipsychotics that combine antagonism or partial agonism at dopamine D2-like 
receptors with agonism at serotonin 5-HT1A receptors. Such an association is anticipated to provide 
therapeutic benefits against a broader range of schizophrenia symptoms. Bifeprunox is one such 
third-generation antipsychotic agent which acts as a partial agonist at D2-like receptors and is an 
efficacious agonist at 5-HT1A receptors, with little interaction at 5HT2A/2C, muscarinic or histaminergic 
H1 receptors. This review summarizes the pharmacological profiles of the current antipsychotic 
agents and describes the rationale behind the development of third-generation antipsychotics. It 
also evaluates current data concerning bifeprunox in comparison with currently available 
antipsychotics, as well as those that are still under clinical development. 
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Pharmacological profiles in rats of novel antipsychotics with combined 
dopamine D2/serotonin 5-HT1A  activity: comparison with typical and 
atypical conventional antipsychotics. 
Bardin L, Auclair A, Kleven MS, Prinssen EP, Koek W, Newman-Tancredi A, Depoortère R. 
Division of Neurobiology, Pierre Fabre Research Centre, Castres, France.  
Combining antagonist/partial agonist activity at dopamine D2 and agonist activity at serotonin 5-HT1A 
receptors is one of the approaches that has recently been chosen to develop new generation 
antipsychotics, including bifeprunox, SSR181507 and SLV313. There have been, however, few 
comparative data on their pharmacological profiles. Here, we have directly compared a wide array of 
these novel dopamine D2/5-HT1A and conventional antipsychotics in rat models predictive of 
antipsychotic activity. Potency of antipsychotics to antagonize conditioned avoidance, 
methylphenidate-induced behaviour and D-amphetamine-induced hyperlocomotion correlated with 
their affinity at dopamine D2 receptors. Potency against ketamine-induced hyperlocomotion was 
independent of affinity at dopamine D2 or 5-HT1A receptors. Propensity to induce catalepsy, 
predictive of occurrence of extrapyramidal side effects, was inversely related to affinity at 5-HT1A 
receptors. As a result, preferential D2/5-HT1A antipsychotics displayed a large separation between 
doses producing 'antipsychotic-like' vs. cataleptogenic actions. These data support the contention 
that 5-HT1A receptor activation greatly reduces or prevents the cataleptogenic potential of novel 
antipsychotics. They also emphasize that interactions at 5-HT1A and D2 receptors, and the nature of 
effects (antagonism or partial agonism) at the latter has a profound influence on pharmacological 
activities, and is likely to affect therapeutic profiles. 
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Putative antipsychotics with pronounced agonism at  serotonin 5-HT1A  
and partial agonist activity at dopamine D2 receptors disrupt basal PPI 
of the startle reflex in rats.  
Auclair AL, Galinier A, Besnard J, Newman-Tancredi A, Depoortère R. 
Division of Neurobiology 2, Centre de Recherche Pierre Fabre, Castres, France.  
INTRODUCTION: Prepulse inhibition (PPI) of the startle reflex has been extensively studied because it 
is disrupted in several psychiatric diseases, most notably schizophrenia. In rats, and to a lesser 
extent, in humans, PPI can be diminished by dopamine (DA) D2/D3 and serotonin 5-HT1A receptor 
agonists. A novel class of potential antipsychotics (SSR181507, bifeprunox, and SLV313) possess 
partial agonist/antagonist properties at D2 receptors and various levels of 5-HT1A activation. 
MATERIALS AND METHODS: It thus appeared warranted to assess, in Sprague-Dawley rats, the 
effects of these antipsychotics on basal PPI. 
RESULTS: SSR181507, sarizotan, and bifeprunox decreased PPI, with a near-complete abolition at 
2.5-10 mg/kg; SLV313 had a significant effect at 0.16 mg/kg only. Co-treatment with the 5-HT1A 
receptor antagonist WAY100635 (0.63 mg/kg) showed that the 5-HT1A agonist activity of SSR181507 
was responsible for its effect. By contrast, antipsychotics with low affinity and/or efficacy at 5-HT1A 
receptors, such as aripiprazole (another DA D2/D3 and 5-HT1A ligand), and established typical and 
atypical antipsychotics (haloperidol, clozapine, risperidone, olanzapine, quetiapine, and ziprasidone) 
had no effect on basal PPI (0.01-2.5 to 2.5-40 mg/kg). 
DISCUSSION: The present data demonstrate that some putative antipsychotics with pronounced 
5-HT1A agonist activity, coupled with partial agonist activity at DA D2 receptors, markedly diminish PPI 
of the startle reflex in rats. 
CONCLUSIONS: These data raise the issue of the influence of such compounds on sensorimotor 
gating in humans. 
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WAY-100635 has high selectivity for serotonin 5-HT1A  versus dopamine 
D4 receptors. 
Martel JC, Leduc N, Ormière AM, Faucillon V, Danty N, Culie C, Cussac D, Newman-Tancredi A. 
Division of Neurobiology 2 Centre de recherche Pierre Fabre, Castres, France.  
The serotonin 5-HT1A receptor antagonist WAY-100635 was recently reported to have potent agonist 
properties at dopamine D4 receptors (Chemel et al., 2006, Psychopharmacology 188, 244-251.). 
Herein WAY-100635 (pKi at human (h) serotonin 5-HT1A receptors=9.51; pKi at dopamine hD4.4 
receptors=7.42) stimulated [
35
S]GTPgammaS incorporation in membranes of Chinese Hamster Ovary 
cells expressing dopamine hD4.4 receptors with only moderate potency and modest efficacy 
(pEC50=6.63; Emax=19% of dopamine). Moreover, in antagonism experiments, WAY-100635 had a 
much lower potency at dopamine hD4.4 receptors (pKB=7.09), than at serotonin h5-HT1A receptors 
(pKB=9.47). These data demonstrate that WAY-100635 has high selectivity for serotonin 
h5-HT1Aversus dopamine hD4.4 receptors. 
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S33138 [N-[4-[2-[(3aS,9bR)-8-cyano-1,3a,4,9b-tetrahydro[1]-
benzopyrano[3,4-c]pyrrol-2(3H)-yl)-ethyl]phenylacetamide], a 
preferential dopamine D3 versus D2 receptor antagonist and potential 
antipsychotic agent: I. Receptor-binding profile and functional actions at 
G-protein-coupled receptors. 
Millan MJ, Mannoury la Cour C, Novi F, Maggio R, Audinot V, Newman-Tancredi A, Cussac D, Pasteau 
V, Boutin JA, Dubuffet T, Lavielle G. 
Institut de Recherches Servier, Psychopharmacology Department, Croissy-sur-Seine, France.  
The novel, potential antipsychotic, S33138 (N-[4-[2-[(3aS,9bR)-8-cyano-1,3a,4,9b-
tetrahydro[1]benzopyrano[3,4-c]pyrrol-2(
3
H)-yl)-ethyl]phenylacetamide), displayed approximately 
25-fold higher affinity at human (h) dopamine D3 versus hD2L (long isoform) and hD2S (short isoform) 
receptors (pKi values, 8.7, 7.1, and 7.3, respectively). Conversely, haloperidol, clozapine, olanzapine, 
and risperidone displayed similar affinities for hD3, hD2L, and hD2S sites. In guanosine-5'-O-(3-
[35S]thio)-triphosphate ([35S]-GTPgammaS) filtration assays, S33138 showed potent, pure, and 
competitive antagonist properties at hD3 receptors, displaying pKB and pA2 values of 8.9 and 8.7, 
respectively. Higher concentrations were required to block hD2L and hD2S receptors. Preferential 
antagonist properties of S33138 at hD3 versus hD2L receptors were underpinned in antibody 
capture/scintillation proximity assays (SPAs) of Galpha(i3) recruitment and in measures of 
extracellular-regulated kinase phosphorylation. In addition, in cells cotransfected with hD3 and hD2L 
receptors that assemble into heterodimers, S33138 blocked (pKB, 8.5) the inhibitory influence of 
quinpirole upon forskolin-stimulated cAMP formation. S33138 had low affinity for hD4 receptors 
(<5.0) but revealed weak antagonist activity at hD1 receptors (Galphas/SPA, pKB, 6.3) and hD5 sites 
(adenylyl cyclase, 6.5). Modest antagonist properties were also seen at human serotonin (5-HT2A) 
receptors (Galpha(q)/SPA, pKB, 6.8, and inositol formation, 6.9 and at 5-HT7 receptors (adenylyl 
cyclase, pKB, 7.1). In addition, S33138 antagonized halpha2C adrenoceptors ([
35S]GTPgammaS, 7.2; 
Galpha(i3)/SPA, 6.9; Galpha(o)/SPA, 7.3, and extracellular-regulated-kinase, 7.1) but not halpha2A or 
halpha2B adrenoceptors (<5.0). Finally, in contrast to haloperidol, clozapine, olanzapine, and 
risperidone, S33138 displayed negligible affinities for multiple subtypes of alpha1-adrenoceptor, 
muscarinic, and histamine receptor. In conclusion, S33138 possesses a distinctive receptor-binding 
profile and behaves, in contrast to clinically available antipsychotics, as a preferential antagonist at 
hD3 versus hD2 receptors. 
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Antipsychotics differ in their ability to internalise human dopamine  D2S 
and human serotonin 5-HT1A  receptors in HEK293 cells.  
Heusler P, Newman-Tancredi A, Loock T, Cussac D. 
Cellular and Molecular Biology Department, Pierre Fabre Research Center, F-81106 Castres, France.  
Antipsychotic drugs act preferentially via dopamine D2 receptor blockade, but interaction with 
serotonin 5-HT1A receptors has attracted interest as additional target for antipsychotic treatment. As 
receptor internalisation is considered crucial for drug action, we tested the propensity of 
antipsychotics to internalise human (h)D2S receptors and h5-HT1A receptors. Agonist-induced 
internalisation of hemaglutinin (HA)-tagged hD2S and HA-h5-HT1A receptors expressed in HEK293 cells 
was increased by coexpression of G-protein coupled receptor kinase 2 and beta-arrestin2. At the HA-
hD2S receptor, dopamine, quinpirole and bromocriptine behaved as full agonists, while S(-)-3-(3-
hydroxyphenyl)-N-n-propylpiperidine [(-)-3PPP] and sarizotan were partial agonists. The typical 
antipsychotic, haloperidol, and the atypical compounds, olanzapine, nemonapride, ziprasidone and 
clozapine did not internalise HA-hD2S receptors, whereas aripiprazole potently internalised these 
receptors (>50% relative efficacy). Among antipsychotics with combined D2/5-HT1A properties, 
bifeprunox and (3-exo)-8-benzoyl-N-[[(2S)7-chloro-2,3-dihydro-1,4-benzodioxin-1-yl]methyl]-8-
azabicyclo-[3.2.1]octane-3-methanamine (SSR181507) partially internalised HA-hD(2S) receptors, 
piperazine, 1-(2,3-dihydro-1,4-benzodioxin-5-yl)-4-[[5-(4-fluorophenyl)-3-pyridinyl]methyl (SLV313) 
and N-[(2,2-dimethyl-2,3-dihydro-benzofuran-7-yloxy)ethyl]-3-(cyclopent-1-enyl)-benzylamine 
(F15063) were inactive. At the HA-h5-HT1A receptor, serotonin, (+)-8-hydroxy-2-(di-n-
propylamino)tetralin [(+)-8-OH-DPAT] and sarizotan were full agonists, buspirone acted as partial 
agonist. (-)-Pindolol showed little activity and no internalising properties were manifested for the 
5-HT1A receptor antagonist N-[2-[4-(2-methoxyphenyl)-1-piperazinyl]-ethyl]-N-(2-
pyridinyl)cyclohexanecarboxamide (WAY100635). Most antipsychotics induced HA-h5-HT1A receptor 
internalisation, with an efficacy rank order: nemonapride>F15063>SSR181507>bifeprunox ~ SLV313 
~ ziprasidone>aripiprazole and potencies: SLV313>SSR181507 ~ F15063>bifeprunox ~ nemonapride 
~ aripiprazole>ziprasidone. Interestingly, the internalisation induced by clozapine was only minimal, 
whereas aripirazole and bifeprunox were more potent for internalisation than for G-protein 
activation. These different profiles of antipsychotics for receptor internalisation may help to 
evaluate their potential therapeutic impact in the treatment of schizophrenia. 
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Effects of antipsychotics and reference monoaminergic ligands on 
marble burying behavior in mice. 
Bruins Slot LA, Bardin L, Auclair AL, Depoortere R, Newman-Tancredi A. 
Department of Cellular and Molecular Biology  and Division of Neurobiology 2, Pierre Fabre Research 
Centre, Castres, France.  
Antipsychotics constitute efficacious augmenting agents in the treatment of anxiety disorders, 
including refractory obsessive-compulsive disorder. We examined the effects of 36 compounds, 
including typical, atypical and novel antipsychotics with dual dopamine D2/5-hydroxytryptamine 1A 
(D2/5-HT1A) actions on marble burying behavior in mice, a putative preclinical test for anxiety 
disorders. One hour after drug administration, male NMRI mice were placed individually in cages 
containing 20 marbles, and the total number of marbles buried after 30 min was counted. The 
selective serotonin reuptake inhibitors, citalopram (2.5-40 mg/kg), fluoxetine (2.5-10 mg/kg) and the 
benzodiazepine diazepam (2.5-10 mg/kg), reduced the number of buried marbles. The atypical 
antipsychotic, clozapine (0.16-10 mg/kg), but not its congener olanzapine, was effective in this test. 
Haloperidol, a typical antipsychotic, also reduced the number of buried marbles, albeit not in a dose-
dependent manner. The atypical risperidone was partially active (0.16-0.63 mg/kg), as was the 
benzamide derivative, amisulpride, albeit at high (10-40 mg/kg) doses. Among the 'third-generation' 
antipsychotics possessing combined D2/5-HT1A properties, bifeprunox was active at 0.0025 mg/kg, 
whereas SLV313 and aripiprazole were active only at the highest doses (2.5 and 10 mg/kg, 
respectively). SSR181507, F15063 and the antidyskinetic agent, sarizotan, were without any effect. 
Among a series of receptor subtype-selective ligands, only the 5-HT1A agonist, (+)-8-OH-DPAT (0.63-
2.5 mg/kg) and the 5-HT2A/2B/2C antagonist, ritanserin (0.63-2.5 mg/kg) were active. Among novel 
antipsychotics with dual D2/5-HT1A properties, only bifeprunox was able to potently reduce the 
number of buried marbles. Inhibition of marble burying behavior may result from the interplay of 
several receptor systems, including 5-HT2 receptor blockade, dopamine D2 partial agonism and 
serotonin 5-HT1A agonism. 
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Agonist and antagonist properties of antipsychotics at human dop amine 
D4.4 receptors: G-protein activation and K+ channel modulation in 
transfected cells. 
Newman-Tancredi A, Heusler P, Martel JC, Ormière AM, Leduc N, Cussac D. 
Division of Neurobiology 2, Centre de Recherche Pierre Fabre, Castres, France.  
Interaction at dopamine D4 receptors may improve cognitive function, which is highly impaired in 
individuals with schizophrenia, but comparative studies of recent antipsychotics in cellular models of 
D4 receptor activation are lacking. Here, we report the in-vitro profile of over 30 ligands at 
recombinant hD4.4 receptors. In [
35
S]GTPgammaS binding experiments using membranes of CHO-
hD4.4 cells, apomorphine, preclamol and the selective D4 agonists, ABT724, CP226269, Ro-10-5824 
and PD168077, behaved as partial agonists (Emax 20-60% vs. dopamine), whereas L745870 and 
RBI257, displayed antagonist properties. The 'conventional' antipsychotic, haloperidol and the 
'atypicals', clozapine and risperidone, exhibited antagonist properties, while 'third generation' 
compounds bifeprunox, SLV313 and F15063, acted as partial agonists (10-30%). Aripiprazole and 
SSR181507 slightly stimulated [
35
S]GTPgammaS binding at micromolar concentrations. In Xenopus 
laevis oocytes co-expressing hD4.4 receptors with G-protein-coupled inwardly rectifying potassium 
(GIRK) channels, apomorphine, preclamol, ABT724, CP226269, and PD168077 stimulated GIRK 
currents (Emax 70-80%). The 5-HT1A receptor ligands, WAY100635 and flibanserin, also exhibited 
partial agonist activity (30% and 15%, respectively). Haloperidol, clozapine, olanzapine and 
nemonapride did not stimulate GIRK currents, whereas aripiprazole, bifeprunox, SLV313 and F15063, 
but not SSR181507, exhibited partial agonism (Emax 20-35%). In-vitro responses depended on 
experimental conditions: increasing NaCl concentration (30 mm to 100 mm) reduced agonist efficacy 
in [35S]GTPgammaS binding, whereas decreasing the amount of hD4.4 cRNA injected into oocytes 
(from 2.0 to 0.5 ng/oocyte) reduced agonist efficacy of several compounds. These data indicate that, 
unlike conventional or 'atypical' antipsychotics, several 'third generation' agents display D4 receptor 
partial agonism that may be sufficient to influence physiological D4 receptor activity in vivo. 
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The antipsychotics clozapine and olanzapine increase plasma glucose 
and corticosterone levels in rats: comparison with aripiprazole, 
ziprasidone, bifeprunox and F15063.  
Assié MB, Carilla-Durand E, Bardin L, Maraval M, Aliaga M, Malfètes N, Barbara M, Newman-Tancredi A. 
Neurobiology II Division, Centre de Recherche Pierre Fabre, Castres, France.  
Several novel antipsychotics activate serotonin 5-HT1A receptors as well as antagonising dopamine 
D2/3 receptors. Such a pharmacological profile is associated with a lowered liability to produce 
extrapyramidal side effects and enhanced efficacy in treating negative and cognitive symptoms of 
schizophrenia. However, 5-HT1A receptor agonists increase plasma corticosterone and many 
antipsychotics disturb the regulation of glucose. Here, we compared the influence on plasma glucose 
and corticosterone of acute treatments with 'new generation' antipsychotics which target dopamine 
D2/3 receptors and 5-HT1A receptors, with that of atypical antipsychotics, and with haloperidol. 
Olanzapine and clozapine, antipsychotics that are known to produce weight gain and diabetes in 
humans, both at 10 mg/kg p.o., substantially increased plasma glucose (from 0.8 to 1.7 g/l) at 1 h 
after administration, an effect that returned to control levels after 4 h. In comparison, F15063 (40 
mg/kg p.o.) was without effect at any time point. Olanzapine and clozapine dose-dependently 
increased plasma glucose concentrations as did SLV313 and SSR181507. Haloperidol and risperidone 
had modest effects whereas aripiprazole, ziprasidone and bifeprunox, antipsychotics that are not 
associated with metabolic dysfunction in humans, and F15063 had little or no influence on plasma 
glucose. The same general pattern of response was found for plasma corticosterone levels. The 
present data provide the first comparative study of conventional, atypical and 'new generation' 
antipsychotics on glucose and corticosterone levels in rats. A variety of mechanisms likely underlie 
the hyperglycemia and corticosterone release observed with clozapine and olanzapine, whilst the 
balance of dopamine D2/3/5-HT1A interaction may contribute to the less favourable impact of SLV313 
and SSR181507 compared with that of bifeprunox and F15063. 
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Agonist-directed trafficking of signalling at serotonin 5-HT2A, 5-HT2B  and 
5-HT2C-VSV receptors mediated Gq/11 activation and calcium 
mobilisation in CHO cells.  
Cussac D, Boutet-Robinet E, Ailhaud MC, Newman-Tancredi A, Martel JC, Danty N, Rauly-Lestienne I. 
Department of Cellular and Molecular Biology, Centre de Recherche Pierre Fabre, Castres, France.  
Several examples of agonist-directed trafficking of receptor signalling at 5-HT2A and 5-HT2C receptors 
have been reported that involve independent downstream transduction pathways. We now report 
the functional selectivity of a series of chemically diverse agonists at human (h)5-HT2A, h5-HT2B and 
h5-HT2C-VSV by examining two related responses, the upstream activation of Gq/11 proteins in 
comparison with its associated cascade of calcium mobilisation. At the h5-HT2A receptor, d-lysergic 
acid diethylamide (LSD) and the antiparkinsonian agents lisuride, bromocriptine and pergolide 
exhibit a higher potency for Gq/11 activation than calcium release in contrast with all the other 
tested ligands such as 5-HT, mCPP and BW723C86, that show an opposite preference of signalling 
pathway. Comparable observations are made at h5-HT2B and h5-HT2C-VSV receptors, suggesting a 
similar mechanism of functional selectivity for the three serotonin receptors. Interestingly, the non-
hallucinogenic compound lisuride behaves as a partial agonist for both Gq/11 activation and calcium 
release at the three 5-HT2 receptors, in contrast with DOI, LSD, pergolide and bromocriptine, which 
are known to provoke hallucinations, and behave as more efficacious agonists. Hence, a functional 
selectivity for Gq/11 activation together with a threshold of efficacy at h5-HT2A (and possibly h5-HT2B 
and/or h5-HT2C-VSV) may contribute to hallucinogenic liability. Thus, our results extend the notion of 
agonist-directed trafficking of receptor signalling to all the 5-HT2-receptor family and indicate that 
measures of Gq/11 activation versus calcium release may be useful to identify more effective 
therapeutic drugs with limited side effects. 
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Apomorphine-induced emesis in dogs: differential sensitivity to 
established and novel dopamine D2/5-HT1A  antipsychotic compounds. 
Depoortère R, Barret-Grévoz C, Bardin L, Newman-Tancredi A. 
Division of Neurobiology 2, Centre de Recherche Pierre Fabre, Castres, France.  
Small rodents (mice, rats) are the species of choice for evaluating the pharmacology of centrally 
acting compounds, such as antipsychotics, whereas toxicology data are routinely obtained from 
other species (rabbits, dogs, monkeys). Whilst there is a substantial number of "therapeutically 
relevant" pharmacological models for "antipsychotic-like" activity in small rodents, based on 
hyperdopaminergic or hypoglutamatergic/NMDA approaches, there is a remarkable paucity of such 
models in other species. Here, we compared the efficacy and potency of reference and new 
generation dopamine D2/5-HT1A putative antipsychotics, administered orally, against apomorphine-
induced emesis in dogs, a model of central D2 receptor activation that can be implemented with 
relative ease. Risperidone potently and fully (10 microg/kg) prevented emesis/retching induced by 
0.1 mg/kg s.c. apomorphine. SLV313 and F15063 (D2 receptor antagonists/5-HT1A receptor agonists) 
also abolished emesis/retching, albeit less potently than risperidone (minimal effective dose, MEDs: 
10 and 40 microg/kg, respectively). The D2 receptor partial agonists/5-HT1A receptor agonists 
aripiprazole and bifeprunox, (up to 80 microg/kg) only partially attenuated emesis, as did the 
peripheral D2 receptor antagonist domperidone. Under the present experimental conditions, 
haloperidol was only efficacious at the highest dose tested (320 microg/kg). To summarize, dogs are 
very sensitive to the dopaminergic blocking effects of antipsychotics in this model of D2 receptor 
activation. This model can thus be advantageously used to investigate the pharmacological activity 
of novel D2 receptor antagonists/partial agonists in dogs. 
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F15063, a potential antipsychotic with dopamine D2/D3 receptor 
antagonist, 5-HT1A  receptor agonist and dopamine D4 receptor partial 
agonist properties: influence on neuronal firing and neurotransmitter 
release. 
Assié MB, Mnie-Filali O, Ravailhe V, Benas C, Marien M, Bétry C, Zimmer L, Haddjeri N, Newman-
Tancredi A. 
Neurobiology II Division, Centre de Recherche Pierre Fabre, Castres, France.  
F15063 (N-[(2,2-dimethyl-2,3-dihydro-benzofuran-7-yloxy)-ethyl]-(3-cyclopenten-1-yl-benzyl)-amine) 
is a potential antipsychotic with dopamine D2/D3 receptor antagonist, 5-HT1A receptor agonist and 
dopamine D4 receptor partial agonist properties. Herein, we compared its effects on rat ventral 
tegmental area dopamine and dorsal raphe serotonin electrical activity with those of the dopamine 
D2 receptor partial agonist/5-HT1A receptor agonist, SSR181507. Further, we investigated the 
modulation of extracellular dopamine and noradrenaline in the medial prefrontal cortex and 
serotonin in the hippocampus of freely moving rats by F15063 using in vivo microdialysis. In the 
ventral tegmental area, F15063 (200-700 microg/kg, i.v.) did not alter the electrical activity of 
dopamine neurons whereas SSR181507 (250-1000 microg/kg, i.v.) partially inhibited it, consistent 
with dopamine D2 receptor partial agonism. Both compounds reduced the inhibition of firing rate 
induced by the full agonist apomorphine. In the dorsal raphe, both ligands suppressed firing activity, 
consistent with agonism at 5-HT1A autoreceptors, although SSR181507 (25-75 microg/kg, i.v.) was 
more potent than F15063 (100-300 microg/kg, i.v.). F15063 (0.63-40 mg/kg, i.p.) dose-dependently 
increased dopamine levels in the prefrontal cortex and decreased hippocampal 5-HT. These effects 
were reversed by the selective 5-HT1A receptor antagonist WAY100635 (0.16 mg/kg, s.c.), indicating 
that they were mediated by 5-HT1A receptors (at post- and pre-synaptic levels, respectively). In the 
medial prefrontal cortex, noradrenaline levels were moderately but significantly increased by 
F15063 at 2.5 mg/kg. In conclusion, whereas SSR181507 exhibits (partial) agonism at dopamine D2 
and 5-HT1A receptors, F15063 blocks dopamine D2-like receptors whilst activating 5-HT1A receptors. 
Such a profile distinguishes F15063 from SSR181507 and currently available antipsychotic drugs. 
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Penile erection and yawning induced by dopamine D2-like receptor 
agonists in rats: influence of strain and contribution of dopamine  D2, but 
not D3 and D4 receptors. 
Depoortère R, Bardin L, Rodrigues M, Abrial E, Aliaga M, Newman-Tancredi A. 
Division of Neurobiology 2, Centre de Recherche Pierre Fabre, Castres, France.  
Dopamine (DA) is implicated in penile erection (PE) and yawning (YA) in rats through activation of D2-
like receptors. However, the exact role of each subtype (D2, D3 and D4) of this receptor family in 
PE/YA is still not clearly elucidated. We recorded concomitantly PE and YA after treatment with 
agonists with various levels of selectivity for the different subtypes of D2-like receptors. In addition, 
we investigated the efficacy of antagonists with selective or preferential affinity for each of the three 
receptor subtypes to prevent apomorphine-induced PE and YA. Wistar rats were more sensitive than 
Long-Evans rats to the erectogenic activity of the nonselective DA agonist apomorphine (0.01-0.08 
mg/kg), whereas Sprague-Dawley rats were insensitive. However, all the three strains were equally 
sensitive to apomorphine-induced YA. In Wistar rats, apomorphine (0.01-0.63 mg/kg), the D2/D3 
agonists quinelorane and (+)7-OH-DPAT (0.000625-10 mg/kg) or PD 128,907 (0.01-10 mg/kg), but 
not the D4 agonists PD-168,077, RO-10-5824 and ABT-724 (0.04-0.63 mg/kg), produced PE and YA 
with bell-shaped dose-response curves. Similarly, ABT-724 and CP226-269 (another D4 agonist) failed 
to elicit PE and YA in Sprague-Dawley rats. Furthermore, in Wistar rats, PE and YA elicited by 
apomorphine (0.08 mg/kg) were not modified by selective D3 (S33084 and SB-277011, 0.63-10 
mg/kg) or D4 (L-745,870 and RBI-257, 0.63-2.5 mg/kg) antagonists, but were prevented by the 
preferential D2 blocker L-741,626 (near-full antagonism at 2.5 mg/kg). The present data do not 
support a major implication of either DA D3 or D4 receptors in the control of PE and YA in rats, but 
indicate a preponderant role of DA D2 receptors. 
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Signal transduction and functional selectivity of F15599, a preferential 
post-synaptic 5-HT1A  receptor agonist. 
Newman-Tancredi A, Martel JC, Assié MB, Buritova J, Lauressergues E, Cosi C, Heusler P, Bruins Slot 
L, Colpaert FC, Vacher B, Cussac D. 
Neurobiology 2 Division, Centre de Recherche Pierre Fabre, Castres, France.  
BACKGROUND AND PURPOSE: Activation of post-synaptic 5-HT1A receptors may provide enhanced 
therapy against depression. We describe the signal transduction profile of F15599, a novel 5-HT1A 
receptor agonist. 
EXPERIMENTAL APPROACH: F15599 was compared with a chemical congener, F13714, and with 
(+)8-OH-DPAT in models of signal transduction in vitro and ex vivo. 
KEY RESULTS: F15599 was highly selective for 5-HT1A receptors in binding experiments and in 
[
35
S]-GTPgammaS autoradiography of rat brain, where F15599 increased labelling in regions 
expressing 5-HT1A receptors. In cell lines expressing h5-HT1A receptors, F15599 more potently 
stimulated extracellular signal-regulated kinase (ERK1/2) phosphorylation, compared with G-protein 
activation, internalization of h5-HT1A receptors or inhibition of cAMP accumulation. F13714, (+)8-OH-
DPAT and 5-HT displayed a different rank order of potency for these responses. F15599 stimulated 
[
35
S]-GTPgammaS binding more potently in frontal cortex than raphe. F15599, unlike 5-HT, more 
potently and efficaciously stimulated G(alphai) than G(alphao) activation. In rat prefrontal cortex (a 
region expressing post-synaptic 5-HT1A receptors), F15599 potently activated ERK1/2 
phosphorylation and strongly induced c-fos mRNA expression. In contrast, in raphe regions 
(expressing pre-synaptic 5-HT1A receptors) F15599 only weakly or did not induce c-fos mRNA 
expression. Finally, despite its more modest affinity in vitro, F15599 bound to 5-HT1A receptors in 
vivo almost as potently as F13714. 
CONCLUSIONS AND IMPLICATIONS: F15599 showed a distinctive activation profiles for 5-HT1A 
receptor-mediated signalling pathways, unlike those of reference agonists and consistent with 
functional selectivity at 5-HT1A receptors. In rat, F15599 potently activated signalling in prefrontal 
cortex, a feature likely to underlie its beneficial effects in models of depression and cognition. 
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The five choice serial reaction time task: comparison between Sprague -
Dawley and Long-Evans rats on acquisition of task, and sensitivity to 
phencyclidine. 
Auclair AL, Besnard J, Newman-Tancredi A, Depoortère R. 
Division of Neurobiology 2, Centre de Recherche Pierre Fabre, Castres, France.  
The 5-choice serial reaction time task (5-CSRTT) allows examination of multiple aspects of 
cognition/executive functions (attention/impulsivity/ perseveration). Most 5-CSRTT studies are 
performed with pigmented (i.e. Long-Evans: LE) rats; however, albino strains (i.e. Sprague-Dawley: 
SD) are more commonly used in behavioural pharmacology experiments. Hence, we compared 
5-CSRTT performances of SD and LE rats and their sensitivity to acute phencyclidine (PCP, 1-2.5 
mg/kg). SD required significantly fewer sessions(35 versus 50) than LE rats for task acquisition, 
especially at shortest stimulus light duration (1 s). However,once trained, under vehicle conditions, 
both strains performed similarly. In contrast, PCP treatment differentially affected the two strains. 
Thus, whilst percentage of accuracy was decreased for both strains, in SD rats number of premature 
responses was more markedly decreased, whereas omissions and latency time to correct responses 
were more notably increased. In addition, PCP monotonically diminished in SD, but augmented (1-
1.5 mg/kg) in LE rats compulsive responding. To summarize, under our experimental conditions, the 
SD offer advantages over LE strain for speed of acquisition of 5-CSRTT. Once trained, basal 
performances of both strains were equivalent and stable enough for challenge with pharmacological 
compounds. However, PCP differentially affected the strains on several parameters considered. 
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Behav Brain Res. 2009 Nov 5;203(2):288-95. Epub 2009 May 21. 
Differences among conventional, atypical and novel putative  D2/5-HT1A  
antipsychotics on catalepsy-associated behaviour in cynomolgus 
monkeys. 
Auclair AL, Kleven MS, Barret-Grévoz C, Barreto M, Newman-Tancredi A, Depoortère R. 
Division of Neurobiology 2, Centre de Recherche Pierre Fabre, Castres, France. 
Typical antipsychotics such as haloperidol exert their therapeutic effects via blockade of dopamine 
(DA) D2 receptors, leading to extrapyramidal symptoms (EPS) in humans and catalepsy in rodents. In 
contrast, atypical antipsychotics and new generation D2/5-HT1A antipsychotics have low 
cataleptogenic potential. However, there has been no systematic comparative study on the effects 
of these different classes of antipsychotics in non-human primates, a species displaying a more 
sophisticated repertoire of behavioural/motor activity than rats. Once weekly, six young adult 
female non-haloperidol-sensitised cynomolgus monkeys were treated i.m. with a test compound and 
videotaped to score catalepsy-associated behaviour (CAB: static postures, unusual positions and 
crouching). Haloperidol, risperidone, olanzapine, nemonapride and remoxipride induced, to different 
extents, an increase in unusual positions (a response akin to dystonia), some crouching and static 
postures. In contrast, clozapine, quetiapine, ziprasidone and aripiprazole produced much lower or no 
unusual positions; clozapine also produced marked increases in static postures and crouching. 
Among novel D2/5-HT1A antipsychotics, SLV313 and F15063 augmented the number of unusual 
positions, albeit at doses 16-63 times higher than those of haloperidol for approximately the same 
score. SSR181507 and bifeprunox produced moderate static postures, little crouching and negligible 
unusual positions. These data provide the first comparative analysis in cynomolgus monkeys of EPS 
liability of conventional, atypical and novel D2/5-HT1A antipsychotics. They indicate that the latter are 
less prone than haloperidol to produce CAB, and provide a basis for comparison with rodent 
catalepsy studies. 
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5-HT1A  receptors are involved in the effects of xaliproden on G -protein 
activation, neurotransmitter release and nociception.  
Martel JC, Assié MB, Bardin L, Depoortère R, Cussac D, Newman-Tancredi A. 
Division of Neurobiology 2, Centre de Recherche Pierre Fabre, Castres, France.  
BACKGROUND AND PURPOSE: Xaliproden (SR57746A) is a 5-HT1A receptor agonist and neurotrophic 
agent that reduces oxaliplatin-mediated neuropathy in clinical trials. The present study investigated 
its profile on in vitro transduction, neurochemical responses and acute nociceptive pain tests in rats. 
EXPERIMENTAL APPROACH: Xaliproden was tested on models associated with 5-HT1A receptor 
activation including G-protein activation, extracellular dopamine and 5-HT levels measured by 
microdialysis and formalin-induced pain. Activation of 5-HT1A receptors was confirmed by 
antagonism with WAY100635. 
KEY RESULTS: Xaliproden exhibited high affinity for rat (r) and human (h) 5-HT1A receptors (pKi= 8.84 
and 9.00). In [35S]GTPgammaS (guanosine 5'-O-(3-[35S]thio)triphosphate) assays it activated both 
hippocampal r5-HT1A[pEC50/EMAX of 7.58/61% (%5-HT)] and recombinant h5-HT1A receptors (glioma 
C6-h5-HT1A: 7.39/62%; HeLa-h5-HT1A: 7.24/93%). In functional [
35S]GTPgammaS autoradiography, 
xaliproden induced labelling in structures enriched with 5-HT1A receptors (hippocampus, lateral 
septum, prefrontal and entorhinal cortices). Xaliproden inhibited in vivo binding of [
3
H]WAY100635 
to 5-HT1A receptors in mouse frontal cortex and hippocampus (ID50: 3.5 and 3.3 mg/kg, p.o. 
respectively). In rat, it increased extracellular dopamine levels in frontal cortex and reduced 
hippocampal 5-HT levels (ED50: 1.2 and 0.7 mg/kg, i.p. respectively). In a rat pain model, xaliproden 
inhibited paw licking and elevation (ED50: 1 and 3 mg/kg, i.p. respectively) following formalin 
injection in the paw. All effects were reversed by pretreatment with WAY100635. 
CONCLUSIONS AND IMPLICATIONS: These results indicate that activation of 5-HT1A receptors is the 
principal mechanism of action of xaliproden and provide further support for the utility of 5-HT1A 
receptor activation as an anti-nociceptive strategy. 
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F15063, a potential antipsychotic with dopamine D2/D3 receptor 
antagonist and 5-HT1A  receptor agonist properties: influence on 
immediate-early gene expression in rat prefrontal cortex  and striatum. 
Bruins Slot LA, Lestienne F, Grevoz-Barret C, Newman-Tancredi A, Cussac D. 
Department of Cellular and Molecular Biology, Centre de Recherche Pierre Fabre, Castres, France. 
Brain region-specific modulation of immediate-early gene (IEG) may constitute a marker of 
antipsychotic drug-like activity. We investigated the effects of the putative antipsychotic drug N-
[(2,2-dimethyl-2,3-dihydro-benzofuran-7-yloxy)ethyl]-3-(cyclopent-1-enyl)-benzylamine (F15063), a 
compound that targets both dopamine D2 and serotonin 5-HT1A receptors, in comparison with 
haloperidol and clozapine on rat mRNA expression of IEG i.e. the zinc-fingered transcription factors 
c-fos, fosB, zif268, c-jun and junB, two transcription factors of the nuclear receptor family nur77 and 
nor1, and the effector IEG arc. F15063 (10 mg/kg) and clozapine (10 mg/kg), but not haloperidol 
(0.63 mg/kg), induced c-fos and fosB mRNA expression in prefrontal cortex, a region associated with 
control of cognition and negative symptoms of schizophrenia. In striatum, only c-fos, fosB, junB and 
nur77 were induced by clozapine whereas all IEG mRNAs were increased by haloperidol and F15063 
(from 2.5 mg/kg) with similar high efficacy despite a total absence of F15063-induced catalepsy. 
However, at 0.63 mg/kg, F15063 induced a lower degree of striatal IEG mRNA expression than 
haloperidol and pretreatment with the serotonin 5-HT1A receptor antagonist N-[2-[4-(2-
methoxyphenyl)-1-piperazinyl]ethyl-N-(2-pyridinyl)cyclohexane carboxamide trihydrochloride 
(WAY100635) (0.63 mg/kg) increased the level of IEG mRNA induction by F15063. Furthermore, 
(+)-8-hydroxy-2-(di-n-propylamino)tetralin [(+)-8-OH-DPAT] at 0.16 mg/kg decreased haloperidol-
induced striatal IEG mRNA expression although it exerted no effects on its own. These results are 
consistent with an activation of serotonin 5-HT1A receptors by F15063, thus reducing D2 blockade-
induced striatal IEG mRNA. Furthermore, the substantial F15063-induced expression of IEGs such as 
c-fos in striatum is not related to cataleptogenic activity and may act more as a marker of efficacious 
dopamine D2 receptor blockade. 
D.Sc. Thesis  Publication Abstracts 
 
Part B: Page 178 of 206 
Reference no. 93 
Eur J Nucl Med Mol Imaging. 2010 Mar;37(3):594-605. Epub 2009 Sep 30. 
[18F]F15599, a novel 5-HT1A  receptor agonist, as a radioligand for PET 
neuroimaging. 
Lemoine L, Verdurand M, Vacher B, Blanc E, Le Bars D, Newman-Tancredi A, Zimmer L. 
Laboratory of Neuropharmacology, Université de Lyon, EAC CNRS 5006, Lyon, France. 
PURPOSE: The serotonin-1A (5-HT1A) receptor is implicated in the pathophysiology of major 
neuropsychiatric disorders. Thus, the functional imaging of 5-HT1A receptors by positron emission 
tomography (PET) may contribute to the understanding of its role in those pathologies and their 
therapeutics. These receptors exist in high- and low-affinity states and it is proposed that agonists 
bind preferentially to the high-affinity state of the receptor and therefore could provide a measure 
of the functional 5-HT1A receptors. Since all clinical PET 5-HT1A radiopharmaceuticals are antagonists, 
it is of great interest to develop a [
18
F]-labelled agonist. 
METHODS: F15599 (3-chloro-4-fluorophenyl-(4-fluoro-4{[(5-methyl-pyrimidin-2-ylmethyl)-amino]-
methyl}-piperidin-1-yl)-methanone) is a novel ligand with high affinity and selectivity for 5-HT1A 
receptors and is currently tested as an antidepressant. In pharmacological tests in rat, it exhibits 
preferential agonist activity at post-synaptic 5-HT1A receptors in cortical brain regions. Here, its nitro-
precursor was synthesised and radiolabelled via a fluoronucleophilic substitution. 
Radiopharmacological evaluations included in vitro and ex vivo autoradiography in rat brain and PET 
scans on rats and cats. Results were compared with simultaneous studies using [
18
F]MPPF, a 
validated 5-HT1A antagonist radiopharmaceutical. 
RESULTS: The chemical and radiochemical purities of [18F]F15599 were >98%. In vitro [18F]F15599 
binding was consistent with the known 5-HT1A receptors distribution (hippocampus, dorsal raphe 
nucleus, and notably cortical areas) and addition of GppNHp inhibited [18F]F15599 binding, 
consistent with a specific binding to G protein-coupled receptors. In vitro binding of [18F]F15599 was 
blocked by WAY100635 and 8-OH-DPAT, respectively, prototypical 5-HT1A antagonist and agonist. 
The ex vivo and in vivo studies demonstrated that the radiotracer readily entered the rat and the cat 
brain and generated few brain radioactive metabolites. Remarkably, in microPET studies, [18F]F15599 
notably displayed a pattern of brain labelling that did not correlate with in vitro observations. Thus, 
in cat, the highest binding was observed in dorsal raphe and cingulate cortex with little binding in 
other cortical regions and none in hippocampus. In vivo binding was abolished by WAY100635, 
indicating specific labelling of 5-HT1A receptors. 
CONCLUSION: [18F]F15599 is a radiofluorinated agonist presenting interesting characteristics for 
probing in vitro and in vivo the high-affinity states of the 5-HT1A receptors. Its differential labelling of 
5-HT1A receptors in vitro and in vivo may result from its reported preferential interaction with 
receptors coupled to specific G-protein subtypes. 
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Preferential in vivo  action of F15599, a novel 5-HT1A  receptor agonist, at 
postsynaptic 5-HT1A  receptors. 
Lladó-Pelfort L, Assié MB, Newman-Tancredi A, Artigas F, Celada P. 
Department of Neurochemistry and Neuropharmacology, Institut d'Investigacions Biomèdiques de 
Barcelona, Consejo Superior de Investigaciones Científicas (CSIC), IDIBAPS, Barcelona, Spain. 
BACKGROUND AND PURPOSE: F15599, a novel 5-hydroxytryptamine 5-HT1A receptor agonist with 
1000-fold selectivity for 5-HT compared with other monoamine receptors, shows antidepressant and 
procognitive activity at very low doses in animal models. We examined the in vivo activity of F15599 
at somatodendritic autoreceptors and postsynaptic 5-HT1A heteroreceptors. 
EXPERIMENTAL APPROACH: In vivo single unit and local field potential recordings and microdialysis 
in the rat. 
KEY RESULTS: F15599 increased the discharge rate of pyramidal neurones in medial prefrontal cortex 
(mPFC) from 0.2 microg/kg i.v and reduced that of dorsal raphe 5-hydroxytryptaminergic neurones 
at doses >10-fold higher (minimal effective dose 8.2 microg/kg i.v.). Both effects were reversed by 
the 5-HT1A antagonist (+/-)WAY100635. F15599 did not alter low frequency oscillations 
(approximately 1 Hz) in mPFC. In microdialysis studies, F15599 increased dopamine output in mPFC 
(an effect dependent on the activation of postsynaptic 5-HT1A receptors) with an ED50 of 30 
microg/kg i.p., whereas it reduced hippocampal 5-HT release (an effect dependent exclusively on 5-
HT1A autoreceptor activation) with an ED50 of 240 microg/kg) i.p. Likewise, application of F15599 by 
reverse dialysis in mPFC increased dopamine output in a concentration-dependent manner. All 
neurochemical responses to F15599 were prevented by administration of (+/-)WAY100635. 
CONCLUSIONS AND IMPLICATIONS: These results indicate that systemic administration of F15599 
preferentially activates postsynaptic 5-HT1A receptors in PFC rather than somatodendritic 5-HT1A 
autoreceptors. This regional selectivity distinguishes F15599 from previously developed 5-HT1A 
receptor agonists, which preferentially activate somatodendritic 5-HT1A autoreceptors, suggesting 
that F15599 may be particularly useful in the treatment of depression and of cognitive deficits in 
schizophrenia. 
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F15599, a preferential post-synaptic 5-HT1A  receptor agonist: activity in 
models of cognition in comparison with reference 5-HT1A  receptor 
agonists. 
Depoortère R, Auclair AL, Bardin L, Colpaert FC, Vacher B, Newman-Tancredi A. 
Neurobiology 2 Division, Centre de Recherche Pierre Fabre, Castres, France.  
We assessed the activity of F15599, a selective and high efficacy 5-HT1A agonist that preferentially 
activates post- versus pre-synaptic receptors, in rat cognition/memory models. F15599 
(0.16 mg/kg i.p.) partially alleviated detrimental effects of phencyclidine on working and reference 
memory deficit in a hole-board model. It also attenuated phencyclidine-induced deficit of cognitive 
flexibility in a reversal learning task, without effects of its own. F13714 (0.04 mg/kg) a chemical 
congener of F15599, and 8-OH-DPAT (0.01 or 0.16), were inactive against these phencyclidine-
induced deficits, and/or even worsened basal performances. F15599 (0.04-2.5) was less disruptive 
than F13714 (0.005-0.16) or 8-OH-DPAT (0.01-0.63), on basal performance in models of attention 
(5-choice serial reaction time task) and working memory (delayed non-matching to position). Finally, 
unlike either comparator, F15599 reduced PPI with modest potency and only partially. To conclude, 
F15599, in models of memory/cognition, has a more favourable profile than F13714 and 8-OH-DPAT. 
This suggests that preferential activation of post-synaptic 5-HT1A receptors could prove useful in 
pathologies characterized by cognitive/memory deficiencies, such as schizophrenia and depression. 
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The importance of 5-HT1A  receptor agonism in antipsychotic drug action: 
rationale and perspectives.  
Newman-Tancredi A. 
NeuroAct Communication, 25 rue des Généraux Ricard, Castres, France.  
Serotonin 5-HT1A receptors are attractive targets for the development of improved antipsychotics. 
Indeed, extensive evidence in rodent models indicates that the activation of these receptors 
prevents extrapyramidal symptoms (EPS) induced by dopamine D2 receptor blockade, favors 
dopaminergic neurotransmission in the frontal cortex, has a positive influence on mood, and 
opposes NMDA receptor antagonist-induced cognitive and social interaction deficits. Therefore, 
'third-generation' antipsychotics that combine partial agonism at 5-HT1A receptors with antagonism 
(or partial agonism) at D2 receptors have been investigated, including aripiprazole, perospirone, 
lurasidone (Dainippon Sumitomo Pharma Co Ltd), cariprazine (Gedeon Richter Ltd/Forest 
Laboratories Inc/Mitsubishi Tanabe Pharma Corp), PF-217830 (Pfizer Inc), F-97013-GD, F-15063 and 
bifeprunox. Such compounds appear to provide therapeutic benefits against a broader range of 
symptoms of schizophrenia, including negative symptoms and cognitive deficits that are poorly 
controlled by established antipsychotics. Recently developed compounds are essentially free of EPS 
liability, and exhibit little or no interaction at sites that are potentially involved in causing side effects 
such as weight gain, metabolic disorders or autonomic disturbance. These compounds differ in their 
balance of 5-HT1A/D2 receptor affinity and agonist or antagonist properties; such differences are 
likely to translate into distinct therapeutic profiles. The balance of 5-HT1A/D2 receptor properties 
should therefore be considered when selecting compounds as antipsychotic development 
candidates. 
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F15599, a highly selective post-synaptic 5-HT1A  receptor agonist: in-vivo 
profile in behavioural models of antidepressant and serotonergic 
activity. 
Assié MB, Bardin L, Auclair AL, Carilla-Durand E, Depoortère R, Koek W, Kleven MS, Colpaert F, 
Vacher B, Newman-Tancredi A. 
Neurobiology II Division, Centre de Recherche Pierre Fabre, Castres, France. 
F15599 is a novel agonist with high selectivity and efficacy at serotonin 5-HT1A receptors (5-HT1ARs). 
In signal transduction, electrophysiological and neurochemical tests, F15599 preferentially activates 
post-synaptic 5-HT1ARs in rat frontal cortex. Such a profile may translate to an improved profile of 
therapeutic activity for mood disorders. The in-vivo effects of F15599 were therefore compared with 
those of a related compound, F13714, in rat models of antidepressant activity and 5-HT1AR 
activation: forced swimming test (FST), conditioned stress-induced ultrasonic vocalization, 5-HT 
syndrome, plasma corticosterone and body temperature. Acute administration of F15599 or F13714 
reduced immobility in the FST at low doses; these effects were long lasting and the effects of F15599 
were maintained after repeated (5 d, p.o.) administration. Both compounds decreased ultrasonic 
vocalization duration at low doses. In contrast, higher doses of F15599 were required to induce 
lower lip retraction, elements of the 5-HT behavioural syndrome, hypothermia and to increase 
plasma corticosterone levels. Notably, there was a greater separation of ED50 between FST and 
other effects for F15599 than for F13714. Thus, the in-vivo potency of F15599 in models of 
antidepressant/anti-stress activity is similar to that of F13714, despite the fact that the latter has an 
in-vitro potency two orders of magnitude greater. In contrast F15599 has a lower propensity than 
F13714 to induce other serotonergic signs. The distinctive pharmacological profile of F15599 
suggests that preferential targeting of post-synaptic 5-HT1ARs constitutes a promising strategy for 
improved antidepressant therapy. 
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The central serotonin 2B receptor: a new pharmacological target to 
modulate the mesoaccumbens dopaminergic pathway activity.  
Auclair AL, Cathala A, Sarrazin F, Depoortère R, Piazza PV, Newman-Tancredi A, Spampinato U. 
Division of Neurobiology 2, Centre de Recherche Pierre Fabre, Castres, France. 
The function of the serotonin2B receptor (5-HT2BR) in the mammalian brain is poorly characterized, 
especially with regard to its influence on dopamine (DA) neuron activity. Here, we assessed this issue 
by evaluating effects of 5-HT2BRs ligands in the control of striatal and accumbal DA outflow, using in 
vivo microdialysis in halothane-anesthetized rats, and amphetamine-induced hyperlocomotion in 
vigil rats. The selective 5-HT2BR antagonist 1-[(2-chloro-3,4-dimethoxyphenyl)methyl]-2,3,4,9-
tetrahydro-6-methyl-1H-pyrido[3,4-B]indole (LY 266097; 0.16 mg/kg, i.p.) had no influence on basal 
accumbal and striatal DA outflow but reduced significantly accumbal DA outflow when injected at 
0.63 mg/kg. A significant reduction of basal DA outflow in the nucleus accumbens was also observed 
after i.p. administration of 0.16 mg/kg 2-amino-4-(4-fluoronaphth-1-yl)-6-isopropylpyrimidine, 
another selective 5-HT2BR antagonist. In contrast, the 5-HT2BR agonist alpha-methyl-5-(2-
thienylmethoxy)-1H-indole-3-ethanamine (3 mg/kg, s.c.) had no influence on basal DA outflow in 
either brain region. The increase in striatal and accumbal DA outflow induced by the 5-HT2CR inverse 
agonist 5-methyl-1-(3-pyridylcarbamoyl)-1,2,3,5-tetrahydropyrrolo[2,3-f] indole (5 mg/kg, i.p.) was 
unaltered by LY 266097 (0.63 mg/kg) pre-treatment. Conversely, LY 266097 (0.63 mg/kg) 
significantly diminished the increase in DA outflow induced by haloperidol (0.01 mg/kg, s.c.) or 
amphetamine (0.5 mg/kg, i.p.) in the nucleus accumbens, but not in the striatum. Amphetamine-
induced hyperlocomotion (1 mg/kg) was also attenuated by LY 266097 (0.63 mg/kg). These findings 
demonstrate that 5-HT2BRs exert a facilitatory control on mesoaccumbens DA pathway activity, and 
suggest that they may constitute a new target for improved treatment of DA-related 
neuropsychiatric disorders. 
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Neuropsychiatry (2011) 1(2), 149–164 
Biased agonism at serotonin 5-HT1A  receptors: preferential postsynaptic 
activity for improved therapy of CNS disorders. 
Newman-Tancredi A 
NeuroAct Communication, 25 rue des Généraux Ricard, Castres, France.  
Serotonin or 5-hydroxytryptamine 5-HT1A receptors are widely expressed in the brain and have 
extensive influence in the control of mood, cognition, movement and pain. In order to achieve 
optimal therapeutic benefit from targeting these receptors, ‘biased agonists’ (also known as 
‘functionally selective agonists’) are desirable in order to preferentially activate receptor 
subpopulations in brain regions that mediate therapeutic activity, whilst avoiding those that control 
other effects. For example, clinical studies indicate that antidepressant activity is favored when 
5-HT1A autoreceptor activation is minimized and postsynaptic 5-HT1A receptor activation is 
reinforced. F15599 is a novel biased agonist that exhibits a distinctive signal transduction 
‘fingerprint’ in vitro and preferential postsynaptic activation of cortical 5-HT1A receptors in vivo. This 
profile confers on F15599 a superior activity in animal models of depression and cognition, with a 
wide therapeutic margin relative to side effects. The use of biased agonists at 5-HT1A receptors 
constitutes an attractive strategy to manage CNS disorders arising from dysfunctional serotonergic 
neurotransmission. 
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Competitive interaction of 5-HT1A  receptors with G-protein subtypes in 
CHO cells demonstrated by RNA interference.  
Rauly-Lestienne I, Lestienne F, Ailhaud MC, Binesse J, Newman-Tancredi A, Cussac D. 
Department of Cellular and Molecular Biology, Centre de Recherche Pierre Fabre, Castres, France.  
Following agonist action, G-protein-coupled receptors may exhibit differential coupling to G-proteins 
or second messenger pathways, supporting the notion of agonist-directed trafficking. To explore 
these mechanisms, we have designed and transfected synthetic siRNA duplexes to knockdown 
different Gα subunits in Chinese hamster ovary (CHO) cells expressing human 
(h)5-hydroxytryptamine-1A receptors (CHO-h5-HT1A). siRNAs against Gαi2 and Gαi3 transfected 
alone or in combination caused a large decrease in the corresponding mRNA level (64-80%) and also 
at the protein level for Gαi3 (60-70%), whereas a non-specific siRNA showed no effect. In 
membranes of CHO-h5-HT1A, 5-HT-stimulated guanosine-5'-O-(3-[
35S]thio)-triphosphate ([35S]GTPγS) 
binding was differentially affected by transfection of siRNAs against Gαi protein, siRNAs against Gαi2 
inducing a more important decrease in the efficacy of 5-HT than transfection of siRNAs against Gαi3. 
The high potency component was abolished after transfection of siRNAs against Gαi3 and the lower 
potency component was suppressed after transfection of siRNAs against Gαi2. To directly investigate 
Gαi3 activation we used an antibody-capture/scintillation proximity assay. (+)8-OH-DPAT yielded 
bell-shaped curves for Gαi3 activation, a response that was abolished after transfection of siRNAs 
against Gαi3 protein. Interestingly, (+)8-OH-DPAT yielded a sigmoidal response when only Gαi3 
protein was expressed. These data suggest that when efficacious agonists attain a high level of 
occupation of h5-HT1A receptors, a change occurs that induces coupling to Gαi2 protein and 
suppresses signalling through Gαi3 subunits. 
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Psychopharmacology (Berl). 2011 Aug;216(4):451-73. Epub 2011 Mar 11. 
Comparative pharmacology of antipsychotics possessing combined 
dopamine D2 and serotonin 5-HT1A  receptor properties.  
Newman-Tancredi A, Kleven MS. 
NeuroAct Communication, 25, rue des Généraux Ricard, 81100, Castres, France,  
RATIONALE: There is increasing interest in antipsychotics intended to manage positive symptoms via 
D2 receptor blockade and improve negative symptoms and cognitive deficits via 5-HT1A activation. 
Such a strategy reduces side-effects such as the extrapyramidal syndrome (EPS), weight gain, and 
autonomic disturbance liability. 
OBJECTIVE: This study aims to review pharmacological literature on compounds interacting at both 
5-HT1A and D2 receptors (as well as at other receptors), including aripiprazole, perospirone, 
ziprasidone, bifeprunox, lurasidone and cariprazine, PF-217830, adoprazine, SSR181507, and F15063. 
METHODS: We examine data on in vitro binding and agonism and in vivo tests related to (1) positive 
symptoms (e.g., psychostimulant-induced hyperactivity or prepulse inhibition deficit), (2) negative 
symptoms (e.g., phencyclidine-induced social interaction deficits and cortical dopamine release), and 
(3) cognitive deficits (e.g., phencyclidine or scopolamine-induced memory deficits). EPS liability is 
assessed by measuring catalepsy and neuroendocrine impact by determining plasma prolactin, 
glucose, and corticosterone levels. 
RESULTS: Compounds possessing "balanced" 5-HT1A receptor agonism and D2 antagonism (or weak 
partial agonism) and, in some cases, combined with other beneficial properties, such as 5-HT2A 
receptor antagonism, are efficacious in a broad range of rodent pharmacological models yet have a 
lower propensity to elicit EPS or metabolic dysfunction. 
CONCLUSIONS: Recent compounds exhibiting combined 5-HT1A/D2 properties may be effective in 
treating a broader range of symptoms of schizophrenia and be better tolerated than existing 
antipsychotics. Nevertheless, further investigations are necessary to evaluate recent compounds, 
notably in view of their differing levels of 5-HT1A affinity and efficacy, which can markedly influence 
activity and side-effect profiles. 
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Reference no. 102 
Psychopharmacology (Berl). 2012 May;221(2):261-72. Epub 2011 Dec 3. 
In vivo electrophysiological and neurochemical effects of the selective 
5-HT1A  receptor agonist, F13640, at pre- and postsynaptic 5-HT1A  
receptors in the rat. 
Lladó-Pelfort L, Assié MB, Newman-Tancredi A, Artigas F, Celada P. 
Department of Neurochemistry and Neuropharmacology, Institut d'Investigacions Biomèdiques de 
Barcelona, CSIC-IDIBAPS, Rosselló 161, 6th floor, 08036, Barcelona, Spain. 
RATIONALE: F13640 (befiradol) is a novel 5-HT1A receptor agonist with exceptional selectivity vs. 
other receptors and binding sites. It shows analgesic activity in animal models and is currently 
developed for human use. 
OBJECTIVES: Given the potential dual role of the serotonergic system in pain, through the 
modulation of ascending signals in spinal cord and their emotional processing by corticolimbic areas, 
we examined the in vivo activity of F13640 at somatodendritic autoreceptors and postsynaptic 5-
HT1A heteroreceptors in medial prefrontal cortex (mPFC). 
METHODS: In vivo single unit recordings and intracerebral microdialysis in the rat. 
RESULTS: F13640 reduced the activity of dorsal raphe serotonergic neurons at 0.2-18.2 μg/kg, i.v. 
(cumulative doses; ED50 = 0.69 μg/kg, i.v.) and increased the discharge rate of 80% of mPFC 
pyramidal neurons in the same dose range (ED50 = 0.62 μg/kg, i.v.). Both effects were reversed by the 
subsequent administration of the 5-HT1A receptor antagonist (±)WAY100635. In microdialysis studies, 
F13640 (0.04-0.63 mg/kg, i.p.) dose-dependently decreased extracellular 5-HT in the hippocampus 
and mPFC. Likewise, F13640 (0.01-2.5 mg/kg, i.p.) dose-dependently increased extracellular DA in 
mPFC, an effect dependent on the activation of postsynaptic 5-HT1A receptors in mPFC. Local 
perfusion of F13640 in mPFC (1-1,000 μM) also increased extracellular DA in a concentration-
dependent manner. Both the systemic and local effects of F13640 were prevented by prior 
(±)WAY100635 administration. 
CONCLUSIONS: These results indicate that, upon systemic administration, F13640 activates both 
5-HT1A autoreceptors and postsynaptic 5-HT1A receptors in prefrontal cortex with a similar potency. 
Both activities are likely involved in the analgesic properties of the compound. 
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Reference no. 103 
J Nuclear Medicine 2012 May; 53:969–976. Epub 2012 May 10 
Radiosynthesis and preclinical evaluation of [ 18F]F13714 as a 
fluorinated 5-HT1A receptor agonist radioligand for PET neuroimaging . 
Lemoine L, Becker G, Vacher B, Billard T, Lancelot S, Newman-Tancredi A, Zimmer L. 
Laboratory of Neuropharmacology, Université de Lyon, EAC CNRS 5006, Lyon, France. 
PET brain imaging of the serotonin 1A (5-hydroxytryptamine 1A [5-HT1A]) receptor has been widely 
used in clinical studies. Currently, only a few well-validated radiolabeled antagonist tracers are 
available for in vivo imaging of this central receptor. 5-HT1A receptors exist in high- and low-affinity 
states, depending on their coupling to G proteins. Agonists bind preferentially to receptors in the 
high-affinity state and thereby could provide a measure of functional 5-HT1A receptors. Therefore, it 
is of great interest to develop an 18F-labeled full agonist 5-HT1A receptor radiotracer. In this study, 
we radiolabeled the high-affinity 5-HT1A receptor agonist [18F]F13714 and investigated its potential 
as a PET tracer.  
Methods: F13714 nitro precursor was synthesized and radiolabeled via a fluoronucleophilic 
substitution. In vitro binding assays were performed using established protocols. 
Radiopharmacologic evaluations included in vitro autoradiography in rat brain and PET scans on 
anesthetized cats.  
Results: The chemical and radiochemical purities of [
18
F]F13714 were greater than 98%. F13714 has 
a high affinity (0.1 nM) and selectivity for 5-HT1A receptors. In vitro [
18F]F13714 binding in rats was 
consistent with the known 5-HT1A receptors distribution (hippocampus and cortical areas) and was 
particularly high in the dorsal raphe. In vitro binding of [18F]F13714 was blocked in a dose-dependent 
fashion by WAY100635, the prototypical 5-HT1A antagonist, and by the endogenous agonist, 
serotonin (5-HT). Addition of Gpp(NH)p also inhibited in vitro [
18
F]F13714 binding, consistent with a 
preferential binding of the compound to G-protein–coupled receptors. Ex vivo tissue measurements 
in rat revealed an absence of brain radioactive metabolites. In vivo studies showed that the 
radiotracer entered the cat brain readily and displayed a preferential labeling of 5-HT1A receptors 
located in cingulate cortex. In vivo labeling was prevented by preinjection of WAY100635. 
Conclusion: [18F]F13714 is a radiofluorinated agonist that presents suitable characteristics for 
probing the high-affinity states of the 5-HT1A receptors in vitro and in vivo. Thus, it is a promising tool 
for investigation of 5-HT1A agonist binding in the living human brain. 
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